

GOKULA KRISHNA COLLEGE OF PHARMACY

HEI CODE: C-26844

NAAC SSR

CYCLE I



3 : RESEARCH, INNOVATIONS & EXTENSION

3.2 Innovation Ecosystem

3.2.1 Institution has Created
an ecosystem for Innovations,
IKS, IRP etc

3.2.1 Documents related to Institution Innovations



Approved by PCI, New Delhi, Government of AP & Affiliated to JNTUA
Recognized by UGC U/S 2(f), An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, Andhra Pradesh - 524121

☎ 9948990116

🌐 www.gkcp.edu.in

✉ gkcpsp@rediffmail.com

Sri Krishna Educational Society's

GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121



Mobile : +91 9948990116

email: gkcpssp@rediffmail.com

Web: www.gkcp.edu.in

LIST OF SEMINARS / WORKSHOPS / CONFERENCES CONDUCTED

A.Y.:2022-23

S.No	Name of the Event	Date	Details of Resource Person	No. of Participants
1	"Thinking Perspectives in Entrepreneurship"	15-09-2022	Mr J. Joseph, Assistant Professor, Dept. of MBA, Gokula Krishna college of Engineering, Sullurupeta. Email : n4loyola@gmail.com Phone : +91 9444304215	25
2	"Hands on Training in Analytical Instrumentation in Research"	29-10-2022	Dr K. Nagaraju, Professor, Deprat. of Pharmaceutical Analysis, Sir C R Reddy college of pharmaceutical sciences, Eluru. Email : nagaraju162@gmail.com Phone : +91 9642166555	35
3	"Essential Statistics in Research for the Pharmaceutical Research "	10-11-2022	Ms P. Sailaja, Associate professor, Department of Pharmacology Ratnam institute of pharmacy Pidathapolur, SPSR Nellore. Email : sailajapharma87@gmail.com Phone : +91 9963366179	33
4	"Intellectual properties Rights- Past, Present and Future"	09-12-2022	Dr S.Shehensha, Associate professor Dept. of Pharmaceutical chemistry Mother Theresa Institute of Pharmaceutical Education and research, Kurnool. Email : shehensah7@gmail.com Phone : +91 9959856721	27



Pavani

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURUPET, TIRUPATI Dt. A.P - 524121

5	"Research in Experimental and Clinical Pharmacology "	01-02-2023	Dr SK. Aminabee, Professor, Dept. of Pharmacology, V.V Institute of Pharmaceutical Sciences, Gudlavalleru Email : aminaammi@gmail.com Phone : 8309116844.	35
6	"Contemporary Research Methods in Pharmacy and Health Sciences	24-02-2023	Mr B. Sudheer chowdary, Assoc. Professor, Dept. of pharmacology, Bapatla College of Pharmacy, Guntur. Email : sudheer.chowdary18@gmail.com, Phone : +91 9966425564	37
7	"Empowering future clinical pharmacist: Role in clinical research"	10-03-2023	Dr C. Rajaram, Professor & Head, Department of pharmacy practice P Rami Reddy Memorial College of Pharmacy, Kadapa Email : rajarampharmacy21@gmail.com Phone : +91 8019504202	41
8	"Entrepreneurship on Pharmaceutical Management"	20-03-2023	K. Siva Naveen, Excutive HR, Divi's laboratories, Vishakapatnam. Email : sivanaveen@gmail.com Phone : +91 8099884722	25
9	"Pharmacovigilance program of India – Current Scenario and Emerging Trends in Research"	05-04-2023	CH. Kiran kumar M.Pharm, Healthcare IT Expert, RISE Trainings, Nellore Email : risetrainings@outlook.com Phone : +91 7993107993	36

P.O. 

COORDINATOR - IQAC
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURUPETA, A.P - 524 121




PRINCIPAL

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

**LIST OF SEMINARS / WORKSHOPS / CONFERENCES CONDUCTED****A.Y.:2021-22**

S.No	Name of the Event	Date	Details of Resource Person	No. of Participants
1	"Procedure for Filling and Grant Patents in India"	05-10-2021	Dr.V. Jayashankar reddy, Professor & Head, Dept. of pharmacology, Krishna Teja Pharmacy College, Tirupati Emai : shankarparmacology@gmail.com Phone : 9959348676.	30
2	"Innovations in Novel Drug Delivery Systems and Clinical Research"	06-11-2021	Dr Y.Ramesh, Professor & HOD, Dept. of Pharmaceutics, Ratnam institute of pharmacy, Pidathapolur, SPSR Nellore. Email : yramesh703@gmail.com Phone : +91 7672026003	38
3	"How to Write a Research Proposal"	10-12-2021	Mr. P.V.S.R Chandra Sekhar, Assoc. Professor, Department of pharmaceutics, Sir C.R Reddy college of pharmaceutical sciences, Eluru. Email : pvsrscs@gmail.com Phone : 9490032224	32
4	"Entrepreneurship in Community Pharmacy"	28-01-2022	Mr B. Thirupathaiah, MBA, Sr.HR, Divi's laboratories, Visakhapatnam Email : bthiru02@gmail.com Phone : +91 8332003643	25



Pavan
Dr. BALAGANI PAVAN KUMAR
 M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
 PROFESSOR & PRINCIPAL
 GOKULA KRISHNA COLLEGE OF PHARMACY
 SULLURPET, TIRUPATI Dt. A.P - 524121

5	"Research on Medication Safety and Error Prevention"	14-03-2022	Mr M. Krishna, Associate Professor, Dept. of Pharmacy practice, Sir C.R Reddy college of pharmaceutical sciences, Eluru. Email : krishnamannem@gmail.com Phone : +91 7702060202	38
6	"Statistical Research Methodology in the Field of Pharmaceutical Sciences "	08-04-2022	Mrs E. Manasa, Associate professor, Dept. of Pharmacognosy, Sun Institute of Pharmaceutical education and Research, Kakupalli, SPSR Nellore. Email : manasa.esr@gmail.com Phone : +91 8985588876	40
7	"Entrepreneurship- Best Ideas for Pharmacist"	25-04-2022	Mr K. Harikrishna, MBA, Sr. Executive, Divi's laboratories, Vishakapatnam. Email : harikrishna.kora16@gmail.com Phone : +91 9493211359	25
8	"Role of Clinical Research in Drug Development Program"	07-05-2022	Mrs P.Prabhavathi, Associate Professor, Dept. of Pharmaceutical chemistry, Ratnam Institute of Pharmacy, Pidathapolur, SPSR Nellore. Email : prabhapellakuri@gmail.com Phone : +91 8897923914	33
9	"Artificial Intelligence in Pharmaceutical Research and Development"	19-05-2022	Mr K.Vinodkumar, Professor, Dept. of Pharmaceutics, SIMS College of Pharmacy, Guntur Email : kvinodkumar8@gmail.com Phone : +91 6305170092	30

Pavan

PRINCIPAL



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Sri Krishna Educational Society's

GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by AICTE & PCI - New Delhi, Government of AP & Affiliated to JNTUA
An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, SPSR Nellore Dist, A.P, INDIA - 524121

Mobile : +91 9948990116

email: gkcp@rediffmail.com

Web: www.gkcp.edu.in

LIST OF SEMINARS / WORKSHOPS / CONFERENCES CONDUCTED

A.Y.: 2020-21

S.No	Name of the Event	Date	Details of Resource Person	No. of Participants
1	"Current Research on Drug Discovery and Development".	15-10-2020	Dr. K. Rajyalakshmi, Assoc. Professor, Dept. of Pharmaceutics, Bapatla College of Pharmacy, Bapatla. Email : rajimanohar3529@gmail.com Phone : +91 9985081813	29
2	"Concept, Innovation and Entrepreneurial Development"	26-10-2020	Mr. S. Chandrasekhar Babu, Professor & Head - MBA, Gokula Krishna College of Engineering, Sullurupeta. Email : cstpogkce@gmail.com Phone : +91 8074260556	30
3	"Pharmaceutical Sciences and Research"	30-11-2020	Mr K. Suresh, Assoc. Professor, Dept. of Pharmacognosy, MIPER, Kurnool. Email : kasaralasuresh@gmail.com Phone : 9866024211	29
4	"Patent Application Filling and Writing Procedure"	10-12-2020	Dr B. Mohan Gandhi, Assoc. Prof., Dept. of Pharmaceutical analysis, V.V Institute of Pharmaceutical Sciences, Gudlalleru. Email : bmgandhipharma@gmail.com Phone : +91 9866847074	30



Pavan

Dr. BALAGANI PAVAN KUMAR

M.Pharm, Ph.D. FIC, FBSS, FACE, FICCP, MISTE
PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, SPSR NELLORE DT., A.P-524121

5	"Applications on Computer Aided Molecular Drug Design and Research"	16-12-2020	Mrs T. Prasanthi, Assoc. Professor, Dept. Pharmaceutical analysis, V.V Institute of Pharmaceutical Sciences, Gudlavaluru. Email : prasanthi8585@gmail.com Phone : +91 9951400935	30
6	"Campus to Corporate: A Strategic Plan for Pharmacy Students"	15-02-2021	Mr. M.Jayakrishna., MBA Assistant Manager TIL Healthcare, Sricity Email : mjayakrishna87@gmail.com Phone : 9949744537.	30
7	"Role of Polymers in Research and its Applications"	25-02-2021	Mrs. D. Kalyani, Assc. Professor, Dept. of Pharmaceutics, Jagans college of pharmacy, Nellore. Email : kevinkarunya@gmail.com, Phone : +91 8106686200	29
8	"Covid-19's Effect on Medical Technology and Research"	12-03-2021	Mr. K. Poorna chandra Rao Assoc. Professor, Dept. of Pharmaceutical chemistry, Bapatla College of Pharmacy, Guntur. Email : poorna7575@gmail.com Phone : +91 9885071976	30

Pavan

PRINCIPAL



Dr. BALAGANI PAVAN KUMAR

M.Pharm, Ph.D. FIC, FBSS, FACE, FICCP, MISTE
PROFESSOR & PRINCIPAL


GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, SPSR NELLORE DT., A.P-524121

Sri Krishna Educational Society's

GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by AICTE & PCI - New Delhi, Government of AP & Affiliated to JNTUA

Behind RTC Depot, Sullurupeta, SPSR Nellore Dist, A.P, INDIA - 524121



Mobile : +91 9948990116

email: gkcpsp@rediffmail.com

Web: www.gkcp.edu.in

LIST OF SEMINARS / WORKSHOPS / CONFERENCES CONDUCTED

A.Y.:2019-20

S.No	Name of the Event	Date	Details of Resource Person	No. of Participants
1	"Advances in Pharmaceutical Sciences and Research"	09-08-2019	Mrs K.Sandhya, Assoc. Professor, Dept. of Pharmaceutical Chemistry, Sun Institute of Pharmaceutical Education and Research, Nellore. Email : sandhyakota@gmail.com, Phone : 8919364830.	30
2	"Entrepreneur's Self Confidence and Self Esteem"	12-08-2019	M. Bharathi, Assistant Professor, Dept. of MBA, Gokula Krishna college of Engineering, Sullurupeta. Email : bharathimooga@gmail.com Phone : 9398176072.	30
3	"Current Paradigms in Pharmaceutical Analytical Techniques and Research Methodology"	13-09-2019	Mr. K. Ranjith, Asst. Professor, Dept. of Pharmaceutical Chemistry and Analysis, Bapatla College of Pharmacy, Bapatla, Guntur Dist. Email : ranjith.kapu mail.com Phone : 9491668829	30
4	"Indian Patent laws: Indian Pharmaceutical Industry "	03-01-2020	Dr.P.Kishor, Professor, Dept. of Pharmacognosy and Phytochemistry ANS Pharmacy college, Tenali. Email : kishorpharmacog@gmail.com, Phone : 9951850662	30




Pavan
Dr. BALAGANI PAVAN KUMAR
M.Pharm, Ph D, FIC, FBSS, FACE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, SPSR NELLORE DT., A.P-524121

5	"Designing of Protocol for BA/BE Studies in Clinical Research "	06-01-2020	Mrs. Neelum Begum, Assoc. Professor, Dept. of Pharmacology. Bapatla College of Pharmacy, Bapatla. Email : neelammpharm@gmail.com Phone : +91 9666810156	30
6	"Designing the Methodology in Research"	08-01-2020	Dr T.Balakrishna, Assoc. Professor Dept. of Pharmaceutics, V.V Institute of Pharmaceutical Sciences, Eluru. Email : balakrishnathalamanchi@gmail.com Phone : +91 9494466340	32
7	"Research Methodology and Biostatistics "	07-02-2020	Mr. K.Sunil Kumar, Assoc. Professor Dept. of Pharmaceutics, SUN Institute of Pharmaceutical Education and Research, Nellore, AP. Email : sunil.kandukuru@gmail.com Phone : 8185090965	31
8	"Pharmaceutical Marketing and Entrepreneurship"	14-02-2020	Mr. M.Prudhviraj, M.Pharm., Pharmacist, Joy Medicals, Sullurupeta. Email : mkunniraj13@gmail.com Phone : +91 8978152617.	30
9	"Clinical Research, Pharmacovigilance: Challenges and Opportunities ".	09-03-2020	Mrs S.L. Savitri, Assoc. Professor, Dept. of Pharmaceutics, SIMS College of pharmacy, Guntur Email : savitri@gmail.com Phone : +91 8639172916	36


PRINCIPAL



Dr. BALAGANI PAVAN KUMAR
M.Pharm, Ph D, FIC, FBSS, FACE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, SPSR NELLORE DT., A.P-524121

**LIST OF SEMINARS / WORKSHOPS / CONFERENCES CONDUCTED****A.Y.: 2018-19**

S.No	Name of the Event	Date	Details of Resource Person	No. of Participants
1	"Pharmacovigilance: Challenges and Opportunities	09-07-2018	CH.Kiran kumar, M.Pharm, Healthcare IT Expert, RISE Trainings, Nellore Email : risetrainings@outlook.com Phone : +91 7993107993	30
2	"Emerging Trends in Pharmacotherapy and Clinical Research"	16-07-2018	Dr. S.Nelson Kumar, Principal & Professor, Dept. of Pharmacology, P.Rami Reddy Memorial College of Pharmacy, Kadapa. Email : nelsonhelpsu@yahoo.co.in Phone : +91 9505242242	30
3	Innovations in Research and Development	06-08-2018	Dr.V.Sai kishore, Professor, Dept. of Pharmaceutics, Bapatla college of pharmacy, Bapatla Email : voiceofsaikishore@yahoo.com, Phone: 9440938249.	29
4	"Ethical Regulations in Animal Experiments"	10-08-2018	1. Dr. D.Sivaraman, Scientist C, Centre for Laboratory animal technology and research, Sathyabama Institute of science and Technology, Chennai 600 119, Tamil Nadu, India. Email : sivaramand83@gmail.com Phone : +91 9841575334	32



Pavay
Dr. BALAGANI PAVAN KUMAR
 M.Pharm, Ph.D, FIC, FBSS, FACE, FICCP, MISTE
 PROFESSOR & PRINCIPAL
 GOKULA KRISHNA COLLEGE OF PHARMACY
 SULLURPET, SPSR NELLORE DT, A.P-524121

			2.Dr. B. Pushpa Kumari, Assoc. Professor and Head, Dept of Pharmacology, Sri Padmavathi School of Pharmacy, Tirupati. Email : pushpahema3@gmail.com Phone : +91 9490827068	
5.	"Employability and Entrepreneurship "	17-09-2018	Mr.B.Rupesh, MBA, Operations Head, VVS Global Forwerders, Krishnapatnam Port Company Ltd., Nellore. Email : rupesh260188@gmail.com Phone : 9491450338	30
6	"Role of Pharmacy Education and Research-Present and Future Challenges"	06-10-2018	Dr. R.Manohar, Professor &Head, Dept. of Pharmacology, P.Rami Reddy Memorial College of Pharmacy, Kadapa Email : reddy.manohar1981@gmail.com Mobile : +91 9963085878	30
7	"Innovative Research Trends in Pharmaceutical Industry"	12-11-2018	Mr. K.Sasikanth, Assoc. Professor, Dept. of Pharmaceutics, SIMS College of pharmacy, Guntur. Email : sasipharma.1982@gmail.com Phone : +919573033210	28
8	"Carrier Path to Entrepreneurship in Clinical Sector"	11-03-2019	Mrs S. Mounika, Asst. Professor, Dept. of MBA, Gokula Krishna college of Engineering, Sullurupeta. Email : s.mounika92@gmail.com, Phone : 9701719127	30
9	"Design of Experiments and Research Methodology"	30-03-2019	Dr. T. Venkateswara Rao, Prof. & Head, Dept. of Pharmaceutics, Bapatla College of Pharmacy, Bapatla, Guntur Dist. Email : tvrao250@gmail.com Phone : +91 8106028256	32



Dr. BALAGANI PAVAN KUMAR
M.Pharm, Ph D. FIC, FBSS, FACE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, SPSR NELLORE DT., A.P-524121

10	"Innovations in cutting Edge Strategies in Drug Discovery and Research"	12-04-2019	Dr. B. Narasimha Rao Professor & Head, Department of Pharmaceutics, P.Rami Reddy Memorial College of Pharmacy, Kadapa. Mobile: +91 9160592004 Email id:simham1985@gmail.com	28
----	---	------------	---	----

Pavan

PRINCIPAL

Dr. BALAGANI PAVAN KUMAR

M.Pharm, Ph.D. FIC, FBSS, FACE, FICCP, MISTE

PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY

SULLURPET, SPSR NELLORE DT., A.P-524121





GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcpsp@rediffmail.com

website: www.gkcp.edu.in

NUMBER OF BOOKS AND CHAPTERS IN EDITED VOLUMES / BOOKS PUBLISHED PER TEACHER DURING THE LAST FIVE YEARS

S.No	Name of the Full Time Teacher	Title of the Book / Chapters Published	Publisher	ISBN Number	Year of Publication
1	Ms A.R.Sridevi	A Text book for Pharmacology	Pragathi Publications	9-788197-096907	2023
2	Dr Balagani Pavan Kumar	A Text book for Pharmacology	Pragathi Publications	9-788197-096907	2023
3	MrsN.Sukanya	A Text book for Pharmacology	Pragathi Publications	9-788197-096907	2023
4	Ms P.Madhavi	A Text book for Pharmacology	Pragathi Publications	9-788197-096907	2023
5	Dr Balagani Pavan Kumar	Pharmaceutics – I	Nitya Publications	978-93-91669-47-8	2021
6	Mr Sivakumar Peta	A Textbook of Pharmaceutical Analysis	Pragathi Publications	9-788196-887599	2021
7	Dr Balagani Pavan Kumar	A Textbook of Pharmaceutical Analysis	Pragathi Publications	9-788196-887599	2021
8	Dr.P.kishor	A Textbook of Pharmaceutical Analysis	Pragathi Publications	9-788196-887599	2021
9	MrsD.Kalyani	A Textbook of Pharmaceutical Analysis	Pragathi Publications	9-788196-887599	2021
10	MrsB.Swathi	A Textbook of Pharmaceutical Analysis	Pragathi Publications	9-788196-887599	2021



Kavay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

11	Ms P.Kavitha	A Text book of Pharmaceutics	Pragathi Publications	9-788196-887568	2021
12	Dr Balagani Pavan kumar	A Text book of Pharmaceutics	Pragathi Publications	9-788196-887568	2021
13	MsSk.Zoofishaan	A Text book of Pharmaceutics	Pragathi Publications	9-788196-887568	2021
14	MsT.Swathi	A Text book of Pharmaceutics	Pragathi Publications	9-788196-887568	2021
15	MrsP.K.Devibala	Physical Pharmaceutics	Pragathi Publications	9-788196-887513	2020
16	MsP.Kavitha	Physical Pharmaceutics	Pragathi Publications	9-788196-887513	2020
17	DrBalaganiPavankumar	Physical Pharmaceutics	Pragathi Publications	9-788196-887513	2020
18	DrM.Soujanya	Physical Pharmaceutics	Pragathi Publications	9-788196-887513	2020
19	DrBalaganiPavankumar	A Text book on Novel Drug Delivery Systems	Pragathi Publications	9-788196-887506	2019
20	MrsP.K.Devibala	A Text book on Novel Drug Delivery Systems	Pragathi Publications	9-788196-887506	2019
21	MsC.B.Hanisha	A Text book on Novel Drug Delivery Systems	Pragathi Publications	9-788196-887506	2019
22	MrSivakumar Peta	A Text book on Novel Drug Delivery Systems	Pragathi Publications	9-788196-887506	2019



Narayana
PRINCIPAL

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Ms. A R Sridevi
Dr Balagani Pavan Kumar
Mrs. N Sukanya
Ms. P Madhavi



TEXTBOOK FOR
PHARMACOLOGY



Navay
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook For Pharmacology

Mr. AR Sridevi, Dr Balagani Pavan kumar, Mrs.N Sukanya,
Ms.P Madavi




Handwritten signature in green ink.

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

CONTENTS

Abbreviations.....	6
Preface	8
Chapter 1. GENERAL PHARMACOLOGY. PHARMACOKINETICS...	9
Chapter 2. GENERAL PHARMACOLOGY. PHARMACODYNAMICS	18
Chapter 3. DRUGS INHIBITING AFFERENT INNERVATION.....	26
Chapter 4. DRUGS STIMULATING AFFERENT INNERVATION	33
Chapter 5. CHOLINERGIC AGONISTS.	42
Chapter 6. CHOLINERGIC ANTAGONISTS.....	52
Chapter 7. ADRENERGIC AGONISTS.	66
Chapter 8. ADRENERGIC ANTAGONISTS. HISTAMINE-, SEROTONIN- AND DOPAMINERGIC DRUGS	77
Chapter 9. DRUGS FOR GENERAL ANESTHESIA.	90
Chapter 10. ETHANOL. HYPNOTICS. ANTIPILEPTIC AND ANTIPARKINSONIAN DRUGS..	100
Chapter 11. NEUROLEPTICS. ANXIOLYTICS. SEDATIVES. LITHIUM SALTS.....	115
Chapter 12. OPIOID (NARCOTIC) ANALGESICS.	130
Chapter 13. NON-OPIOID ANALGESICS	143
Chapter 14. ANALEPTICS. PSYCHOMOTOR STIMULANTS	160
Chapter 15. ANTI-DEPRESSANTS. ADAPTOGENS. NOOTROPS. ANOREXIGENS.....	172
Chapter 16. INOTROPIC DRUGS.	186
Chapter 17. ANTIANGINAL DRUGS	197
Chapter 18. ANTI-ARRHYTHMICS	212
Chapter 19. ANTIHYPERTENSIVE DRUGS. HYPERTENSIVE AGENTS	226
Chapter 20. ANTI-ATHEROSCLEROTIC DRUGS	240
Chapter 21. DRUGS ACTING ON HEMOPOIESIS (HEMATINICS) ...	252
Chapter 22. DRUGS ACTING ON BLOOD COAGULATION AND FIBRINOLYSIS	266
Chapter 23. DRUGS ACTING ON RESPIRATORY SYSTEM.....	281
Chapter 24. GASTROINTESTINAL DRUGS	295
Chapter 25. DIURETICS. ANTI-GOAT DRUGS. DRUGS	




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXTBOOK FOR PHARMACOLOGY



Navay

Dr. BALAGANIPAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Ms. A R Sridevi
Dr Balagani Pavan Kumar
Mrs. N Sukanya
Ms. P Madhavi



TEXTBOOK FOR
PHARMACOLOGY



Narayana

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook For Pharmacology

Mr. AR Sridevi, **Dr Balagani Pavan kumar**, Mrs.N Sukanya,
Ms.P Madavi





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121


CONTENTS

Abbreviations.....	6
Preface	8
Chapter 1. GENERAL PHARMACOLOGY. PHARMACOKINETICS...	9
Chapter 2. GENERAL PHARMACOLOGY. PHARMACODYNAMICS	18
Chapter 3. DRUGS INHIBITING AFFERENT INNERVATION.....	26
Chapter 4. DRUGS STIMULATING AFFERENT INNERVATION	33
Chapter 5. CHOLINERGIC AGONISTS.	42
Chapter 6. CHOLINERGIC ANTAGONISTS.....	52
Chapter 7. ADRENERGIC AGONISTS.	66
Chapter 8. ADRENERGIC ANTAGONISTS. HISTAMINE-, SEROTONIN- AND DOPAMINERGIC DRUGS	77
Chapter 9. DRUGS FOR GENERAL ANESTHESIA.	90
Chapter 10. ETHANOL. HYPNOTICS. ANTIPILEPTIC AND ANTIPARKINSONIAN DRUGS..	100
Chapter 11. NEUROLEPTICS. ANXIOLYTICS. SEDATIVES. LITHIUM SALTS.....	115
Chapter 12. OPIOID (NARCOTIC) ANALGESICS.	130
Chapter 13. NON-OPIOID ANALGESICS	143
Chapter 14. ANALEPTICS. PSYCHOMOTOR STIMULANTS	160
Chapter 15. ANTI-DEPRESSANTS. ADAPTOGENS. NOOTROPS. ANOREXIGENS.....	172
Chapter 16. INOTROPIC DRUGS.	186
Chapter 17. ANTIANGINAL DRUGS	197
Chapter 18. ANTI-ARRHYTHMICS	212
Chapter 19. ANTIHYPERTENSIVE DRUGS. HYPERTENSIVE AGENTS	2
26	
Chapter 20. ANTI-ATHEROSCLEROTIC DRUGS	240
Chapter 21. DRUGS ACTING ON HEMOPOIESIS (HEMATINICS) ...	252
Chapter 22. DRUGS ACTING ON BLOOD COAGULATION AND FIBRINOLYSIS	266
Chapter 23. DRUGS ACTING ON RESPIRATORY SYSTEM.....	281
Chapter 24. GASTROINTESTINAL DRUGS	295
Chapter 25. DIURETICS. ANTI-GOAT DRUGS. DRUGS	




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXTBOOK FOR PHARMACOLOGY



Kavay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Ms. A R Sridevi
Dr Balagani Pavan Kumar
Mrs. N Sukanya
Ms. P Madhavi



TEXTBOOK FOR
PHARMACOLOGY



Narayana

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook For Pharmacology

Mr. AR Sridevi, Dr Balagani Pavan kumar, Mrs. N Sukanya,
Ms. P Madavi



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121


CONTENTS

Abbreviations	6
Preface	8
Chapter 1. GENERAL PHARMACOLOGY. PHARMACOKINETICS...	9
Chapter 2. GENERAL PHARMACOLOGY. PHARMACODYNAMICS	18
Chapter 3. DRUGS INHIBITING AFFERENT INNERVATION.....	26
Chapter 4. DRUGS STIMULATING AFFERENT INNERVATION	33
Chapter 5. CHOLINERGIC AGONISTS.	42
Chapter 6. CHOLINERGIC ANTAGONISTS.....	52
Chapter 7. ADRENERGIC AGONISTS.	66
Chapter 8. ADRENERGIC ANTAGONISTS. HISTAMINE-, SEROTONIN- AND DOPAMINERGIC DRUGS	77
Chapter 9. DRUGS FOR GENERAL ANESTHESIA.	90
Chapter 10. ETHANOL. HYPNOTICS. ANTIPILEPTIC AND ANTIPARKINSONIAN DRUGS..	100
Chapter 11. NEUROLEPTICS. ANXIOLYTICS. SEDATIVES. LITHIUM SALTS.....	115
Chapter 12. OPIOID (NARCOTIC) ANALGESICS.	130
Chapter 13. NON-OPIOID ANALGESICS	143
Chapter 14. ANALEPTICS. PSYCHOMOTOR STIMULANTS	160
Chapter 15. ANTI-DEPRESSANTS. ADAPTOGENS. NOOTROPS. ANOREXIGENS.....	172
Chapter 16. INOTROPIC DRUGS.	186
Chapter 17. ANTIANGINAL DRUGS	197
Chapter 18. ANTI-ARRHYTHMICS	212
Chapter 19. ANTIHYPERTENSIVE DRUGS. HYPERTENSIVE AGENTS	2
26	
Chapter 20. ANTI-ATHEROSCLEROTIC DRUGS	240
Chapter 21. DRUGS ACTING ON HEMOPOIESIS (HEMATINICS) ...	252
Chapter 22. DRUGS ACTING ON BLOOD COAGULATION AND FIBRINOLYSIS	266
Chapter 23. DRUGS ACTING ON RESPIRATORY SYSTEM.....	281
Chapter 24. GASTROINTESTINAL DRUGS	295
Chapter 25. DIURETICS. ANTI-GOAT DRUGS. DRUGS	




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121


A TEXTBOOK FOR PHARMACOLOGY



Handwritten signature

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Ms. A R Sridevi
Dr Balagani Pavan Kumar
Mrs. N Sukanya
Ms. P Madhavi



TEXTBOOK FOR
PHARMACOLOGY




Narayana
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook For Pharmacology

Mr. AR Sridevi, Dr Balagani Pavan kumar, Mrs. N Sukanya,
Ms. P Madavi




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121


CONTENTS

Abbreviations.....	6
Preface	8
Chapter 1. GENERAL PHARMACOLOGY. PHARMACOKINETICS...	9
Chapter 2. GENERAL PHARMACOLOGY. PHARMACODYNAMICS	18
Chapter 3. DRUGS INHIBITING AFFERENT INNERVATION.....	26
Chapter 4. DRUGS STIMULATING AFFERENT INNERVATION	33
Chapter 5. CHOLINERGIC AGONISTS.	42
Chapter 6. CHOLINERGIC ANTAGONISTS.....	52
Chapter 7. ADRENERGIC AGONISTS.	66
Chapter 8. ADRENERGIC ANTAGONISTS. HISTAMINE-, SEROTONIN- AND DOPAMINERGIC DRUGS	77
Chapter 9. DRUGS FOR GENERAL ANESTHESIA.	90
Chapter 10. ETHANOL. HYPNOTICS. ANTIPILEPTIC AND ANTIPARKINSONIAN DRUGS..	100
Chapter 11. NEUROLEPTICS. ANXIOLYTICS. SEDATIVES. LITHIUM SALTS.....	115
Chapter 12. OPIOID (NARCOTIC) ANALGESICS.	130
Chapter 13. NON-OPIOID ANALGESICS	143
Chapter 14. ANALEPTICS. PSYCHOMOTOR STIMULANTS	160
Chapter 15. ANTI-DEPRESSANTS. ADAPTOGENS. NOOTROPS. ANOREXIGENS.....	172
Chapter 16. INOTROPIC DRUGS.	186
Chapter 17. ANTIANGINAL DRUGS	197
Chapter 18. ANTI-ARRHYTHMICS	212
Chapter 19. ANTIHYPERTENSIVE DRUGS. HYPERTENSIVE AGENTS	2
26	
Chapter 20. ANTI-ATHEROSCLEROTIC DRUGS	240
Chapter 21. DRUGS ACTING ON HEMOPOIESIS (HEMATINICS) ...	252
Chapter 22. DRUGS ACTING ON BLOOD COAGULATION AND FIBRINOLYSIS	266
Chapter 23. DRUGS ACTING ON RESPIRATORY SYSTEM.....	281
Chapter 24. GASTROINTESTINAL DRUGS	295
Chapter 25. DIURETICS. ANTI-GOAT DRUGS. DRUGS	




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXTBOOK FOR PHARMACOLOGY



Narayana

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



NITYA
PUBLICATIONS

As per PCI Regulations Syllabus

PHARMACEUTICS-I



AUTHOR

Dr. K. Kranthi Kumar

CO-AUTHORS

Dr. L. SRINIVAS

Dr. Vema Kiran

Dr. Balagani Pavan Kumar



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



A Hand Book of Pharmaceutics-1

AUTHOR

Dr. K. Kranthi Kumar M.PHARM, PH.D, M.B.A., PRAF
Professor cum Head, Dept. of Pharmaceutics
Mahathi college of Pharmacy, CTM Cross Roads
Madanapalle-517319, Chittoor (Dit)
Andhra Pradesh INDIA

Co- AUTHORS

Dr. L. Srinivas M.PHARM, PH.D
Professor, GITAM Institute of Pharmacy
GITAM Deemed to be University
Gandhinagar campus, Rushikonda
Visakhapatnam – 530 045 Andhra Pradesh INDIA

Dr. Vema Kiran M. PHARM, PH.D,
Head cum Asso.Professor, School of Health and Allied
Sciences, APEX PROFESSIONAL University
Pasighat, Arunachal Pradesh, INDIA

Dr. Balagani Pavan Kumar M.Pharm, Ph.D., FIC, FAGE, FBSS, FICCP
Professor and Principal, Gokula Krishna College of Pharmacy,
Sullurpet, SPSR Nellore Dist, Andhra Pradesh, India



Nitya Publications, Bhopal


Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

First Edition 2021

Publisher's Disclaimer: Due care has been taken while publishing this book, but the Author, Publisher, Printers are not responsible in any manner for any mistake that may have inadvertently crept in.

All rights reserved. No part of this book may be reprinted or reproduced or utilized in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system without permission in writing from the publishers.

Any comments or suggestions should be sent to author and no other place including public domain.

ISBN: 978-93-91669-47-8

Price: Rs.499.00

Published & Printed by:

Nitya Publications, Bhopal MP India

Web: www.nityapublications.com

Email: info@nityapublications.com

Mob. 9009291840

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Authors Profiles



DR.K.KRANTHIKUMAR M.PHARM, PH.D, M.B.A. is working as Professor cum Head Dept. Of Pharmaceutics in Mahathi College of Pharmacy Madanapalle, Andhra Pradesh 517319 Affiliated to JNTU-A Anantapuramu Andhra Pradesh INDIA. He is done certified PG course in Industrial Regulatory Affairs and Medical content writing. He has 12 years teaching experience in both U.G – B.Pharmacy and P.G-M.PHARMACY courses on Pharmaceutical Technology, NDDS, Physical Pharmacy, Regulatory Affairs etc. He has 29 National, 2 International publications in his credit. He actively involved in research in pharmacy and guided the research work of 29 M.Pharm graduates and 35 B.Pharm under graduates. Till now 21 Conferences attended, 04 UGC sponsored Conferences conducted, 05 Faculty development programmes and 04 Pharmacy text books published. He has a 01 Patent in Herbal gel for therapy of Acne. He is also an Editorial member and reviewer for various pharmacy journals. He is life time member of APTI.



DR. L. SRINIVAS M.PHARM, PH.D. is working as Professor in GITAM Institute of Pharmacy GITAM Deemed to be University Gandhinagar campus, Rushikonda Visakhapatnam – 530 045. He has 17 years teaching experience in both U.G – B.Pharmacy and P.G-M.PHARMACY courses .He actively involved in research in pharmacy and guided the research work of 48 He has a 01 international Patent. He is also an Editorial member and reviewer for various pharmacy journals. He has life member of APTI, IPGA and IHPA.



Dr. Vema Kiran M. PHARM, PH.D, is working as Head cum Asso.Professor in School of Health and Allied Sciences APEX PROFESSIONAL University Pasighat, Arunachal Pradesh INDIA. He has 14 years of teaching experience in both B. PHARMACY&M. PHARMACY courses on pharmaceutical technology, NDDS etc. He has several research publications in his credit. He actively involved in research in pharmacy and guided the research work of 4 M. Pharmacy graduates and 8 B. Pharmacy under graduates.



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Dr. Balagani Pavan Kumar, (M.Pharm, Ph.D., FIC, FAGE, FBSS, FICCP) was awarded the degree of Doctor of Philosophy (PhD) in Pharmaceutical Sciences by JNTUA, Anantapuramu. He is presently working as Professor and Principal at Gokula Krishna College of Pharmacy, Sullurpet, SPSR Nellore dist., Andhra Pradesh, India. He is having 15 years of teaching and research experience. He is having 02 patents to his credit. He has published more than 40 research and review articles in various indexed, peer-reviewed national and international journals with good impact factor. Currently he is serving as Editor-in-Chief in Journal of Comprehensive Pharmacy and as technical Editor in Science Alert Publishing Group. He has received several awards and rewards includes Best Teacher award, APP Appreciation Award and Inspiring Role Model & Leader. In the year 2017 he received the most prestigious —Sushrutha Best Scientist award from the Tamil Nadu Scientific Research Organization (Bose Science Society).

Narayana



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

List of Contents

Ch.No.	Content	Page No.
1	History of profession of Pharmacy in India in relation to Pharmacy education, industry and associations	01
2	Prescription	16
3	Tablets	31
4	Capsules	52
5	Liquid oral preparations	72
6	Topical Preparations	101
7	Nasal preparations	136
8	Powders and granules	143
9	Sterile formulations	154
10	Pharmaceutical aerosols	181
11	Immunological products	193
12	Quality assurance	205
13	Packaging materials	219
14	Pharmaceutical aids	225
15	Novel drug delivery system	232



Raway
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Chapter 1

History of profession of Pharmacy in India in relation to Pharmacy education, industry and associations

History:

The history of pharmacy as an independent science dates back to the first third of the 19th century. Before then, pharmacy evolved from antiquity as part of medicine. The history of pharmacy coincides well with the history of medicine, but it's important that there is a distinction between the two topics. Pharmaceuticals is one of the most-researched fields in the academic industry, but the history surrounding that particular topic is sparse compared to the impact it's made world-wide. Before the advent of pharmacists, there existed apothecaries that worked alongside priests and physicians in regard to patient care.

Asia:

The earliest known Chinese manual on materia medica is the Shennong Bencao Jing (The Divine Farmer's Herb-Root Classic), dating back to the 1st century AD. It was compiled during the Han dynasty and was attributed to the mythical Shennong. Earlier literature included lists of prescriptions for specific ailments, exemplified by a manuscript "Recipes for 52 Ailments", found in the Mawangdui, sealed in 168 BC. Further details on Chinese pharmacy can be found in the Pharmacy in China article. The earliest known compilation of medicinal substances in Indian traditional medicine dates to the 3rd or 4th century AD (attributed to Sushruta, who is recorded as a physician of the 6th century BC). There is a stone sign for a pharmacy with a tripod, a mortar, and a pestle opposite one for a doctor in the Arcadian Way in Ephesus, Turkey.

In Japan, at the end of the Asuka period (538-710) and the early Nara period (710-794), the men who fulfilled roles similar to those of modern pharmacists were highly respected. The place of pharmacists in society was expressly defined in the Taihō Code (701) and re-stated in the Yōrō Code (718). Ranked positions in the pre-Heian Imperial court were established; and this organizational structure remained largely intact until the Meiji Restoration (1868). In this highly stable hierarchy, the pharmacists and even pharmacist assistants were assigned status superior to all others in health-related fields such as physicians and acupuncturists. In the Imperial household, the pharmacist was even ranked above the two personal physicians of the Emperor. Following are the provisions which pharmacist should keep in mind while dealing with his trade:

- (i) Price structure the prices charged should be fair keeping with the quality, quantity and labor or skill required.
- (ii) Fair trade practice Fair practice should be adopted by a pharmacist in the trade without any attempt to capture other pharmacist's business. If a customer brings a prescription (by



The basis for this text book originally stemmed from my passion for developing better methods prevention of diseases and novel methods in development of clinical methods in various treatments of diseases. As the world moves into the digital age, generating vast amount of data and born digital content, there will be a greater need to access legacy material created with outdated technology. It is my passion to not only find out, but to develop tools to break down barriers of accessibility for future generation.

In truth, I could not have achieved my current level of success without a strong support group. First of all, my parents, who supported me with love and understanding? And secondly, my committee members, each of whom has provided patient advice and guidance throughout the research process. Thank you all for your unwavering support.

Pharmacology is the branch of science focused on health. There are two main approaches to health science the study and research of the body and health-related issues to understand how humans (and animals) function, and the application of that knowledge to improve health and to prevent and cure diseases and other physical and mental impairments. The science builds on many sub-fields, including biology, biochemistry, physics, epidemiology, pharmacology, medical sociology. Applied health sciences endeavor to better understand and improve human health through applications in areas such as health education, biomedical engineering, biotechnology and public health.

Organized interventions to improve health based on the principles and procedures developed through the health sciences are provided by practitioners trained in medicine, nursing, nutrition, pharmacy, social work, psychology, occupational therapy, physical therapy and other health care professions. Clinical practitioners focus mainly on the health of individuals, while public health practitioners consider the overall health of communities and populations.

About The Author



DR.K.KRANTHIKUMAR M.PHARM, PH.D, M.B.A. is working as Professor cum Head Dept. Of Pharmaceutics in Mahathi college of Pharmacy Madanapalle, Andhra Pradesh 517319 Affiliated to JNTU-A Anantapuramu Andhra Pradesh INDIA. He is done certified PG course in Industrial Regulatory Affairs and Medical content writing. He has 12 years teaching experience in both U.G – B.Pharmacy and P.G-M.PHARMACY courses on Pharmaceutical Technology, NDDS, Physical Pharmacy, Regulatory Affairs etc. He has 29 National, 2 International publications in his credit. He actively involved in research in pharmacy and guided the research work of 29 M.Pharm graduates and 35 B.Pharm under graduates. Till now 21 Conferences attended, 04 UGC sponsored Conferences conducted, 05 Faculty development programmes and 03 Pharmacy text books. He has a 01 Patent in Herbal gel for therapy of Acne. He is also an Editorial member and reviewer for various pharmacy journals. He has life member of APTI.

DR. BALAGANI RAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524124

Published & Printed By :


NITYA
PUBLICATIONS

Copyright @ Dr.k.kranthi Kumar


Nitya Publications, Bhopal MP India
Web: www.nityapublications.com
Email : info@nityapublications.com
Mob. : +91-9009291840

MRP Rs.

ISBN 978-93-91257-73-5



● **Mr. Sivakumar Peta, Dr. Balagani Pavan Kumar,
Dr. P Kishor, Mrs. D Kalyani, Mrs. B Swathi**



**A TEXTBOOK OF
PHARMACEUTICAL
ANALYSIS**



Nava
DR. BALAGANI PAVAN KUMAR
M.Pharm., Ph.D., PGD, FICP, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook of Pharmaceutical Analysis

Mr.Siva kumar Peta, Dr.Balagani Pavan kumar, Dr.P.Kishor, Mrs.D Kalyani,
Mrs.B.Swathi




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Contents...

Preface Contributors

1. Form Selection of Pharmaceutical Compounds
2. Preparation of Drug Samples for Analysis
3. High-Performance Liquid Chromatography
4. Mass Spectroscopy in Pharmaceutical Analysis
5. Ultraviolet–Visible Spectroscopy
6. Immunoassay Techniques
7. Applications of Capillary Electrophoresis Technology in the Pharmaceutical Industry
8. Atomic Spectroscopy
9. Luminescence Spectroscopy
10. Solid-State Nuclear Magnetic Resonance Spectroscopy
11. Vibrational Spectroscopy
12. Statistical Considerations in Pharmaceutical Process Development and Validation




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXTBOOK OF PHARMACEUTICAL ANALYSIS




Kavay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



● Mr. Sivakumar Peta, Dr. Balagani Pavan Kumar,
Dr. P. Kishor, Mrs. D Kalyani, Mrs. B Swathi



|
**A TEXTBOOK OF
PHARMACEUTICAL
ANALYSIS**



Balagani Pavan Kumar
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook of Pharmaceutical Analysis

Mr.Siva kumar Peta, **Dr.Balagani Pavan kumar**, Dr.P.Kishor, Mrs.D Kalyani,
Mrs.B.Swathi



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Contents...

Preface Contributors

1. Form Selection of Pharmaceutical Compounds
2. Preparation of Drug Samples for Analysis
3. High-Performance Liquid Chromatography
4. Mass Spectroscopy in Pharmaceutical Analysis
5. Ultraviolet–Visible Spectroscopy
6. Immunoassay Techniques
7. Applications of Capillary Electrophoresis Technology in the Pharmaceutical Industry
8. Atomic Spectroscopy
9. Luminescence Spectroscopy
10. Solid-State Nuclear Magnetic Resonance Spectroscopy
11. Vibrational Spectroscopy
12. Statistical Considerations in Pharmaceutical Process Development and Validation



Navay
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXTBOOK OF PHARMACEUTICAL ANALYSIS




Narayana

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



● Mr. Sivakumar Peta, Dr. Balagani Pavan Kumar,
Dr. P. Kishor, Mrs. D Kalyani, Mrs. B Swathi



|
**A TEXTBOOK OF
PHARMACEUTICAL
ANALYSIS**



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook of Pharmaceutical Analysis

Mr.Siva kumar Peta, Dr.Balagani Pavan kumar, Dr.P.Kishor, Mrs.D Kalyani,
Mrs.B.Swathi




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Contents...

Preface Contributors

1. Form Selection of Pharmaceutical Compounds
2. Preparation of Drug Samples for Analysis
3. High-Performance Liquid Chromatography
4. Mass Spectroscopy in Pharmaceutical Analysis
5. Ultraviolet–Visible Spectroscopy
6. Immunoassay Techniques
7. Applications of Capillary Electrophoresis Technology in the Pharmaceutical Industry
8. Atomic Spectroscopy
9. Luminescence Spectroscopy
10. Solid-State Nuclear Magnetic Resonance Spectroscopy
11. Vibrational Spectroscopy
12. Statistical Considerations in Pharmaceutical Process Development and Validation





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXTBOOK OF PHARMACEUTICAL ANALYSIS




Review

Dr. BALAGANI PAVAN KUMAR
M.Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
SRI KRISHNA COLLEGE OF PHARMACY
SULLURPET, GODPATI Dt. A.P - 524121



● Mr. Sivakumar Peta, Dr. Balagani Pavan Kumar,
Dr. P. Kishor, Mrs. D Kalyani, Mrs. B Swathi



A TEXTBOOK OF
PHARMACEUTICAL
ANALYSIS



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook of Pharmaceutical Analysis

Mr.Siva kumar Peta, Dr.Balagani Pavan kumar, Dr.P.Kishor, Mrs.D Kalyani,
Mrs.B.Swathi



A handwritten signature in green ink, appearing to read 'Kavay'.

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Contents...

Preface Contributors

1. Form Selection of Pharmaceutical Compounds
2. Preparation of Drug Samples for Analysis
3. High-Performance Liquid Chromatography
4. Mass Spectroscopy in Pharmaceutical Analysis
5. Ultraviolet-Visible Spectroscopy
6. Immunoassay Techniques
7. Applications of Capillary Electrophoresis Technology in the Pharmaceutical Industry
8. Atomic Spectroscopy
9. Luminescence Spectroscopy
10. Solid-State Nuclear Magnetic Resonance Spectroscopy
11. Vibrational Spectroscopy
12. Statistical Considerations in Pharmaceutical Process Development and Validation





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXTBOOK OF PHARMACEUTICAL ANALYSIS




Kavay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
SRI KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



● Mr. Sivakumar Peta, Dr. Balagani Pavan Kumar,
Dr. P. Kishor, Mrs. D Kalyani, Mrs. B Swathi



|
**A TEXTBOOK OF
PHARMACEUTICAL
ANALYSIS**

Navay
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



A Textbook of Pharmaceutical Analysis

Mr.Siva kumar Peta, Dr.Balagani Pavan kumar, Dr.P.Kishor, Mrs.D Kalyani,
Mrs.B.Swathi




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Contents...

Preface Contributors

1. Form Selection of Pharmaceutical Compounds
2. Preparation of Drug Samples for Analysis
3. High-Performance Liquid Chromatography
4. Mass Spectroscopy in Pharmaceutical Analysis
5. Ultraviolet-Visible Spectroscopy
6. Immunoassay Techniques
7. Applications of Capillary Electrophoresis Technology in the Pharmaceutical Industry
8. Atomic Spectroscopy
9. Luminescence Spectroscopy
10. Solid-State Nuclear Magnetic Resonance Spectroscopy
11. Vibrational Spectroscopy
12. Statistical Considerations in Pharmaceutical Process Development and Validation





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXTBOOK OF PHARMACEUTICAL ANALYSIS

Navay

Dr. BALAGANI PAVAN KUMAR
Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
SRI SATHYANARAYANA COLLEGE OF PHARMACY
SULLURPET, THIRUPATI Dt. A.P - 524121






A TEXTBOOK OF PHARMACEUTICS

**Ms. P Kavitha, Dr. Balagani Pavan Kumar,
Ms. S K Zoofishaan, Ms. T Swathi**




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook of Pharmaceutics

Ms P Kavitha , Dr Balagani Pavan Kumar, Ms S K Zoofishaan,

Ms. T Swathi



Dr. BALAGANI PAVAN KUMAR

M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121








Contents

UNIT-1 : Historical Background, Dosage Forms, Prescription and Posology	1.1 – 1.42
1.1 History of Pharmacy	1.1
1.2 Pharmacy as a Career	1.3
1.3 Introduction to Pharmacopoeia	1.6
1.3.1 Pharmacopoeia	1.6
1.3.2 Indian Pharmacopoeia	1.7
1.3.3 British Pharmacopoeia	1.9
1.3.4 United State Pharmacopoeia	1.11
1.3.5 Extra Pharmacopoeia	1.12
1.4 Introduction to Pharmaceutical Dosage Form	1.13
1.5 Prescription	1.23
1.5.1 Parts of the Prescription	1.23
1.5.2 Handling of Prescription	1.25
1.5.3 Sources of Errors in Prescriptions	1.27
1.5.4 Abbreviation used in Prescription	1.28
1.6 Posology	1.37
1.6.1 Factors Affecting Posology	1.37
1.6.2 Formulae used in Calculations of Pediatric Dose	1.39
Questions	1.41
UNIT-2: Pharmaceutical Calculations, Powders & Liquid Dosage Forms	2.1 – 2.36
2.1 Pharmaceutical Calculation	2.1
2.2 Calculation of Isotonocity	2.3
2.3 Proof Spirit	2.15
2.4 Powder	2.16
2.4.1 Dusting Powder	2.17
2.4.2 Effervescent Powder	2.17
2.4.3 Dentrifices (Tooth Powder)	2.22
2.4.4 Insufflations	2.23
2.4.5 Snuffs	2.23
2.5 Liquid Dosage Form	2.23
2.5.1 Advantages of Liquid Dosage Forms	2.24
2.5.2 Excipients used in Formulation of Liquid Dosage Forms	2.25
2.6 Solubility	2.32
2.7 Techniques of Solubilization	2.33
Questions	2.36





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXTBOOK OF PHARMACEUTICS



Naray

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



A TEXTBOOK OF PHARMACEUTICS

Ms. P Kavitha, **Dr. Balagani Pavan Kumar**,
Ms. S K Zoofishaan, Ms. T Swathi



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook of Pharmaceutics

Ms P Kavitha , **Dr Balagani Pavan Kumar**, Ms S K Zoofishaan,
Ms. T Swathi



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121







Contents

UNIT-1 : Historical Background, Dosage Forms, Prescription and Posology	1.1 – 1.42
1.1 History of Pharmacy	1.1
1.2 Pharmacy as a Career	1.3
1.3 Introduction to Pharmacopoeia	1.6
1.3.1 Pharmacopoeia	1.6
1.3.2 Indian Pharmacopoeia	1.7
1.3.3 British Pharmacopoeia	1.9
1.3.4 United State Pharmacopoeia	1.11
1.3.5 Extra Pharmacopoeia	1.12
1.4 Introduction to Pharmaceutical Dosage Form	1.13
1.5 Prescription	1.23
1.5.1 Parts of the Prescription	1.23
1.5.2 Handling of Prescription	1.25
1.5.3 Sources of Errors in Prescriptions	1.27
1.5.4 Abbreviation used in Prescription	1.28
1.6 Posology	1.37
1.6.1 Factors Affecting Posology	1.37
1.6.2 Formulae used in Calculations of Pediatric Dose	1.39
Questions	1.41
UNIT-2: Pharmaceutical Calculations, Powders & Liquid Dosage Forms	2.1 – 2.36
2.1 Pharmaceutical Calculation	2.1
2.2 Calculation of Isotonocity	2.3
2.3 Proof Spirit	2.15
2.4 Powder	2.16
2.4.1 Dusting Powder	2.17
2.4.2 Effervescent Powder	2.17
2.4.3 Dentrifices (Tooth Powder)	2.22
2.4.4 Insufflations	2.23
2.4.5 Snuffs	2.23
2.5 Liquid Dosage Form	2.23
2.5.1 Advantages of Liquid Dosage Forms	2.24
2.5.2 Excipients used in Formulation of Liquid Dosage Forms	2.25
2.6 Solubility	2.32
2.7 Techniques of Solubilization	2.33
Questions	2.36



Navay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



9 788196 887568



Narayana

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXTBOOK OF PHARMACEUTICS

Ms. P Kavitha, Dr. Balagani Pavan Kumar,
Ms. S K Zoofishaan, Ms. T Swathi



Narayana
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook of Pharmaceutics

Ms P Kavitha , Dr Balagani Pavan Kumar, Ms S K Zoofishaan,

Ms. T Swathi




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121


Contents

UNIT-1 : Historical Background, Dosage Forms, Prescription and Posology		1.1 – 1.42
1.1	History of Pharmacy	1.1
1.2	Pharmacy as a Career	1.3
1.3	Introduction to Pharmacopoeia	1.6
1.3.1	Pharmacopoeia	1.6
1.3.2	Indian Pharmacopoeia	1.7
1.3.3	British Pharmacopoeia	1.9
1.3.4	United State Pharmacopoeia	1.11
1.3.5	Extra Pharmacopoeia	1.12
1.4	Introduction to Pharmaceutical Dosage Form	1.13
1.5	Prescription	1.23
1.5.1	Parts of the Prescription	1.23
1.5.2	Handling of Prescription	1.25
1.5.3	Sources of Errors in Prescriptions	1.27
1.5.4	Abbreviation used in Prescription	1.28
1.6	Posology	1.37
1.6.1	Factors Affecting Posology	1.37
1.6.2	Formulae used in Calculations of Pediatric Dose	1.39
	Questions	1.41
UNIT-2: Pharmaceutical Calculations, Powders & Liquid Dosage Forms		2.1 – 2.36
2.1	Pharmaceutical Calculation	2.1
2.2	Calculation of Isotonocity	2.3
2.3	Proof Spirit	2.15
2.4	Powder	2.16
2.4.1	Dusting Powder	2.17
2.4.2	Effervescent Powder	2.17
2.4.3	Dentrifices (Tooth Powder)	2.22
2.4.4	Insufflations	2.23
2.4.5	Snuffs	2.23
2.5	Liquid Dosage Form	2.23
2.5.1	Advantages of Liquid Dosage Forms	2.24
2.5.2	Excipients used in Formulation of Liquid Dosage Forms	2.25
2.6	Solubility	2.32
2.7	Techniques of Solubilization	2.33
	Questions	2.36



Balagani

Dr. BALAGANI PAVAN KUMAR
 M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
 PROFESSOR & PRINCIPAL
 GOKULA KRISHNA COLLEGE OF PHARMACY
 SULLURPET, TIRUPATI Dt. A.P - 524121



9 788196 887568



Navay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



A TEXTBOOK OF PHARMACEUTICS

Ms. P Kavitha, Dr. Balagani Pavan Kumar,
Ms. S K Zoofishaan, Ms. T Swathi




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Textbook of Pharmaceutics

Ms P Kavitha , Dr Balagani Pavan Kumar, Ms S K Zoofishaan,

Ms. T Swathi






Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Contents

UNIT-1 : Historical Background, Dosage Forms, Prescription and Posology		1.1 – 1.42
1.1	History of Pharmacy	1.1
1.2	Pharmacy as a Career	1.3
1.3	Introduction to Pharmacopoeia	1.6
1.3.1	Pharmacopoeia	1.6
1.3.2	Indian Pharmacopoeia	1.7
1.3.3	British Pharmacopoeia	1.9
1.3.4	United State Pharmacopoeia	1.11
1.3.5	Extra Pharmacopoeia	1.12
1.4	Introduction to Pharmaceutical Dosage Form	1.13
1.5	Prescription	1.23
1.5.1	Parts of the Prescription	1.23
1.5.2	Handling of Prescription	1.25
1.5.3	Sources of Errors in Prescriptions	1.27
1.5.4	Abbreviation used in Prescription	1.28
1.6	Posology	1.37
1.6.1	Factors Affecting Posology	1.37
1.6.2	Formulae used in Calculations of Pediatric Dose	1.39
	Questions	1.41
UNIT-2: Pharmaceutical Calculations, Powders & Liquid Dosage Forms		2.1 – 2.36
2.1	Pharmaceutical Calculation	2.1
2.2	Calculation of Isotonocity	2.3
2.3	Proof Spirit	2.15
2.4	Powder	2.16
2.4.1	Dusting Powder	2.17
2.4.2	Effervescent Powder	2.17
2.4.3	Dentifrices (Tooth Powder)	2.22
2.4.4	Insufflations	2.23
2.4.5	Snuffs	2.23
2.5	Liquid Dosage Form	2.23
2.5.1	Advantages of Liquid Dosage Forms	2.24
2.5.2	Excipients used in Formulation of Liquid Dosage Forms	2.25
2.6	Solubility	2.32
2.7	Techniques of Solubilization	2.33
	Questions	2.36




Dr. BALAGANI PAVAN KUMAR
 M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
 PROFESSOR & PRINCIPAL
 GOKULA KRISHNA COLLEGE OF PHARMACY
 SULLURPET, TIRUPATI Dt. A.P - 524121



9 788196 887568





Kavay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Physical Pharmaceutics

Mrs. P K Devi Bala, Ms.P Kavitha, Dr. Balagani Pavan Kumar, Dr. M Soujanya



Kavay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Physical Pharmaceutics

Mrs.P K Devi Bala,Ms.P Kavitha,Dr.Balagani Pavan kumar,
Dr.M Soujanya





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

1. Solubility of Drugs	1.1 - 1.32
1.1 Introduction	1.1
1.2 Solubility Expressions	1.2
1.3 Mechanisms of Solute Solvent Interactions	1.5
1.4 Ideal Solubility Parameters	1.6
1.5 Solvation	1.7
1.6 Association	1.8
1.7 Quantitative Approach to the Factors Influencing Solubility of Drugs	1.9
1.8 Diffusion Principles in Biological Systems	1.11
1.9 Solubility of Gas in Liquids	1.12
1.10 Solubility of Liquids in Liquids	1.14
1.10.1 Binary Solutions	1.14
1.10.2 Ideal Solutions	1.15
1.11 Raoult's Law	1.17
1.12 Real Solutions	1.21
1.13 Partially Miscible Liquids	1.21
1.14 Critical Solution temperature and its Applications	1.22
1.15 Distribution Law	1.26
1.15.1 Limitations of Distribution Law	1.29
1.15.2 Applications of Distribution Law	1.29
• Exercise	1.30
2. States and Properties of Matter and Physicochemical Properties of Drug Molecules	2.1 - 2.78
2.1 States of Matter and Properties of Matter	2.1
2.1.1 States of Matter	2.1
2.1.2 Changes in the State of Matter	2.5
2.1.3 Latent Heat	2.6
2.1.4 Vapour Pressure	2.7
2.1.5 Sublimation	2.11
2.1.6 Critical Point	2.12
2.1.7 Eutectic Mixtures	2.13
2.1.8 Gases	2.14
2.1.9 Aerosols	2.22



Naray

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



9 788196 887513





Kavay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FESS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Physical Pharmaceutics

Mrs. P K Devi Bala, **Ms.P Kavitha**, Dr. Balagani Pavan Kumar, Dr. M Soujanya



M. Soujanya
DR. BALAGANI PAVAN KUMAR
M.B.A., M.C. P.B.S.B., FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
SRI KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P. - 524121

Physical Pharmaceutics

Mrs.P K Devi Bala, Ms.P Kavitha, Dr.Balagani Pavan kumar,
Dr.M Soujanya




Pavan
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

1. Solubility of Drugs	1.1 - 1.32
1.1 Introduction	1.1
1.2 Solubility Expressions	1.2
1.3 Mechanisms of Solute Solvent Interactions	1.5
1.4 Ideal Solubility Parameters	1.6
1.5 Solvation	1.7
1.6 Association	1.8
1.7 Quantitative Approach to the Factors Influencing Solubility of Drugs	1.9
1.8 Diffusion Principles in Biological Systems	1.11
1.9 Solubility of Gas in Liquids	1.12
1.10 Solubility of Liquids in Liquids	1.14
1.10.1 Binary Solutions	1.14
1.10.2 Ideal Solutions	1.15
1.11 Raoult's Law	1.17
1.12 Real Solutions	1.21
1.13 Partially Miscible Liquids	1.21
1.14 Critical Solution temperature and its Applications	1.22
1.15 Distribution Law	1.26
1.15.1 Limitations of Distribution Law	1.29
1.15.2 Applications of Distribution Law	1.29
• Exercise	1.30
2. States and Properties of Matter and Physicochemical Properties of Drug Molecules	2.1 - 2.78
2.1 States of Matter and Properties of Matter	2.1
2.1.1 States of Matter	2.1
2.1.2 Changes in the State of Matter	2.5
2.1.3 Latent Heat	2.6
2.1.4 Vapour Pressure	2.7
2.1.5 Sublimation	2.11
2.1.6 Critical Point	2.12
2.1.7 Eutectic Mixtures	2.13
2.1.8 Gases	2.14
2.1.9 Aerosols	2.22




Dr. BALAGANI PAVAN KUMAR
 M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
 SULLURPET, TIRUPATI Dt. A.P - 524121





Handwritten signature

DR. M. LAGANI PAVAN KUMAR
M.B.B.S., M.D., FRCM, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Physical Pharmaceutics

Mrs. P K Devi Bala, Ms. P Kavitha, **Dr. Balagani Pavan Kumar**, Dr. M Soujanya



Balay
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Physical Pharmaceutics

Mrs.P K Devi Bala,Ms.P Kavitha,**Dr.Balagani Pavan kumar,**
Dr.M Soujanya




A handwritten signature in green ink, appearing to read "Pavan", with a horizontal line underneath.

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

1. Solubility of Drugs	1.1 - 1.32
1.1 Introduction	1.1
1.2 Solubility Expressions	1.2
1.3 Mechanisms of Solute Solvent Interactions	1.5
1.4 Ideal Solubility Parameters	1.6
1.5 Solvation	1.7
1.6 Association	1.8
1.7 Quantitative Approach to the Factors Influencing Solubility of Drugs	1.9
1.8 Diffusion Principles in Biological Systems	1.11
1.9 Solubility of Gas in Liquids	1.12
1.10 Solubility of Liquids in Liquids	1.14
1.10.1 Binary Solutions	1.14
1.10.2 Ideal Solutions	1.15
1.11 Raoult's Law	1.17
1.12 Real Solutions	1.21
1.13 Partially Miscible Liquids	1.21
1.14 Critical Solution temperature and its Applications	1.22
1.15 Distribution Law	1.26
1.15.1 Limitations of Distribution Law	1.29
1.15.2 Applications of Distribution Law	1.29
• Exercise	1.30
2. States and Properties of Matter and Physicochemical Properties of Drug Molecules	2.1 - 2.78
2.1 States of Matter and Properties of Matter	2.1
2.1.1 States of Matter	2.1
2.1.2 Changes in the State of Matter	2.5
2.1.3 Latent Heat	2.6
2.1.4 Vapour Pressure	2.7
2.1.5 Sublimation	2.11
2.1.6 Critical Point	2.12
2.1.7 Eutectic Mixtures	2.13
2.1.8 Gases	2.14
2.1.9 Aerosols	2.22






Dr. BALAGANI PAVAN KUMAR
 M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
 PROFESSOR & PRINCIPAL
 GOKULA KRISHNA COLLEGE OF PHARMACY
 SULLURPET, TIRUPATI Dt. A.P - 524121



[Handwritten Signature]
DR. BALAKRISHNAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCI, MSTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Physical Pharmaceutics

Mrs. P K Devi Bala, Ms.P Kavitha, Dr. Balagani Pavan Kumar, **Dr. M Soujanya**



Moulay
Dr. BALAGANI PAVAN KUMAR
M.Pharm, FIC, FSS, FAGE, FICP, MSTE
PROFESSOR & PRINCIPAL
ANNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Physical Pharmaceutics

Mrs.P K Devi Bala,Ms.P Kavitha,Dr.Balagani Pavan kumar,

Dr.M Soujanya




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



1. Solubility of Drugs	1.1 - 1.32
1.1 Introduction	1.1
1.2 Solubility Expressions	1.2
1.3 Mechanisms of Solute Solvent Interactions	1.5
1.4 Ideal Solubility Parameters	1.6
1.5 Solvation	1.7
1.6 Association	1.8
1.7 Quantitative Approach to the Factors Influencing Solubility of Drugs	1.9
1.8 Diffusion Principles in Biological Systems	1.11
1.9 Solubility of Gas in Liquids	1.12
1.10 Solubility of Liquids in Liquids	1.14
1.10.1 Binary Solutions	1.14
1.10.2 Ideal Solutions	1.15
1.11 Raoult's Law	1.17
1.12 Real Solutions	1.21
1.13 Partially Miscible Liquids	1.21
1.14 Critical Solution temperature and its Applications	1.22
1.15 Distribution Law	1.26
1.15.1 Limitations of Distribution Law	1.29
1.15.2 Applications of Distribution Law	1.29
• Exercise	1.30
2. States and Properties of Matter and Physicochemical Properties of Drug Molecules	2.1 - 2.78
2.1 States of Matter and Properties of Matter	2.1
2.1.1 States of Matter	2.1
2.1.2 Changes in the State of Matter	2.5
2.1.3 Latent Heat	2.6
2.1.4 Vapour Pressure	2.7
2.1.5 Sublimation	2.11
2.1.6 Critical Point	2.12
2.1.7 Eutectic Mixtures	2.13
2.1.8 Gases	2.14
2.1.9 Aerosols	2.22







Dr. BALAGANI PAVAN KUMAR
 M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
 PROFESSOR & PRINCIPAL
 GOKULA KRISHNA COLLEGE OF PHARMACY
 SULLURPET, TIRUPATI Dt. A.P - 524121



DR. BALASANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXT BOOK ON NOVEL DRUG DELIVERY SYSTEMS




Dr. Balagani Pavan Kumar

Mrs. P K Devi Bala

Ms. C B Hanisha

Mr Sivakumar Peta



Kavay
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121


A Text Book on Novel Drug Delivery Systems

**Dr. Balagani Pavan Kumar, Mrs. P.K Devi Bala,
Ms. CB Hanisha, Mr Sivakumar Peta**



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121




A TEXT BOOK ON NOVEL DRUG DELIVERY SYSTEMS



Balagani

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXT BOOK ON NOVEL DRUG DELIVERY SYSTEMS



Dr. Balagani Pavan Kumar
Mrs. P K Devi Bala
Ms. C B Hanisha
Mr Sivakumar Peta



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A Text Book on Novel Drug Delivery Systems

Dr. Balagani Pavan Kumar, Mrs. P. K. Devi Bala,
Ms. CB Hanisha, Mr. Sivakumar Peta



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121




A TEXT BOOK ON NOVEL DRUG DELIVERY SYSTEMS



Navay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXT BOOK ON NOVEL DRUG DELIVERY SYSTEMS



Dr. Balagani Pavan Kumar
Mrs. P K Devi Bala
Ms. C B Hanisha
Mr Sivakumar Peta




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC. FBSS. FAGE. FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121


A Text Book on Novel Drug Delivery Systems

Dr. Balagani Pavan Kumar, Mrs. P.K Devi Bala,
Ms. CB Hanisha, Mr Sivakumar Peta







Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXT BOOK ON NOVEL DRUG DELIVERY SYSTEMS



Navay
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXT BOOK ON NOVEL DRUG DELIVERY SYSTEMS



Dr. Balagani Pavan Kumar
Mrs. P K Devi Bala
Ms. C B Hanisha
Mr. Sivakumar Peta



DR. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121


A Text Book on Novel Drug Delivery Systems

Dr. Balagani Pavan Kumar, Mrs. P.K Devi Bala,
Ms. CB Hanisha, Mr Sivakumar Peta




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A TEXT BOOK ON NOVEL DRUG DELIVERY SYSTEMS



Narayana
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

LIST OF PATENTS GRANTED / PUBLISHED IN THE LAST FIVE YEARS

S.No	Name of the Inventor (s)	Application No	Title of the Patent	Status	Agency to which application is made	Date
1	Dr Balagani Pavan Kumar	383386-001	Portable Electro Spinning Device for Development of Nanofibres	Applied	Intellectual Property India	08-04-2023
2	Dr Balagani Pavan Kumar	2021104266	Enhanced Effectiveness of Meloxicam Through Hydrogel Formulations	Granted	Commissioner of Patents, Australia	25-08-2021
3	Dr Balagani Pavan Kumar	2021104955	Reversible Hydrogel Formulation for Prolonged Antimicrobial Activity	Granted	Commissioner of Patents, Australia	02-11-2021




PRINCIPAL

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

Design Application Details

Application Number:

383386-001

Cbr Number:

204430

Cbr Date:

08/04/2023 22:02:29

Applicant Name:

1. Dr. Sachinkumar Dnyaneshwar Gunjal 2. Dr. Balagani Pavan Kumar 3. Dr. Channabasavaraj. S
4. Bhawana Kapoor 5. Mr. Vishal ramdas tagalpallewar 6. Dr. B.Sree Giri Prasad
7. Dr.Navakanth Raju Ramayanam 8. Dr. Satyanarayan Pattnaik

Design Application Status

Application Status:

Examination Report has been Generated ,Online Reply Document Recived(FER generated on 19/06/2023)

[Back \(/DesignApplicationStatus/\)](#)

Disclaimer: Application status is available for the application filed on or after 1st April 2009 with application no 222230. The information under "Design Application Status" is dynamically retrieved and is under testing, therefore the information retrieved by this system is not valid for any legal proceedings under the Design Act 2000. In case of any discrepancy you may contact the appropriate Patent Office or send your comments to following email IDs:

Design Office, Kolkata : controllerdesign.ipo@nic.in

Controller General of Patents, Designs and Trademarks




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



Australian Government

IP Australia

CERTIFICATE OF GRANT INNOVATION PATENT

Patent number: 2021104955

The Commissioner of Patents has granted the above patent on 2 November 2021, and certifies that the below particulars have been registered in the Register of Patents.

Name and address of patentee(s):

Dr. Balagani Pavan Kumar, Gokula Krishna College of Pharmacy, Sullurpet, SPSR Nellore, Andhra Pradesh, India - 524121

Dr. G. Sridhar Babu, Sri Shivani College of Pharmacy, Doctor's colony, near mulugu road, Warangal, India - 506007

Dr. Bhavani Boddeda, Koringa College of Pharmacy, Korangi, East Godavari, Andhra Pradesh, India

Dr. Manish Kumar Thimmaraju, Balaji Institute of Pharmaceutical Sciences, Narsampet, Warangal, Telangana, India - 508132

Dr. Goje Arjun, Teegala Ram Reddy College of Pharmacy, Hyderabad, Telangana, India

Title of invention:

REVERSIBLE HYDROGEL FORMULATION FOR PROLONGED ANTIMICROBIAL ACTIVITY

Name of inventor(s):

Kumar, Balagani Pavan ; Babu, G. Sridhar ; Boddeda, Bhavani ; Thimmaraju, Manish Kumar ; Arjun, Goje

Term of Patent:


Eight years from 5 August 2021

NOTE: This Innovation Patent cannot be enforced unless and until it has been examined by the Commissioner of Patents and a Certificate of Examination has been issued. See sections 120(1A) and 129A of the Patents Act 1990, set out on the reverse of this document.

Dated this 2nd day of November 2021

Commissioner of Patents




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121

PATENTS ACT 1990





Australian Government

IP Australia

CERTIFICATE OF GRANT INNOVATION PATENT

Patent number: 2021104266

The Commissioner of Patents has granted the above patent on 25 August 2021, and certifies that the below particulars have been registered in the Register of Patents.

Name and address of patentee(s):

Manish Kumar Thimmaraju of Balaji Institute of Pharmaceutical Sciences, Narsampet Warangal Telangana 506132 India

G Sridhar Babu of Sri Shivani College of Pharmacy, Doctor's colony. Near Mulugu road Warangal Telangana 506007 India

Balagani Pavan Kumar of Gokula Krishna College of Pharmacy, Sullurpet SPSR Nellore Andhra Pradesh 524121 India

Deepak Kumar of Ranchi College of Pharmacy, Kute ToliTetri, Namkum Ranchi Jharkhand 834010 India

Goje Arjun of Teegala Ram Reddy College of Pharmacy Hyderabad Telangana India

Title of invention:

ENHANCED EFFECTIVENESS OF MELOXICAM THROUGH HYDROGEL FORMULATIONS

Name of inventor(s):

Thimmaraju, Manish Kumar; Babu, G. Sridhar; Kumar, Balagani Pavan; Kumar, Deepak and Arjun, Goje

Term of Patent:

Eight years from 17 July 2021

NOTE: This Innovation Patent cannot be enforced unless and until it has been examined by the Commissioner of Patents and a Certificate of Examination has been issued. See sections 120(1A) and 129A of the Patents Act 1990, set out on the reverse of this document.



Dr. **BALAGANI PAVAN KUMAR**
Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

Dated this 25th day of August 2021

Commissioner of Patents

PATENTS ACT 1990





GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

NO. OF RESEARCH PAPERS PUBLISHED PER TEACHER IN THE JOURNALS NOTIFIED ON UGC CARE LIST DURING THE LAST FIVE YEARS

CALENDER YEAR - 2022

S.No	Title of the Paper	Name of the Author/s	Name of the Journal	ISSN No
1	Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system	Mrs B Swathi	International Journal of Gender, Science and Technology	2040-0748
2	Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system	Mrs P Kavitha	International Journal of Gender, Science and Technology	2040-0748
3	Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system	Mrs CH Harika	International Journal of Gender, Science and Technology	2040-0748
4	Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system	Mr Y Naveen Kumar	International Journal of Gender, Science and Technology	2040-0748
5	Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system	Mr.AVLS Ramakrishna	International Journal of Gender, Science and Technology,	2040-0748
6	Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells	Dr.Balagani Pavan Kumar	Indo-American Journal of Pharma and Bio science	2347-2251



Naveen

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

7	Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer	Mr.M.Kalyan babu	Indo-American Journal of Pharma and Bio science	2347-2251
8	Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer	Mr.N.Praveenkumar	Indo-American Journal of Pharma and Bio science	2347-2251
9	A Study on Synthesis and Characterization of some Novel Quinazolinones.	P.Sivakumar	European Journal of Biomedical and Pharmaceutical Sciences	2349-8870
10	Pharmacokinetic Variability in Pediatrics and Intensive care / towards a personalized dosing approach	Mrs D Kalyani	Indo-American Journal of pharma and Bio science	2347-2251
11	Pharmacokinetic Variability in Pediatrics and Intensive care / towards a personalized dosing approach	Ms A R Sridevi	Indo-American Journal of pharma and Bio science	2347-2251
12	Pharmacokinetic Variability in Pediatrics and Intensive care / towards a personalized dosing approach	Mrs P Sukanya	Indo-American Journal of pharma and Bio science	2347-2251
13	Pharmacokinetic Variability in Pediatrics and Intensive care / towards a personalized dosing approach	Mrs A Aksa anvija	Indo-American Journal of pharma and Bio science	2347-2251
14	Pharmacokinetic Variability in Pediatrics and Intensive care / towards a personalized dosing approach	Mr C G Bhaskar	Indo-American Journal of pharma and Bio science	2347-2251
15	How Solvents Affect the Rate of Polymorphic Transformation in Polymorph Screening	Mrs D Kalyani	History of Medicine studies	1300-669



Narayana

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

16	How Solvents Affect the Rate of Polymorphic Transformation in Polymorph Screening	Mrs T Swathi	History of Medicine studies	1300-669
17	How Solvents Affect the Rate of Polymorphic Transformation in Polymorph Screening	Mrs P Sukanya	History of Medicine studies	1300-669
18	How Solvents Affect the Rate of Polymorphic Transformation in Polymorph Screening	Mrs CH Harika	History of Medicine studies	1300-669
19	How Solvents Affect the Rate of Polymorphic Transformation in Polymorph Screening	Mrs K Vanitha Devi	History of Medicine studies	1300-669
20	The Sensitive Method of Subvisible Particle Counting for the Detection and Quantification of Monoclonal Antibody Aggregation Caused by Freeze-Thawing: New Understanding of Particle Function in the Protein Aggregation Process	Mrs N Sukanya	History of Medicine studies	1300-669
21	The Sensitive Method of Subvisible Particle Counting for the Detection and Quantification of Monoclonal Antibody Aggregation Caused by Freeze-Thawing: New Understanding of Particle Function in the Protein Aggregation Process	Mrs P K Devibala	History of Medicine studies	1300-669
22	The Sensitive Method of Subvisible Particle Counting for the Detection and Quantification of Monoclonal Antibody Aggregation Caused by Freeze-Thawing: New Understanding of Particle Function in the Protein Aggregation Process	Ms.SK Zoofishaan	History of Medicine studies	1300-669



Navay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

23	The Sensitive Method of Subvisible Particle Counting for the Detection and Quantification of Monoclonal Antibody Aggregation Caused by Freeze-Thawing: New Understanding of Particle Function in the Protein Aggregation Process	Mr.M R Pavan Kumar	History of Medicine studies	1300-669
24	The Sensitive Method of Subvisible Particle Counting for the Detection and Quantification of Monoclonal Antibody Aggregation Caused by Freeze-Thawing: New Understanding of Particle Function in the Protein Aggregation Process	Mr S Sivakoteswa Rao	History of Medicine studies	1300-669
25	Cytotoxic Compounds from Kibataliagitingensis Woodson (Elm.)	Dr.P Kishor	International Journal of Gender, Science and Technology	2040-0748
26	Cytotoxic Compounds from Kibataliagitingensis Woodson (Elm.)	Mr.Sivakumar Peta	International Journal of Gender, Science and Technology	2040-0748
27	Cytotoxic Compounds from Kibataliagitingensis Woodson (Elm.)	Dr.M Soujanya	International Journal of Gender, Science and Technology	2040-0748
28	Cytotoxic Compounds from Kibataliagitingensis Woodson (Elm.)	Mrs S Usha Rani	International Journal of Gender, Science and Technology	2040-0748
29	Cytotoxic Compounds from Kibataliagitingensis Woodson (Elm.)	Mrs Vanitha Devi	International Journal of Gender, Science and Technology	2040-0748
30	Development and Standardization of a Polyherbal Anti-Urolithiatic Suspension	Pallepati Kishor	Future Journal of Pharmaceutical and Health Sciences	2583-116X



Navay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

31	Development and Standardization of a Polyherbal Anti-Urolithiatic Suspension	Pallepati Kavitha	Future Journal of Pharmaceutical and Health Sciences	2583-116X
32	Development and Standardization of a Polyherbal Anti-Urolithiatic Suspension	Sivakumar Peta	Future Journal of Pharmaceutical and Health Sciences	2583-116X

PRINCIPAL



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system

Mrs B Swathi, Mrs P Kavitha, Mrs CH Harika, Mr Y Naveen Kumar, Mr. AVLS Ramakrishna
Department of Pharmaceutical analysis

Email ID: swathi.nrnppharma@gmail.com, Mobile no: 7095658810

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

Unauthorized persons run the risk of abusing unused pharmaceuticals, which may lead to significant injury. In order to keep people safe and keep the environment free of any dangers, the Food and Drug Administration (FDA) recommends that people properly dispose of any unwanted prescription medicine. Unfortunately, safety is an issue that is overlooked by many of the present disposal methods. Granular activated carbon, when added to a drug disposal pouch, provides a novel, easy, and safe way to dispose of unused or expired medicine. We examined the disposal system's deactivation effectiveness and developed a robust and verified technique for methylphenidate hydrochloride and loxapine succinate using high-performance liquid chromatography (HPLC). A C18 analytical column with the following dimensions: 250 mm × 4.60 mm and 100Å, was used to evaluate methylphenidate hydrochloride. The mobile phase consisted of acetonitrile-water with 0.05% (v/v) trifluoroacetic acid, and the flow rate was

1.5 mL/min, with a 15-minute run and a 7.8-minute retention period. Using a flow rate of 1.0 mL/min, loxapine succinate was isolated on a C8 100Å column (250 mm × 4.6 mm, 5 mm) that was kept at 25 °C. The medication had a retention duration of around 4.6 minutes, and the run time was 10 minutes. At a pH of 3.0, the mobile phase consisted of 40:60 (v/v) acetonitrile and water with 0.3% triethylamine. Both medications were dissolved in mobile phases to create reference standard solutions with a concentration of 100 mg/mL. Over the concentration range of 5-100 mg/mL for methylphenidate hydrochloride and 0.1-100 mg/mL for loxapine succinate, these techniques exhibit acceptable linearity ($R^2 \geq 0.999$). Research on the inactivation of these medications made good use of the test methodologies. Xi'an Jiaotong University, 2018. This website is created and hosted by Elsevier B.V. An open access paper published in accordance with the

1. Introduction

A major issue now is how to properly dispose of leftover prescription drugs. Accidental exposure, purposeful use or misuse, or both might result from storing undesired or outdated pharmaceuticals. There are social and economic

ramifications to the public health problem of the possibility of abuse and addiction to prescriptive pharmaceuticals, even those used to treat pain. Heroin addiction affected 591,000 people in 2015, and over 33,000 people died from opioid overdoses or drug misuse disorders associated with prescription opioid painkillers [1,2]. Medication is a lifesaver when it comes to alleviating acute and severe chronic pain, but it may have disastrous consequences when prescribed excessively or without proper safety measures. The National Survey on Drug Use and Health found that after five years of non-medical prescription painkiller usage, less than 4% of individuals began using heroin [1]. Therefore, it is important to dispose of prescription medicine correctly. The disposal of two psychoactive drugs, loxapine succinate and methylphenidate hydrochloride (MPH), was the primary focus of the current investigation. By activating the neurological system, the popular prescription medicine MPH influences the brain's dopamine balance, making it an effective treatment for attention-deficit hyperactivity disorder (ADHD) [3]. When administered intranasally, MPH has a pharmacological effect comparable to cocaine, resulting in a fast release of dopamine [4]. Like morphine, it has the potential to create serious physiological dependency and is hence classified as a Schedule I federally-controlled narcotic, due to its significant abuse potential. Because of its very satisfying euphoric effect, MPH is highly addictive [5]. Loxapine succinate is another medicine with abuse potential. For schizophrenia, doctors prescribe this medicine, which is a tricyclic antipsychotic. To control the thoughts, feelings, and behaviors often associated with schizophrenia, loxapine succinate is administered by inhibiting the activity of dopamine. The misuse of loxapine succinate is possible since it is used for the management of schizophrenia and only gives short relief [6]. There is a higher risk of misuse for these medicines because of how often they are given.

Given the considerable misuse potential of MPH and loxapine succinate, we aimed to explore their deactivation profile via the drug disposal system. Also investigated was the analytical accuracy of the developed technique for both medications. There aren't many analytical procedures for loxapine succinate [9] and MPH [7,8] published in the



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system

Mrs B Swathi, Mrs P Kavitha, Mrs CH Harika, Mr Y Naveen Kumar, Mr. AVLS Ramakrishna
Department of Pharmaceutical analysis

Email ID: swathi.nrnppharma@gmail.com, Mobile no: 7095658810

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

Unauthorized persons run the risk of abusing unused pharmaceuticals, which may lead to significant injury. In order to keep people safe and keep the environment free of any dangers, the Food and Drug Administration (FDA) recommends that people properly dispose of any unwanted prescription medicine. Unfortunately, safety is an issue that is overlooked by many of the present disposal methods. Granular activated carbon, when added to a drug disposal pouch, provides a novel, easy, and safe way to dispose of unused or expired medicine. We examined the disposal system's deactivation effectiveness and developed a robust and verified technique for methylphenidate hydrochloride and loxapine succinate using high-performance liquid chromatography (HPLC). A C18 analytical column with the following dimensions: 250 mm × 4.60 mm and 100Å, was used to evaluate methylphenidate hydrochloride. The mobile phase consisted of acetonitrile-water with 0.05% (v/v) trifluoroacetic acid, and the flow rate was

1.5 mL/min, with a 15-minute run and a 7.8-minute retention period. Using a flow rate of 1.0 mL/min, loxapine succinate was isolated on a C8 100Å column (250 mm × 4.6 mm, 5 mm) that was kept at 25 °C. The medication had a retention duration of around 4.6 minutes, and the run time was 10 minutes. At a pH of 3.0, the mobile phase consisted of 40:60 (v/v) acetonitrile and water with 0.3% triethylamine. Both medications were dissolved in mobile phases to create reference standard solutions with a concentration of 100 mg/mL. Over the concentration range of 5-100 mg/mL for methylphenidate hydrochloride and 0.1-100 mg/mL for loxapine succinate, these techniques exhibit acceptable linearity ($R^2 \geq 0.999$). Research on the inactivation of these medications made good use of the test methodologies. Xi'an Jiaotong University, 2018. This website is created and hosted by Elsevier B.V. An open access paper published in accordance with the

1. Introduction

A major issue now is how to properly dispose of leftover prescription drugs. Accidental exposure, purposeful use or misuse, or both might result from storing undesired or outdated pharmaceuticals. There are social and economic

ramifications to the public health problem of the possibility of abuse and addiction to prescription pharmaceuticals, even those used to treat pain. Heroin addiction affected 591,000 people in 2015, and over 33,000 people died from opioid overdoses or drug misuse disorders associated with prescription opioid painkillers [1,2]. Medication is a lifesaver when it comes to alleviating acute and severe chronic pain, but it may have disastrous consequences when prescribed excessively or without proper safety measures. The National Survey on Drug Use and Health found that after five years of non-medical prescription painkiller usage, less than 4% of individuals began using heroin [1]. Therefore, it is important to dispose of prescription medicine correctly. The disposal of two psychoactive drugs, loxapine succinate and methylphenidate hydrochloride (MPH), was the primary focus of the current investigation. By activating the neurological system, the popular prescription medicine MPH influences the brain's dopamine balance, making it an effective treatment for attention-deficit hyperactivity disorder (ADHD) [3]. When administered intranasally, MPH has a pharmacological effect comparable to cocaine, resulting in a fast release of dopamine [4]. Like morphine, it has the potential to create serious physiological dependency and is hence classified as a Schedule I federally-controlled narcotic, due to its significant abuse potential. Because of its very satisfying euphoric effect, MPH is highly addictive [5]. Loxapine succinate is another medicine with abuse potential. For schizophrenia, doctors prescribe this medicine, which is a tricyclic antipsychotic. To control the thoughts, feelings, and behaviors often associated with schizophrenia, loxapine succinate is administered by inhibiting the activity of dopamine. The misuse of loxapine succinate is possible since it is used for the management of schizophrenia and only gives short relief [6]. There is a higher risk of misuse for these medicines because of how often they are given.

Given the considerable misuse potential of MPH and loxapine succinate, we aimed to explore their deactivation profile via the drug disposal system. Also investigated was the analytical accuracy of the developed technique for both medications. There aren't many analytical procedures for loxapine succinate [9] and MPH [7,8] published in the



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system

Mrs B Swathi ,Mrs P Kavitha, Mrs CH Harika, Mr Y Naveen Kumar ,Mr.AVLS Ramakrishna
Department of Pharmaceutical analysis

Email ID: swathi.nrnppharma@gmail.com, Mobile no: 7095658810

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

Unauthorized persons run the risk of abusing unused pharmaceuticals, which may lead to significant injury. In order to keep people safe and keep the environment free of any dangers, the Food and Drug Administration (FDA) recommends that people properly dispose of any unwanted prescription medicine. Unfortunately, safety is an issue that is overlooked by many of the present disposal methods. Granular activated carbon, when added to a drug disposal pouch, provides a novel, easy, and safe way to dispose of unused or expired medicine. We examined the disposal system's deactivation effectiveness and developed a robust and verified technique for methylphenidate hydrochloride and loxapine succinate using high-performance liquid chromatography (HPLC). A C18 analytical column with the following dimensions: 250 mm × 4.60 mm and 100Å, was used to evaluate methylphenidate hydrochloride. The mobile phase consisted of acetonitrile-water with 0.05% (v/v) trifluoroacetic acid, and the flow rate was

1.5 mL/min, with a 15-minute run and a 7.8-minute retention period. Using a flow rate of 1.0 mL/min, loxapine succinate was isolated on a C8 100Å column (250 mm × 4.6 mm, 5 mm) that was kept at 25 °C. The medication had a retention duration of around 4.6 minutes, and the run time was 10 minutes. At a pH of 3.0, the mobile phase consisted of 40:60 (v/v) acetonitrile and water with 0.3% triethylamine. Both medications were dissolved in mobile phases to create reference standard solutions with a concentration of 100 mg/mL. Over the concentration range of 5-100 mg/mL for methylphenidate hydrochloride and 0.1-100 mg/mL for loxapine succinate, these techniques exhibit acceptable linearity ($R^2 \geq 0.999$). Research on the inactivation of these medications made good use of the test methodologies. Xi'an Jiaotong University, 2018. This website is created and hosted by Elsevier B.V. An open access paper published in accordance with the

1. Introduction

A major issue now is how to properly dispose of leftover prescription drugs. Accidental exposure, purposeful use or misuse, or both might result from storing undesired or outdated pharmaceuticals. There are social and economic

ramifications to the public health problem of the possibility of abuse and addiction to prescriptive pharmaceuticals, even those used to treat pain. Heroin addiction affected 591,000 people in 2015, and over 33,000 people died from opioid overdoses or drug misuse disorders associated with prescription opioid painkillers [1,2]. Medication is a lifesaver when it comes to alleviating acute and severe chronic pain, but it may have disastrous consequences when prescribed excessively or without proper safety measures. The National Survey on Drug Use and Health found that after five years of non-medical prescription painkiller usage, less than 4% of individuals began using heroin [1]. Therefore, it is important to dispose of prescription medicine correctly. The disposal of two psychoactive drugs, loxapine succinate and methylphenidate hydrochloride (MPH), was the primary focus of the current investigation. By activating the neurological system, the popular prescription medicine MPH influences the brain's dopamine balance, making it an effective treatment for attention-deficit hyperactivity disorder (ADHD) [3]. When administered intranasally, MPH has a pharmacological effect comparable to cocaine, resulting in a fast release of dopamine [4]. Like morphine, it has the potential to create serious physiological dependency and is hence classified as a Schedule I federally-controlled narcotic, due to its significant abuse potential. Because of its very satisfying euphoric effect, MPH is highly addictive [5]. Loxapine succinate is another medicine with abuse potential. For schizophrenia, doctors prescribe this medicine, which is a tricyclic antipsychotic. To control the thoughts, feelings, and behaviors often associated with schizophrenia, loxapine succinate is administered by inhibiting the activity of dopamine. The misuse of loxapine succinate is possible since it is used for the management of schizophrenia and only gives short relief [6]. There is a higher risk of misuse for these medicines because of how often they are given.

Given the considerable misuse potential of MPH and loxapine succinate, we aimed to explore their deactivation profile via the drug disposal system. Also investigated was the analytical accuracy of the developed technique for both medications. There aren't many analytical procedures for loxapine succinate [9] and MPH [7,8] published in the



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL.A.P - 524121

Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system

Mrs B Swathi, Mrs P Kavitha, Mrs CH Harika, Mr Y Naveen Kumar, Mr. AVLS Ramakrishna

Department of Pharmaceutical analysis

Email ID: swathi.nrnppharma@gmail.com, Mobile no: 7095658810

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

Unauthorized persons run the risk of abusing unused pharmaceuticals, which may lead to significant injury. In order to keep people safe and keep the environment free of any dangers, the Food and Drug Administration (FDA) recommends that people properly dispose of any unwanted prescription medicine. Unfortunately, safety is an issue that is overlooked by many of the present disposal methods. Granular activated carbon, when added to a drug disposal pouch, provides a novel, easy, and safe way to dispose of unused or expired medicine. We examined the disposal system's deactivation effectiveness and developed a robust and verified technique for methylphenidate hydrochloride and loxapine succinate using high-performance liquid chromatography (HPLC). A C18 analytical column with the following dimensions: 250 mm × 4.60 mm and 100Å, was used to evaluate methylphenidate hydrochloride. The mobile phase consisted of acetonitrile-water with 0.05% (v/v) trifluoroacetic acid, and the flow rate was

1.5 mL/min, with a 15-minute run and a 7.8-minute retention period. Using a flow rate of 1.0 mL/min, loxapine succinate was isolated on a C8 100Å column (250 mm × 4.6 mm, 5 mm) that was kept at 25 °C. The medication had a retention duration of around 4.6 minutes, and the run time was 10 minutes. At a pH of 3.0, the mobile phase consisted of 40:60 (v/v) acetonitrile and water with 0.3% triethylamine. Both medications were dissolved in mobile phases to create reference standard solutions with a concentration of 100 mg/mL. Over the concentration range of 5-100 mg/mL for methylphenidate hydrochloride and 0.1-100 mg/mL for loxapine succinate, these techniques exhibit acceptable linearity ($R^2 \geq 0.999$). Research on the inactivation of these medications made good use of the test methodologies. Xi'an Jiaotong University, 2018. This website is created and hosted by Elsevier B.V. An open access paper published in accordance with the

1. Introduction

A major issue now is how to properly dispose of leftover prescription drugs. Accidental exposure, purposeful use or misuse, or both might result from storing undesired or outdated pharmaceuticals. There are social and economic

ramifications to the public health problem of the possibility of abuse and addiction to prescriptive pharmaceuticals, even those used to treat pain. Heroin addiction affected 591,000 people in 2015, and over 33,000 people died from opioid overdoses or drug misuse disorders associated with prescription opioid painkillers [1,2]. Medication is a lifesaver when it comes to alleviating acute and severe chronic pain, but it may have disastrous consequences when prescribed excessively or without proper safety measures. The National Survey on Drug Usage and Health found that after five years of non-medical prescription painkiller usage, less than 4% of individuals began using heroin [1]. Therefore, it is important to dispose of prescription medicine correctly. The disposal of two psychoactive drugs, loxapine succinate and methylphenidate hydrochloride (MPH), was the primary focus of the current investigation. By activating the neurological system, the popular prescription medicine MPH influences the brain's dopamine balance, making it an effective treatment for attention-deficit hyperactivity disorder (ADHD) [3]. When administered intranasally MPH has a pharmacological effect comparable to cocaine resulting in a fast release of dopamine [4]. Like morphine it has the potential to create serious physiological dependency and is hence classified as a Schedule II federally-controlled narcotic, due to its significant abuse potential. Because of its very satisfying euphoric effects MPH is highly addictive [5]. Loxapine succinate is another medicine with abuse potential. For schizophrenia, doctors prescribe this medicine, which is a tricyclic antipsychotic. To control the thoughts, feelings, and behaviors often associated with schizophrenia, loxapine succinate is administered by inhibiting the activity of dopamine. The misuse of loxapine succinate is possible, since it is used for the management of schizophrenia and only gives short relief [6]. There is a higher risk of misuse for these medicines because of how often they are given.

Given the considerable misuse potential of MPH and loxapine succinate, we aimed to explore their deactivation profile via the drug disposal system. Also investigated was the analytical accuracy of the developed technique for both medications. There aren't many analytical procedures for loxapine succinate [9] and MPH [7,8] published in the



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system

Mrs B Swathi ,Mrs P Kavitha,Mrs CH Harika,Mr Y Naveen Kumar ,Mr.AVLS Ramakrishna

Department of Pharmaceutical analysis

Email ID: swathi.nrnppharma@gmail.com, Mobile no:7095658810

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

Unauthorized persons run the risk of abusing unused pharmaceuticals, which may lead to significant injury. In order to keep people safe and keep the environment free of any dangers, the Food and Drug Administration (FDA) recommends that people properly dispose of any unwanted prescription medicine. Unfortunately, safety is an issue that is overlooked by many of the present disposal methods. Granular activated carbon, when added to a drug disposal pouch, provides a novel, easy, and safe way to dispose of unused or expired medicine. We examined the disposal system's deactivation effectiveness and developed a robust and verified technique for methylphenidate hydrochloride and loxapine succinate using high-performance liquid chromatography (HPLC). A C18 analytical column with the following dimensions: 250 mm × 4.60 mm and 100Å, was used to evaluate methylphenidate hydrochloride. The mobile phase consisted of acetonitrile-water with 0.05% (v/v) trifluoroacetic acid, and the flow rate was

1.5 mL/min, with a 15-minute run and a 7.8-minute retention period. Using a flow rate of 1.0 mL/min, loxapine succinate was isolated on a C8 100Å column (250 mm × 4.6 mm, 5 mm) that was kept at 25 °C. The medication had a retention duration of around 4.6 minutes, and the run time was 10 minutes. At a pH of 3.0, the mobile phase consisted of 40:60 (v/v) acetonitrile and water with 0.3% triethylamine. Both medications were dissolved in mobile phases to create reference standard solutions with a concentration of 100 mg/mL. Over the concentration range of 5-100 mg/mL for methylphenidate hydrochloride and 0.1-100 mg/mL for loxapine succinate, these techniques exhibit acceptable linearity ($R^2 \geq 0.999$). Research on the inactivation of these medications made good use of the test methodologies. Xi'an Jiaotong University, 2018. This website is created and hosted by Elsevier B.V. An open access paper published in accordance with the

1. Introduction

A major issue now is how to properly dispose of leftover prescription drugs. Accidental exposure, purposeful use or misuse, or both might result from storing undesired or outdated pharmaceuticals. There are social and economic

ramifications to the public health problem of the possibility of abuse and addiction to prescription pharmaceuticals, even those used to treat pain. Heroin addiction affected 591,000 people in 2015, and over 33,000 people died from opioid overdoses or drug misuse disorders associated with prescription opioid painkillers [1,2]. Medication is a lifesaver when it comes to alleviating acute and severe chronic pain, but it may have disastrous consequences when prescribed excessively or without proper safety measures. The National Survey on Drug Usage and Health found that after five years of non-medical prescription painkiller usage, less than 4% of individuals began using heroin [1]. Therefore, it is important to dispose of prescription medicine correctly. The disposal of two psychoactive drugs, loxapine succinate and methylphenidate hydrochloride (MPH), was the primary focus of the current investigation. By activating the neurological system, the popular prescription medicine MPH influences the brain's dopamine balance, making it an effective treatment for attention-deficit hyperactivity disorder (ADHD) [3]. When administered intranasally, MPH has a pharmacological effect comparable to cocaine, resulting in a fast release of dopamine [4]. Like morphine, it has the potential to create serious physiological dependency and is hence classified as a Schedule II, federally-controlled narcotic, due to its significant abuse potential. Because of its very satisfying euphoric effects, MPH is highly addictive [5]. Loxapine succinate is another medicine with abuse potential. For schizophrenia, doctors prescribe this medicine, which is a tricyclic antipsychotic. To control the thoughts, feelings, and behaviors often associated with schizophrenia, loxapine succinate is administered by inhibiting the activity of dopamine. The misuse of loxapine succinate is possible since it is used for the management of schizophrenia and only gives short relief [6]. There is a higher risk of misuse for these medicines because of how often they are given.

Given the considerable misuse potential of MPH and loxapine succinate, we aimed to explore their deactivation profile via the drug disposal system. Also investigated was the analytical accuracy of the developed technique for both medications. There aren't many analytical procedures for loxapine succinate [9] and MPH [7,8] published in the




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com

editor@iajpb.com



Dr. BALAGAN PAVAN KUMAR
M. Pharm, Ph.D, FIC, FNS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells

Dr. Balagani Pavan Kumar, Mr. M. Kalyan babu, Mr. N. Praveenkumar

ABSTRACT

The lack of efficient and cost-effective methods for gene delivery has significantly hindered the applications of gene therapy. In this paper, a simple one step and cost effective salting-out method has been explored to fabricate silk-PEI nanoparticles (SPPs) and magnetic-silk/PEI core-shell nanoparticles (MSPPs) for targeted delivery of c-myc antisense oligodeoxynucleotides (ODNs) into MDA-MB-231 breast cancer cells. The size and zeta potential of the particles were controlled by adjusting the amount of silk fibroin in particle synthesis. Lower surface charges and reduced cytotoxicity were achieved for MSPPs compared with PEI coated magnetic nanoparticles (MPPs). Both SPPs and MSPPs were capable of delivering the ODNs into MDA-MB-231 cells and significantly inhibited the cell growth. Through magnetofection, high ODN uptake efficiencies (over 70%) were achieved within 20 min using MSPPs as carriers, exhibiting a significantly enhanced uptake effect compared to the same carriers via non-magnetofection. Both SPPs and MSPPs exhibited a significantly higher inhibition effect against MDA-MB-231 breast cancer cells compared to human dermal fibroblast (HDF) cells. Targeted ODN delivery was achieved using MSPPs with the help of a magnet, making them promising candidates for targeted gene therapy applications.

Keywords: Silk PEI Magnetic nanoparticles Gene delivery Cancer ODN Magnetofection

1. Introduction

Gene therapy has shown great potential for the treatment of many diseases (Zhao et al., 2007; Zhang et al., 2014; Zhang et al., 2016). Efficient gene therapy requires the delivery of genes to the cell nucleus or cytoplasm replacing or regulating the defective genes (Zhang et al., 2014). However, several intracellular barriers such as the cell membrane and endosome membrane have significantly reduced its efficiency (De Smedt et al., 2005; Pack et al., 2005). Therefore, carriers are needed to help the gene delivery (Zhang et al., 2014). Efficient and cost-effective carriers are particularly desired for clinical applications.

Due to the potential toxicity and immunogenicity concerns of viral systems (El-Aneed, 2004; Plank et al., 2003; Lungwitz et al., 2005), non-viral gene delivery systems have been explored as an

alternative method for gene therapy (Lungwitz et al., 2005; Zhang et al., 2014;

Zhang et al., 2016). The advantages of non-viral systems include low cost, ease of fabrication and modification, and high *in vivo* stability (Zhang et al., 2016). One of the most efficient and cost-effective agents is polyethyleneimine (PEI) (Lungwitz et al., 2005; Dey et al., 2011; Xiang et al., 2007; Forrest et al., 2003; Seow et al., 2013). Once mixed with DNAs, PEI is able to condense DNAs into nano complexes that are suitable for the cell internalization through endocytosis (Zhang et al., 2014; Wang et al., 2009). In addition, PEI is able to destabilize the endosomal membrane by the 'proton sponge effect' to protect DNAs

Department of pharmaceuticals,

Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
 M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
 PROFESSOR & PRINCIPAL
 GOKULA KRISHNA COLLEGE OF PHARMACY
 SULLURPET, TIRUPATI DL.A.P - 524121



ISSN : 2347-2251
**Indo-American Journal of
Pharma and Bio Sciences**



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com



[Signature]
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells

Dr. Balagani Pavan Kumar, Mr. M. Kalyan babu, Mr. N. Praveenkumar

ABSTRACT

The lack of efficient and cost-effective methods for gene delivery has significantly hindered the applications of gene therapy. In this paper, a simple one step and cost effective salting-out method has been explored to fabricate silk-PEI nanoparticles (SPPs) and magnetic-silk/PEI core-shell nanoparticles (MSPPs) for targeted delivery of c-myc antisense oligodeoxynucleotides (ODNs) into MDA-MB-231 breast cancer cells. The size and zeta potential of the particles were controlled by adjusting the amount of silk fibroin in particle synthesis. Lower surface charges and reduced cytotoxicity were achieved for MSPPs compared with PEI coated magnetic nanoparticles (MPPs). Both SPPs and MSPPs were capable of delivering the ODNs into MDA-MB-231 cells and significantly inhibited the cell growth. Through magnetofection, high ODN uptake efficiencies (over 70%) were achieved within 20 min using MSPPs as carriers, exhibiting a significantly enhanced uptake effect compared to the same carriers via non-magnetofection. Both SPPs and MSPPs exhibited a significantly higher inhibition effect against MDA-MB-231 breast cancer cells compared to human dermal fibroblast (HDF) cells. Targeted ODN delivery was achieved using MSPPs with the help of a magnet, making them promising candidates for targeted gene therapy applications.

Keywords: Silk PEI Magnetic nanoparticles Gene delivery Cancer ODN Magnetofection

1. Introduction

Gene therapy has shown great potential for the treatment of many diseases (Zhao et al., 2007; Zhang et al., 2014; Zhang et al., 2016). Efficient gene therapy requires the delivery of genes to the cell nucleus or cytoplasm replacing or regulating the defective genes (Zhang et al., 2014). However, several intracellular barriers such as the cell membrane and endosome membrane have significantly reduced its efficiency (De Smedt et al., 2005; Pack et al., 2005). Therefore, carriers are needed to help the gene delivery (Zhang et al., 2014). Efficient and cost-effective carriers are particularly desired for clinical applications.

Due to the potential toxicity and immunogenicity concerns of viral systems (El-Aneed, 2004; Plank et al., 2003; Lungwitz et al., 2005), non-viral gene delivery systems have been explored as an

alternative method for gene therapy (Lungwitz et al., 2005; Zhang et al., 2014;

Zhang et al., 2016). The advantages of non-viral systems include low cost, ease of fabrication and modification, and high *in vivo* stability (Zhang et al., 2016). One of the most efficient and cost-effective agents is polyethyleneimine (PEI) (Lungwitz et al., 2005; Dey et al., 2011; Xiang et al., 2007; Forrest et al., 2003; Seow et al., 2013). Once mixed with DNAs, PEI is able to condense DNAs into nano complexes that are suitable for the cell internalization through endocytosis (Zhang et al., 2014; Wang et al., 2009). In addition, PEI is able to destabilize the endosomal membrane by the 'proton sponge effect' to protect DNAs

Department of pharmaceuticals,

Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380

GOKULA KRISHNA COLLEGE OF PHARMACY



Dr. BALAGANI PAVAN KUMAR

M. Pharm, Ph D, FIC, FESS, FAGE, FICCP, MISTE

PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY

SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347-2251
**Indo-American Journal of
Pharma and Bio Sciences**



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, F855, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells

Dr. Balagani Pavan Kumar, Mr. M. Kalyan babu, Mr. N. Praveenkumar

ABSTRACT

The lack of efficient and cost-effective methods for gene delivery has significantly hindered the applications of gene therapy. In this paper, a simple one step and cost effective salting-out method has been explored to fabricate silk-PEI nanoparticles (SPPs) and magnetic-silk/PEI core-shell nanoparticles (MSPPs) for targeted delivery of c-myc antisense oligodeoxynucleotides (ODNs) into MDA-MB-231 breast cancer cells. The size and zeta potential of the particles were controlled by adjusting the amount of silk fibroin in particle synthesis. Lower surface charges and reduced cytotoxicity were achieved for MSPPs compared with PEI coated magnetic nanoparticles (MPPs). Both SPPs and MSPPs were capable of delivering the ODNs into MDA-MB-231 cells and significantly inhibited the cell growth. Through magnetofection, high ODN uptake efficiencies (over 70%) were achieved within 20 min using MSPPs as carriers, exhibiting a significantly enhanced uptake effect compared to the same carriers via non-magnetofection. Both SPPs and MSPPs exhibited a significantly higher inhibition effect against MDA-MB-231 breast cancer cells compared to human dermal fibroblast (HDF) cells. Targeted ODN delivery was achieved using MSPPs with the help of a magnet, making them promising candidates for targeted gene therapy applications.

Keywords: Silk PEI Magnetic nanoparticles Gene delivery Cancer ODN Magnetofection

1. Introduction

Gene therapy has shown great potential for the treatment of many diseases (Zhao et al., 2007; Zhang et al., 2014; Zhang et al., 2016). Efficient gene therapy requires the delivery of genes to the cell nucleus or cytoplasm replacing or regulating the defective genes (Zhang et al., 2014). However, several intracellular barriers such as the cell membrane and endosome membrane have significantly reduced its efficiency (De Smedt et al., 2005; Pack et al., 2005). Therefore, carriers are needed to help the gene delivery (Zhang et al., 2014). Efficient and cost-effective carriers are particularly desired for clinical applications.

Due to the potential toxicity and immunogenicity concerns of viral systems (El-Aneed, 2004; Plank et al., 2003; Lungwitz et al., 2005), non-viral gene delivery systems have been explored as an

alternative method for gene therapy (Lungwitz et al., 2005; Zhang et al., 2014;

Zhang et al., 2016). The advantages of non-viral systems include low cost, ease of fabrication and modification, and high *in vivo* stability (Zhang et al., 2016). One of the most efficient and cost-effective agents is polyethyleneimine (PEI) (Lungwitz et al., 2005; Dey et al., 2011; Xiang et al., 2007; Forrest et al., 2003; Seow et al., 2013). Once mixed with DNAs, PEI is able to condense DNAs into nano complexes that are suitable for the cell internalization through endocytosis (Zhang et al., 2014; Wang et al., 2009). In addition, PEI is able to destabilize the endosomal membrane by the 'proton sponge effect' to protect DNAs

Department of pharmaceuticals,

Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FGSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



**A STUDY ON SYNTHESIS AND CHARACTERISATION OF SOME NOVEL
QUINAZOLINONES**

P. Siva Kumar^{1*}, S. Saddam Hussain² and AVS Geetha Sameera³

¹Department of Pharmaceutical Chemistry, Gokula Krishna College of Pharmacy, Sullurpeta, Nellore, Andhra Pradesh, India.

²Department of Pharmacy Practice, Jagans College of Pharmacy, Nellore, Andhra Pradesh, India.

³Department of Pharmaceutical Analysis, Narayana Pharmacy College, Nellore, Andhra Pradesh, India.

*Corresponding Author: P. Siva Kumar

Department of Pharmaceutical Chemistry, Gokula Krishna College of Pharmacy, Sullurpeta, Nellore, Andhra Pradesh, India.

Article Received on 12/07/2022

Article Revised on 02/08/2022

Article Accepted on 22/08/2022

ABSTRACT

Heterocyclic chemistry comprises at least half of all organic chemistry research worldwide. In particular, heterocyclic structures form the basis of many pharmaceutical, agrochemical and veterinary products. The heterocyclic compounds are fundamentals of life, like haeme derivatives in blood & chlorophyll essential for photosynthesis in plants. Also the DNA & RNA are containing heterocycles. The study aims to synthesize simple derivatives of quinazoline by combining with aromatic primary amine, hydrazine hydrate and benzoxazine. The synthesized compounds were characterized by melting point analysis. Melting point was recorded and compared with the standard references. The characterization of compounds provided further scope in the research towards the discovery of new derivatives for several ailments. The biological evaluation could be beneficial for future studies.

KEYWORDS: Heterocyclic compounds, benzoxazine, quinazoline, primary amine, hydrazine hydrate and benzoxazine.

INTRODUCTION

Any of a class of organic compounds whose molecules contain one or more rings of atoms with at least one atom being an element other than carbon, most frequently oxygen, nitrogen, or sulfur are called heterocyclic compounds. Heterocyclic chemistry is the branch of chemistry dealing with the synthesis, properties, and applications of heterocycles. Heterocyclic chemistry comprises at least half of all organic chemistry research worldwide. In particular, heterocyclic structures form the basis of many pharmaceutical, agrochemical and veterinary products. The word hetero means "different from carbon and hydrogen". Many heterocyclic compounds are biosynthesized by plants & animals are biologically active. Some heterocyclic compounds are fundamentals of life, like haeme derivatives in blood & chlorophyll essential for photosynthesis in plants. Also the DNA & RNA are containing heterocycles. Dyestuffs of plant origins include indigo blue used to dye jeans. Several heterocycles are the basic structure nucleus for nicotine, pyridoxine, cocaine, morphine etc. Among a wide variety of nitrogen heterocycles that have been explored for developing pharmaceutically, quinazolinone plays an important role in medicinal chemistry and subsequently has emerged as a pharmacophore. Quinazoline is a compound made up of two fused six


member simple aromatic rings- benzene & pyrimidine ring. It is a yellow colored compound, found usually in crystalline form. Medicinally it is used as ant malarial agent. It was first prepared by Gabriel in 1903 and first isolated from the Chinese plant aseru. The development of research on biological activity of quinazolinone compounds started when the compound 2-methyl-1,3-aryl-4-quinazoline was synthesized. This compound has soporific & sedative action.^[1-4] In last 10 to 15 years of research for medicinal has been characterized by significant advances. In 1968 only two derivatives were used, soporific & anticonvulsant-methaqualone and diuretic quinathiazone. By 1980, about 50 kinds of derivatives of this class includes medicinal with different biological actions like 'soporific, sedative, tranquilizing, analgesic, anticonvulsant, antitussive, myorelexant, anti rheumatic, hypotensive, antiallergic, bronchodilating, antidiabetic, cholagogue, diuretic, cystatic, antimalarial, spermicidal etc.

Quinazolinone scaffold has been considered as a magic moiety possessing myriad spectrum of medicinal activities. Diversity of biological response profile has attracted considerable interest of several researchers across the globe to explore this skeleton for its assorted






ISSN : 2347-2251
Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FDES, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



Pharmacokinetic Variability in Pediatrics and Intensive Care: Toward a Personalized Dosing Approach

Mrs D Kalyani, Ms A R Sridevi, Mrs P Sukanya, Mrs A Akshaya, Mr C G Bhaskar

ABSTRACT - Providing a safe and efficacious drug therapy for large and often heterogeneous populations is a challenging objective in clinical drug development and routine clinical practice. It has been known for years that the optimum dose required for many therapeutic agents among individuals is quite variable. A wide interindividual pharmacokinetic variability was described in clinically relevant populations such as pediatrics and critically ill patients. The aim of this article was to present the main individual factors influencing variability in these two populations and their applications. Growth and development are two specific features of children that are not observed in adults. And critically ill patients have a much higher level of sickness severity that is associated with profound pathophysiological changes. These particular features could lead to difficulties to attain therapeutic targets. Nonlinear mixed effects modeling is a common approach to identify unexplained population variability. This approach is often applied to evaluate and optimize drug therapy in particular populations. Numerous studies have been conducted in these two specific populations to characterize pharmacokinetic parameters and to identify individual factors influencing variability. Size, age and organ function appeared to be the main factors influencing pharmacokinetics in pediatrics. Factors influencing pharmacokinetics in critically ill patients were mainly cardiovascular system, organ dysfunction and organ support. Dosage individualization seems to be a key issue to optimize drug treatment in these specific populations. Clinical utility and safety of a model-based personalized drug therapy has been demonstrated for vancomycin in pediatrics. Many programs were available to optimize drug regimens, especially for antibiotic drugs in critically ill patients. This innovative personalized dosing approach is a promising way to optimize drug therapy in clinically relevant populations, such as pediatrics and critically ill patients.

INTRODUCTION

Providing a safe and efficacious drug therapy for large and often heterogeneous populations is a challenging objective in clinical drug development and routine clinical practice. On the one hand, a therapeutic effect of the drug is desired to be achieved for all patients; on the other hand too high concentrations have to be avoided to reduce adverse events [1,2]. It has been known for years that the optimum dose required for many therapeutic agents among individuals is quite variable. Anatomical and physiological properties have a great influence on the pharmacokinetics of drugs and lead to inter- and intra-individual variability in the pharmacokinetics outcome [3]. Both inter- and intrasubject pharmacokinetic variability may be important. Intersubject variability is fundamental to the argument for using a wide interindividual

pharmacokinetic variability was described in clinically relevant populations such as pediatrics and critically ill patients. Growth and development are two specific features of children that are not observed in adults. And critically ill patients have a much higher level of sickness severity that is associated with profound pathophysiological changes. These particular features could lead to difficulties to attain therapeutic targets. One well-known approach to characterize variability in pharmacokinetic parameters is nonlinear mixed effects modeling. It is a common approach to identify unexplained population variability in parameters of pharmacokinetic models and to identify covariates, which explain the variability of the data. Population models can then be developed using bayesian logistics to therapeutic drug monitoring.

Department of Pharmaceutics,
Email ID: kevinkarunva@gmail.com, Mobile no: 8106686200
GOKULA KRISHNA COLLEGE OF PHARMACY



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FICP, FICP, FICP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P. - 524121



ISSN : 2347-2251
**Indo-American Journal of
Pharma and Bio Sciences**



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICGP, MSTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



Pharmacokinetic Variability in Pediatrics and Intensive Care: Toward a Personalized Dosing Approach

Mrs D Kalyani , Ms A R Sridevi , Mrs P Sukanya , Mrs A Aksa anvija , Mr C G Bhaskar

ABSTRACT - Providing a safe and efficacious drug therapy for large and often heterogeneous populations is a challenging objective in clinical drug development and routine clinical practice. It has been known for years that the optimum dose required for many therapeutic agents among individuals is quite variable. A wide interindividual pharmacokinetic variability was described in clinically relevant populations such as pediatrics and critically ill patients. The aim of this article was to present the main individual factors influencing variability in these two populations and their applications. Growth and development are two specific features of children that are not observed in adults. And critically ill patients have a much higher level of sickness severity that is associated with profound pathophysiological changes. These particular features could lead to difficulties to attain therapeutic targets. Nonlinear mixed effects modeling is a common approach to identify unexplained population variability. This approach is often applied to evaluate and optimize drug therapy in particular populations. Numerous studies have been conducted in these two specific populations to characterize pharmacokinetic parameters and to identify individual factors influencing variability. Size, age and organ function appeared to be the main factors influencing pharmacokinetics in pediatrics. Factors influencing pharmacokinetics in critically ill patients were mainly cardiovascular system, organ dysfunction and organ support. Dosage individualization seems to be a key issue to optimize drug treatment in these specific populations. Clinically utility and safety of a model-based personalized drug therapy has been demonstrated for vancomycin in pediatrics. Many programs were available to optimize drug regimens, especially for antibiotic drugs in critically ill patients. This innovative personalized dosing approach is a promising way to optimize drug therapy in clinically relevant populations, such as pediatrics and critically ill patients.

INTRODUCTION

Providing a safe and efficacious drug therapy for large and often heterogeneous populations is a challenging objective in clinical drug development and routine clinical practice. On the one hand, a therapeutic effect of the drug is desired to be achieved for all patients; on the other hand too high concentrations have to be avoided to reduce adverse events [1,2]. It has been known for years that the optimum dose required for many therapeutic agents among individuals is quite variable. Anatomical and physiological properties have a great influence on the pharmacokinetics of drugs and lead to inter- and intra-individual variability in the pharmacokinetics outcome [3]. Both inter- and intrasubject pharmacokinetic variability may be important. Intersubject variability is fundamental to the argument for using A wide interindividual

pharmacokinetic variability was described in clinically relevant populations such as pediatrics and critically ill patients. Growth and development are two specific features of children that are not observed in adults. And critically ill patients have a much higher level of sickness severity that is associated with profound pathophysiological changes. These particular features could lead to difficulties to attain therapeutic targets. One well-known approach to characterize variability in pharmacokinetic parameters is nonlinear mixed effects modeling. It is a common approach to identify unexplained population variability in parameters of pharmacokinetic models and to identify covariates, which explain the variability of the data. Population models can then be developed using Bayesian logistics to therapeutic drug monitoring.

Department of Pharmaceutics,

Email ID: kevinakarunya@gmail.com , Mobile no:8106686200

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FDS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Pharmacokinetic Variability in Pediatrics and Intensive Care: Toward a Personalized Dosing Approach

Mrs D Kalyani , Ms A R Sridevi , Mrs P Sukanya , Mrs A Aksa anvija , Mr C G Bhaskar

ABSTRACT - Providing a safe and efficacious drug therapy for large and often heterogeneous populations is a challenging objective in clinical drug development and routine clinical practice. It has been known for years that the optimum dose required for many therapeutic agents among individuals is quite variable. A wide interindividual pharmacokinetic variability was described in clinically relevant populations such as pediatrics and critically ill patients. The aim of this article was to present the main individual factors influencing variability in these two populations and their applications. Growth and development are two specific features of children that are not observed in adults. And critically ill patients have a much higher level of sickness severity that is associated with profound pathophysiological changes. These particular features could lead to difficulties to attain therapeutic targets. Nonlinear mixed effects modeling is a common approach to identify unexplained population variability. This approach is often applied to evaluate and optimize drug therapy in particular populations. Numerous studies have been conducted in these two specific populations to characterize pharmacokinetic parameters and to identify individual factors influencing variability. Size, age and organ function appeared to be the main factors influencing pharmacokinetics in pediatrics. Factors influencing pharmacokinetics in critically ill patients were mainly cardiovascular system, organ dysfunction and organ support. Dosage individualization seems to be a key issue to optimize drug treatment in these specific populations. Clinically utility and safety of a model-based personalized drug therapy has been demonstrated for vancomycin in pediatrics. Many programs were available to optimize drug regimens, especially for antibiotic drugs in critically ill patients. This innovative personalized dosing approach is a promising way to optimize drug therapy in clinically relevant populations, such as pediatrics and critically ill patients.


INTRODUCTION

Providing a safe and efficacious drug therapy for large and often heterogeneous populations is a challenging objective in clinical drug development and routine clinical practice. On the one hand, a therapeutic effect of the drug is desired to be achieved for all patients; on the other hand too high concentrations have to be avoided to reduce adverse events [1,2]. It has been known for years that the optimum dose required for many therapeutic agents among individuals is quite variable. Anatomical and physiological properties have a great influence on the pharmacokinetics of drugs and lead to inter- and intra-individual variability in the pharmacokinetics outcome [3]. Both inter- and intrasubject pharmacokinetic variability may be important. Intersubject variability is fundamental to the argument for using A wide interindividual

pharmacokinetic variability was described in clinically relevant populations such as pediatrics and critically ill patients. Growth and development are two specific features of children that are not observed in adults. And critically ill patients have a much higher level of sickness severity that is associated with profound pathophysiological changes. These particular features could lead to difficulties to attain therapeutic targets. One well-known approach to characterize variability in pharmacokinetic parameters is nonlinear mixed effects modeling. It is a common approach to identify unexplained population variability in parameters of pharmacokinetic models and to identify covariates, which explain the variability of the data. Population models can then be developed using bayesian logistics to therapeutic drug monitoring.

Department of Pharmaceutics,
Email ID: kevinkarunya@gmail.com , Mobile no:8106686200
GOKULA KRISHNA COLLEGE OF PHARMACY





Dr. BALAGANI PAVAN KUMAR
M. Pharm, PhD, FICP, FDS, FASE, FICCP, MSTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FPC, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



Pharmacokinetic Variability in Pediatrics and Intensive Care: Toward a Personalized Dosing Approach

Mrs D Kalyani , Ms A R Sridevi , Mrs P Sukanya , Mrs A Aksa anvija , Mr C G Bhaskar

ABSTRACT - Providing a safe and efficacious drug therapy for large and often heterogeneous populations is a challenging objective in clinical drug development and routine clinical practice. It has been known for years that the optimum dose required for many therapeutic agents among individuals is quite variable. A wide interindividual pharmacokinetic variability was described in clinically relevant populations such as pediatrics and critically ill patients. The aim of this article was to present the main individual factors influencing variability in these two populations and their applications. Growth and development are two specific features of children that are not observed in adults. And critically ill patients have a much higher level of sickness severity that is associated with profound pathophysiological changes. These particular features could lead to difficulties to attain therapeutic targets. Nonlinear mixed effects modeling is a common approach to identify unexplained population variability. This approach is often applied to evaluate and optimize drug therapy in particular populations. Numerous studies have been conducted in these two specific populations to characterize pharmacokinetic parameters and to identify individual factors influencing variability. Size, age and organ function appeared to be the main factors influencing pharmacokinetics in pediatrics. Factors influencing pharmacokinetics in critically ill patients were mainly cardiovascular system, organ dysfunction and organ support. Dosage individualization seems to be a key issue to optimize drug treatment in these specific populations. Clinically utility and safety of a model-based personalized drug therapy has been demonstrated for vancomycin in pediatrics. Many programs were available to optimize drug regimens, especially for antibiotic drugs in critically ill patients. This innovative personalized dosing approach is a promising way to optimize drug therapy in clinically relevant populations, such as pediatrics and critically ill patients.


INTRODUCTION

Providing a safe and efficacious drug therapy for large and often heterogeneous populations is a challenging objective in clinical drug development and routine clinical practice. On the one hand, a therapeutic effect of the drug is desired to be achieved for all patients; on the other hand too high concentrations have to be avoided to reduce adverse events [1,2]. It has been known for years that the optimum dose required for many therapeutic agents among individuals is quite variable. Anatomical and physiological properties have a great influence on the pharmacokinetics of drugs and lead to inter- and intra-individual variability in the pharmacokinetics outcome [3]. Both inter- and intrasubject pharmacokinetic variability may be important. Intersubject variability is fundamental to the argument for using A wide interindividual

pharmacokinetic variability was described in clinically relevant populations such as pediatrics and critically ill patients. Growth and development are two specific features of children that are not observed in adults. And critically ill patients have a much higher level of sickness severity that is associated with profound pathophysiological changes. These particular features could lead to difficulties to attain therapeutic targets. One well-known approach to characterize variability in pharmacokinetic parameters is nonlinear mixed effects modeling. It is a common approach to identify unexplained population variability in parameters of pharmacokinetic models and to identify covariates, which explain the variability of the data. Population models can then be developed using bayesian logistics to therapeutic drug monitoring.

Department of Pharmaceutics,
Email ID: kevinkarunya@gmail.com , Mobile no:8106686200
GOKULA KRISHNA COLLEGE OF PHARMACY





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBS, FAGE, FICCR, MSTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FDS, FAI, FICP, MSTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



Pharmacokinetic Variability in Pediatrics and Intensive Care: Toward a Personalized Dosing Approach

Mrs D Kalyani , Ms A R Sridevi , Mrs P Sukanya , Mrs A Aksa anvija , Mr C G Bhaskar

ABSTRACT - Providing a safe and efficacious drug therapy for large and often heterogeneous populations is a challenging objective in clinical drug development and routine clinical practice. It has been known for years that the optimum dose required for many therapeutic agents among individuals is quite variable. A wide interindividual pharmacokinetic variability was described in clinically relevant populations such as pediatrics and critically ill patients. The aim of this article was to present the main individual factors influencing variability in these two populations and their applications. Growth and development are two specific features of children that are not observed in adults. And critically ill patients have a much higher level of sickness severity that is associated with profound pathophysiological changes. These particular features could lead to difficulties to attain therapeutic targets. Nonlinear mixed effects modeling is a common approach to identify unexplained population variability. This approach is often applied to evaluate and optimize drug therapy in particular populations. Numerous studies have been conducted in these two specific populations to characterize pharmacokinetic parameters and to identify individual factors influencing variability. Size, age and organ function appeared to be the main factors influencing pharmacokinetics in pediatrics. Factors influencing pharmacokinetics in critically ill patients were mainly cardiovascular system, organ dysfunction and organ support. Dose individualization seems to be a key issue to optimize drug treatment in these specific populations. Clinical utility and safety of a model-based personalized drug therapy has been demonstrated for vancomycin in pediatrics. Many programs were available to optimize drug regimens, especially for antibiotic drugs in critically ill patients. This innovative personalized dosing approach is a promising way to optimize drug therapy in clinically relevant populations, such as pediatrics and critically ill patients.

INTRODUCTION

Providing a safe and efficacious drug therapy for large and often heterogeneous populations is a challenging objective in clinical drug development and routine clinical practice. On the one hand, a therapeutic effect of the drug is desired to be achieved for all patients; on the other hand too high concentrations have to be avoided to reduce adverse events [1,2]. It has been known for years that the optimum dose required for many therapeutic agents among individuals is quite variable. Anatomical and physiological properties have a great influence on the pharmacokinetics of drugs and lead to inter- and intra-individual variability in the pharmacokinetics outcome [3]. Both inter- and intrasubject pharmacokinetic variability may be important. Intersubject variability is fundamental to the argument for using a wide interindividual

pharmacokinetic variability was described in clinically relevant populations such as pediatrics and critically ill patients. Growth and development are two specific features of children that are not observed in adults. And critically ill patients have a much higher level of sickness severity that is associated with profound pathophysiological changes. These particular features could lead to difficulties to attain therapeutic targets. One well-known approach to characterize variability in pharmacokinetic parameters is nonlinear mixed effects modeling. It is a common approach to identify unexplained population variability in parameters of pharmacokinetic models and to identify covariates, which explain the variability of the data. Population models can then be developed using Bayesian logistics to therapeutic drug monitoring.

Department of Pharmaceutics,
Email ID: kevinakarunya@gmail.com , Mobile no:8106686200
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FESS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

How Solvents Affect the Rate of Polymorphic Transformation in Polymorph Screening

Mrs D Kalyani, Mrs T Swathi, Mrs P Sukanya, Mrs CH Harika, Mrs K Vanitha Devi

Abstract

The most stable polymorph may be efficiently obtained via solvent-mediated polymorphic transformation. Form II's nucleation rate controls the rate of solvent-mediated polymorphic transformation of sulfamerazine at 24°C in different solvents and solvent combinations. In general, a greater solubility is caused by a faster transformation rate in a solvent, and a low solubility by a slower rate (8 mmol/L). Nucleation is prevented in these solvents due to a high interfacial energy, which causes the metastable zone to be broader than the solubility difference between two polymorphs. The solubility is only one factor in deciding the transformation rate; the intensity of the solvent-solute interactions is equally crucial. Sulfamerazine undergoes a slower transition in solvents that are more likely to accept hydrogen bonds. Because a solvent's solubility is proportional to its hydrogen bond acceptor propensity, the rate of polymorphic transformation is a function of both the solute's and the solvent's solubility and the strength of their hydrogen bonding interactions. Temperature and agitation level affect the crystallization kinetics of the stable polymorph, which in turn affects the pace of polymorphic transition. The American Pharmaceutical Association and Wiley-Liss, Inc. published this work in 2001. "Journal of Pharmaceutical Science" 90:1878-1890, 2001

Introduction

Polymorphism, crystallization, hydrogen bonding, solubility, solvatochromic parameters, solvent-mediated transformation, and sulfamerazine are some of the terms used to describe this process. Introduction: A chemical may exhibit polymorphism if it can exist in many crystalline forms with various molecular groupings and/or conformations in the crystal lattice.¹ Preformulation in pharmaceutical R&D requires the identification, synthesis, and characterization of polymorphs due to the fact that various polymorphs display substantially varied pharmaceutically important characteristics.² Since other polymorphs are metastable and might undergo transformation to the more stable

form during storage, the more stable polymorphic form is often used in a commercial formulation. Bioavailability alterations, solid dosage form physical instability, precipitation from solutions, and other formulation issues might result from such a phase transition. Products like ritonavir, which undergo phase transition during storage, might fail if the most stable polymorph is overlooked. In the field of polymorph screening, recrystallization from various solvents is now among the most used procedures.⁴ Nevertheless, a metastable polymorph is often acquired initially along this process, as per Ostwald's rule of stages.⁵ A streamlined process for identifying the most reliable

Department of pharmaceuticals, Email ID: kevinkarunya@gmail.com, Mobile no:8106686200 GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

How Solvents Affect the Rate of Polymorphic Transformation in Polymorph Screening

Mrs D Kalyani , Mrs T Swathi , Mrs P Sukanya , Mrs CH Harika , Mrs K Vanitha Devi

Abstract

The most stable polymorph may be efficiently obtained via solvent-mediated polymorphic transformation. Form II's nucleation rate controls the rate of solvent-mediated polymorphic transformation of sulfamerazine at 24°C in different solvents and solvent combinations. In general, a greater solubility is caused by a faster transformation rate in a solvent, and a low solubility by a slower rate (8 mmol/L). Nucleation is prevented in these solvents due to a high interfacial energy, which causes the metastable zone to be broader than the solubility difference between two polymorphs. The solubility is only one factor in deciding the transformation rate; the intensity of the solvent-solute interactions is equally crucial. Sulfamerazine undergoes a slower transition in solvents that are more likely to accept hydrogen bonds. Because a solvent's solubility is proportional to its hydrogen bond acceptor propensity, the rate of polymorphic transformation is a function of both the solute's and the solvent's solubility and the strength of their hydrogen bonding interactions. Temperature and agitation level affect the crystallization kinetics of the stable polymorph, which in turn affects the pace of polymorphic transition. The American Pharmaceutical Association and Wiley-Liss, Inc. published this work in 2001. "Journal of Pharmaceutical Science" 90:1878-1890, 2001

Introduction

Polymorphism, crystallization, hydrogen bonding, solubility, solvatochromic parameters, solvent-mediated transformation, and sulfamerazine are some of the terms used to describe this process. Introduction: A chemical may exhibit polymorphism if it can exist in many crystalline forms with various molecular groupings and/or conformations in the crystal lattice.¹ Preformulation in pharmaceutical R&D requires the identification, synthesis, and characterization of polymorphs due to the fact that various polymorphs display substantially varied pharmaceutically important characteristics.² Since other polymorphs are metastable and might undergo transformation to the more stable

form during storage, the more stable polymorphic form is often used in a commercial formulation. Bioavailability alterations, solid dosage form physical instability, precipitation from solutions, and other formulation issues might result from such a phase transition. Products like ritonavir, which undergo phase transition during storage, might fail if the most stable polymorph is overlooked. In the field of polymorph screening, recrystallization from various solvents is now among the most used procedures.⁴ Nevertheless, a metastable polymorph is often acquired initially along this process, as per Ost-wald's rule of stages 5. A streamlined process for identifying the most reliable

Department of pharmaceutics, Email ID: kevinakarunya@gmail.com , Mobile no:8106686200 GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

How Solvents Affect the Rate of Polymorphic Transformation in Polymorph Screening

Mrs D Kalyani , Mrs T Swathi , Mrs P Sukanya , Mrs CH Harika , Mrs K Vanitha Devi

Abstract

The most stable polymorph may be efficiently obtained via solvent-mediated polymorphic transformation. Form II's nucleation rate controls the rate of solvent-mediated polymorphic transformation of sulfamerazine at 24°C in different solvents and solvent combinations. In general, a greater solubility is caused by a faster transformation rate in a solvent, and a low solubility by a slower rate (8 mmol/L). Nucleation is prevented in these solvents due to a high interfacial energy, which causes the metastable zone to be broader than the solubility difference between two polymorphs. The solubility is only one factor in deciding the transformation rate; the intensity of the solvent-solute interactions is equally crucial. Sulfamerazine undergoes a slower transition in solvents that are more likely to accept hydrogen bonds. Because a solvent's solubility is proportional to its hydrogen bond acceptor propensity, the rate of polymorphic transformation is a function of both the solute's and the solvent's solubility and the strength of their hydrogen bonding interactions. Temperature and agitation level affect the crystallization kinetics of the stable polymorph, which in turn affects the pace of polymorphic transition. The American Pharmaceutical Association and Wiley-Liss, Inc. published this work in 2001. "Journal of Pharmaceutical Science" 90:1878-1890, 2001

Introduction

Polymorphism, crystallization, hydrogen bonding, solubility, solvatochromic parameters, solvent-mediated transformation, and sulfamerazine are some of the terms used to describe this process. Introduction: A chemical may exhibit polymorphism if it can exist in many crystalline forms with various molecular groupings and/or conformations in the crystal lattice.¹ Preformulation in pharmaceutical R&D requires the identification, synthesis, and characterization of polymorphs due to the fact that various polymorphs display substantially varied pharmaceutically important characteristics.² Since other polymorphs are metastable and might undergo transformation to the more stable

form during storage, the more stable polymorphic form is often used in a commercial formulation. Bioavailability alterations, solid dosage form physical instability, precipitation from solutions, and other formulation issues might result from such a phase transition. Products like ritonavir, which undergo phase transition during storage, might fail if the most stable polymorph is overlooked. In the field of polymorph screening, recrystallization from various solvents is now among the most used procedures.⁴ Nevertheless, a metastable polymorph is often acquired initially along this process, as per Ost-wald's rule of stages 5. A streamlined process for identifying the most reliable

Department of pharmaceutics, Email ID: kevinkarunya@gmail.com , Mobile no:8106686200 GOKULA KRISHNA COLLEGE OF PHARMACY



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

How Solvents Affect the Rate of Polymorphic Transformation in Polymorph Screening

Mrs D Kalyani , Mrs T Swathi , Mrs P Sukanya , Mrs CH Harika , Mrs K Vanitha Devi

Abstract

The most stable polymorph may be efficiently obtained via solvent-mediated polymorphic transformation. Form II's nucleation rate controls the rate of solvent-mediated polymorphic transformation of sulfamerazine at 24°C in different solvents and solvent combinations. In general, a greater solubility is caused by a faster transformation rate in a solvent, and a low solubility by a slower rate (8 mmol/L). Nucleation is prevented in these solvents due to a high interfacial energy, which causes the metastable zone to be broader than the solubility difference between two polymorphs. The solubility is only one factor in deciding the transformation rate; the intensity of the solvent-solute interactions is equally crucial. Sulfamerazine undergoes a slower transition in solvents that are more likely to accept hydrogen bonds. Because a solvent's solubility is proportional to its hydrogen bond acceptor propensity, the rate of polymorphic transformation is a function of both the solute's and the solvent's solubility and the strength of their hydrogen bonding interactions. Temperature and agitation level affect the crystallization kinetics of the stable polymorph, which in turn affects the pace of polymorphic transition. The American Pharmaceutical Association and Wiley-Liss, Inc. published this work in 2001. "Journal of Pharmaceutical Science" 90:1878-1890, 2001

Introduction

Polymorphism, crystallization, hydrogen bonding, solubility, solvatochromic parameters, solvent-mediated transformation, and sulfamerazine are some of the terms used to describe this process. Introduction: A chemical may exhibit polymorphism if it can exist in many crystalline forms with various molecular groupings and/or conformations in the crystal lattice.¹ Preformulation in pharmaceutical R&D requires the identification, synthesis, and characterization of polymorphs due to the fact that various polymorphs display substantially varied pharmaceutically important characteristics.² Since other polymorphs are metastable and might undergo transformation to the more stable

form during storage, the more stable polymorphic form is often used in a commercial formulation. Bioavailability alterations, solid dosage form physical instability, precipitation from solutions, and other formulation issues might result from such a phase transition. Products like ritonavir, which undergo phase transition during storage, might fail if the most stable polymorph is overlooked. In the field of polymorph screening, recrystallization from various solvents is now among the most used procedures.⁴ Nevertheless, a metastable polymorph is often acquired initially along this process, as per Ostwald's rule of stages.⁵ A streamlined process for identifying the most reliable

Department of pharmaceuticals, Email ID: kevinkarunva@gmail.com , Mobile no:8106686200 GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

How Solvents Affect the Rate of Polymorphic Transformation in Polymorph Screening

Mrs D Kalyani , Mrs T Swathi , Mrs P Sukanya , Mrs CH Harika , Mrs K Vanitha Devi

Abstract

The most stable polymorph may be efficiently obtained via solvent-mediated polymorphic transformation. Form II's nucleation rate controls the rate of solvent-mediated polymorphic transformation of sulfamerazine at 24°C in different solvents and solvent combinations. In general, a greater solubility is caused by a faster transformation rate in a solvent, and a low solubility by a slower rate (8 mmol/L). Nucleation is prevented in these solvents due to a high interfacial energy, which causes the metastable zone to be broader than the solubility difference between two polymorphs. The solubility is only one factor in deciding the transformation rate; the intensity of the solvent-solute interactions is equally crucial. Sulfamerazine undergoes a slower transition in solvents that are more likely to accept hydrogen bonds. Because a solvent's solubility is proportional to its hydrogen bond acceptor propensity, the rate of polymorphic transformation is a function of both the solute's and the solvent's solubility and the strength of their hydrogen bonding interactions. Temperature and agitation level affect the crystallization kinetics of the stable polymorph, which in turn affects the pace of polymorphic transition. The American Pharmaceutical Association and Wiley-Liss, Inc. published this work in 2001. "Journal of Pharmaceutical Science" 90:1878-1890, 2001

Introduction

Polymorphism, crystallization, hydrogen bonding, solubility, solvatochromic parameters, solvent-mediated transformation, and sulfamerazine are some of the terms used to describe this process. Introduction: A chemical may exhibit polymorphism if it can exist in many crystalline forms with various molecular groupings and/or conformations in the crystal lattice.¹ Preformulation in pharmaceutical R&D requires the identification, synthesis, and characterization of polymorphs due to the fact that various polymorphs display substantially varied pharmaceutically important characteristics.² Since other polymorphs are metastable and might undergo transformation to the more stable

form during storage, the more stable polymorphic form is often used in a commercial formulation. Bioavailability alterations, solid dosage form physical instability, precipitation from solutions, and other formulation issues might result from such a phase transition. Products like ritonavir, which undergo phase transition during storage, might fail if the most stable polymorph is overlooked. In the field of polymorph screening, recrystallization from various solvents is now among the most used procedures.⁴ Nevertheless, a metastable polymorph is often acquired initially along this process, as per Ostwald's rule of stages.⁵ A streamlined process for identifying the most reliable

Department of pharmaceutics, Email ID: kevinkarunva@gmail.com , Mobile no:8106686200 GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P. - 524121

The Sensitive Method of Subvisible Particle Counting for the Detection and Quantification of Monoclonal Antibody Aggregation Caused by Freeze-Thawing: New Understanding of Particle Function in the Protein Aggregation Process

Mrs N Sukanya, Mrs P K Devibala, Ms.SK Zoofishaan, Mr.M R Pavan Kumar, Mr S Sivakoteswa Rao

Abstract

The purpose of this research was to measure the amount of subvisible particles formed throughout the freeze-thaw cycle of an IgG2 monoclonal antibody (mAb) using microflow imaging (MFI), a sensitive technique. Protein solutions in 20 mM histidine buffer (pH 5.5) were frozen and thawed three times before being examined using multiple-fraction isolation (MFI) and size-exclusion chromatography (SEC). While SEC could not identify aggregates, MFI demonstrated an increase in particle counts with each freeze-thaw cycle. Monitoring particle production enables the identification of protein aggregates containing just a tenth of a percent of the total protein mass, according to estimates of the total mass of particles generated. Even while SEC did not identify protein aggregation, variations in levels caused by various formulations or freeze-thaw protocols were addressed. The purpose of the freeze-thaw process in phosphate-buffered saline was to determine whether the total aggregate mass estimates derived from SEC and MFI were quantitatively compatible. This procedure reduced the monomer peak area in the chromatogram, which allowed SEC to identify insoluble aggregates at a detectable level. The amount of monomer lost as measured by SEC and the total mass of subvisible particles as measured by MFI were in excellent agreement. The following is a copyright notice from Wiley-Liss, Inc. and the American Pharmacists Association: J Pharm Sci 100:492-503, 2011 Protein formulation, infrared spectroscopy, particle size, liquid chromatography, and protein aggregation are all relevant terms.

Introduction :

A decrease in product purity and quality and the possibility that aggregates may induce an immunogenic response in patients make therapeutic protein aggregation a big concern.¹ Proteins in solution may aggregate due to a variety of stressors, including heat, agitation, light, surface contact, and freeze-thaw cycles.²⁻⁸ Most frequently, the resultant aggregation and loss of native protein may be recognized and

quantified. evaluated using size-exclusion chromatography (SEC). One drawback of utilizing SEC to detect aggregates is that it can only detect aggregates within a very small size range, around 5 to 1000 kDa, which is considered soluble.² One other drawback of SEC is that it takes around 0.1% to 0.5% of the total protein to be soluble aggregates and/or native protein lost before a change can be accurately detected in practice.

Department of Pharmaceutics

Email ID: nallamekalasukanya38@gmail.com, Mobile no:9491169765

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY



The Sensitive Method of Subvisible Particle Counting for the Detection and Quantification of Monoclonal Antibody Aggregation Caused by Freeze-Thawing: New Understanding of Particle Function in the Protein Aggregation Process

Mrs N Sukanya , Mrs P K Devibala , Ms.SK Zoofishaan , Mr.M R Pavan Kumar ,
Mr S Sivakoteswa Rao

Abstract

The purpose of this research was to measure the amount of subvisible particles formed throughout the freeze-thaw cycle of an IgG2 monoclonal antibody (mAb) using microflow imaging (MFI), a sensitive technique. Protein solutions in 20 mM histidine buffer (pH 5.5) were frozen and thawed three times before being examined using multiple-fraction isolation (MFI) and size-exclusion chromatography (SEC). While SEC could not identify aggregates, MFI demonstrated an increase in particle counts with each freeze-thaw cycle. Monitoring particle production enables the identification of protein aggregates containing just a tenth of a percent of the total protein mass, according to estimates of the total mass of particles generated. Even while SEC did not identify protein aggregation, variations in levels caused by various formulations or freeze-thaw protocols were addressed. The purpose of the freeze-thaw process in phosphate-buffered saline was to determine whether the total aggregate mass estimates derived from SEC and MFI were quantitatively compatible. This procedure reduced the monomer peak area in the chromatogram, which allowed SEC to identify insoluble aggregates at a detectable level. The amount of monomer lost as measured by SEC and the total mass of subvisible particles as measured by MFI were in excellent agreement. The following is a copyright notice from Wiley-Liss, Inc. and the American Pharmacists Association: J Pharm Sci 100:492-503, 2011 Protein formulation, infrared spectroscopy, particle size, liquid chromatography, and protein aggregation are all relevant terms.

Introduction :

A decrease in product purity and quality and the possibility that aggregates may induce an immunogenic response in patients make therapeutic protein aggregation a big concern.¹ Proteins in solution may aggregate due to a variety of stressors, including heat, agitation, light, surface contact, and freeze-thaw cycles.²⁻⁸ Most frequently, the resultant aggregation and loss of native protein may be recognized and

quantified. evaluated using size-exclusion chromatography (SEC). One drawback of utilizing SEC to detect aggregates is that it can only detect aggregates within a very small size range, around 5 to 1000 kDa, which is considered soluble.² One other drawback of SEC is that it takes around 0.1% to 0.5% of the total protein to be soluble aggregates and/or native protein lost before a change can be accurately detected in practice.

Department of Pharmaceutics

Email ID: nallamekalasukanya38@gmail.com , Mobile no:9491169765

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

The Sensitive Method of Subvisible Particle Counting for the Detection and Quantification of Monoclonal Antibody Aggregation Caused by Freeze-Thawing: New Understanding of Particle Function in the Protein Aggregation Process

Mrs N Sukanya , Mrs P K Devibala , Ms.SK Zoofishaan , Mr.M R Pavan Kumar ,
Mr S Sivakoteswa Rao

Abstract

The purpose of this research was to measure the amount of subvisible particles formed throughout the freeze-thaw cycle of an IgG2 monoclonal antibody (mAb) using microflow imaging (MFI), a sensitive technique. Protein solutions in 20 mM histidine buffer (pH 5.5) were frozen and thawed three times before being examined using multiple-fraction isolation (MFI) and size-exclusion chromatography (SEC). While SEC could not identify aggregates, MFI demonstrated an increase in particle counts with each freeze-thaw cycle. Monitoring particle production enables the identification of protein aggregates containing just a tenth of a percent of the total protein mass, according to estimates of the total mass of particles generated. Even while SEC did not identify protein aggregation, variations in levels caused by various formulations or freeze-thaw protocols were addressed. The purpose of the freeze-thaw process in phosphate-buffered saline was to determine whether the total aggregate mass estimates derived from SEC and MFI were quantitatively compatible. This procedure reduced the monomer peak area in the chromatogram, which allowed SEC to identify insoluble aggregates at a detectable level. The amount of monomer lost as measured by SEC and the total mass of subvisible particles as measured by MFI were in excellent agreement. The following is a copyright notice from Wiley-Liss, Inc. and the American Pharmacists Association: J Pharm Sci 100:492-503, 2011 Protein formulation, infrared spectroscopy, particle size, liquid chromatography, and protein aggregation are all relevant terms.

Introduction :

A decrease in product purity and quality and the possibility that aggregates may induce an immunogenic response in patients make therapeutic protein aggregation a big concern.¹ Proteins in solution may aggregate due to a variety of stressors, including heat, agitation, light, surface contact, and freeze-thaw cycles.²⁻⁸ Most frequently, the resultant aggregation and loss of native protein may be recognized and

quantified. evaluated using size-exclusion chromatography (SEC). One drawback of utilizing SEC to detect aggregates is that it can only detect aggregates within a very small size range, around 5 to 1000 kDa, which is considered soluble.² One other drawback of SEC is that it takes around 0.1% to 0.5% of the total protein to be soluble aggregates and/or native protein lost before a change can be accurately detected in practice.

Department of Pharmaceutics

Email ID: nallamekalasukanya38@gmail.com , Mobile no:9491169765

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DI. A.P - 524121



The Sensitive Method of Subvisible Particle Counting for the Detection and Quantification of Monoclonal Antibody Aggregation Caused by Freeze-Thawing: New Understanding of Particle Function in the Protein Aggregation Process

Mrs N Sukanya , Mrs P K Devibala , Ms.SK Zoofishaan , Mr.M R Pavan Kumar ,
Mr S Sivakoteswa Rao

Abstract

The purpose of this research was to measure the amount of subvisible particles formed throughout the freeze-thaw cycle of an IgG2 monoclonal antibody (mAb) using microflow imaging (MFI), a sensitive technique. Protein solutions in 20 mM histidine buffer (pH 5.5) were frozen and thawed three times before being examined using multiple-fraction isolation (MFI) and size-exclusion chromatography (SEC). While SEC could not identify aggregates, MFI demonstrated an increase in particle counts with each freeze-thaw cycle. Monitoring particle production enables the identification of protein aggregates containing just a tenth of a percent of the total protein mass, according to estimates of the total mass of particles generated. Even while SEC did not identify protein aggregation, variations in levels caused by various formulations or freeze-thaw protocols were addressed. The purpose of the freeze-thaw process in phosphate-buffered saline was to determine whether the total aggregate mass estimates derived from SEC and MFI were quantitatively compatible. This procedure reduced the monomer peak area in the chromatogram, which allowed SEC to identify insoluble aggregates at a detectable level. The amount of monomer lost as measured by SEC and the total mass of subvisible particles as measured by MFI were in excellent agreement. The following is a copyright notice from Wiley-Liss, Inc. and the American Pharmacists Association: J Pharm Sci 100:492-503, 2011 Protein formulation, infrared spectroscopy, particle size, liquid chromatography, and protein aggregation are all relevant terms.

Introduction :

A decrease in product purity and quality and the possibility that aggregates may induce an immunogenic response in patients make therapeutic protein aggregation a big concern.¹ Proteins in solution may aggregate due to a variety of stressors, including heat, agitation, light, surface contact, and freeze-thaw cycles.²⁻⁸ Most frequently, the resultant aggregation and loss of native protein may be recognized and

quantified. evaluated using size-exclusion chromatography (SEC). One drawback of utilizing SEC to detect aggregates is that it can only detect aggregates within a very small size range, around 5 to 1000 kDa, which is considered soluble.² One other drawback of SEC is that it takes around 0.1% to 0.5% of the total protein to be soluble aggregates and/or native protein lost before a change can be accurately detected in practice.

Department of Pharmaceutics

Email ID: nallamekalasukanya38@gmail.com , Mobile no:9491169765

GOKULA KRISHNA COLLEGE OF PHARMACY



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC FBSS FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



The Sensitive Method of Subvisible Particle Counting for the Detection and Quantification of Monoclonal Antibody Aggregation Caused by Freeze-Thawing: New Understanding of Particle Function in the Protein Aggregation Process

Mrs N Sukanya , Mrs P K Devibala , Ms.SK Zoofishaan , Mr.M R Pavan Kumar ,

Mr S Sivakoteswa Rao

Abstract

The purpose of this research was to measure the amount of subvisible particles formed throughout the freeze-thaw cycle of an IgG2 monoclonal antibody (mAb) using microflow imaging (MFI), a sensitive technique. Protein solutions in 20 mM histidine buffer (pH 5.5) were frozen and thawed three times before being examined using multiple-fraction isolation (MFI) and size-exclusion chromatography (SEC). While SEC could not identify aggregates, MFI demonstrated an increase in particle counts with each freeze-thaw cycle. Monitoring particle production enables the identification of protein aggregates containing just a tenth of a percent of the total protein mass, according to estimates of the total mass of particles generated. Even while SEC did not identify protein aggregation, variations in levels caused by various formulations or freeze-thaw protocols were addressed. The purpose of the freeze-thaw process in phosphate-buffered saline was to determine whether the total aggregate mass estimates derived from SEC and MFI were quantitatively compatible. This procedure reduced the monomer peak area in the chromatogram, which allowed SEC to identify insoluble aggregates at a detectable level. The amount of monomer lost as measured by SEC and the total mass of subvisible particles as measured by MFI were in excellent agreement. The following is a copyright notice from Wiley-Liss, Inc. and the American Pharmacists Association: J Pharm Sci 100:492-503, 2011 Protein formulation, infrared spectroscopy, particle size, liquid chromatography, and protein aggregation are all relevant terms.

Introduction :

A decrease in product purity and quality and the possibility that aggregates may induce an immunogenic response in patients make therapeutic protein aggregation a big concern.¹ Proteins in solution may aggregate due to a variety of stressors, including heat, agitation, light, surface contact, and freeze-thaw cycles.²⁻⁸ Most frequently, the resultant aggregation and loss of native protein may be recognized and

quantified. evaluated using size-exclusion chromatography (SEC). One drawback of utilizing SEC to detect aggregates is that it can only detect aggregates within a very small size range, around 5 to 1000 kDa, which is considered soluble.² One other drawback of SEC is that it takes around 0.1% to 0.5% of the total protein to be soluble aggregates and/or native protein lost before a change can be accurately detected in practice.

Department of Pharmaceutics

Email ID: nailamekalasukanya38@gmail.com , Mobile no:9491169765

GOKULA KRISHNA COLLEGE OF PHARMACY



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FSS, FAGE, FICOP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Cytotoxic Compounds from *Kibatalia gitingensis* (Elm.) Woodson

Dr.P Kishor, Mr.Sivakumar Peta, Dr.M Soujanya, Mrs S Usha Rani, Mrs Vanitha Devi

Department of Pharmacognosy
Email ID: kishorpharmacog@gmail.com, Mobile no:9951850662

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

The cytotoxic activities of ursolic acid (1), squalene (2), a mixture of α -amyrin acetate (3a) and lupeol acetate (3b), and isoscopoletin (4), which were extracted from the dichloromethane extracts of *Kibatalia gitingensis*'s leaves and twigs, were tested against three human cancer cell lines: MCF-7 for breast cancer, HT-29 and HCT-116 for colon cancer, and HDFn, a normal cell line, using the in vitro PrestoBlue® cell viability assay. The IC₅₀ values for compounds 1-4 ranged from 0.6931 to 1.083 μ g/mL, indicating high cytotoxic effects against HT-29 cells. In addition, the IC₅₀ values for 1-4 ranged from 4.065 to 11.09 μ g/mL, indicating significant cytotoxicity against HCT-116 cells.

The MCF-7 cells were least affected by these substances, with IC₅₀ values varying between 8.642 and 25.87 μ g/mL. On the one hand, 2, 4 and 1, respectively, are the most cytotoxic to HT-29 cells, HCT-116 cells, and MCF-7 cells.

Key words: Subfamily Apocynaceae, *Kibatalia gitingensis* Cytotoxicity, MCF-7, HCT-116, HT-29, HDFn, ursolic acid, squalene, α -amyrin acetate, Lupeol acetate, isoscopoletin, and PrestoBlue® cell viability test.

INTRODUCTION

Local names for the Apocynaceae family member *Kibatalia gitingensis* (Elm.) Woodson include "laniti" and "laneteng-gubat" in the Philippines. According to the International Union for the Conservation of Nature's Red List of Threatened Species, it is considered susceptible to extinction. The alkaloid concentration gives it therapeutic benefits, and it is also widely utilized as a construction material and for ornamental carvings. *gitingensine*, a steroidal alkaloid isolated from *K. gitingensis* leaves, has ataraxic effects (the ability to relax smooth muscles) and antispasmodic activity (the ability to widen the arteries of skeletal muscles and the splanchnic area).⁵ *Kibataline*^{6,7} and 20-(*epi-N*-methyl) paravallarine were found in *K. gitingensis* leaves in other research.⁸ The azasteroidal

alkaloid found in the plant eliminated serotonin-induced spasms and stimulated spontaneous movement in canines and mice. Paravallarine, *N*-methylparavallarine, and 20-*epi*paravallarine are among the several alkaloids extracted from *K. gitingensis* bark. Not only that, but lanitine (2 α -hydroxy-*N*-methylparavallarine) and its 2 β -isomer were found in the plant's stem bark, according to reports.¹¹

Our ongoing investigation into the bioactivities and chemical compositions of native and indigenous Philippine plants includes this study. In a previous paper, we detailed the procedure for extracting and identifying ursolic acid (1), squalene (2), a combination of α -amyrin acetate (3a) and lupeol acetate (3b) from the leaves, and 1-3 and isoscopoletin.

MATERIALS AND METHODS

Sample Collection

Samples of leaves and twigs of *Kibatalia gitingensis* (Elm.) Woodson were collected from the De La Salle University-Science and Technology Complex (DLSU-STC) reforested area in February 2014. The samples were authenticated and deposited at the De La Salle University Herbarium with voucher specimen #908.

Isolation and Structure Elucidation

The isolation and structure elucidation of 1-4 from the leaves and twigs of *K. gitingensis* were reported previously.¹²

Preparation of Compounds for Cytotoxicity Tests

The compounds (1-4) from *K. gitingensis* were dissolved in dimethyl sulfoxide (DMSO) to make a 4 mg/mL stock solution. Working solutions were prepared in complete growth medium to a final non-toxic DMSO concentration of 0.1%.




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Cytotoxic Compounds from *Kibatalia gitingensis* (Elm.) Woodson

Dr.P Kishor , Mr.Sivakumar Peta , Dr.M Soujanya , Mrs S Usha Rani ,Mrs Vanitha Devi

Department of Pharmacognosy
Email ID:kishorpharmacog@gmail.com , Mobile no:9951850662

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

The cytotoxic activities of ursolic acid (1), squalene (2), a mixture of α -amyirin acetate (3a) and lupeol acetate (3b), and isoscopoletin (4), which were extracted from the dichloromethane extracts of *Kibatalia gitingensis*'s leaves and twigs, were tested against three human cancer cell lines: MCF-7 for breast cancer, HT-29 and HCT-116 for colon cancer, and HDFn, a normal cell line, using the in vitro PrestoBlue® cell viability assay. The IC₅₀ values for compounds 1-4 ranged from 0.6931 to 1.083 μ g/mL, indicating high cytotoxic effects against HT-29 cells. In addition, the IC₅₀ values for 1-4 ranged from 4.065 to 11.09 μ g/mL, indicating significant cytotoxicity against HCT-116 cells.

The MCF-7 cells were least affected by these substances, with IC₅₀ values varying between 8.642 and 25.87 μ g/mL. On the one hand, 2, 4 and 1, respectively, are the most cytotoxic to HT-29 cells, HCT-116 cells, and MCF-7 cells.

Key words: Subfamily Apocynaceae, *Kibatalia gitingensis* Cytotoxicity, MCF-7, HCT-116, HT-29, HDFn, ursolic acid, squalene, α -amyirin acetate, Lupeol acetate, isoscopoletin, and PrestoBlue® cell viability test.

INTRODUCTION

Local names for the Apocynaceae family member *Kibatalia gitingensis* (Elm.) Woodson include "laniti" and "lanitengubat" in the Philippines. According to the International Union for the Conservation of Nature's Red List of Threatened Species, it is considered susceptible to extinction. The alkaloid concentration gives it therapeutic benefits, and it is also widely utilized as a construction material and for ornamental carvings. *gitingensine*, a steroidal alkaloid isolated from *K. gitingensis* leaves, has ataraxic effects (the ability to relax smooth muscles) and antispasmodic activity (the ability to widen the arteries of skeletal muscles and the splanchnic area).⁵ *Kibataline*,^{6,7} and 20-(*epi*-N-methyl) paravallarine were found in *K. gitingensis* leaves in other research.⁸ The azasteroidal

alkaloid found in the plant eliminated serotonin-induced spasm and stimulated spontaneous movement in canines and mice. Paravallarine, N-methylparavallarine, and 20-*epi*paravallarine are among the several alkaloids extracted from *K. gitingensis* bark. Not only that, but lanitine (2 α -hydroxy-N-methylparavallarine) and its 2 β -isomer were found in the plant's stem bark, according to reports.¹¹

Our ongoing investigation into the bioactivities and chemical compositions of native and indigenous Philippine plants includes this study. In a previous paper, we detailed the procedure for extracting and identifying ursolic acid (1), squalene (2), a combination of α -amyirin acetate (3a) and lupeol acetate (3b) from the leaves, and 1-3 and isoscopoletin.

MATERIALS AND METHODS

Sample Collection

Samples of leaves and twigs of *Kibatalia gitingensis* (Elm.) Woodson were collected from the De La Salle University-Science and Technology Complex (DLSU-STC) reforested area in February 2014. The samples were authenticated and deposited at the De La Salle University Herbarium with voucher specimen #908.

Isolation and Structure Elucidation

The isolation and structure elucidation of 1-4 from the leaves and twigs of *K. gitingensis* were reported previously.¹²

Preparation of Compounds for Cytotoxicity Tests

The compounds (1-4) from *K. gitingensis* were dissolved in dimethyl sulfoxide (DMSO) to make a 4 mg/mL stock solution. Working solutions were prepared in complete growth medium to a final non-toxic DMSO concentration of 0.1%.



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P. - 524121

Cytotoxic Compounds from *Kibatalia gitingensis* (Elm.) Woodson

Dr.P Kishor , Mr.Sivakumar Peta , Dr.M Soujanya , Mrs S Usha Rani ,Mrs Vanitha Devi

Department of Pharmacognosy
Email ID:kishorpharmacog@gmail.com , Mobile no:9951850662

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

The cytotoxic activities of ursolic acid (1), squalene (2), a mixture of α -amyrin acetate (3a) and lupeol acetate (3b), and isoscopoletin (4), which were extracted from the dichloromethane extracts of *Kibatalia gitingensis*'s leaves and twigs, were tested against three human cancer cell lines: MCF-7 for breast cancer, HT-29 and HCT-116 for colon cancer, and HDFn, a normal cell line, using the in vitro PrestoBlue® cell viability assay. The IC₅₀ values for compounds 1-4 ranged from 0.6931 to 1.083 μ g/mL, indicating high cytotoxic effects against HT-29 cells. In addition, the IC₅₀ values for 1-4 ranged from 4.065 to 11.09 μ g/mL, indicating significant cytotoxicity against HCT-116 cells.

The MCF-7 cells were least affected by these substances, with IC₅₀ values varying between 8.642 and 25.87 μ g/mL. On the one hand, 2, 4 and 1, respectively, are the most cytotoxic to HT-29 cells, HCT-116 cells, and MCF-7 cells.

Key words: Subfamily Apocynaceae, *Kibatalia gitingensis* Cytotoxicity, MCF-7, HCT-116, HT-29, HDFn, ursolic acid, squalene, α -amyrin acetate, Lupeol acetate, isoscopoletin, and PrestoBlue® cell viability test.

INTRODUCTION

Local names for the Apocynaceae family member *Kibatalia gitingensis* (Elm.) Woodson include "laniti" and "lanetong-gubat" in the Philippines. According to the International Union for the Conservation of Nature's Red List of Threatened Species, it is considered susceptible to extinction. The alkaloid concentration gives it therapeutic benefits, and it is also widely utilized as a construction material and for ornamental carvings. *gitingensine*, a steroidal alkaloid isolated from *K. gitingensis* leaves, has ataraxic effects (the ability to relax smooth muscles) and antispasmodic activity (the ability to widen the arteries of skeletal muscles and the splanchnic area).⁵ *Kibataline*^{6,7} and 20-(epi-N-methyl) paravallarine were found in *K. gitingensis* leaves in other research.⁸ The azasteroidal

alkaloid found in the plant eliminated serotonin-induced spasms and stimulated spontaneous movement in canines and mice. Paravallarine, N-methylparavallarine, and 20-epiparavallarine are among the several alkaloids extracted from *K. gitingensis* bark. Not only that, but lanitine (2 α -hydroxy-N-methylparavallarine) and its 2 β -isomer were found in the plant's stem bark, according to reports.¹¹

Our ongoing investigation into the bioactivities and chemical compositions of native and indigenous Philippine plants includes this study. In a previous paper, we detailed the procedure for extracting and identifying ursolic acid (1), squalene (2), a combination of α -amyrin acetate (3a) and lupeol acetate (3b) from the leaves, and 1-3 and isoscopoletin.

MATERIALS AND METHODS

Sample Collection

Samples of leaves and twigs of *Kibatalia gitingensis* (Elm.) Woodson were collected from the De La Salle University-Science and Technology Complex (DLSU-STC) reforested area in February 2014. The samples were authenticated and deposited at the De La Salle University Herbarium with voucher specimen#908.

Isolation and Structure Elucidation

The isolation and structure elucidation of 1-4 from the leaves and twigs of *K. gitingensis* were reported previously.¹²

Preparation of Compounds for Cytotoxicity Tests

The compounds (1-4) from *K. gitingensis* were dissolved in dimethyl sulfoxide (DMSO) to make a 4 mg/mL stock solution. Working solutions were prepared in complete growth medium to a final non-toxic DMSO concentration of 0.1%.



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC FBSS, PAGE, FICCP, MSTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P. - 524121

Cytotoxic Compounds from *Kibatalia gitingensis* (Elm.) Woodson

Dr.P Kishor , Mr.Sivakumar Peta , Dr.M Soujanya , Mrs S Usha Rani ,Mrs Vanitha Devi

Department of Pharmacognosy

Email ID:kishorpharmacog@gmail.com , Mobile no:9951850662

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

The cytotoxic activities of ursolic acid (1), squalene (2), a mixture of α -amyrin acetate (3a) and lupeol acetate (3b), and isoscopoletin (4), which were extracted from the dichloromethane extracts of *Kibatalia gitingensis*'s leaves and twigs, were tested against three human cancer cell lines: MCF-7 for breast cancer, HT-29 and HCT-116 for colon cancer, and HDFn, a normal cell line, using the in vitro PrestoBlue® cell viability assay. The IC₅₀ values for compounds 1-4 ranged from 0.6931 to 1.083 μ g/mL, indicating high cytotoxic effects against HT-29 cells. In addition, the IC₅₀ values for 1-4 ranged from 4.065 to 11.09 μ g/mL, indicating significant cytotoxicity against HCT-116 cells.

The MCF-7 cells were least affected by these substances, with IC₅₀ values varying between 8.642 and 25.87 μ g/mL. On the one hand, 2, 4 and 1, respectively, are the most cytotoxic to HT-29 cells, HCT-116 cells, and MCF-7 cells.

Key words: Subfamily Apocynaceae, *Kibatalia gitingensis* Cytotoxicity, MCF-7, HCT-116, HT-29, HDFn, ursolic acid, squalene, α -amyrin acetate, Lupeol acetate, isoscopoletin, and PrestoBlue® cell viability test.

INTRODUCTION

Local names for the Apocynaceae family member *Kibatalia gitingensis* (Elm.) Woodson include "laniti" and "lanetonggubat" in the Philippines. According to the International Union for the Conservation of Nature's Red List of Threatened Species, it is considered susceptible to extinction. The alkaloid concentration gives it therapeutic benefits, and it is also widely utilized as a construction material and for ornamental carvings. *gitingensine*, a steroidal alkaloid isolated from *K. gitingensis* leaves, has ataraxic effects (the ability to relax smooth muscles) and antispasmodic activity (the ability to widen the arteries of skeletal muscles and the splanchnic area). 5 *Kibataline* 6,7 and 20-(*epi-N*-methyl) paravallarine were found in *K. gitingensis* leaves in other research. 8 The azasteroidal

alkaloid found in the plant eliminated serotonin-induced spasm and stimulated spontaneous movement in canines and mice. Paravallarine, *N*-methylparavallarine, and 20-*epi*paravallarine are among the several alkaloids extracted from *K. gitingensis* bark. Not only that, but lanitine (2 α -hydroxy-*N*-methylparavallarine) and its 2 β -isomer were found in the plant's stem bark, according to reports. 11

Our ongoing investigation into the bioactivities and chemical compositions of native and indigenous Philippine plants includes this study. In a previous paper, we detailed the procedure for extracting and identifying ursolic acid (1) squalene (2), a combination of α -amyrin acetate (3a) and lupeol acetate (3b) from the leaves, and 1-3 and isoscopoletin.

MATERIALS AND METHODS

Sample Collection

Samples of leaves and twigs of *Kibatalia gitingensis* (Elm.) Woodson were collected from the De La Salle University-Science and Technology Complex (DLSU-STC) reforested area in February 2014. The samples were authenticated and deposited at the De La Salle University Herbarium with voucher specimen #908.

Isolation and Structure Elucidation

The isolation and structure elucidation of 1-4 from the leaves and twigs of *K. gitingensis* were reported previously. 12

Preparation of Compounds for Cytotoxicity Tests

The compounds (1-4) from *K. gitingensis* were dissolved in dimethyl sulfoxide (DMSO) to make a 4 mg/mL stock solution. Working solutions were prepared in complete growth medium to a final non-toxic DMSO concentration of 0.1%.




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P. - 524121

Cytotoxic Compounds from *Kibatalia gitingensis* (Elm.) Woodson

Dr.P Kishor , Mr.Sivakumar Peta , Dr.M Soujanya , Mrs S Usha Rani , Mrs Vanitha Devi

Department of Pharmacognosy

Email ID:kishorpharmacog@gmail.com , Mobile no:9951850662

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

The cytotoxic activities of ursolic acid (1), squalene (2), a mixture of α -amyrin acetate (3a) and lupeol acetate (3b), and isoscopoletin (4), which were extracted from the dichloromethane extracts of *Kibatalia gitingensis*'s leaves and twigs, were tested against three human cancer cell lines: MCF-7 for breast cancer, HT-29 and HCT-116 for colon cancer, and HDFn, a normal cell line, using the in vitro PrestoBlue® cell viability assay. The IC₅₀ values for compounds 1-4 ranged from 0.6931 to 1.083 μ g/mL, indicating high cytotoxic effects against HT-29 cells. In addition, the IC₅₀ values for 1-4 ranged from 4.065 to 11.09 μ g/mL, indicating significant cytotoxicity against HCT-116 cells.

The MCF-7 cells were least affected by these substances, with IC₅₀ values varying between 8.642 and 25.87 μ g/mL. On the one hand, 2, 4 and 1, respectively, are the most cytotoxic to HT-29 cells, HCT-116 cells, and MCF-7 cells.

Key words: Subfamily Apocynaceae, *Kibatalia gitingensis* Cytotoxicity, MCF-7, HCT-116, HT-29, HDFn, ursolic acid, squalene, α -amyrin acetate, Lupeol acetate, isoscopoletin, and PrestoBlue® cell viability test.

INTRODUCTION

Local names for the Apocynaceae family member *Kibatalia gitingensis* (Elm.) Woodson include "laniti" and "laneteng-gubat" in the Philippines. According to the International Union for the Conservation of Nature's Red List of Threatened Species, it is considered susceptible to extinction. The alkaloid concentration gives it therapeutic benefits, and it is also widely utilized as a construction material and for ornamental carvings. *gitingensine*, a steroidal alkaloid isolated from *K. gitingensis* leaves, has ataraxic effects (the ability to relax smooth muscles) and antispasmodic activity (the ability to widen the arteries of skeletal muscles and the splanchnic area).⁵ *Kibataline*,^{6,7} and 20-(*epi-N*-methyl) paravallarine were found in *K. gitingensis* leaves in other research.⁸ The azasteroidal

alkaloid found in the plant eliminated serotonin-induced spasm and stimulated spontaneous movement in canines and mice. Paravallarine, *N*-methylparavallarine, and 20-*epi*paravallarine are among the several alkaloids extracted from *K. gitingensis* bark. Not only that, but lanitine (2 α -hydroxy-*N*-methylparavallarine) and its 2 β -isomer were found in the plant stem bark, according to reports.¹¹

Our ongoing investigation into the bioactivities and chemical compositions of native and indigenous Philippine plants includes this study. In a previous paper, we detailed the procedure for extracting and identifying ursolic acid (1), squalene (2), a combination of α -amyrin acetate (3a) and lupeol acetate (3b) from the leaves, and 1-3 and isoscopoletin.

MATERIALS AND METHODS

Sample Collection

Samples of leaves and twigs of *Kibatalia gitingensis* (Elm.) Woodson were collected from the De La Salle University-Science and Technology Complex (DLSU-STC) reforested area in February 2014. The samples were authenticated and deposited at the De La Salle University Herbarium with voucher specimen #908.


Isolation and Structure Elucidation

The isolation and structure elucidation of 1-4 from the leaves and twigs of *K. gitingensis* were reported previously.¹²

Preparation of Compounds for Cytotoxicity Tests

The compounds (1-4) from *K. gitingensis* were dissolved in dimethyl sulfoxide (DMSO) to make a 4 mg/mL stock solution. Working solutions were prepared in complete growth medium to a final non-toxic DMSO concentration of 0.1%.




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Development and Standardization of a Polyherbal Anti Urolithiatic Suspension

Pallepati Kishor^{1*}, Pallepati Kavitha², Siva Kumar Peta³

¹Department of Pharmacognosy and Phytochemistry, Gokula Krishna College of Pharmacy, Sullurupeta, Nellore District, Andhra Pradesh, India

²Department of Pharmaceutical Chemistry, Gokula Krishna College of Pharmacy, Sullurupeta, Nellore District, Andhra Pradesh, India

³Department of Pharmaceutics, Gokula Krishna College of Pharmacy, Sullurupeta, Nellore District, Andhra Pradesh, India

Article History:

Received on: 15 Feb 2022
Revised on: 03 Mar 2022
Accepted on: 04 Mar 2022

Keywords:

Urolithiasis,
Polyherbal Suspension,
Antilithiatic Effect,
Herbal Treatment,
Cystone

ABSTRACT

Renal terrific concentration with respect to stone forming components is mostly recognized to become one of the casual factors such as Calculogenesis. At this work, the preparation and standardization of polyherbal suspension was carried out. Proximate analysis values include percentage of the overall residue, proportion like acetone non-soluble residue, fraction of water soluble ash, percentage of moisture content and percentage of extractive values were analysed for various plants. Preliminary phytochemical analysis of various extracts of the plant revealed the presence of various constituents like glycosides, flavonoids, saponins, steroids etc. Poly-herbal anti-urolithiatic suspension was prepared by combining the prepared extracts of *Tribulus terrestris* L., *Aerva lanata* L., *Crataeva religiosa* Hook & Frost and *Embllica officinalis* L. with suspension base. The prepared formulation showed good stability and redispersibility. Inside the research project, male mice have been chosen to urolithiasis so because excretory system of male mice starts to resemble that from people and then also existing research show that having the quantity like stone discharge through female mice had been substantially lower. Such research results, thereby stimulate the need for any further research to hold over the antilithiatic effect of the polyherbal suspension to prove that more effective treatment for lithiasis with polyherbal suspension can be achieved.

1 *Corresponding Author

2 Name: Pallepati Kishor
3 Phone: +91 9951850662
4 Email: kishorpharmacog@gmail.com

6 eISSN: 2583-116X

pISSN:

7 DOI: <https://doi.org/10.26452/>



Production and Hosted by
Pharmasprings.com
© 2022 | All rights reserved.

INTRODUCTION

Urolithiasis is a condition where stones form in the kidneys or the bladder. These stones are made of minerals and salts. Patients with this condition can have a variety of symptoms, depending on how severe it is. Urinary stones are calcifications that form in the kidney, ureter, or bladder [1]. They are most common in children and older adults. Urinary stones can be just like a little like a dust particle or even as big as either a tennis ball. Symptoms of urinary stones include blood in your urine, an inability to urinate, pain when urinating, increased thirst and dark urine. If untreated there is a high risk for acute renal failure resulting in kidney problems [2]. Urolithiasis is a medical term for bladder, kidney or





Development and Standardization of a Polyherbal Anti Urolithiatic Suspension

Pallepati Kishor¹, Pallepati Kavitha², Siva Kumar Peta³

¹Department of Pharmacognosy and Phytochemistry, Gokula Krishna College of Pharmacy, Sullurupeta, Nellore District, Andhra Pradesh, India

²Department of Pharmaceutical Chemistry, Gokula Krishna College of Pharmacy, Sullurupeta, Nellore District, Andhra Pradesh, India

³Department of Pharmaceutics, Gokula Krishna College of Pharmacy, Sullurupeta, Nellore District, Andhra Pradesh, India

Article History:

Received on: 15 Feb 2022
Revised on: 03 Mar 2022
Accepted on: 04 Mar 2022

Keywords:

Urolithiasis,
Polyherbal Suspension,
Antilithiatic Effect,
Herbal Treatment,
Cystone

ABSTRACT

Renal terrific concentration with respect to stone forming components is mostly recognized to become one of the casual factors such as Calculogenesis. At this work, the preparation and standardization of polyherbal suspension was carried out. Proximate analysis values include percentage of the overall residue, proportion like acetone non-soluble residue, fraction of water soluble ash, percentage of moisture content and percentage of extractive values were analysed for various plants. Preliminary phytochemical analysis of various extracts of the plant revealed the presence of various constituents like glycosides, flavonoids, saponins, steroids etc. Poly-herbal anti-urolithiatic suspension was prepared by combining the prepared extracts of *Tribulus terrestris* L., *Aerva lanata* L., *Crataeva religiosa* Hook & Frost and *Embllica officinalis* L. with suspension base. The prepared formulation showed good stability and redispersibility. Inside the research project, male mice have been chosen to urolithiasis so because excretory system of male mice starts to resemble that from people and then also existing research show that having the quantity like stone discharge through female mice had been substantially lower. Such research results, thereby stimulate the need for any further research to hold over the antilithiatic effect of the polyherbal suspension to prove that more effective treatment for lithiasis with polyherbal suspension can be achieved.

1 * Corresponding Author

2 Name: Pallepati Kishor
3 Phone: +91 9951850662
4 Email: kishorpharmacog@gmail.com

6 eISSN: 2583-116X

pISSN:

7 DOI: <https://doi.org/10.26452/>



Production and Hosted by

Pharmaspings.com
© 2022 | All rights reserved.

INTRODUCTION

Urolithiasis is a condition where stones form in the kidneys or the bladder. These stones are made of minerals and salts. Patients with this condition can have a variety of symptoms, depending on how severe it is. Urinary stones are calcifications that form in the kidney, ureter, or bladder [1]. They are most common in children and older adults. Urinary stones can be just like a little like a dust particle or even as big as either a tennis ball. Symptoms of urinary stones include blood in your urine, an inability to urinate, pain when urinating, increased thirst and dark urine. If untreated there is a high risk for acute renal failure resulting in kidney problems [2]. Urolithiasis is a medical term for bladder, kidney or



Dr. Balagopalavan Kumar
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURUPETA, TIRUPATI DL. A.P. - 524121



Development and Standardization of a Polyherbal Anti Urolithiatic Suspension

Pallepati Kishor^{*1}, Pallepati Kavitha², Siva Kumar Peta³

¹Department of Pharmacognosy and Phytochemistry, Gokula Krishna College of Pharmacy, Sullurupeta, Nellore District, Andhra Pradesh, India

²Department of Pharmaceutical Chemistry, Gokula Krishna College of Pharmacy, Sullurupeta, Nellore District, Andhra Pradesh, India

³Department of Pharmaceutics, Gokula Krishna College of Pharmacy, Sullurupeta, Nellore District, Andhra Pradesh, India

Article History:

Received on: 15 Feb 2022
Revised on: 03 Mar 2022
Accepted on: 04 Mar 2022

Keywords:

Urolithiasis,
Polyherbal Suspension,
Antilithiatic Effect,
Herbal Treatment,
Cystone

ABSTRACT

Renal terrific concentration with respect to stone forming components is mostly recognized to become one of the casual factors such as Calculogenesis. At this work, the preparation and standardization of polyherbal suspension was carried out. Proximate analysis values include percentage of the overall residue, proportion like acetone non-soluble residue, fraction of water soluble ash, percentage of moisture content and percentage of extractive values were analysed for various plants. Preliminary phytochemical analysis of various extracts of the plant revealed the presence of various constituents like glycosides, flavonoids, saponins, steroids etc. Poly-herbal anti-urolithiatic suspension was prepared by combining the prepared extracts of *Tribulus terrestris* L., *Aerva lanata* L., *Crataeva religiosa* Hook & Frost and *Embllica officinalis* L. with suspension base. The prepared formulation showed good stability and redispersibility. Inside the research project, male mice have been chosen to urolithiasis so because excretory system of male mice starts to resemble that from people and then also existing research show that having the quantity like stone discharge through female mice had been substantially lower. Such research results, thereby stimulate the need for any further research to hold over the antilithiatic effect of the polyherbal suspension to prove that more effective treatment for lithiasis with polyherbal suspension can be achieved.

1 * Corresponding Author

2 Name: Pallepati Kishor

3 Phone: +91 9951850662

4 Email: kishorpharmacog@gmail.com

6 eISSN: 2583-116X

pISSN:

7 DOI: <https://doi.org/10.26452/>



Production and Hosted by

Pharmaspings.com

© 2022 | All rights reserved.

INTRODUCTION

Urolithiasis is a condition where stones form in the kidneys or the bladder. These stones are made of minerals and salts. Patients with this condition can have a variety of symptoms, depending on how severe it is. Urinary stones are calcifications that form in the kidney, ureter, or bladder [1]. They are most common in children and older adults. Urinary stones can be just like a little like a dust particle or even as big as either a tennis ball. Symptoms of urinary stones include blood in your urine, an inability to urinate, pain when urinating, increased thirst and dark urine. If untreated there is a high risk for acute renal failure resulting in kidney problems [2]. Urolithiasis is a medical term for bladder, kidney or

Dr. BALAGANI PAVAN KUMAR

M. Pharm, Ph.D, FIC, FSSG, FAGE, FICOP, MSTE

PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY

SULLURPET, TIRUPATI DL. A.P. - 524121





GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

NO. OF RESEARCH PAPERS PUBLISHED PER TEACHER IN THE JOURNALS NOTIFIED ON UGC CARE LIST DURING THE LAST FIVE YEARS

CALENDER YEAR - 2021

S.No	Title of the Paper	Name of the Author/s	Name of the Journal	ISSN NO
1	An Investigation of Effectiveness of Aluminium chloride induced Alzheimer's disease in various Experimental Rats	P.Kishor	Asian Journal of Phytomedicine and Clinical Research	2321-0915
2	An Investigation of Effectiveness of Aluminium chloride induced Alzheimer's disease in various Experimental Rats	P.Kavitha	Asian Journal of Phytomedicine and Clinical Research	2321-0915
3	UV/VIS imaging-based PAT tool for drug particle size inspection in intact tablets supported by pattern recognition neural networks	Dr.Balagani Pavan Kumar	Indo-American Journal of Pharma and Biosciences	2347-2251
4	UV/VIS imaging-based PAT tool for drug particle size inspection in intact tablets supported by pattern recognition neural networks	Ms.P Kavitha	Indo-American Journal of Pharma and Biosciences	2347-2251
5	UV/VIS imaging-based PAT tool for drug particle size inspection in intact tablets supported by pattern recognition neural networks	Mr.C G Bhaskar	Indo-American Journal of Pharma and Biosciences	2347-2251
6	UV/VIS imaging-based PAT tool for drug particle size inspection in intact tablets supported by pattern recognition neural networks	Mrs.Y Swarupa	Indo-American Journal of Pharma and Biosciences	2347-2251

Navay



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

7	UV/VIS imaging-based PAT tool for drug particle size inspection in intact tablets supported by pattern recognition neural networks	Mr.N Praveen Kumar	Indo-American Journal of Pharma and Biosciences	2347-2251
8	Screening of Antidepressant Activity of Punicagranatum in Mice	Dr.P Kishor	International Journal of Gender, Science and Technology	2040-0748
9	Screening of Antidepressant Activity of Punicagranatum in Mice	Ms.A R Sridevi	International Journal of Gender, Science and Technology	2040-0748
10	Screening of Antidepressant Activity of Punicagranatum in Mice	Ms SK Zoofishaan	International Journal of Gender, Science and Technology	2040-0748
11	Screening of Antidepressant Activity of Punicagranatum in Mice	Mr.M Kalyan babu	International Journal of Gender, Science and Technology	2040-0748
12	Screening of Antidepressant Activity of Punicagranatum in Mice	Ms A Aksa Anvija	International Journal of Gender, Science and Technology	2040-0748
13	How the Effectiveness of Aluminum Salt Adjuvants in a Model Lysozyme Vaccine Is Affected by Particle Size and Antigen Binding	Ms.P Kavitha	History of Medicine studies	1300-669
14	How the Effectiveness of Aluminum Salt Adjuvants in a Model Lysozyme Vaccine Is Affected by Particle Size and Antigen Binding	Mrs. C B Hanisha	History of Medicine studies	1300-669

Navay



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

15	How the Effectiveness of Aluminum Salt Adjuvants in a Model Lysozyme Vaccine Is Affected by Particle Size and Antigen Binding	Dr.M Soujanya	History of Medicine studies	1300-669
16	How the Effectiveness of Aluminum Salt Adjuvants in a Model Lysozyme Vaccine Is Affected by Particle Size and Antigen Binding	Mr N Praveen Kumar	History of Medicine studies	1300-669
17	How the Effectiveness of Aluminum Salt Adjuvants in a Model Lysozyme Vaccine Is Affected by Particle Size and Antigen Binding	Ms M Soumya	History of Medicine studies	1300-669
18	The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development	Dr.Balagani Pavan Kumar	Indo-American Journal of Lifesciences and Biotechnology	2347-2243
19	The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development	Mrs.P K Devi Bala	Indo-American Journal of Lifesciences and Biotechnology	2347-2243
20	The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development	Mrs P Madhavi	Indo-American Journal of Lifesciences and Biotechnology	2347-2243
21	The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development	Mrs M Sindhuri	Indo-American Journal of Lifesciences and Biotechnology	2347-2243



Navay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL, A.P. - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

22	The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development	Mrs.S K Lathifa	Indo-American Journal of Lifesciences and Biotechnology	2347-2243
23	The Synthesis of Diverse Annulated Pyridines with 6-Membered Functionalized Saturated Cycles for Medical Chemistry Research	Mr.Sivakumar Peta	International Journal of Pharmaceutical Sciences Letters	2277-2685
24	The Synthesis of Diverse Annulated Pyridines with 6-Membered Functionalized Saturated Cycles for Medical Chemistry Research	Dr.C Rajaram	International Journal of Pharmaceutical Sciences Letters	2277-2685
25	The Synthesis of Diverse Annulated Pyridines with 6-Membered Functionalized Saturated Cycles for Medical Chemistry Research	Mr.AVLS Ramakrishna	International Journal of Pharmaceutical Sciences Letters	2277-2685
26	The Synthesis of Diverse Annulated Pyridines with 6-Membered Functionalized Saturated Cycles for Medical Chemistry Research	Mr M R Pavan Kumar	International Journal of Pharmaceutical Sciences Letters	2277-2685
27	The Synthesis of Diverse Annulated Pyridines with 6-Membered Functionalized Saturated Cycles for Medical Chemistry Research	Mr Y Naveen Kumar	International Journal of Pharmaceutical Sciences Letters	2277-2685
28	A randomised, parallel, open-label clinical study comparing the effectiveness and safety of apremilast with methotrexate in individuals with moderate to severe palmoplantar psoriasis.	Mrs T Swathi	International Journal of Pharmaceutical Sciences Letters	2277-2685



Kavay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

29	A randomised, parallel, open-label clinical study comparing the effectiveness and safety of apremilast with methotrexate in individuals with moderate to severe palmoplantar psoriasis.	Mr.T Nagendra Kumar	International Journal of Pharmaceutical Sciences Letters	2277-2685
30	A randomised, parallel, open-label clinical study comparing the effectiveness and safety of apremilast with methotrexate in individuals with moderate to severe palmoplantar psoriasis.	Mr.M R Pavan Kumar	International Journal of Pharmaceutical Sciences Letters	2277-2685
31	A randomised, parallel, open-label clinical study comparing the effectiveness and safety of apremilast with methotrexate in individuals with moderate to severe palmoplantar psoriasis.	Mrs. Y R Anitha	International Journal of Pharmaceutical Sciences Letters	2277-2685
32	A randomised, parallel, open-label clinical study comparing the effectiveness and safety of apremilast with methotrexate in individuals with moderate to severe palmoplantar psoriasis.	Mrs.P Sukanya	International Journal of Pharmaceutical Sciences Letters	2277-2685

PRINCIPAL



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL, A.P - 524121



Asian Journal of Phytomedicine and Clinical Research

Journal home page: www.ajpcrjournal.com

<https://doi.org/10.36673/AJPCR.2021.v09.i04.A18>



AN INVESTIGATION OF EFFECTIVENESS OF ALUMINIUM CHLORIDE INDUCED ALZHEIMER'S DISEASE IN VARIOUS EXPERIMENTAL RATS

P. Kishore*¹ and P. Kavitha²

¹Department of Pharmacognosy and Phytochemistry, Gokula Krishna College of Pharmacy, Sullurupet, Nellore, Andhra Pradesh, India.

²Department of Pharmaceutics, Gokula Krishna College of Pharmacy, Sullurupet, Nellore, Andhra Pradesh, India.

ABSTRACT

The Neuroprotective against AlCl₃ induced toxicity. Enhanced learning and memory was allied to ingestion of extract in rats. Al overload, AChE hyperactivity are responsible for alzheimers disease which are neutralized or reduced with treatment of extract, which might be due to the synergistic action of its active constituents. However extensive research is needed to validate the anti-alzheimeric effect of extract active components against a variety of models of AD, prior to entering into the clinical trials.

KEYWORDS

Anti-alzheimeric effect, AlCl₃ and AChE hyperactivity.

Author for Correspondence:

Kishore P,
Department of Pharmacognosy and Phytochemistry,
Gokula Krishna College of Pharmacy, Sullurupet,
Nellore, Andhra Pradesh, India.

Email: kirn1987@gmail.com

INTRODUCTION

As of 2020 globally, there were approximately 51 million people worldwide with Alzheimer's disease. It most often begins in people over 65 years of age, although up to 11% of cases are early-onset affecting those in their 30s to mid 60s. Women get sick more often than men. It affects about 6% of people 65 years and older¹. In 2015, all forms of dementia resulted in about 1.9 million deaths.

Causes

Less than 1% of the time, Alzheimer's is caused by specific genetic changes that virtually guarantee a person will develop the disease.





Asian Journal of Phytomedicine and Clinical Research

Journal home page: www.ajpcrjournal.com

<https://doi.org/10.36673/AJPCR.2021.v09.i04.A18>



AN INVESTIGATION OF EFFECTIVENESS OF ALUMINIUM CHLORIDE INDUCED ALZHEIMER'S DISEASE IN VARIOUS EXPERIMENTAL RATS

P. Kishore*¹ and P. Kavitha²

¹Department of Pharmacognosy and Phytochemistry, Gokula Krishna College of Pharmacy, Sullurupet, Nellore, Andhra Pradesh, India.

²Department of Pharmaceutics, Gokula Krishna College of Pharmacy, Sullurupet, Nellore, Andhra Pradesh, India.

ABSTRACT

The Neuroprotective against $AlCl_3$ induced toxicity. Enhanced learning and memory was allied to ingestion of extract in rats. Al overload, AChE hyperactivity are responsible for alzheimers disease which are neutralized or reduced with treatment of extract, which might be due to the synergistic action of its active constituents. However extensive research is needed to validate the anti-alzheimeric effect of extract active components against a variety of models of AD, prior to entering into the clinical trials.

KEYWORDS

Anti-alzheimeric effect, $AlCl_3$ and AChE hyperactivity.

Author for Correspondence:

Kishore P,
Department of Pharmacognosy and Phytochemistry,
Gokula Krishna College of Pharmacy, Sullurupet,
Nellore, Andhra Pradesh, India.

Email: kirn1987@gmail.com

INTRODUCTION

As of 2020 globally, there were approximately 51 million people worldwide with Alzheimer's disease. It most often begins in people over 65 years of age, although up to 11% of cases are early-onset affecting those in their 30s to mid 60s. Women get sick more often than men. It affects about 6% of people 65 years and older¹. In 2015, all forms of dementia resulted in about 1.9 million deaths.


Causes

Less than 1% of the time, Alzheimer's is caused by specific genetic changes that virtually guarantee a person will develop the disease.





ISSN : 2347-2251
Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com



Narayana

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FDSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



UV/VIS imaging-based PAT tool for drug particle size inspection in intact tablets supported by pattern recognition neural networks

Dr. Balagani Pavan Kumar, Ms. P Kavitha, Mr. C G Bhaskar, Mrs. Y Swarupa, Mr. N Praveen Kumar

ABSTRACT

The potential of machine vision systems has not currently been exploited for pharmaceutical applications, although expected to provide revolutionary solutions for in-process and final product testing. The presented paper aimed to analyze the particle size of meloxicam, a yellow model active pharmaceutical ingredient, in intact tablets by a digital UV/VIS imaging-based machine vision system. Two image processing algorithms were developed and coupled with pattern recognition neural networks for UV and VIS images for particle size-based classification of the prepared tablets. The developed method can identify tablets containing finer or larger particles than the target with more than 97% accuracy. Two algorithms were developed for UV and VIS images for particle size analysis of the prepared tablets. According to the applied statistical tests, the obtained particle size distributions were similar to the results of the laser diffraction-based reference method. Digital UV/VIS imaging combined with multivariate data analysis can provide a new non-destructive, rapid, in-line tool for particle size analysis in tablets.

Keywords: Image analysis Machine vision Tablet inspection Particle size distribution Particle size analysis Pattern recognition neural network


1. Introduction

Tablets represent a significant portion of the pharmaceutical dosage forms, due to their several advantageous properties, for example, convenient administration, stability, portability, and dosing accuracy (Gaikwad and Kshirsagar, 2020; Sayeed, 2015; Skelbæk-Pedersen et al., 2020). In 2015, the U.S Food and Drug Administration (FDA) approved the first commercial product, Orkambi by Vertex, manufactured using continuous technology. Thus, the modern manufacturing of pharmaceutical solid dosage forms has begun (Kensaku et al., 2019). Since then, continuous manufacturing, emerging technologies, modernization, and innovation have been the focus of attention and supported by the regulatory agencies (Yeaton, 2019). The published recommendations, guidelines, and frameworks, including process analytical technology (PAT) and the concept of quality-by-design (QbD), enable

production monitoring and controlling, data collection, and process understanding (U.S. Food and Drug Administration, 2004; U.S. Food and Drug Administration, 2009). The initiative of PAT published by the U.S. FDA reinforces the in-line or on-line data-based process control (am Ende and am Ende, 2019; U.S. Food and Drug Administration, 2004). The development of PAT tools can provide consistent quality throughout the manufacturing by monitoring and controlling process parameters and quality attributes (Scott et al., 1998). In the modernization concept, data-driven solutions can contribute to understanding the processes and controlling the intermittent variability to enable consistent quality in each step of the production. These reserve an essential role in implementing QbD and real-time release testing (RTRT) approaches (Ramadan et al., 2021).


Department of pharmaceuticals,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC FDSS FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347-2251
Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com



Balagan
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC FSS FAGE FICP MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



UV/VIS imaging-based PAT tool for drug particle size inspection in intact tablets supported by pattern recognition neural networks

Dr. Balagani Pavan Kumar, Ms. P Kavitha, Mr. C G Bhaskar, Mrs. Y Swarupa, Mr. N Praveen Kumar

ABSTRACT

The potential of machine vision systems has not currently been exploited for pharmaceutical applications, although expected to provide revolutionary solutions for in-process and final product testing. The presented paper aimed to analyze the particle size of meloxicam, a yellow model active pharmaceutical ingredient, in intact tablets by a digital UV/VIS imaging-based machine vision system. Two image processing algorithms were developed and coupled with pattern recognition neural networks for UV and VIS images for particle size-based classification of the prepared tablets. The developed method can identify tablets containing finer or larger particles than the target with more than 97% accuracy. Two algorithms were developed for UV and VIS images for particle size analysis of the prepared tablets. According to the applied statistical tests, the obtained particle size distributions were similar to the results of the laser diffraction-based reference method. Digital UV/VIS imaging combined with multivariate data analysis can provide a new non-destructive, rapid, in-line tool for particle size analysis in tablets.

Keywords: Image analysis Machine vision Tablet inspection Particle size distribution Particle size analysis Pattern recognition neural network

1. Introduction

Tablets represent a significant portion of the pharmaceutical dosage forms, due to their several advantageous properties, for example, convenient administration, stability, portability, and dosing accuracy (Gaikwad and Kshirsagar, 2020; Sayeed, 2015; Skelbæk-Pedersen et al., 2020). In 2015, the U.S Food and Drug Administration (FDA) approved the first commercial product, Orkambi by Vertex, manufactured using continuous technology. Thus, the modern manufacturing of pharmaceutical solid dosage forms has begun (Kensaku et al., 2019). Since then, continuous manufacturing, emerging technologies, modernization, and innovation have been the focus of attention and supported by the regulatory agencies (Yeaton, 2019). The published recommendations, guidelines, and frameworks, including process analytical technology (PAT) and the concept of quality-by-design (QbD), enable

production monitoring and controlling, data collection, and process understanding (U.S. Food and Drug Administration, 2004; U.S. Food and Drug Administration, 2009). The initiative of PAT published by the U.S. FDA reinforces the in-line or on-line data-based process control (am Ende and am Ende, 2019; U.S. Food and Drug Administration, 2004). The development of PAT tools can provide consistent quality throughout the manufacturing by monitoring and controlling process parameters and quality attributes (Scott et al., 1998). In the modernization concept, data-driven solutions can contribute to understanding the processes and controlling the intermittent variability to enable consistent quality in each step of the production. These reserve an essential role in implementing QbD and real-time release testing (RTRT) approaches (Ramadan et al., 2021).

Department of pharmaceuticals,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FDS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



UV/VIS imaging-based PAT tool for drug particle size inspection in intact tablets supported by pattern recognition neural networks

Dr. Balagani Pavan Kumar, Ms. P Kavitha, Mr. C G Bhaskar, Mrs. Y Swarupa, Mr. N Praveen Kumar

ABSTRACT

The potential of machine vision systems has not currently been exploited for pharmaceutical applications, although expected to provide revolutionary solutions for in-process and final product testing. The presented paper aimed to analyze the particle size of meloxicam, a yellow model active pharmaceutical ingredient, in intact tablets by a digital UV/VIS imaging-based machine vision system. Two image processing algorithms were developed and coupled with pattern recognition neural networks for UV and VIS images for particle size-based classification of the prepared tablets. The developed method can identify tablets containing finer or larger particles than the target with more than 97% accuracy. Two algorithms were developed for UV and VIS images for particle size analysis of the prepared tablets. According to the applied statistical tests, the obtained particle size distributions were similar to the results of the laser diffraction-based reference method. Digital UV/VIS imaging combined with multivariate data analysis can provide a new non-destructive, rapid, in-line tool for particle size analysis in tablets.

Keywords: Image analysis Machine vision Tablet inspection Particle size distribution Particle size analysis Pattern recognition neural network

1. Introduction

Tablets represent a significant portion of the pharmaceutical dosage forms, due to their several advantageous properties, for example, convenient administration, stability, portability, and dosing accuracy (Gaikwad and Kshirsagar, 2020; Sayeed, 2015; Skelbæk-Pedersen et al., 2020). In 2015, the U.S Food and Drug Administration (FDA) approved the first commercial product, Orkambi by Vertex, manufactured using continuous technology. Thus, the modern manufacturing of pharmaceutical solid dosage forms has begun (Kensaku et al., 2019). Since then, continuous manufacturing, emerging technologies, modernization, and innovation have been the focus of attention and supported by the regulatory agencies (Yeaton, 2019). The published recommendations, guidelines, and frameworks, including process analytical technology (PAT) and the concept of quality-by-design (QbD), enable

production monitoring and controlling, data collection, and process understanding (U.S. Food and Drug Administration, 2004; U.S. Food and Drug Administration, 2009). The initiative of PAT published by the U.S. FDA reinforces the in-line or on-line data-based process control (am Ende and am Ende, 2019; U.S. Food and Drug Administration, 2004). The development of PAT tools can provide consistent quality throughout the manufacturing by monitoring and controlling process parameters and quality attributes (Scott et al., 1998). In the modernization concept, data-driven solutions can contribute to understanding the processes and controlling the intermittent variability to enable consistent quality in each step of the production. These reserve an essential role in implementing QbD and real-time release testing (RTRT) approaches (Ramadan et al., 2021).


Department of pharmaceuticals,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347-2251
Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com



Balagan

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC-FBSS FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



UV/VIS imaging-based PAT tool for drug particle size inspection in intact tablets supported by pattern recognition neural networks

Dr. Balagani Pavan Kumar, Ms. P Kavitha, Mr. C G Bhaskar, Mrs. Y Swarupa, Mr. N Praveen Kumar

ABSTRACT

The potential of machine vision systems has not currently been exploited for pharmaceutical applications, although expected to provide revolutionary solutions for in-process and final product testing. The presented paper aimed to analyze the particle size of meloxicam, a yellow model active pharmaceutical ingredient, in intact tablets by a digital UV/VIS imaging-based machine vision system. Two image processing algorithms were developed and coupled with pattern recognition neural networks for UV and VIS images for particle size-based classification of the prepared tablets. The developed method can identify tablets containing finer or larger particles than the target with more than 97% accuracy. Two algorithms were developed for UV and VIS images for particle size analysis of the prepared tablets. According to the applied statistical tests, the obtained particle size distributions were similar to the results of the laser diffraction-based reference method. Digital UV/VIS imaging combined with multivariate data analysis can provide a new non-destructive, rapid, in-line tool for particle size analysis in tablets.

Keywords: Image analysis Machine vision Tablet inspection Particle size distribution Particle size analysis Pattern recognition neural network


1. Introduction

Tablets represent a significant portion of the pharmaceutical dosage forms, due to their several advantageous properties, for example, convenient administration, stability, portability, and dosing accuracy (Gaikwad and Kshirsagar, 2020; Sayeed, 2015; Skelbæk-Pedersen et al., 2020). In 2015, the U.S Food and Drug Administration (FDA) approved the first commercial product, Orkambi by Vertex, manufactured using continuous technology. Thus, the modern manufacturing of pharmaceutical solid dosage forms has begun (Kensaku et al., 2019). Since then, continuous manufacturing, emerging technologies, modernization, and innovation have been the focus of attention and supported by the regulatory agencies (Yeaton, 2019). The published recommendations, guidelines, and frameworks, including process analytical technology (PAT) and the concept of quality-by-design (QbD), enable

production monitoring and controlling, data collection, and process understanding (U.S. Food and Drug Administration, 2004; U.S. Food and Drug Administration, 2009). The initiative of PAT published by the U.S. FDA reinforces the in-line or on-line data-based process control (am Ende and am Ende, 2019; U.S. Food and Drug Administration, 2004). The development of PAT tools can provide consistent quality throughout the manufacturing by monitoring and controlling process parameters and quality attributes (Scott et al., 1998). In the modernization concept, data-driven solutions can contribute to understanding the processes and controlling the intermittent variability to enable consistent quality in each step of the production. These reserve an essential role in implementing QbD and real-time release testing (RTRT) approaches (Ramadan et al., 2021).


Department of pharmaceuticals,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347-2251
Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, F855, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



UV/VIS imaging-based PAT tool for drug particle size inspection in intact tablets supported by pattern recognition neural networks

Dr. Balagani Pavan Kumar, Ms. P Kavitha, Mr. C G Bhaskar, Mrs. Y Swarupa, Mr. N Praveen Kumar

ABSTRACT

The potential of machine vision systems has not currently been exploited for pharmaceutical applications, although expected to provide revolutionary solutions for in-process and final product testing. The presented paper aimed to analyze the particle size of meloxicam, a yellow model active pharmaceutical ingredient, in intact tablets by a digital UV/VIS imaging-based machine vision system. Two image processing algorithms were developed and coupled with pattern recognition neural networks for UV and VIS images for particle size-based classification of the prepared tablets. The developed method can identify tablets containing finer or larger particles than the target with more than 97% accuracy. Two algorithms were developed for UV and VIS images for particle size analysis of the prepared tablets. According to the applied statistical tests, the obtained particle size distributions were similar to the results of the laser diffraction-based reference method. Digital UV/VIS imaging combined with multivariate data analysis can provide a new non-destructive, rapid, in-line tool for particle size analysis in tablets.

Keywords: Image analysis Machine vision Tablet inspection Particle size distribution Particle size analysis Pattern recognition neural network

1. Introduction

Tablets represent a significant portion of the pharmaceutical dosage forms, due to their several advantageous properties, for example, convenient administration, stability, portability, and dosing accuracy (Gaikwad and Kshirsagar, 2020; Sayeed, 2015; Skelbæk-Pedersen et al., 2020). In 2015, the U.S Food and Drug Administration (FDA) approved the first commercial product, Orkambi by Vertex, manufactured using continuous technology. Thus, the modern manufacturing of pharmaceutical solid dosage forms has begun (Kensaku et al., 2019). Since then, continuous manufacturing, emerging technologies, modernization, and innovation have been the focus of attention and supported by the regulatory agencies (Yeaton, 2019). The published recommendations, guidelines, and frameworks, including process analytical technology (PAT) and the concept of quality-by-design (QbD), enable

production monitoring and controlling, data collection, and process understanding (U.S. Food and Drug Administration, 2004; U.S. Food and Drug Administration, 2009). The initiative of PAT published by the U.S. FDA reinforces the in-line or on-line data-based process control (am Ende and am Ende, 2019; U.S. Food and Drug Administration, 2004). The development of PAT tools can provide consistent quality throughout the manufacturing by monitoring and controlling process parameters and quality attributes (Scott et al., 1998). In the modernization concept, data-driven solutions can contribute to understanding the processes and controlling the intermittent variability to enable consistent quality in each step of the production. These reserve an essential role in implementing QbD and real-time release testing (RTRT) approaches (Ramadan et al., 2021).

Department of pharmaceuticals,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Screening of Antidepressant Activity of *Punica granatum* in Mice

Dr.P Kishor , Ms.A R Sridevi , Ms SK Zoofishaan , Mr.M Kalyan babu , Ms A Aksa Anvija

Department of Pharmacognosy

Email ID: kishorpharmacog@gmail.com , Mobile no:9951850662

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

Introduction: There are many different mental health issues, including depression, that may be alleviated with the use of the medicinal plants found in India. Acute and chronic administration of *Punica granatum* (pomegranate) whole fruit had an antidepressant effect on rats, which was the aim of this research. We employed an oral regimen of *Punica granatum* aqueous extract (250 and 500 mg/kg daily), imipramine (10 mg/kg), and gum acacia (10 ml/kg) as a carrier. Each of the four animal groupings consisted of six creatures. The acute study required the administration of medicines or vehicles 60 minutes before the experiments began. All medications and vehicles used in the long-term trial were given for a total of 14 days, with the last dosage given 60 minutes before the experiment on day 14. To evaluate the efficacy of antidepressants, researchers used the Forced Swim Test and the Tail Suspension Test. An analysis of variance (ANOVA) was performed on the data, with drug therapy being the independent variable. We used Dunnett's test to do post hoc comparisons. The results showed that the period of immobility was greatly decreased in the acute tail suspension test, chronic forced swim test, and acute swim test by the PG 500 mg/kg group, but not in the 250 mg/kg group. The groups treated with PG 250 mg/kg and 500 mg/kg showed a significant reduction in the duration of immobility in the chronic tail suspension test. At 500 mg/kg, the antidepressant effect was similar to that of 10 mg/kg of imipramine. In conclusion, this research provides further evidence that 500 mg/kg of aqueous extract of entire *P. granatum* fruit has antidepressant effect. Given the nutritional and functional benefits of pomegranate extract, it would be wise to recommend its use to patients suffering from depression.

Key words: Feeling down, tests for tail suspension and forced swimming, pomegranate.


INTRODUCTION

Depression is a long-term mental health condition that may strike anybody at any time. The existing arsenal of treatment is often insufficient, with disappointing outcomes in around one-third of all people treated, despite the availability of numerous powerful antidepressants.¹ This gives researchers a reason to keep looking for better antidepressants. There are now more options for treating depression than the currently available synthetic medications due to their limitations. Herbal medicines are an example of an old therapy that has persisted over the years since plants have always been a source of medications. Pomegranate, scientifically

known as *Punica granatum* L. (PG), is a popular fruit and juice variety. The Punicaceae family includes it. The Himalayas in northern India are its natural habitat. From ancient times, it has been farmed all throughout the Mediterranean.² Valuable chemicals are found in several portions of the pomegranate fruit, including the skin, seeds, and arils. The peel contains a myriad of compounds and minerals, including gallic acid, ellagic acid, catechin, epicatechin, epigallocatechin-3-gallate, quercetin, kaempferol, luteolin, rutin, kaempferol-3-O-glycoside, gallagylidilacton, pedunculagin, tellimagrandin, and many more. The seeds contain punicic acid, linoleic acid, oleic acid, palmitic acid, stigmasterol, β -sitosterol, dau-costerol, campesterol, cholesterol, estriol, estrone, estriol, estriol, tocopherols, ursolic acid, oleanolic acid, isoflavones, and phenyl aliphatic glycosides/lignins, among other major chemical components. The components found in the aril include sugars, pectin, polyphenols, anthocyanins, fatty acids, amino and organic acids, indoleamines, sterols, triterpenoids, and α -tocopherol.^{3,4}

In traditional medicine, pomegranate is used to cure a variety of conditions, including parasite infestations, diarrhea, acidosis, dysentery, bleeding, microbiological infections, respiratory disorders, and aphthous ulcers. It is also used as an antipyretic and vermifuge.⁵ Various components of the *P. granatum* fruit have shown anti-inflammatory, anti-cancer, anti-tumor, antihepatotoxic, anti-Diabetic, and antiatherogenic³ characteristics. Reportedly, it also helps with Alzheimer's illness.^{3, 7} Juice, wine,⁸ dried arils⁹, and jam are just a few examples of PG-based products that have been the subject of academic investigation.¹⁰ Despite this, research on the health benefits of *P. granatum* in its entire fruit form is limited. It is possible that the combined effect of the fruit's components is more effective than the sum of its parts. The central nervous system (CNS) effects of *P. granatum* have received little attention, and the antidepressant effects of the whole fruit have not been documented. Therefore, the purpose




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

Screening of Antidepressant Activity of *Punica granatum* in Mice

Dr.P Kishor , Ms.A R Sridevi , Ms SK Zoofishaan , Mr.M Kalyan babu , Ms A Aksa Anvija
Department of Pharmacognosy

Email ID: kishorpharmacog@gmail.com , Mobile no:9951850662

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

Introduction: There are many different mental health issues, including depression, that may be alleviated with the use of the medicinal plants found in India. Acute and chronic administration of *Punica granatum* (pomegranate) whole fruit had an antidepressant effect on rats, which was the aim of this research. We employed an oral regimen of *Punica granatum* aqueous extract (250 and 500 mg/kg daily), imipramine (10 mg/kg), and gum acacia (10 ml/kg) as a carrier. Each of the four animal groupings consisted of six creatures. The acute study required the administration of medicines or vehicles 60 minutes before the experiments began. All medications and vehicles used in the long-term trial were given for a total of 14 days, with the last dosage given 60 minutes before the experiment on day 14. To evaluate the efficacy of antidepressants, researchers used the Forced Swim Test and the Tail Suspension Test. An analysis of variance (ANOVA) was performed on the data, with drug therapy being the independent variable. We used Dunnett's test to do post hoc comparisons. The results showed that the period of immobility was greatly decreased in the acute tail suspension test, chronic forced swim test, and acute swim test by the PG 500 mg/kg group, but not in the 250 mg/kg group. The groups treated with PG 250 mg/kg and 500 mg/kg showed a significant reduction in the duration of immobility in the chronic tail suspension test. At 500 mg/kg, the antidepressant effect was similar to that of 10 mg/kg of imipramine. In conclusion, this research provides further evidence that 500 mg/kg of aqueous extract of entire *P. granatum* fruit has antidepressant effect. Given the nutritional and functional benefits of pomegranate extract, it would be wise to recommend its use to patients suffering from depression.

Key words: Feeling down, tests for tail suspension and forced swimming, pomegranate.

INTRODUCTION

Depression is a long-term mental health condition that may strike anybody at any time. The existing arsenal of treatment is often insufficient, with disappointing outcomes in around one-third of all people treated, despite the availability of numerous powerful antidepressants.¹ This gives researchers a reason to keep looking for better antidepressants. There are now more options for treating depression than the currently available synthetic medications due to their limitations. Herbal medicines are an example of an old therapy that has persisted over the years since plants have always been a source of medications. Pomegranate, scientifically

known as *Punica granatum* L. (PG), is a popular fruit and juice variety. The Punicaceae family includes it. The Himalayas in northern India are its natural habitat. From ancient times, it has been farmed all throughout the Mediterranean.² Valuable chemicals are found in several portions of the pomegranate fruit, including the skin, seeds, and arils. The peel contains a myriad of compounds and minerals, including gallic acid, ellagic acid, catechin, epicatechin, epigallocatechin-3-gallate, quercetin, kaempferol, luteolin, rutin, kaempferol-3-O-glycoside, gallagylidilacton, pedunculagin, tellimagrandin, and many more. The seeds contain punicalic acid, linoleic acid, oleic acid, palmitic acid, stigmasterol, β -sitosterol, dau-costerol, campesterol, cholesterol, estriol, estrone, estriol, estriol, tocopherols, ursolic acid, oleanolic acid, isoflavones, and phenyl aliphatic glycosides/lignins, among other major chemical components. The components found in the aril include sugars, pectin, polyphenols, anthocyanins, fatty acids, amino and organic acids, indoleamines, sterols, triterpenoids, and α -tocopherol.^{3,4}

In traditional medicine, pomegranate is used to cure a variety of conditions, including parasite infestations, diarrhea, acidosis, dysentery, bleeding, microbiological infections, respiratory disorders, and aphthous ulcers. It is also used as an antipyretic and vermifuge.⁵ Various components of the *P. granatum* fruit have shown anti-inflammatory, anti-cancer, anti-tumor, antihepatotoxic, anti-Diabetic, and antiatherogenic³ characteristics. Reportedly, it also helps with Alzheimer's illness.^{3, 7} Juice, wine,⁸ dried arils⁹, and jam are just a few examples of PG-based products that have been the subject of academic investigation.¹⁰ Despite this, research on the health benefits of *P. granatum* in its entire fruit form is limited. It is possible that the combined effect of the fruit's components is more effective than the sum of its parts. The central nervous system (CNS) effects of *P. granatum* have received little attention, and the antidepressant effects of the whole fruit have not been documented. Therefore, the purpose




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Screening of Antidepressant Activity of *Punica granatum* in Mice

Dr.P Kishor , Ms.A R Sridevi , Ms SK Zoofishaan , Mr.M Kalyan babu , Ms A Aksa Anvija
Department of Pharmacognosy

Email ID: kishorpharmacog@gmail.com , Mobile no:9951850662

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

Introduction: There are many different mental health issues, including depression, that may be alleviated with the use of the medicinal plants found in India. Acute and chronic administration of *Punica granatum* (pomegranate) whole fruit had an antidepressant effect on rats, which was the aim of this research. We employed an oral regimen of *Punica granatum* aqueous extract (250 and 500 mg/kg daily), imipramine (10 mg/kg), and gum acacia (10 ml/kg) as a carrier. Each of the four animal groupings consisted of six creatures. The acute study required the administration of medicines or vehicles 60 minutes before the experiments began. All medications and vehicles used in the long-term trial were given for a total of 14 days, with the last dosage given 60 minutes before the experiment on day 14. To evaluate the efficacy of antidepressants, researchers used the Forced Swim Test and the Tail Suspension Test. An analysis of variance (ANOVA) was performed on the data, with drug therapy being the independent variable. We used Dunnett's test to do post hoc comparisons. The results showed that the period of immobility was greatly decreased in the acute tail suspension test, chronic forced swim test, and acute swim test by the PG 500 mg/kg group, but not in the 250 mg/kg group. The groups treated with PG 250 mg/kg and 500 mg/kg showed a significant reduction in the duration of immobility in the chronic tail suspension test. At 500 mg/kg, the antidepressant effect was similar to that of 10 mg/kg of imipramine. In conclusion, this research provides further evidence that 500 mg/kg of aqueous extract of entire *P. granatum* fruit has antidepressant effect. Given the nutritional and functional benefits of pomegranate extract, it would be wise to recommend its use to patients suffering from depression.

Key words: Feeling down, tests for tail suspension and forced swimming, pomegranate.

INTRODUCTION

Depression is a long-term mental health condition that may strike anybody at any time. The existing arsenal of treatment is often insufficient, with disappointing outcomes in around one-third of all people treated, despite the availability of numerous powerful antidepressants.¹ This gives researchers a reason to keep looking for better antidepressants. There are now more options for treating depression than the currently available synthetic medications due to their limitations. Herbal medicines are an example of an old therapy that has persisted over the years since plants have always been a source of medications. Pomegranate, scientifically

known as *Punica granatum* L. (PG), is a popular fruit and juice variety. The Punicaceae family includes it. The Himalayas in northern India are its natural habitat. From ancient times, it has been farmed all throughout the Mediterranean.² Valuable chemicals are found in several portions of the pomegranate fruit, including the skin, seeds, and arils. The peel contains a myriad of compounds and minerals, including gallic acid, ellagic acid, catechin, epicatechin, epigallocatechin-3-gallate, quercetin, kaempferol, luteolin, rutin, kaempferol-3-O-glycoside, galloyl di lacton, pedunculagin, tellimagrandin, and many more. The seeds contain punicalic acid, linoleic acid, oleic acid, palmitic acid, stigmasterol, β -sitosterol, dau-costerol, campesterol, cholesterol, estriol, estrone, estriol, estriol, tocopherols, ursolic acid, oleanolic acid, isoflavones, and phenyl aliphatic glycosides/lignins, among other major chemical components. The components found in the aril include sugars, pectin, polyphenols, anthocyanins, fatty acids, amino and organic acids, indoleamines, sterols, triterpenoids, and α -tocopherol.^{3,4}

In traditional medicine, pomegranate is used to cure a variety of conditions, including parasite infestations, diarrhea, acidosis, dysentery, bleeding, microbiological infections, respiratory disorders, and aphthous ulcers. It is also used as an antipyretic and vermifuge.⁵ Various components of the *P. granatum* fruit have shown anti-inflammatory, anti-cancer, anti-tumor, antihepatotoxic, anti-Diabetic, and antiatherogenic³ characteristics. Reportedly, it also helps with Alzheimer's illness.^{3, 7} Juice, wine,⁸ dried arils⁹, and jam are just a few examples of PG-based products that have been the subject of academic investigation.¹⁰ Despite this, research on the health benefits of *P. granatum* in its entire fruit form is limited. It is possible that the combined effect of the fruit's components is more effective than the sum of its parts. The central nervous system (CNS) effects of *P. granatum* have received little attention, and the antidepressant effects of the whole fruit have not been documented. Therefore, the purpose



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

Screening of Antidepressant Activity of *Punica granatum* in Mice

Dr.P Kishor , Ms.A R Sridevi , Ms SK Zoofishaan , **Mr.M Kalyan babu** , Ms A Aksa Anvija
Department of Pharmacognosy

Email ID: kishorpharmacog@gmail.com , Mobile no:9951850662

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

Introduction: There are many different mental health issues, including depression, that may be alleviated with the use of the medicinal plants found in India. Acute and chronic administration of *Punica granatum* (pomegranate) whole fruit had an antidepressant effect on rats, which was the aim of this research. We employed an oral regimen of *Punica granatum* aqueous extract (250 and 500 mg/kg daily), imipramine (10 mg/kg), and gum acacia (10 ml/kg) as a carrier. Each of the four animal groupings consisted of six creatures. The acute study required the administration of medicines or vehicles 60 minutes before the experiments began. All medications and vehicles used in the long-term trial were given for a total of 14 days, with the last dosage given 60 minutes before the experiment on day 14. To evaluate the efficacy of antidepressants, researchers used the Forced Swim Test and the Tail Suspension Test. An analysis of variance (ANOVA) was performed on the data, with drug therapy being the independent variable. We used Dunnett's test to do post hoc comparisons. The results showed that the period of immobility was greatly decreased in the acute tail suspension test, chronic forced swim test, and acute swim test by the PG 500 mg/kg group, but not in the 250 mg/kg group. The groups treated with PG 250 mg/kg and 500 mg/kg showed a significant reduction in the duration of immobility in the chronic tail suspension test. At 500 mg/kg, the antidepressant effect was similar to that of 10 mg/kg of imipramine. In conclusion, this research provides further evidence that 500 mg/kg of aqueous extract of entire *P. granatum* fruit has antidepressant effect. Given the nutritional and functional benefits of pomegranate extract, it would be wise to recommend its use to patients suffering from depression.

Key words: Feeling down, tests for tail suspension and forced swimming, pomegranate.

INTRODUCTION

Depression is a long-term mental health condition that may strike anybody at any time. The existing arsenal of treatment is often insufficient, with disappointing outcomes in around one-third of all people treated, despite the availability of numerous powerful antidepressants.¹ This gives researchers a reason to keep looking for better antidepressants. There are now more options for treating depression than the currently available synthetic medications due to their limitations. Herbal medicines are an example of an old therapy that has persisted over the years since plants have always been a source of medications. Pomegranate, scientifically

known as *Punica granatum* L. (PG), is a popular fruit and juice variety. The Punicaceae family includes it. The Himalayas in northern India are its natural habitat. From ancient times, it has been farmed all throughout the Mediterranean.² Valuable chemicals are found in several portions of the pomegranate fruit, including the skin, seeds, and arils. The peel contains a myriad of compounds and minerals, including gallic acid, ellagic acid, catechin, epicatechin, epigallocatechin-3-gallate, quercetin, kaempferol, luteolin, rutin, kaempferol-3-O-glycoside, gallagylidilacton, pedunculagin, tellimagrandin, and many more. The seeds contain punical acid, linoleic acid, oleic acid, palmitic acid, stigmasterol, β -sitosterol, dau-costerol, campesterol, cholesterol, estriol, estrone, estriol, estriol, tocopherols, ursolic acid, oleanolic acid, isoflavones, and phenyl aliphatic glycosides/lignins, among other major chemical components. The components found in the aril include sugars, pectin, polyphenols, anthocyanins, fatty acids, amino and organic acids, indoleamines, sterols, triterpenoids, and α -tocopherol.^{3,4}

In traditional medicine, pomegranate is used to cure a variety of conditions, including parasite infestations, diarrhea, acidosis, dysentery, bleeding, microbiological infections, respiratory disorders, and aphthous ulcers. It is also used as an antipyretic and vermifuge.⁵ Various components of the *P. granatum* fruit have shown anti-inflammatory, anti-cancer, anti-tumor, antihepatotoxic, anti-Diabetic, and antiatherogenic³ characteristics. Reportedly, it also helps with Alzheimer's illness.^{3, 7} Juice, wine,⁸ dried arils⁹, and jam are just a few examples of PG-based products that have been the subject of academic investigation.¹⁰ Despite this, research on the health benefits of *P. granatum* in its entire fruit form is limited. It is possible that the combined effect of the fruit's components is more effective than the sum of its parts. The central nervous system (CNS) effects of *P. granatum* have received little attention, and the antidepressant effects of the whole fruit have not been documented. Therefore, the purpose



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

Screening of Antidepressant Activity of *Punica granatum* in Mice

Dr.P Kishor , Ms.A R Sridevi , Ms SK Zoofishaan , Mr.M Kalyan babu , Ms A Aksa Anviya

Department of Pharmacognosy

Email ID: kishorpharmacog@gmail.com , Mobile no:9951850662

GOKULA KRISHNA COLLEGE OF PHARMACY

ABSTRACT

Introduction: There are many different mental health issues, including depression, that may be alleviated with the use of the medicinal plants found in India. Acute and chronic administration of *Punica granatum* (pomegranate) whole fruit had an antidepressant effect on rats, which was the aim of this research. We employed an oral regimen of *Punica granatum* aqueous extract (250 and 500 mg/kg daily), imipramine (10 mg/kg), and gum acacia (10 ml/kg) as a carrier. Each of the four animal groupings consisted of six creatures. The acute study required the administration of medicines or vehicles 60 minutes before the experiments began. All medications and vehicles used in the long-term trial were given for a total of 14 days, with the last dosage given 60 minutes before the experiment on day 14. To evaluate the efficacy of antidepressants, researchers used the Forced Swim Test and the Tail Suspension Test. An analysis of variance (ANOVA) was performed on the data, with drug therapy being the independent variable. We used Dunnett's test to do post hoc comparisons. The results showed that the period of immobility was greatly decreased in the acute tail suspension test, chronic forced swim test, and acute swim test by the PG 500 mg/kg group, but not in the 250 mg/kg group. The groups treated with PG 250 mg/kg and 500 mg/kg showed a significant reduction in the duration of immobility in the chronic tail suspension test. At 500 mg/kg, the antidepressant effect was similar to that of 10 mg/kg of imipramine. In conclusion, this research provides further evidence that 500 mg/kg of aqueous extract of entire *P. granatum* fruit has antidepressant effect. Given the nutritional and functional benefits of pomegranate extract, it would be wise to recommend its use to patients suffering from depression.

Key words: Feeling down, tests for tail suspension and forced swimming, pomegranate.

INTRODUCTION

Depression is a long-term mental health condition that may strike anybody at any time. The existing arsenal of treatment is often insufficient, with disappointing outcomes in around one-third of all people treated, despite the availability of numerous powerful antidepressants.¹ This gives researchers a reason to keep looking for better antidepressants. There are now more options for treating depression than the currently available synthetic medications due to their limitations. Herbal medicines are an example of an old therapy that has persisted over the years since plants have always been a source of medications. Pomegranate, scientificall

known as *Punica granatum* L. (PG), is a popular fruit and juice variety. The Punicaceae family includes it. The Himalayas in northern India are its natural habitat. From ancient times, it has been farmed all throughout the Mediterranean.² Valuable chemicals are found in several portions of the pomegranate fruit, including the skin, seeds, and arils. The peel contains a myriad of compounds and minerals, including gallic acid, ellagic acid, catechin, epicatechin, epigallocatechin-3-gallate, quercetin, kaempferol, luteolin, rutin, kaempferol-3-O-glycoside, gallagylidacton, pedunculagin, tellimagrandin, and many more. The seeds contain punical acid, linoleic acid, oleic acid, palmitic acid, stigmaterol, β -sitosterol, dau-costerol, campesterol, cholesterol, estriol, estrone, estriol, estriol, tocopherols, ursolic acid, oleanolic acid, isoflavones, and phenyl aliphatic glycosides/lignins, among other major chemical components. The components found in the aril include sugars, pectin, polyphenols, anthocyanins, fatty acids, amino and organic acids, indoleamines, sterols, triterpenoids, and α -tocopherol.^{3,4}

In traditional medicine, pomegranate is used to cure a variety of conditions, including parasite infestations, diarrhea, acidosis, dysentery, bleeding, microbiological infections, respiratory disorders, and aphthous ulcers. It is also used as an antipyretic and vermifuge.⁵ Various components of the *P. granatum* fruit have shown anti-inflammatory, anti-cancer, anti-tumor, antihepatotoxic, anti-Diabetic, and antiatherogenic³ characteristics. Reportedly, it also helps with Alzheimer's illness.^{3, 7} Juice, wine,⁸ dried arils⁹, and jam are just a few examples of PG-based products that have been the subject of academic investigation.¹⁰ Despite this, research on the health benefits of *P. granatum* in its entire fruit form is limited. It is possible that the combined effect of the fruit's components is more effective than the sum of its parts. The central nervous system (CNS) effects of *P. granatum* have received little attention, and the antidepressant effects of the whole fruit have not been documented. Therefore, the purpose



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL.A.P - 524121

How the Effectiveness of Aluminum Salt Adjuvants in a Model Lysozyme Vaccine Is Affected by Particle Size and Antigen Binding

Ms.P Kavitha , Mrs. C B Hanisha , Dr.M Soujanya , Mr N Praveen Kumar , Ms M Soumya

Abstract

The immunogenicity of vaccines made using aluminum salt adjuvants may be diminished if these particles aggregate during the freezing and drying processes, according to certain claims. We used lysozyme as a model antigen and evaluated this notion by looking at the immune response in a mouse model to several vaccine formulations—liquid, freeze-thawed, and lyophilized. Particle size distributions (PSDs) and degrees of antigen-adjuvant binding were shown to vary greatly due to the different processing procedures and excipient quantities. Vaccines adjuvanted with aluminum hydroxide or aluminum phosphate showed anti-lysozyme titers that were unaffected by the degree of antigen binding to the adjuvant and were independent of the PSD. Copyright 2008 by Wiley-Liss, Inc. and the American Pharmacists Association, Journal of Pharmaceutical Science, 97, 5252–5262, 2008. Plurality of particles, adjuvant, lysozyme, aluminum hydroxide, and aluminum phosphate

INTRODUCTION

In order to stimulate an adequate immune response, adjuvants are necessary for vaccines that include recombinant proteins.^{1, 2} The only adjuvants used in U.S.-approved vaccinations that are now available for purchase are aluminum hydroxide, aluminum phosphate, and aluminum salt adjuvants. In contrast to aluminum phosphate, which has a plate-like

molecular structure, aluminum hydroxide, also known as boehmite (AlOOH),³ is composed of needle-like particles with sizes of 2 nm. main particles in the 50 nm range and their phology.⁵ When combined in a solution, the two adjuvants produce stable porous aggregates with a diameter of 1–10 nm.^{4,5} Several factors are likely responsible for the incompletely known mechanisms of action of aluminum salt adjuvants.

Department of Pharmaceutics,
Email ID: kavithapharma147@gmail.com , Mobile no: 9393835500
GOKULA KRISHNA COLLEGE OF PHARMACY



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

How the Effectiveness of Aluminum Salt Adjuvants in a Model Lysozyme Vaccine Is Affected by Particle Size and Antigen Binding

Ms.P Kavitha , Mrs. C B Hanisha , Dr.M Soujanya , Mr N Praveen Kumar , Ms M Soumya

Abstract

The immunogenicity of vaccines made using aluminum salt adjuvants may be diminished if these particles aggregate during the freezing and drying processes, according to certain claims. We used lysozyme as a model antigen and evaluated this notion by looking at the immune response in a mouse model to several vaccine formulations—liquid, freeze-thawed, and lyophilized. Particle size distributions (PSDs) and degrees of antigen-adjuvant binding were shown to vary greatly due to the different processing procedures and excipient quantities. Vaccines adjuvanted with aluminum hydroxide or aluminum phosphate showed anti-lysozyme titers that were unaffected by the degree of antigen binding to the adjuvant and were independent of the PSD. Copyright 2008 by Wiley-Liss, Inc. and the American Pharmacists Association, Journal of Pharmaceutical Science, 97, 5252–5262, 2008. Plurality of particles, adjuvant, lysozyme, aluminum hydroxide, and aluminum phosphate

INTRODUCTION

In order to stimulate an adequate immune response, adjuvants are necessary for vaccines that include recombinant proteins.^{1, 2} The only adjuvants used in U.S.-approved vaccinations that are now available for purchase are aluminum hydroxide, aluminum phosphate, and aluminum salt adjuvants. In contrast to aluminum phosphate, which has a plate-like

molecular structure, aluminum hydroxide, also known as boehmite (AlOOH),³ is composed of needle-like particles with sizes of 2 nm. main particles in the 50 nm range and their phology.⁵ When combined in a solution, the two adjuvants produce stable porous aggregates with a diameter of 1–10 μm .^{4,5} Several factors are likely responsible for the incompletely known mechanisms of action of aluminum salt adjuvants.

Department of Pharmaceutics,
Email ID: kavithapharma147@gmail.com , Mobile no: 9393835500
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICGP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

How the Effectiveness of Aluminum Salt Adjuvants in a Model Lysozyme Vaccine Is Affected by Particle Size and Antigen Binding

Ms.P Kavitha , Mrs. C B Hanisha , **Dr.M Soujanya** , Mr N Praveen Kumar , Ms M Soumya

Abstract

The immunogenicity of vaccines made using aluminum salt adjuvants may be diminished if these particles aggregate during the freezing and drying processes, according to certain claims. We used lysozyme as a model antigen and evaluated this notion by looking at the immune response in a mouse model to several vaccine formulations—liquid, freeze-thawed, and lyophilized. Particle size distributions (PSDs) and degrees of antigen-adjuvant binding were shown to vary greatly due to the different processing procedures and excipient quantities. Vaccines adjuvanted with aluminum hydroxide or aluminum phosphate showed anti-lysozyme titers that were unaffected by the degree of antigen binding to the adjuvant and were independent of the PSD. Copyright 2008 by Wiley-Liss, Inc. and the American Pharmacists Association, Journal of Pharmaceutical Science, 97, 5252–5262, 2008. Plurality of particles, adjuvant, lysozyme, aluminum hydroxide, and aluminum phosphate

INTRODUCTION

In order to stimulate an adequate immune response, adjuvants are necessary for vaccines that include recombinant proteins.^{1, 2} The only adjuvants used in U.S.-approved vaccinations that are now available for purchase are aluminum hydroxide, aluminum phosphate, and aluminum salt adjuvants. In contrast to aluminum phosphate, which has a plate-like

molecular structure, aluminum hydroxide, also known as boehmite ($\text{Al}(\text{OH})_3$),³ is composed of needle-like particles with sizes of 2 nm. main particles in the 50 nm range and their phology.⁵ When combined in a solution, the two adjuvants produce stable porous aggregates with a diameter of 1–10 nm.^{4,5} Several factors are likely responsible for the incompletely known mechanisms of action of aluminum salt adjuvants.

Department of Pharmaceutics,
Email ID: kavithapharma147@gmail.com , Mobile no: 9393835500
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FISS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P. - 524121

How the Effectiveness of Aluminum Salt Adjuvants in a Model Lysozyme Vaccine Is Affected by Particle Size and Antigen Binding

Ms.P Kavitha , Mrs. C B Hanisha , Dr.M Soujanya , **Mr N Praveen Kumar** , Ms M Soumya

Abstract

The immunogenicity of vaccines made using aluminum salt adjuvants may be diminished if these particles aggregate during the freezing and drying processes, according to certain claims. We used lysozyme as a model antigen and evaluated this notion by looking at the immune response in a mouse model to several vaccine formulations—liquid, freeze-thawed, and lyophilized. Particle size distributions (PSDs) and degrees of antigen-adjuvant binding were shown to vary greatly due to the different processing procedures and excipient quantities. Vaccines adjuvanted with aluminum hydroxide or aluminum phosphate showed anti-lysozyme titers that were unaffected by the degree of antigen binding to the adjuvant and were independent of the PSD. Copyright 2008 by Wiley-Liss, Inc. and the American Pharmacists Association, *Journal of Pharmaceutical Science*, 97, 5252–5262, 2008. Plurality of particles, adjuvant, lysozyme, aluminum hydroxide, and aluminum phosphate

INTRODUCTION

In order to stimulate an adequate immune response, adjuvants are necessary for vaccines that include recombinant proteins.^{1, 2} The only adjuvants used in U.S.-approved vaccinations that are now available for purchase are aluminum hydroxide, aluminum phosphate, and aluminum salt adjuvants. In contrast to aluminum phosphate, which has a plate-like

molecular structure, aluminum hydroxide, also known as boehmite (AlOOH),³ is composed of needle-like particles with sizes of 2 nm. main particles in the 50 nm range and their phology.⁵ When combined in a solution, the two adjuvants produce stable porous aggregates with a diameter of 1–10 mm.^{4,5} Several factors are likely responsible for the incompletely known mechanisms of action of aluminum salt adjuvants.

Department of Pharmaceutics,
Email ID: kavithapharma147@gmail.com , Mobile no: 9393835500
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

How the Effectiveness of Aluminum Salt Adjuvants in a Model Lysozyme Vaccine Is Affected by Particle Size and Antigen Binding

Ms.P Kavitha , Mrs. C B Hanisha , Dr.M Soujanya , Mr N Praveen Kumar , Ms M Soumya

Abstract

The immunogenicity of vaccines made using aluminum salt adjuvants may be diminished if these particles aggregate during the freezing and drying processes, according to certain claims. We used lysozyme as a model antigen and evaluated this notion by looking at the immune response in a mouse model to several vaccine formulations—liquid, freeze-thawed, and lyophilized. Particle size distributions (PSDs) and degrees of antigen-adjuvant binding were shown to vary greatly due to the different processing procedures and excipient quantities. Vaccines adjuvanted with aluminum hydroxide or aluminum phosphate showed anti-lysozyme titers that were unaffected by the degree of antigen binding to the adjuvant and were independent of the PSD. Copyright 2008 by Wiley-Liss, Inc. and the American Pharmacists Association, Journal of Pharmaceutical Science, 97, 5252–5262, 2008. Plurality of particles, adjuvant, lysozyme, aluminum hydroxide, and aluminum phosphate

INTRODUCTION

In order to stimulate an adequate immune response, adjuvants are necessary for vaccines that include recombinant proteins.^{1, 2} The only adjuvants used in U.S.-approved vaccinations that are now available for purchase are aluminum hydroxide, aluminum phosphate, and aluminum salt adjuvants. In contrast to aluminum phosphate, which has a plate-like

molecular structure, aluminum hydroxide, also known as boehmite ($\text{Al}(\text{OH})_3$),³ is composed of needle-like particles with sizes of 2 nm. main particles in the 50 nm range and their phology.⁵ When combined in a solution, the two adjuvants produce stable porous aggregates with a diameter of 1–10 nm.^{4,5} Several factors are likely responsible for the incompletely known mechanisms of action of aluminum salt adjuvants.

Department of Pharmaceutics,
Email ID: kavithapharma147@gmail.com , Mobile no: 9393835500
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347 - 2243

*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gamil.com



Narayan
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development

Dr. Balagani Pavan Kumar, Mrs. P K Devi Bala, Mrs P Madhavi, Mrs M Sindhuri, Mrs. S K Lathifa

ABSTRACT: A revised classification system for oral drugs was developed using the biopharmaceutics classification system (BCS) as a starting point. The revised system is designed to have a greater focus on drug developability. Intestinal solubility, the compensatory nature of solubility and permeability in the small intestine and an estimate of the particle size needed to overcome dissolution rate limited absorption were all considered in the revised system. The system was then validated by comparison with literature on the *in vivo* performance of a number of test compounds. Observations on the test compounds were consistent with the revised classification, termed the developability classification system (DCS), showing it to be of greater value in predicting what factors are critical to *in vivo* performance than the widely used BCS.

INTRODUCTION

Following its introduction in the 1990s, the biopharmaceutics categorization system (BCS) had a significant impact on the creation of oral dosage forms with instant release (IR). This method replaced *in vivo* human trials with *in vitro* data to prove bioequivalence of low risk (BCS class I) chemicals. One, two Furthermore, the BCS provides a framework for considering critical factors (dosage, solubility, permeability, and dissolution rate) that may impact a drug's efficacy in the body. Beyond identifying biowaiver-friendly medications, these factors likely also characterize the CQAs that affect *in vivo* effectiveness. When thinking about quality by design (QbD), it is very important to have a

good understanding of these when developing oral pharmaceutical items.³ Because of the heavy regulatory burden on the BCS, the classification scheme rightfully treads carefully when deciding which product properties, such as solubility and/or dissolution rate, are most important for limiting oral absorption. Considering that To prioritize patient safety, it is vital to accurately categorize product modifications that cause changes to *in vivo* performance rather than misclassify those that do not. Permeability is a feature of the drug molecule that is not expected to vary with product and process changes, hence changes to the

Department of pharmaceutics,
Email ID: pavan.gkep@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347 - 2243

*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com

Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development

Dr. Balagani Pavan Kumar, Mrs. P K Devi Bala, Mrs P Madhavi, Mrs M Sindhuri, Mrs. S K Lathifa

ABSTRACT: A revised classification system for oral drugs was developed using the biopharmaceutics classification system (BCS) as a starting point. The revised system is designed to have a greater focus on drug developability. Intestinal solubility, the compensatory nature of solubility and permeability in the small intestine and an estimate of the particle size needed to overcome dissolution rate limited absorption were all considered in the revised system. The system was then validated by comparison with literature on the *in vivo* performance of a number of test compounds. Observations on the test compounds were consistent with the revised classification, termed the developability classification system (DCS), showing it to be of greater value in predicting what factors are critical to *in vivo* performance than the widely used BCS.


INTRODUCTION

Following its introduction in the 1990s, the biopharmaceutics categorization system (BCS) had a significant impact on the creation of oral dosage forms with instant release (IR). This method replaced *in vivo* human trials with *in vitro* data to prove bioequivalence of low risk (BCS class I) chemicals. One, two Furthermore, the BCS provides a framework for considering critical factors (dosage, solubility, permeability, and dissolution rate) that may impact a drug's efficacy in the body. Beyond identifying biowaiver-friendly medications, these factors likely also characterize the CQAs that affect *in vivo* effectiveness. When thinking about quality by design (QbD), it is very important to have a

good understanding of these when developing oral pharmaceutical items.³ Because of the heavy regulatory burden on the BCS, the classification scheme rightfully treads carefully when deciding which product properties, such as solubility and/or dissolution rate, are most important for limiting oral absorption. Considering that To prioritize patient safety, it is vital to accurately categorize product modifications that cause changes to *in vivo* performance rather than misclassify those that do not. Permeability is a feature of the drug molecule that is not expected to vary with product and process changes, hence changes to the

Department of pharmaceuticals,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347 - 2243

*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com

Email : editor@iajlb.com or iajlb.editor@gmail.com



Kumar
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development

Dr. Balagani Pavan Kumar, Mrs. P K Devi Bala, Mrs P Madhavi, Mrs M Sindhuri, Mrs. S K Lathifa

ABSTRACT: A revised classification system for oral drugs was developed using the biopharmaceutics classification system (BCS) as a starting point. The revised system is designed to have a greater focus on drug developability. Intestinal solubility, the compensatory nature of solubility and permeability in the small intestine and an estimate of the particle size needed to overcome dissolution rate limited absorption were all considered in the revised system. The system was then validated by comparison with literature on the *in vivo* performance of a number of test compounds. Observations on the test compounds were consistent with the revised classification, termed the developability classification system (DCS), showing it to be of greater value in predicting what factors are critical to *in vivo* performance than the widely used BCS.

INTRODUCTION

Following its introduction in the 1990s, the biopharmaceutics categorization system (BCS) had a significant impact on the creation of oral dosage forms with instant release (IR). This method replaced *in vivo* human trials with *in vitro* data to prove bioequivalence of low risk (BCS class I) chemicals. One, two Furthermore, the BCS provides a framework for considering critical factors (dosage, solubility, permeability, and dissolution rate) that may impact a drug's efficacy in the body. Beyond identifying biowaiver-friendly medications, these factors likely also characterize the CQAs that affect *in vivo* effectiveness. When thinking about quality by design (QbD), it is very important to have a

good understanding of these when developing oral pharmaceutical items.³ Because of the heavy regulatory burden on the BCS, the classification scheme rightfully treads carefully when deciding which product properties, such as solubility and/or dissolution rate, are most important for limiting oral absorption. Considering that to prioritize patient safety, it is vital to accurately categorize product modifications that cause changes to *in vivo* performance rather than misclassify those that do not. Permeability is a feature of the drug molecule that is not expected to vary with product and process changes, hence changes to the

Department of pharmaceuticals,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347 - 2243

*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com

Email : editor@iajlb.com or iajlb.editor@gmail.com



Kavay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development

Dr. Balagani Pavan Kumar, Mrs. P K Devi Bala, Mrs P Madhavi, Mrs M Sindhuri, Mrs. S K Lathifa

ABSTRACT: A revised classification system for oral drugs was developed using the biopharmaceutics classification system (BCS) as a starting point. The revised system is designed to have a greater focus on drug developability. Intestinal solubility, the compensatory nature of solubility and permeability in the small intestine and an estimate of the particle size needed to overcome dissolution rate limited absorption were all considered in the revised system. The system was then validated by comparison with literature on the *in vivo* performance of a number of test compounds. Observations on the test compounds were consistent with the revised classification, termed the developability classification system (DCS), showing it to be of greater value in predicting what factors are critical to *in vivo* performance than the widely used BCS.

INTRODUCTION

Following its introduction in the 1990s, the biopharmaceutics categorization system (BCS) had a significant impact on the creation of oral dosage forms with instant release (IR). This method replaced *in vivo* human trials with *in vitro* data to prove bioequivalence of low risk (BCS class I) chemicals. One, two Furthermore, the BCS provides a framework for considering critical factors (dosage, solubility, permeability, and dissolution rate) that may impact a drug's efficacy in the body. Beyond identifying biowaiver-friendly medications, these factors likely also characterize the CQAs that affect *in vivo* effectiveness. When thinking about quality by design (QbD), it is very important to have a

good understanding of these when developing oral pharmaceutical items.³ Because of the heavy regulatory burden on the BCS, the classification scheme rightfully treads carefully when deciding which product properties, such as solubility and/or dissolution rate, are most important for limiting oral absorption. Considering that To prioritize patient safety, it is vital to accurately categorize product modifications that cause changes to *in vivo* performance rather than misclassify those that do not. Permeability is a feature of the drug molecule that is not expected to vary with product and process changes, hence changes to the

Department of pharmaceuticals,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICOP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347 - 2243

Indo - American Journal of Life Sciences and Biotechnology



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Naval
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



The Developability Classification System: Application of Biopharmaceutics Concepts to Formulation Development

Dr. Balagani Pavan Kumar, Mrs. P K Devi Bala, Mrs P Madhavi, Mrs M Sindhuri, Mrs. S K Lathifa

ABSTRACT: A revised classification system for oral drugs was developed using the biopharmaceutics classification system (BCS) as a starting point. The revised system is designed to have a greater focus on drug developability. Intestinal solubility, the compensatory nature of solubility and permeability in the small intestine and an estimate of the particle size needed to overcome dissolution rate limited absorption were all considered in the revised system. The system was then validated by comparison with literature on the *in vivo* performance of a number of test compounds. Observations on the test compounds were consistent with the revised classification, termed the developability classification system (DCS), showing it to be of greater value in predicting what factors are critical to *in vivo* performance than the widely used BCS.

INTRODUCTION

Following its introduction in the 1990s, the biopharmaceutics categorization system (BCS) had a significant impact on the creation of oral dosage forms with instant release (IR). This method replaced *in vivo* human trials with *in vitro* data to prove bioequivalence of low risk (BCS class I) chemicals. One, two Furthermore, the BCS provides a framework for considering critical factors (dosage, solubility, permeability, and dissolution rate) that may impact a drug's efficacy in the body. Beyond identifying biowaiver-friendly medications, these factors likely also characterize the CQAs that affect *in vivo* effectiveness. When thinking about quality by design (QbD), it is very important to have a

good understanding of these when developing oral pharmaceutical items.³ Because of the heavy regulatory burden on the BCS, the classification scheme rightfully treads carefully when deciding which product properties, such as solubility and/or dissolution rate, are most important for limiting oral absorption. Considering that To prioritize patient safety, it is vital to accurately categorize product modifications that cause changes to *in vivo* performance rather than misclassify those that do not. Permeability is a feature of the drug molecule that is not expected to vary with product and process changes, hence changes to the

Department of pharmaceuticals,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

The Synthesis of Diverse Annulated Pyridines with 6-Membered Functionalized Saturated Cycles for Medical Chemistry Research

Mr.Sivakumar Peta, Dr,C Rajaram,Mr.AVLS Ramakrishna,Mr M R Pavan Kumar,Mr Y Naveen Kumar
Department of Pharmaceutical Chemistry,
Email ID: sivapeta369@gmail.com, Mobile no: 9494144800
GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

The article describes a set of pyridines annulated with functionalized 6-membered saturated rings, which are attractive building blocks for the synthesis of diversified compound libraries in medical chemistry. A certain array of compounds includes pyridines with condensed cyclohexane, piperidine and tetrahydropyran cycles containing keto-, amino-, carboxylic groups, as well as fluorinated fragments. The synthesis of the compounds using the procedure previously developed by us *via* CuCl₂-catalyzed condensation of propargylamine with ketones was performed. The limits of application of this reaction were further expanded and determined in this work compared to our previous results. Condensed pyridines, which proved problematic or impossible to obtain by this method, were synthesized using other synthetic pathways. Thus, the study offers a number of new building blocks for use in drug discovery.

Keywords: organic synthesis; heterocyclic compounds; pyridines; building blocks; organofluorines; "magic methyl"; scaffold hopping

Introduction

Pyridines annulated to saturated cycles (PASCs) are widely used in drug discovery. Among the compounds containing this fragment there are substances demonstrating anti-HIV [1], antire-sorptive [2, 3], antibacterial [4] and antimigraine [5] activity (Figure 1).

Due to such a wide spectrum of the biological activity demonstrated, chemists need convenient and cost-effective methods for the synthesis of diverse functionalized PASCs in multigram and/or even semi-industrial scales. In this research, we demonstrate our strategy for solving this problem and propose a synthetic strategy for producing a set of bicyclic building blocks containing pyridine and an annulated saturated core with various substituents and functional groups. According to the development of "magic methyl" and "magic fluorine" concepts, along with classical functions, we included compounds bearing methyl-methylene (2), dimethylmethylene (3) and difluoromethylene (4) moieties in our short-list. Isomeric conformationally restricted ketones 6a-d, carboxylic acids 7a-d, PASCs with exocyclic amine function 8a-d and those featuring endocyclic one 9a-d were also treated as utility building blocks for modern combinatorial chemistry and drug discovery (Figure 2).

Reported approaches towards pyridines annulated with 6-membered saturated cycles include: (A) the partial reduction of the corresponding

aromatic compounds, (B) the construction of the saturated 6-membered ring and (C) the construction of the pyridine ring. Viable routes to implement the approaches are illustrated by a retrosynthetic analysis of compound 9c (Figure 3).

Approach C can also be illustrated by the intermolecular Diels-Alder reaction with an inverse electron demand [6], intermolecular oxidative cyclization [7, 8] or [4+2]-cyclization. Examples of [4+2]-cyclization include reactions catalyzed by gold [9] and ruthenium [10-13]. Recently, our research group proposed a simple and scalable method *via* the condensation catalyzed by available and cheap CuCl₂ [14] (Figure 4). Thanks to our research, this approach has become cost-effective and, along with good scalability and diversity, very promising for obtaining such compounds.

In this light, we aimed to extend and determine the scope of the method and perform the synthesis of the set of diverse PASCs. In addition, in some cases of the method, we proposed other approaches for the synthesis of the target molecules.




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

The Synthesis of Diverse Annulated Pyridines with 6-Membered Functionalized Saturated Cycles for Medical Chemistry Research

Mr.Sivakumar Peta, Dr.C Rajaram, Mr.AVLS Ramakrishna, Mr M R Pavan Kumar, Mr Y Naveen Kumar

Department of Pharmaceutical Chemistry,

Email ID: sivapeta369@gmail.com, Mobile no: 9494144800

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

The article describes a set of pyridines annulated with functionalized 6-membered saturated rings, which are attractive building blocks for the synthesis of diversified compound libraries in medical chemistry. A certain array of compounds includes pyridines with condensed cyclohexane, piperidine and tetrahydropyran cycles containing keto-, amino-, carboxylic groups, as well as fluorinated fragments. The synthesis of the compounds using the procedure previously developed by us via CuCl_2 -catalyzed condensation of propargylamine with ketones was performed. The limits of application of this reaction were further expanded and determined in this work compared to our previous results. Condensed pyridines, which proved problematic or impossible to obtain by this method, were synthesized using other synthetic pathways. Thus, the study offers a number of new building blocks for use in drug discovery.

Keywords: organic synthesis; heterocyclic compounds; pyridines; building blocks; organofluorines; "magic methyl"; scaffold hopping

Introduction

Pyridines annulated to saturated cycles (PASCs) are widely used in drug discovery. Among the compounds containing this fragment there are substances demonstrating anti-HIV [1], antire-sorptive [2, 3], antibacterial [4] and antimigraine [5] activity (Figure 1).

Due to such a wide spectrum of the biological activity demonstrated, chemists need convenient and cost-effective methods for the synthesis of diverse functionalized PASCs in multigram and/or even semi-industrial scales. In this research, we demonstrate our strategy for solving this problem and propose a synthetic strategy for producing a set of bicyclic building blocks containing pyridine and an annulated saturated core with various substituents and functional groups. According to the development of "magic methyl" and "magic fluorine" concepts, along with classical functions, we included compounds bearing methyl-methylene (2), dimethylmethylene (3) and difluoromethylene (4) moieties in our short-list. Isomeric conformationally restricted ketones 6a-d, carboxylic acids 7a-d, PASCs with exocyclic aminefunction 8a-d and those featuring endocyclic one 9a-d were also treated as utility building blocks for modern combinatorial chemistry and drug discovery (Figure 2).

Reported approaches towards pyridines annulated with 6-membered saturated cycles include: (A) the partial reduction of the corresponding

aromatic compounds, (B) the construction of the saturated 6-membered ring and (C) the construction of the pyridine ring. Viable routes to implement the approaches are illustrated by a retrosynthetic analysis of compound 9c (Figure 3).

Approach C can also be illustrated by the intermolecular Diels-Alder reaction with an inverse electron demand [6], intermolecular oxidative cyclization [7, 8] or [4+2]-cyclization. Examples of [4+2]-cyclization include reactions catalyzed by gold [9] and ruthenium [10-13]. Recently, our research group proposed a simple and scalable method via the condensation catalyzed by available and cheap CuCl_2 [14] (Figure 4). Thanks to our research, this approach has become cost-effective and, along with good scalability and diversity, very promising for obtaining such compounds.

In this light, we aimed to extend and determine the scope of the method and perform the synthesis of the set of diverse PASCs. In addition, in some cases of the method, we proposed other approaches for the synthesis of the target molecules.




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

The Synthesis of Diverse Annulated Pyridines with 6-Membered Functionalized Saturated Cycles for Medical Chemistry Research

Mr.Sivakumar Peta , Dr,C Rajaram, Mr.AVLS Ramakrishna, Mr M R Pavan Kumar, Mr Y Naveen Kumar
Department of Pharmaceutical Chemistry,
Email ID: sivapeta369@gmail.com , Mobile no: 9494144800
GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

The article describes a set of pyridines annulated with functionalized 6-membered saturated rings, which are attractive building blocks for the synthesis of diversified compound libraries in medical chemistry. A certain array of compounds includes pyridines with condensed cyclohexane, piperidine and tetrahydropyran cycles containing keto-, amino-, carboxylic groups, as well as fluorinated fragments. The synthesis of the compounds using the procedure previously developed by us *via* CuCl₂-catalyzed condensation of propargylamine with ketones was performed. The limits of application of this reaction were further expanded and determined in this work compared to our previous results. Condensed pyridines, which proved problematic or impossible to obtain by this method, were synthesized using other synthetic pathways. Thus, the study offers a number of new building blocks for use in drug discovery.

Keywords: organic synthesis; heterocyclic compounds; pyridines; building blocks; organofluorines; "magic methyl"; scaffold hopping

Introduction

Pyridines annulated to saturated cycles (PASCs) are widely used in drug discovery. Among the compounds containing this fragment there are substances demonstrating anti-HIV [1], antiretroviral [2, 3], antibacterial [4] and antimigraine [5] activity (Figure 1).

Due to such a wide spectrum of the biological activity demonstrated, chemists need convenient and cost-effective methods for the synthesis of diverse functionalized PASCs in multigram and/or even semi-industrial scales. In this research, we demonstrate our strategy for solving this problem and propose a synthetic strategy for producing a set of bicyclic building blocks containing pyridine and an annulated saturated core with various substituents and functional groups. According to the development of "magic methyl" and "magic fluorine" concepts, along with classical functions, we included compounds bearing methyl-methylene (2), dimethylmethylene (3) and difluoromethylene (4) moieties in our short-list. Isomeric conformationally restricted ketones 6a-d, carboxylic acids 7a-d, PASCs with exocyclic amine function 8a-d and those featuring endocyclic one 9a-d were also treated as utility building blocks for modern combinatorial chemistry and drug discovery (Figure 2).


Reported approaches towards pyridines annulated with 6-membered saturated cycles include: (A) the partial reduction of the corresponding

aromatic compounds, (B) the construction of the saturated 6-membered ring and (C) the construction of the pyridine ring. Viable routes to implement the approaches are illustrated by a retrosynthetic analysis of compound 9c (Figure 3).

Approach C can also be illustrated by the intermolecular Diels-Alder reaction with an inverse electron demand [6], intermolecular oxidative cyclization [7, 8] or [4+2]-cyclization. Examples of [4+2]-cyclization include reactions catalyzed by gold [9] and ruthenium [10-13]. Recently, our research group proposed a simple and scalable method *via* the condensation catalyzed by available and cheap CuCl₂ [14] (Figure 4). Thanks to our research, this approach has become cost-effective and, along with good scalability and diversity, very promising for obtaining such compounds.

In this light, we aimed to extend and determine the scope of the method and perform the synthesis of the set of diverse PASCs. In addition, in some cases of the method, we proposed other approaches for the synthesis of the target molecules.




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

The Synthesis of Diverse Annulated Pyridines with 6-Membered Functionalized Saturated Cycles for Medical Chemistry Research

Mr.Sivakumar Peta, Dr.C Rajaram, Mr.AVLS Ramakrishna, Mr M R Pavan Kumar, Mr Y Naveen Kumar

Department of Pharmaceutical Chemistry,

Email ID: sivapeta369@gmail.com, Mobile no: 9494144800

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

The article describes a set of pyridines annulated with functionalized 6-membered saturated rings, which are attractive building blocks for the synthesis of diversified compound libraries in medical chemistry. A certain array of compounds includes pyridines with condensed cyclohexane, piperidine and tetrahydropyran cycles containing keto-, amino-, carboxylic groups, as well as fluorinated fragments. The synthesis of the compounds using the procedure previously developed by us *via* CuCl₂-catalyzed condensation of propargylamine with ketones was performed. The limits of application of this reaction were further expanded and determined in this work compared to our previous results. Condensed pyridines, which proved problematic or impossible to obtain by this method, were synthesized using other synthetic pathways. Thus, the study offers a number of new building blocks for use in drug discovery.

Keywords: organic synthesis; heterocyclic compounds; pyridines; building blocks; organofluorines; "magic methyl"; scaffold hopping

Introduction

Pyridines annulated to saturated cycles (PASCs) are widely used in drug discovery. Among the compounds containing this fragment there are substances demonstrating anti-HIV [1], antire-sorptive [2, 3], antibacterial [4] and antimigraine [5] activity (Figure 1).

Due to such a wide spectrum of the biological activity demonstrated, chemists need convenient and cost-effective methods for the synthesis of diverse functionalized PASCs in multigram and/or even semi-industrial scales. In this research, we demonstrate our strategy for solving this problem and propose a synthetic strategy for producing a set of bicyclic building blocks containing pyridine and an annulated saturated core with various substituents and functional groups. According to the development of "magic methyl" and "magic fluorine" concepts, along with classical functions, we included compounds bearing methyl-methylene (2), dimethylmethylene (3) and difluoromethylene (4) moieties in our short-list. Isomeric conformationally restricted ketones 6a-d, carboxylic acids 7a-d, PASCs with exocyclic amine function 8a-d and those featuring endocyclic one 9a-d were also treated as utility building blocks for modern combinatorial chemistry and drug discovery (Figure 2).

Reported approaches towards pyridines annulated with 6-membered saturated cycles include: (A) the partial reduction of the corresponding

aromatic compounds, (B) the construction of the saturated 6-membered ring and (C) the construction of the pyridine ring. Viable routes to implement the approaches are illustrated by a retrosynthetic analysis of compound 9c (Figure 3).

Approach C can also be illustrated by the intermolecular Diels-Alder reaction with an inverse electron demand [6], intermolecular oxidative cyclization [7, 8] or [4+2]-cyclization. Examples of [4+2]-cyclization include reactions catalyzed by gold [9] and ruthenium [10-13]. Recently, our research group proposed a simple and scalable method *via* the condensation catalyzed by available and cheap CuCl₂ [14] (Figure 4). Thanks to our research, this approach has become cost-effective and, along with good scalability and diversity, very promising for obtaining such compounds.

In this light, we aimed to extend and determine the scope of the method and perform the synthesis of the set of diverse PASCs. In addition, in some cases of the method, we proposed other approaches for the synthesis of the target molecules.




Dr. BALAGAN PAVAN KUMAR
M. Pharm, Ph.D. FIC, F.B.S.S, F.A.G.E, F.I.C.C.P, M.I.S.T.E
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

The Synthesis of Diverse Annulated Pyridines with 6-Membered Functionalized Saturated Cycles for Medical Chemistry Research

Mr.Sivakumar Peta, Dr.C Rajaram, Mr.AVLS Ramakrishna, Mr M R Pavan Kumar, Mr Y Naveen Kumar

Department of Pharmaceutical Chemistry,

Email ID: sivapeta369@gmail.com, Mobile no: 9494144800

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

The article describes a set of pyridines annulated with functionalized 6-membered saturated rings, which are attractive building blocks for the synthesis of diversified compound libraries in medical chemistry. A certain array of compounds includes pyridines with condensed cyclohexane, piperidine and tetrahydropyran cycles containing keto-, amino-, carboxylic groups, as well as fluorinated fragments. The synthesis of the compounds using the procedure previously developed by us *via* CuCl₂-catalyzed condensation of propargylamine with ketones was performed. The limits of application of this reaction were further expanded and determined in this work compared to our previous results. Condensed pyridines, which proved problematic or impossible to obtain by this method, were synthesized using other synthetic pathways. Thus, the study offers a number of new building blocks for use in drug discovery.

Keywords: organic synthesis; heterocyclic compounds; pyridines; building blocks; organofluorines; "magic methyl"; scaffold hopping

Introduction

Pyridines annulated to saturated cycles (PASCs) are widely used in drug discovery. Among the compounds containing this fragment there are substances demonstrating anti-HIV [1], antiretroviral [2, 3], antibacterial [4] and antimigraine [5] activity (Figure 1).

Due to such a wide spectrum of the biological activity demonstrated, chemists need convenient and cost-effective methods for the synthesis of diverse functionalized PASCs in multigram and/or even semi-industrial scales. In this research, we demonstrate our strategy for solving this problem and propose a synthetic strategy for producing a set of bicyclic building blocks containing pyridine and an annulated saturated core with various substituents and functional groups. According to the development of "magic methyl" and "magic fluorine" concepts, along with classical functions, we included compounds bearing methyl-methylene (2), dimethylmethylene (3) and difluoromethylene (4) moieties in our short-list. Isomeric conformationally restricted ketones 6a-d, carboxylic acids 7a-d, PASCs with exocyclic amine function 8a-d and those featuring endocyclic one 9a-d were also treated as utility building blocks for modern combinatorial chemistry and drug discovery (Figure 2).


Reported approaches towards pyridines annulated with 6-membered saturated cycles include: (A) the partial reduction of the corresponding

aromatic compounds, (B) the construction of the saturated 6-membered ring and (C) the construction of the pyridine ring. Viable routes to implement the approaches are illustrated by a retrosynthetic analysis of compound 9c (Figure 3).

Approach C can also be illustrated by the intermolecular Diels-Alder reaction with an inverse electron demand [6], intermolecular oxidative cyclization [7, 8] or [4+2]-cyclization. Examples of [4+2]-cyclization include reactions catalyzed by gold [9] and ruthenium [10-13]. Recently, our research group proposed a simple and scalable method *via* the condensation catalyzed by available and cheap CuCl₂ [14] (Figure 4). Thanks to our research, this approach has become cost-effective and, along with good scalability and diversity, very promising for obtaining such compounds.

In this light, we aimed to extend and determine the scope of the method and perform the synthesis of the set of diverse PASCs. In addition, in some cases of the method, we proposed other approaches for the synthesis of the target molecules.




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A randomised, parallel, open-label clinical study comparing the effectiveness and safety of apremilast with methotrexate in individuals with moderate to severe palmoplantar psoriasis.

Mrs T Swathi, Mr.T Nagendra Kumar, Mr.M R Pavan Kumar, Mrs. Y R Anitha, Mrs.P Sukanya

Department of Pharmacology

Email ID: swathibhaskarthumma25@gmail.com, Mobile no:9494640005

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

Various studies have revealed varying outcomes regarding the safety and effectiveness of apremilast in comparison to methotrexate. Therefore, more research into the function of Apremilast in palmoplantar psoriasis is required. Patients with moderate to severe palmoplantar psoriasis were the subjects of a randomized, prospective, parallel-group, open-label trial. For 16 weeks, they were randomly assigned to either the methotrexate group (n = 19) or the apremilast group (n = 22). Reduced scores on the modified palmoplantar psoriasis severity index (mPPPASI) from week 0 to week 16 served as the primary effectiveness metric. Additional metrics included the percentage of patients who achieved a Static Physician Global Assessment score of 0 (clear) or 1 (almost clear), the percentage of patients who achieved mPPPASI75 (75% reduction in mPPPASI score) by the end of 16 weeks, and the proportion of patients who demonstrated a dermatology life quality index decline of at least 5 points from the beginning. At 16 weeks, there was no statistically significant difference between the two groups in terms of mPPPASI score drop, however there was a significant decline from week 0 to week 16 within the group. The secondary efficacy measures had identical outcomes. Out of the twenty-four adverse events documented in the methotrexate group, three individuals had abnormal liver function tests. Out of the 19 adverse events documented in the apremilast group, 2 patients had an infection of the upper respiratory tract. In the treatment of moderate to severe palmoplantar psoriasis, apremilast is just as effective as methotrexate, but it is more tolerable. Static Physician Global Assessment, Dermatology Life Quality Index, Palmoplantar Psoriasis, Palmoplantar Psoriasis Area and Severity Index, Apremilast

It is more likely for psoriasis to appear before the age of 30. The high expense of therapy and the significant psychological and social effects of psoriasis have a negative effect on sufferers' quality of life (QOL).[2]

Scalp, face, intertriginous, genital, palmoplantar, and nail psoriasis are the many types of psoriasis that may be found. Patients with palmoplantar psoriasis have more limited mobility and fewer self-care options, and they also have varying responses to medicines. the third Topical




Dr. BALAGANIPAVAN KUMAR
M. Pharm, Ph.D, FIC, FESS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A randomised, parallel, open-label clinical study comparing the effectiveness and safety of apremilast with methotrexate in individuals with moderate to severe palmoplantar psoriasis.

Mrs T Swathi , Mr.T Nagendra Kumar, Mr.M R Pavan Kumar, Mrs. Y R Anitha, Mrs.P Sukanya

Department of Pharmacology

Email ID: swathibhaskarthumma25@gmail.com, Mobile no:9494640005

GOKULA KRISHNA COLLEGE OF PHARMACY


Abstract:

Various studies have revealed varying outcomes regarding the safety and effectiveness of apremilast in comparison to methotrexate. Therefore, more research into the function of Apremilast in palmoplantar psoriasis is required. Patients with moderate to severe palmoplantar psoriasis were the subjects of a randomized, prospective, parallel-group, open-label trial. For 16 weeks, they were randomly assigned to either the methotrexate group (n = 19) or the apremilast group (n = 22). Reduced scores on the modified palmoplantar psoriasis severity index (mPPPASI) from week 0 to week 16 served as the primary effectiveness metric. Additional metrics included the percentage of patients who achieved a Static Physician Global Assessment score of 0 (clear) or 1 (almost clear), the percentage of patients who achieved mPPPASI75 (75% reduction in mPPPASI score) by the end of 16 weeks, and the proportion of patients who demonstrated a dermatology life quality index decline of at least 5 points from the beginning. At 16 weeks, there was no statistically significant difference between the two groups in terms of mPPPASI score drop, however there was a significant decline from week 0 to week 16 within the group. The secondary efficacy measures had identical outcomes. Out of the twenty-four adverse events documented in the methotrexate group, three individuals had abnormal liver function tests. Out of the 19 adverse events documented in the apremilast group, 2 patients had an infection of the upper respiratory tract. In the treatment of moderate to severe palmoplantar psoriasis, apremilast is just as effective as methotrexate, but it is more tolerable. Static Physician Global Assessment, Dermatology Life Quality Index, Palmoplantar Psoriasis, Palmoplantar Psoriasis Area and Severity Index, Apremilast

It is more likely for psoriasis to appear before the age of 30. The high expense of therapy and the significant psychological and social effects of psoriasis have a negative effect on sufferers' quality of life (QOL).[2]

Scalp, face, intertriginous, genital, palmoplantar, and nail psoriasis are the many types of psoriasis that may be found. Patients with palmoplantar psoriasis have more limited mobility and fewer self-care options, and they also have varying responses to medicines. the third Topical




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, PAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

A randomised, parallel, open-label clinical study comparing the effectiveness and safety of apremilast with methotrexate in individuals with moderate to severe palmoplantar psoriasis.

Mrs T Swathi , Mr.T Nagendra Kumar, Mr.M R Pavan Kumar, Mrs. Y R Anitha, Mrs.P Sukanya

Department of Pharmacology

Email ID: swathibhaskarthunma25@gmail.com, Mobile no:9494640005

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

Various studies have revealed varying outcomes regarding the safety and effectiveness of apremilast in comparison to methotrexate. Therefore, more research into the function of Apremilast in palmoplantar psoriasis is required. Patients with moderate to severe palmoplantar psoriasis were the subjects of a randomized, prospective, parallel-group, open-label trial. For 16 weeks, they were randomly assigned to either the methotrexate group (n = 19) or the apremilast group (n = 22). Reduced scores on the modified palmoplantar psoriasis severity index (mPPPASI) from week 0 to week 16 served as the primary effectiveness metric. Additional metrics included the percentage of patients who achieved a Static Physician Global Assessment score of 0 (clear) or 1 (almost clear), the percentage of patients who achieved mPPPASI75 (75% reduction in mPPPASI score) by the end of 16 weeks, and the proportion of patients who demonstrated a dermatology life quality index decline of at least 5 points from the beginning. At 16 weeks, there was no statistically significant difference between the two groups in terms of mPPPASI score drop, however there was a significant decline from week 0 to week 16 within the group. The secondary efficacy measures had identical outcomes. Out of the twenty-four adverse events documented in the methotrexate group, three individuals had abnormal liver function tests. Out of the 19 adverse events documented in the apremilast group, 2 patients had an infection of the upper respiratory tract. In the treatment of moderate to severe palmoplantar psoriasis, apremilast is just as effective as methotrexate, but it is more tolerable. Static Physician Global Assessment, Dermatology Life Quality Index, Palmoplantar Psoriasis, Palmoplantar Psoriasis Area and Severity Index, Apremilast

It is more likely for psoriasis to appear before the age of 30. The high expense of therapy and the significant psychological and social effects of psoriasis have a negative effect on sufferers' quality of life (QOL).[2]

Scalp, face, intertriginous, genital, palmoplantar, and nail psoriasis are the many types of psoriasis that may be found. Patients with palmoplantar psoriasis have more limited mobility and fewer self-care options, and they also have varying responses to medicines. the third Topical




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A randomised, parallel, open-label clinical study comparing the effectiveness and safety of apremilast with methotrexate in individuals with moderate to severe palmoplantar psoriasis.

Mrs T Swathi , Mr.T Nagendra Kumar,Mr.M R Pavan Kumar,Mrs. Y R Anitha,Mrs.P Sukanya

Department of Pharmacology

Email ID: swathibhaskarthumma25@gmail.com, Mobile no:9494640005

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

Various studies have revealed varying outcomes regarding the safety and effectiveness of apremilast in comparison to methotrexate. Therefore, more research into the function of Apremilast in palmoplantar psoriasis is required. Patients with moderate to severe palmoplantar psoriasis were the subjects of a randomized, prospective, parallel-group, open-label trial. For 16 weeks, they were randomly assigned to either the methotrexate group (n = 19) or the apremilast group (n = 22). Reduced scores on the modified palmoplantar psoriasis severity index (mPPPASI) from week 0 to week 16 served as the primary effectiveness metric. Additional metrics included the percentage of patients who achieved a Static Physician Global Assessment score of 0 (clear) or 1 (almost clear), the percentage of patients who achieved mPPPASI75 (75% reduction in mPPPASI score) by the end of 16 weeks, and the proportion of patients who demonstrated a dermatology life quality index decline of at least 5 points from the beginning. At 16 weeks, there was no statistically significant difference between the two groups in terms of mPPPASI score drop, however there was a significant decline from week 0 to week 16 within the group. The secondary efficacy measures had identical outcomes. Out of the twenty-four adverse events documented in the methotrexate group, three individuals had abnormal liver function tests. Out of the 19 adverse events documented in the apremilast group, 2 patients had an infection of the upper respiratory tract. In the treatment of moderate to severe palmoplantar psoriasis, apremilast is just as effective as methotrexate, but it is more tolerable. Static Physician Global Assessment, Dermatology Life Quality Index, Palmoplantar Psoriasis, Palmoplantar Psoriasis Area and Severity Index, Apremilast

It is more likely for psoriasis to appear before the age of 30. The high expense of therapy and the significant psychological and social effects of psoriasis have a negative effect on sufferers' quality of life (QOL).[2]

Scalp, face, intertriginous, genital, palmoplantar, and nail psoriasis are the many types of psoriasis that may be found. Patients with palmoplantar psoriasis have more limited mobility and fewer self-care options, and they also have varying responses to medicines. the third Topical




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

A randomised, parallel, open-label clinical study comparing the effectiveness and safety of apremilast with methotrexate in individuals with moderate to severe palmoplantar psoriasis.

Mrs T Swathi , Mr.T Nagendra Kumar,Mr.M R Pavan Kumar,Mrs. Y R Anitha,Mrs.P Sukanya

Department of Pharmacology

Email ID: swathibhaskarthumma25@gmail.com, Mobile no:9494640005

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

Various studies have revealed varying outcomes regarding the safety and effectiveness of apremilast in comparison to methotrexate. Therefore, more research into the function of Apremilast in palmoplantar psoriasis is required. Patients with moderate to severe palmoplantar psoriasis were the subjects of a randomized, prospective, parallel-group, open-label trial. For 16 weeks, they were randomly assigned to either the methotrexate group (n = 19) or the apremilast group (n = 22). Reduced scores on the modified palmoplantar psoriasis severity index (mPPPASI) from week 0 to week 16 served as the primary effectiveness metric. Additional metrics included the percentage of patients who achieved a Static Physician Global Assessment score of 0 (clear) or 1 (almost clear), the percentage of patients who achieved mPPPASI75 (75% reduction in mPPPASI score) by the end of 16 weeks, and the proportion of patients who demonstrated a dermatology life quality index decline of at least 5 points from the beginning. At 16 weeks, there was no statistically significant difference between the two groups in terms of mPPPASI score drop, however there was a significant decline from week 0 to week 16 within the group. The secondary efficacy measures had identical outcomes. Out of the twenty-four adverse events documented in the methotrexate group, three individuals had abnormal liver function tests. Out of the 19 adverse events documented in the apremilast group, 2 patients had an infection of the upper respiratory tract. In the treatment of moderate to severe palmoplantar psoriasis, apremilast is just as effective as methotrexate, but it is more tolerable. Static Physician Global Assessment, Dermatology Life Quality Index, Palmoplantar Psoriasis, Palmoplantar Psoriasis Area and Severity Index, Apremilast

It is more likely for psoriasis to appear before the age of 30. The high expense of therapy and the significant psychological and social effects of psoriasis have a negative effect on sufferers' quality of life (QOL).[2]

Scalp, face, intertriginous, genital, palmoplantar, and nail psoriasis are the many types of psoriasis that may be found. Patients with palmoplantar psoriasis have more limited mobility and fewer self-care options, and they also have varying responses to medicines. the third Topical




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FDS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

NO. OF RESEARCH PAPERS PUBLISHED PER TEACHER IN THE JOURNALS NOTIFIED ON UGC CARE LIST DURING THE LAST FIVE YEARS

CALENDER YEAR - 2020

S.No	Title of the Paper	Name of the Author/s	Name of the Journal	ISSN NO
1	The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition	Ms. C B Hanisha	History of Medicine studies	1300-669
2	The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition	Mr.Sivakumar Peta	History of Medicine studies	1300-669
3	The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition	Mr.S Bugga Reddy	History of Medicine studies	1300-669
4	The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition	Mr AVLS Ramakrishna	History of Medicine studies	1300-669
5	The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition	Ms M Sowmya	History of Medicine studies	1300-669
6	Highly Accurate and Reliable RP-HPLC Approach for the Measurement of Valethamate Bromide in Pharmaceutical Compounds	Mrs S Usha Rani	Indo-American Journal of Pharma and Biosciences	2347-2251
7	Highly Accurate and Reliable RP-HPLC Approach for the Measurement of Valethamate Bromide in Pharmaceutical Compounds	Dr.M.Soujanya	Indo-American Journal of Pharma and Biosciences	2347-2251



Kavay
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph D, FIC, FDSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

8	Highly Accurate and Reliable RP-HPLC Approach for the Measurement of Valethamate Bromide in Pharmaceutical Compounds	Ms.B Silpa	Indo-American Journal of Pharma and Biosciences	2347-2251
9	Highly Accurate and Reliable RP-HPLC Approach for the Measurement of Valethamate Bromide in Pharmaceutical Compounds	Mr.N.Praveen Kumar	Indo-American Journal of Pharma and Biosciences	2347-2251
10	Highly Accurate and Reliable RP-HPLC Approach for the Measurement of Valethamate Bromide in Pharmaceutical Compounds	Mrs.M.Sindhuri	Indo-American Journal of Pharma and Biosciences	2347-2251
11	A tertiary care hospital's drug resistance profile in instances of gastrointestinal and postbiliary surgical-site infections	Ms.A R Sridevi	International Journal of Pharmaceutical Sciences Letters	2277-2685
12	A tertiary care hospital's drug resistance profile in instances of gastrointestinal and postbiliary surgical-site infections	Mrs.S Usharani	International Journal of Pharmaceutical Sciences Letters	2277-2685
13	A tertiary care hospital's drug resistance profile in instances of gastrointestinal and postbiliary surgical-site infections	Mr.SSivakotewara Rao	International Journal of Pharmaceutical Sciences Letters	2277-2685
14	A tertiary care hospital's drug resistance profile in instances of gastrointestinal and postbiliary surgical-site infections	Mr.B Nagendra Prasad	International Journal of Pharmaceutical Sciences Letters	2277-2685
15	A tertiary care hospital's drug resistance profile in instances of gastrointestinal and postbiliary surgical-site infections	Mr.M Kalyan Babu	International Journal of Pharmaceutical Sciences Letters	2277-2685



Navay
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FESS, FALP, FICOP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

16	The Impact of Shear Stress on Compression-induced Polymorphic Transformation in Tablets and Creation of Strategies to Minimize it	Mrs.P K Devi Bala	Indo-American Journal of Life sciences and Biotechnology	2347-2243
17	The Impact of Shear Stress on Compression-induced Polymorphic Transformation in Tablets and Creation of Strategies to Minimize it	Dr.M.Soujanya	Indo-American Journal of Life sciences and Biotechnology	2347-2243
18	The Impact of Shear Stress on Compression-induced Polymorphic Transformation in Tablets and Creation of Strategies to Minimize it	Ms.A Manogna	Indo-American Journal of Life sciences and Biotechnology	2347-2243
19	The Impact of Shear Stress on Compression-induced Polymorphic Transformation in Tablets and Creation of Strategies to Minimize it	Mr B Kondal rao	Indo-American Journal of Life sciences and Biotechnology	2347-2243
20	The Impact of Shear Stress on Compression-induced Polymorphic Transformation in Tablets and Creation of Strategies to Minimize it	Mrs.Y R Anitha	Indo-American Journal of Life sciences and Biotechnology	2347-2243


PRINCIPAL



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FDS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition

Ms. C B Hanisha, Mr.Sivakumar Peta, Mr.S Bugga Reddy, Mr AVLS Ramakrishna, Ms M Sowmya

Abstract

Research on the physiology of intestinal cells and drug transport often makes use of Caco-2 cells. In this study, the total protein technique was used to quantify the global proteome of filter-grown Caco-2 cells. The results were compared with proteomes from the human colon and jejunum. There were a total of 8096 proteins found. Thorough examination of proteins that characterize enterocyte development, such as adherens and tight junctions, integrins, and brush-border hydrolases, provided almost exhaustive coverage of the anticipated proteins. Out of the 327 proteins that were found, 112 were solute carriers and 20 were ATP-binding cassette transporters; these proteins were involved in absorption, distribution, metabolism, and excretion. The levels of OATP2B1 were sixteen times more in Caco-2 cells compared to jejunum. At clinically relevant intestine concentrations, OATP2B1 accounted for 60%-70% of the uptake kinetics of pitavastatin, an OATP2B1 substrate, in Caco-2 monolayers. We aimed to understand how this discrepancy affected in vitro-in vivo extrapolations. Together, pitavastatin kinetics and transporter concentrations were used to simulate the role of active transport and membrane penetration in the jejunum. Pitavastatin absorption in vivo is mostly mediated via transmembrane diffusion, as shown by the much decreased transporter contribution (<5%) caused by the lower OATP2B1 expression in the jejunum. The first comprehensive measurement of the Caco-2 proteome produced in a filter has been presented here. To correctly interpret drug transport pathways in the human gut, we also show that transporter expression levels are very important. The American Pharmacists Association® owns the copyright for the year 2016. This publication is protected by copyright from Elsevier Inc.

Introduction

The human colon carcinoma Caco-2 cell line was originally isolated by Fogh et al.¹ Zweibaum et al. introduced the use of filter-grown Caco-2 monolayers for studies of epithelial cell physiology and reported on its spontaneous differentiation to an enterocyte-like phenotype.^{2,3} This paved the way for scientists in the pharmaceutical field to apply this cell line for the study of solute transport and absorption.⁴⁻⁷

Borchardt and Wilson were the first to use Caco-2 cells to study active transport processes, including transport of bile proteins, vitamins, amino acids, and peptides.^{6,8-10} Since methods for identifying or knocking off the target transporter were just recently developed, functional studies dominated their groundbreaking work and the subsequent many investigations. Modern mass spectrometry has made it feasible to map the whole Caco-2 cell proteome.

Department of Pharmaceutics
Email ID: hanisha777@gmail.com, Mobile no:8019538344
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition

Ms. C B Hanisha , Mr.Sivakumar Peta , Mr.S Bugga Reddy , Mr AVLS Ramakrishna ,
Ms M Sowmya

Abstract

Research on the physiology of intestinal cells and drug transport often makes use of Caco-2 cells. In this study, the total protein technique was used to quantify the global proteome of filter-grown Caco-2 cells. The results were compared with proteomes from the human colon and jejunum. There were a total of 8096 proteins found. Thorough examination of proteins that characterize enterocyte development, such as adherens and tight junctions, integrins, and brush-border hydrolases, provided almost exhaustive coverage of the anticipated proteins. Out of the 327 proteins that were found, 112 were solute carriers and 20 were ATP-binding cassette transporters; these proteins were involved in absorption, distribution, metabolism, and excretion. The levels of OATP2B1 were sixteen times more in Caco-2 cells compared to jejunum. At clinically relevant intestine concentrations, OATP2B1 accounted for 60%-70% of the uptake kinetics of pitavastatin, an OATP2B1 substrate, in Caco-2 monolayers. We aimed to understand how this discrepancy affected in vitro-in vivo extrapolations. Together, pitavastatin kinetics and transporter concentrations were used to simulate the role of active transport and membrane penetration in the jejunum. Pitavastatin absorption in vivo is mostly mediated via transmembrane diffusion, as shown by the much decreased transporter contribution (<5%) caused by the lower OATP2B1 expression in the jejunum. The first comprehensive measurement of the Caco-2 proteome produced in a filter has been presented here. To correctly interpret drug transport pathways in the human gut, we also show that transporter expression levels are very important. The American Pharmacists Association® owns the copyright for the year 2016. This publication is protected by copyright from Elsevier Inc.

Introduction

The human colon carcinoma Caco-2 cell line was originally isolated by Fogh et al.¹ Zweibaum et al. introduced the use of filter-grown Caco-2 monolayers for studies of epithelial cell physiology and reported on its spontaneous differentiation to an enterocyte-like phenotype.^{2,3} This paved the way for scientists in the pharmaceutical field to apply this cell line for the study of solute transport and absorption.⁴⁻⁷

Borchardt and Wilson were the first to use Caco-2 cells to study active transport processes, including transport of bile proteins, vitamins, amino acids, and peptides.^{6,8-10} Since methods for identifying or knocking off the target transporter were just recently developed, functional studies dominated their groundbreaking work and the subsequent many investigations. Modern mass spectrometry has made it feasible to map the whole Caco-2 cell proteome.

Department of Pharmaceutics
Email ID: hanisha777@gmail.com , Mobile no:8019538344
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FDSS, FAGE, FICCP, MSTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition

Ms. C B Hanisha , Mr.Sivakumar Peta ,Mr.S Bugga Reddy , Mr AVLS Ramakrishna ,
Ms M Sowmya

Abstract

Research on the physiology of intestinal cells and drug transport often makes use of Caco-2 cells. In this study, the total protein technique was used to quantify the global proteome of filter-grown Caco-2 cells. The results were compared with proteomes from the human colon and jejunum. There were a total of 8096 proteins found. Thorough examination of proteins that characterize enterocyte development, such as adherens and tight junctions, integrins, and brush-border hydrolases, provided almost exhaustive coverage of the anticipated proteins. Out of the 327 proteins that were found, 112 were solute carriers and 20 were ATP-binding cassette transporters; these proteins were involved in absorption, distribution, metabolism, and excretion. The levels of OATP2B1 were sixteen times more in Caco-2 cells compared to jejunum. At clinically relevant intestine concentrations, OATP2B1 accounted for 60%-70% of the uptake kinetics of pitavastatin, an OATP2B1 substrate, in Caco-2 monolayers. We aimed to understand how this discrepancy affected in vitro-in vivo extrapolations. Together, pitavastatin kinetics and transporter concentrations were used to simulate the role of active transport and membrane penetration in the jejunum. Pitavastatin absorption in vivo is mostly mediated via transmembrane diffusion, as shown by the much decreased transporter contribution (<5%) caused by the lower OATP2B1 expression in the jejunum. The first comprehensive measurement of the Caco-2 proteome produced in a filter has been presented here. To correctly interpret drug transport pathways in the human gut, we also show that transporter expression levels are very important. The American Pharmacists Association® owns the copyright for the year 2016. This publication is protected by copyright from Elsevier Inc.

Introduction

The human colon carcinoma Caco-2 cell line was originally isolated by Fogh et al.¹ Zweibaum et al. introduced the use of filter-grown Caco-2 monolayers for studies of epithelial cell physiology and reported on its spontaneous differentiation to an enterocyte-like phenotype.^{2,3} This paved the way for scientists in the pharmaceutical field to apply this cell line for the study of solute transport and absorption.⁴⁻⁷

Borchardt and Wilson were the first to use Caco-2 cells to study active transport processes, including transport of bile proteins, vitamins, amino acids, and peptides.^{6,8-10} Since methods for identifying or knocking off the target transporter were just recently developed, functional studies dominated their groundbreaking work and the subsequent many investigations. Modern mass spectrometry has made it feasible to map the whole Caco-2 cell proteome.

Department of Pharmaceutics
Email ID: hanisha777@gmail.com , Mobile no:8019538344
GOKULA KRISHNA COLLEGE OF PHARMACY



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition

Ms. C B Hanisha , Mr.Sivakumar Peta ,Mr.S Bugga Reddy , Mr AVLS Ramakrishna ,
Ms M Sowmya

Abstract

Research on the physiology of intestinal cells and drug transport often makes use of Caco-2 cells. In this study, the total protein technique was used to quantify the global proteome of filter-grown Caco-2 cells. The results were compared with proteomes from the human colon and jejunum. There were a total of 8096 proteins found. Thorough examination of proteins that characterize enterocyte development, such as adherens and tight junctions, integrins, and brush-border hydrolases, provided almost exhaustive coverage of the anticipated proteins. Out of the 327 proteins that were found, 112 were solute carriers and 20 were ATP-binding cassette transporters; these proteins were involved in absorption, distribution, metabolism, and excretion. The levels of OATP2B1 were sixteen times more in Caco-2 cells compared to jejunum. At clinically relevant intestine concentrations, OATP2B1 accounted for 60%-70% of the uptake kinetics of pitavastatin, an OATP2B1 substrate, in Caco-2 monolayers. We aimed to understand how this discrepancy affected in vitro-in vivo extrapolations. Together, pitavastatin kinetics and transporter concentrations were used to simulate the role of active transport and membrane penetration in the jejunum. Pitavastatin absorption in vivo is mostly mediated via transmembrane diffusion, as shown by the much decreased transporter contribution (<5%) caused by the lower OATP2B1 expression in the jejunum. The first comprehensive measurement of the Caco-2 proteome produced in a filter has been presented here. To correctly interpret drug transport pathways in the human gut, we also show that transporter expression levels are very important. The American Pharmacists Association® owns the copyright for the year 2016. This publication is protected by copyright from Elsevier Inc.

Introduction

The human colon carcinoma Caco-2 cell line was originally isolated by Fogh et al.¹ Zweibaum et al. introduced the use of filter-grown Caco-2 monolayers for studies of epithelial cell physiology and reported on its spontaneous differentiation to an enterocyte-like phenotype.^{2,3} This paved the way for scientists in the pharmaceutical field to apply this cell line for the study of solute transport and absorption.⁴⁻⁷

Borchardt and Wilson were the first to use Caco-2 cells to study active transport processes, including transport of bile proteins, vitamins, amino acids, and peptides.^{6,8-10} Since methods for identifying or knocking off the target transporter were just recently developed, functional studies dominated their groundbreaking work and the subsequent many investigations. Modern mass spectrometry has made it feasible to map the whole Caco-2 cell proteome.

Department of Pharmaceutics
Email ID: hanisha777@gmail.com , Mobile no:8019538344
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition

Ms. C B Hanisha , Mr.Sivakumar Peta ,Mr.S Bugga Reddy , Mr AVLS Ramakrishna ,
Ms M Sowmya

Abstract

Research on the physiology of intestinal cells and drug transport often makes use of Caco-2 cells. In this study, the total protein technique was used to quantify the global proteome of filter-grown Caco-2 cells. The results were compared with proteomes from the human colon and jejunum. There were a total of 8096 proteins found. Thorough examination of proteins that characterize enterocyte development, such as adherens and tight junctions, integrins, and brush-border hydrolases, provided almost exhaustive coverage of the anticipated proteins. Out of the 327 proteins that were found, 112 were solute carriers and 20 were ATP-binding cassette transporters; these proteins were involved in absorption, distribution, metabolism, and excretion. The levels of OATP2B1 were sixteen times more in Caco-2 cells compared to jejunum. At clinically relevant intestine concentrations, OATP2B1 accounted for 60%-70% of the uptake kinetics of pitavastatin, an OATP2B1 substrate, in Caco-2 monolayers. We aimed to understand how this discrepancy affected in vitro-in vivo extrapolations. Together, pitavastatin kinetics and transporter concentrations were used to simulate the role of active transport and membrane penetration in the jejunum. Pitavastatin absorption in vivo is mostly mediated via transmembrane diffusion, as shown by the much decreased transporter contribution (<5%) caused by the lower OATP2B1 expression in the jejunum. The first comprehensive measurement of the Caco-2 proteome produced in a filter has been presented here. To correctly interpret drug transport pathways in the human gut, we also show that transporter expression levels are very important. The American Pharmacists Association® owns the copyright for the year 2016. This publication is protected by copyright from Elsevier Inc.


Introduction

The human colon carcinoma Caco-2 cell line was originally isolated by Fogh et al.¹ Zweibaum et al. introduced the use of filter-grown Caco-2 monolayers for studies of epithelial cell physiology and reported on its spontaneous differentiation to an enterocyte-like phenotype.^{2,3} This paved the way for scientists in the pharmaceutical field to apply this cell line for the study of solute transport and absorption.⁴⁻⁷

Borchardt and Wilson were the first to use Caco-2 cells to study active transport processes, including transport of bile proteins, vitamins, amino acids, and peptides.^{6,8-10} Since methods for identifying or knocking off the target transporter were just recently developed, functional studies dominated their groundbreaking work and the subsequent many investigations. Modern mass spectrometry has made it feasible to map the whole Caco-2 cell proteome.

Department of Pharmaceutics
Email ID: hanisha777@gmail.com , Mobile no:8019538344
GOKULA KRISHNA COLLEGE OF PHARMACY





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com

Navay



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, F855, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Highly Accurate and Reliable RP-HPLC Approach for the Measurement of Valethamate Bromide in Pharmaceutical Compounds

Mrs S Usha Rani, Dr. M. Soujanya, Ms. B Silpa, Mr. N. Praveen Kumar, Mrs. M. Sindhuri

ABSTRACT

The developed and confirmed RP-HPLC technique for the measurement of Valethamate bromide in pharmaceutical formulation is presented in this paper. The method is simple, reliable, sensitive, and robust. The mobile phase was composed of acetonitrile and water in a ratio of 20:80 % v/v. The chromatographic system included LC 2010cHT, Luna HPLC analytical C18 100 A°, 250 X 4.6 mm, 5 µm columns. At 200 nm, a PDA detector was used for detection. The half-life of valethamate bromide was 4.62 minutes. In the 5-30 µg/ml range, the method demonstrates a linear response ($r^2=0.9975$). LOQ was 0.68 µg/ml and LOD was 0.22 µg/ml. Following the requirements laid forth by ICH Q2 (R1), the method was verified. Linearity, precision, specificity, accuracy, and robustness were the parameters that were validated. There was less than a 2% RSD for all of the metrics. The method's accuracy ranged from 99.67 to 100.66% after the typical addition of the medication. A research was conducted to assess robustness using a 2³-1 factorial design. The described approach may be used to determine the concentration of Valethamate bromide in pharmaceutical formulations.

Keywords: Factorial Design; Validation; RP-HPLC; ICH guideline; Valethamate bromide (VLB)

INTRODUCTION

N, N-Diethyl-N-methyl-2-(3-methyl-1-oxo-2-phenylpentyl) oxyl ethanaminium bromide is the chemical name for valethamate bromide (VLB) (Fig.1). An antispasmodic medication called 1-3 VLB is used to induce labor.⁴ Valethamate bromide in medicinal dose form has only been documented to be estimated using the

HPTLC⁵ technique in the literature. This research used a complete factorial design to conduct a robustness analysis and validate the established technique according to the ICH Q2(R1) guideline⁶, and it used RP-HPLC as an alternate analytical approach for estimating valethamate bromide in both bulk and pharmaceutical dose form.

Department of Pharmaceutical Chemistry
Email ID: ushapharma107@gmail.com, Mobile no: 9491835288
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com

editor@iajpb.com



Narayana

Dr. BALAGANI PAVAN KUMAR

M. Pharm., Ph.D., F.C., F.B.S.S., F.A.G.E., F.I.C.C.P., M.I.S.T.E.

PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY

SULLURPET, TIRUPATI DI. A.P - 524121



Highly Accurate and Reliable RP-HPLC Approach for the Measurement of Valethamate Bromide in Pharmaceutical Compounds

Mrs S Usha Rani, Dr. M. Soujanya, Ms. B Silpa, Mr. N. Praveen Kumar, Mrs. M. Sindhuri

ABSTRACT

The developed and confirmed RP-HPLC technique for the measurement of Valethamate bromide in pharmaceutical formulation is presented in this paper. The method is simple, reliable, sensitive, and robust. The mobile phase was composed of acetonitrile and water in a ratio of 20:80 % v/v. The chromatographic system included LC 2010cHT, Luna HPLC analytical C18 100 A^o, 250 X 4.6 mm, 5 μm columns. At 200 nm, a PDA detector was used for detection. The half-life of valethamate bromide was 4.62 minutes. In the 5-30 μg/ml range, the method demonstrates a linear response ($r^2=0.9975$). LOQ was 0.68 μg/ml and LOD was 0.22 μg/ml. Following the requirements laid forth by ICH Q2 (R1), the method was verified. Linearity, precision, specificity, accuracy, and robustness were the parameters that were validated. There was less than a 2% RSD for all of the metrics. The method's accuracy ranged from 99.67 to 100.66% after the typical addition of the medication. A research was conducted to assess robustness using a 2³-1 factorial design. The described approach may be used to determine the concentration of Valethamate bromide in pharmaceutical formulations.

Keywords: Factorial Design; Validation; RP-HPLC; ICH guideline; Valethamate bromide (VLB)

INTRODUCTION

N, N-Diethyl-N-methyl-2-(3-methyl-1-oxo-2-phenylpentyl) oxyl ethanaminium bromide is the chemical name for valethamate bromide (VLB) (Fig.1). An antispasmodic medication called 1-3 VLB is used to induce labor. Valethamate bromide in medicinal dose form has only been documented to be estimated using the

HPTLC5 technique in the literature. This research used a complete factorial design to conduct a robustness analysis and validate the established technique according to the ICH Q2(R1) guideline⁶, and it used RP-HPLC as an alternate analytical approach for estimating valethamate bromide in both bulk and pharmaceutical dose form.

Department of Pharmaceutical Chemistry

Email ID: ushapharma107@gmail.com, Mobile no: 9491835288

GOKULA KRISHNA COLLEGE OF PHARMACY



Navay

Dr. BALAGANI PAVAN KUMAR


M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MSTE
PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com

editor@iajpb.com



Navya

Dr. BALAGANI PAVAN KUMAR

M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE

PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Highly Accurate and Reliable RP-HPLC Approach for the Measurement of Valethamate Bromide in Pharmaceutical Compounds

Mrs S Usha Rani, Dr. M. Soujanya, Ms. B Silpa, Mr. N. Praveen Kumar, Mrs. M. Sindhuri

ABSTRACT

The developed and confirmed RP-HPLC technique for the measurement of Valethamate bromide in pharmaceutical formulation is presented in this paper. The method is simple, reliable, sensitive, and robust. The mobile phase was composed of acetonitrile and water in a ratio of 20:80 % v/v. The chromatographic system included LC 2010cHT, Luna HPLC analytical C18 100 A°, 250 X 4.6 mm, 5 µm columns. At 200 nm, a PDA detector was used for detection. The half-life of valethamate bromide was 4.62 minutes. In the 5-30 µg/ml range, the method demonstrates a linear response ($r^2=0.9975$). LOQ was 0.68 µg/ml and LOD was 0.22 µg/ml. Following the requirements laid forth by ICH Q2 (R1), the method was verified. Linearity, precision, specificity, accuracy, and robustness were the parameters that were validated. There was less than a 2% RSD for all of the metrics. The method's accuracy ranged from 99.67 to 100.66% after the typical addition of the medication. A research was conducted to assess robustness using a 23-1 factorial design. The described approach may be used to determine the concentration of Valethamate bromide in pharmaceutical formulations.

Keywords: Factorial Design; Validation; RP-HPLC; ICH guideline; Valethamate bromide (VLB)

INTRODUCTION

N, N-Diethyl-N-methyl-2-(3-methyl-1-oxo-2-phenylpentyl) oxyl ethanaminium bromide is the chemical name for valethamate bromide (VLB) (Fig.1). An antispasmodic medication called 1-3 VLB is used to induce labor. Valethamate bromide in medicinal dose form has only been documented to be estimated using the

HPTLC5 technique in the literature. This research used a complete factorial design to conduct a robustness analysis and validate the established technique according to the ICH Q2(R1) guideline⁶, and it used RP-HPLC as an alternate analytical approach for estimating valethamate bromide in both bulk and pharmaceutical dose form.

Department of Pharmaceutical Chemistry
Email ID: ushapharma107@gmail.com, Mobile no: 9491835288
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com

editor@iajpb.com



Neway

Dr. BALAGANI PAVAN KUMAR

M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MSTE
PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



Highly Accurate and Reliable RP-HPLC Approach for the Measurement of Valethamate Bromide in Pharmaceutical Compounds

Mrs S Usha Rani, Dr. M. Soujanya, Ms. B Silpa, Mr. N. Praveen Kumar, Mrs. M. Sindhuri

ABSTRACT

The developed and confirmed RP-HPLC technique for the measurement of Valethamate bromide in pharmaceutical formulation is presented in this paper. The method is simple, reliable, sensitive, and robust. The mobile phase was composed of acetonitrile and water in a ratio of 20:80 % v/v. The chromatographic system included LC 2010cHT, Luna HPLC analytical C18 100 A^o, 250 X 4.6 mm, 5 μ m columns. At 200 nm, a PDA detector was used for detection. The half-life of valethamate bromide was 4.62 minutes. In the 5-30 μ g/ml range, the method demonstrates a linear response ($r^2=0.9975$). LOQ was 0.68 μ g/ml and LOD was 0.22 μ g/ml. Following the requirements laid forth by ICH Q2 (R1), the method was verified. Linearity, precision, specificity, accuracy, and robustness were the parameters that were validated. There was less than a 2% RSD for all of the metrics. The method's accuracy ranged from 99.67 to 100.66% after the typical addition of the medication. A research was conducted to assess robustness using a 23-1 factorial design. The described approach may be used to determine the concentration of Valethamate bromide in pharmaceutical formulations.

Keywords: Factorial Design; Validation; RP-HPLC; ICH guideline; Valethamate bromide (VLB)

INTRODUCTION

N, N-Diethyl-N-methyl-2-(3-methyl-1-oxo-2-phenylpentyl) oxyl ethanaminium bromide is the chemical name for valethamate bromide (VLB) (Fig.1). An antispasmodic medication called 1-3 VLB is used to induce labor. Valethamate bromide in medicinal dose form has only been documented to be estimated using the

HPTLC5 technique in the literature. This research used a complete factorial design to conduct a robustness analysis and validate the established technique according to the ICH Q2(R1) guideline⁶, and it used RP-HPLC as an alternate analytical approach for estimating valethamate bromide in both bulk and pharmaceutical dose form.

Department of Pharmaceutical Chemistry

Email ID: ushapharma107@gmail.com, Mobile no: 9491835288

GOKULA KRISHNA COLLEGE OF PHARMACY




Kavay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com



Kavay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



Highly Accurate and Reliable RP-HPLC Approach for the Measurement of Valethamate Bromide in Pharmaceutical Compounds

Mrs S Usha Rani, Dr. M. Soujanya, Ms. B Silpa, Mr. N. Praveen Kumar, Mrs. M. Sindhuri

ABSTRACT

The developed and confirmed RP-HPLC technique for the measurement of Valethamate bromide in pharmaceutical formulation is presented in this paper. The method is simple, reliable, sensitive, and robust. The mobile phase was composed of acetonitrile and water in a ratio of 20:80 % v/v. The chromatographic system included LC 2010cHT, Luna HPLC analytical C18 100 A°, 250 X 4.6 mm, 5 µm columns. At 200 nm, a PDA detector was used for detection. The half-life of valethamate bromide was 4.62 minutes. In the 5-30 µg/ml range, the method demonstrates a linear response ($r^2=0.9975$). LOQ was 0.68 µg/ml and LOD was 0.22 µg/ml. Following the requirements laid forth by ICH Q2 (R1), the method was verified. Linearity, precision, specificity, accuracy, and robustness were the parameters that were validated. There was less than a 2% RSD for all of the metrics. The method's accuracy ranged from 99.67 to 100.66% after the typical addition of the medication. A research was conducted to assess robustness using a 23-1 factorial design. The described approach may be used to determine the concentration of Valethamate bromide in pharmaceutical formulations.

Keywords: Factorial Design; Validation; RP-HPLC; ICH guideline; Valethamate bromide (VLB)

INTRODUCTION

N, N-Diethyl-N-methyl-2-(3-methyl-1-oxo-2-phenylpentyl) oxyl ethanaminium bromide is the chemical name for valethamate bromide (VLB) (Fig.1). An antispasmodic medication called 1-3 VLB is used to induce labor. Valethamate bromide in medicinal dose form has only been documented to be estimated using the

HPTLC5 technique in the literature. This research used a complete factorial design to conduct a robustness analysis and validate the established technique according to the ICH Q2(R1) guideline⁶, and it used RP-HPLC as an alternate analytical approach for estimating valethamate bromide in both bulk and pharmaceutical dose form.

Department of Pharmaceutical Chemistry

Email ID: ushapharma107@gmail.com, Mobile no: 9491835288

GOKULA KRISHNA COLLEGE OF PHARMACY



Navay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A tertiary care hospital's drug resistance profile in instances of gastrointestinal and postbiliary surgical-site infections

Ms.A.R Sridevi, Mrs.S Usharani, Mr.S Sivakotewara Rao, Mr.B Nagendra Prasad,
Mr.M Kalyan Babu
Department of pharmacology
Email ID: sridevipharma93@gmail.com, Mobile no: 9182727657
GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

Surgical-site infection (SSI)-associated bacteria in underdeveloped regions are showing signs of increasing medication resistance, which is leading to more severe complications and increased healthcare expenses. The pattern of medication resistance in our SSI-related isolates was our aim in this analysis. Wound swabs were treated using standard aerobic and anaerobic culture for 191 clinically confirmed SSIs (postbiliary tract and postgastrointestinal surgery) during a 2-year period. The Epsilometer was used to determine the minimum inhibitory concentration (MIC) of the antibiotic. According to the criteria, phenotypes of multidrug resistance were identified. There were 5.3% SSIs, mostly caused by *Klebsiella*, *Staphylococcus*, and *Pseudomonas*, with no anaerobes found. Nineteen percent of the *Staphylococcus aureus* bacteria were resistant to methicillin, and a third of those bacteria showed an elevated macrolide minimum inhibitory concentration (MIC). Out of all the Enterobacteriaceae isolates, about 58.2% were found to generate extended-spectrum beta-lactamases. We found isolates that had a higher meropenem MIC. The dangerously increasing proportion of antibiotic resistance in SSI patients is accompanied with MICs that are rapidly nearing resistance in susceptible isolates. Immediate remedial measures are required by law.

Search Terms:

Minimum inhibitory concentration, health care-associated infection, surgical-site infection, extended-spectrum beta-lactamase, and methicillin-resistant *Staphylococcus aureus*. Despite being avoidable in over half of instances, surgical-site infections (SSIs) are linked to higher rates of patient morbidity, death, and healthcare-associated costs. Up to 30% of patients in poor and medium income countries who have surgery are affected by surgical site infections (SSIs), making them the most prevalent kind of healthcare-associated illness (HAI). [2] SSI is the second most common kind of healthcare-associated infection (HAI), accounting for up to 20% of all HAIs in developed nations. [5]

Introduction

The average SSI rate here was 4.2%, according to a comprehensive multicentric research that included data from six Indian cities. Bacterial isolates associated with SSIs are typically found in healthcare settings, where medication resistance is prevalent. Drug resistance may be associated with surgery-related variables such as emergency operations and extended surgical prophylaxis. For




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A tertiary care hospital's drug resistance profile in instances of gastrointestinal and postbiliary surgical-site infections

Ms.A R Sridevi ,Mrs.S Usharani ,Mr.SSivakotewara Rao ,Mr.B Nagendra Prasad,
Mr.M Kalyan Babu

Department of pharmacology

Email ID: sridevipharma93@gmail.com, Mobile no: 9182727657

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:


Surgical-site infection (SSI)-associated bacteria in underdeveloped regions are showing signs of increasing medication resistance, which is leading to more severe complications and increased healthcare expenses. The pattern of medication resistance in our SSI-related isolates was our aim in this analysis. Wound swabs were treated using standard aerobic and anaerobic culture for 191 clinically confirmed SSIs (postbiliary tract and postgastrointestinal surgery) during a 2-year period. The Epsilometer was used to determine the minimum inhibitory concentration (MIC) of the antibiotic. According to the criteria, phenotypes of multidrug resistance were identified. There were 5.3% SSIs, mostly caused by *Klebsiella*, *Staphylococcus*, and *Pseudomonas*, with no anaerobes found. Nineteen percent of the *Staphylococcus aureus* bacteria were resistant to methicillin, and a third of those bacteria showed an elevated macrolide minimum inhibitory concentration (MIC). Out of all the Enterobacteriaceae isolates, about 58.2% were found to generate extended-spectrum beta-lactamases. We found isolates that had a higher meropenem MIC. The dangerously increasing proportion of antibiotic resistance in SSI patients is accompanied with MICs that are rapidly nearing resistance in susceptible isolates. Immediate remedial measures are required by law.

Search Terms:

Minimum inhibitory concentration, health care-associated infection, surgical-site infection, extended-spectrum beta-lactamase, and methicillin-resistant *Staphylococcus aureus* Despite being avoidable in over half of instances, surgical-site infections (SSIs) are linked to higher rates of patient morbidity, death, and healthcare-associated costs. Up to 30% of patients in poor and medium income countries who have surgery are affected by surgical site infections (SSIs), making them the most prevalent kind of healthcare-associated illness (HAI). [2] SSI is the second most common kind of healthcare-associated infection (HAI), accounting for up to 20% of all HAIs in developed nations. [5]

Introduction

The average SSI rate here was 4.2%, according to a comprehensive multicentric research that included data from six Indian cities. Bacterial isolates associated with SSIs are typically found in healthcare settings, where medication resistance is prevalent. Drug resistance may be associated with surgery-related variables such emergency operations and extended surgical prophylaxis. For



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A tertiary care hospital's drug resistance profile in instances of gastrointestinal and postbiliary surgical-site infections

Ms.A R Sridevi ,Mrs.S Usharani ,Mr.S Sivakotewara Rao ,Mr.B Nagendra Prasad,
Mr.M Kalyan Babu

Department of pharmacology

Email ID: sridevipharma93@gmail.com, Mobile no: 9182727657

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

Surgical-site infection (SSI)-associated bacteria in underdeveloped regions are showing signs of increasing medication resistance, which is leading to more severe complications and increased healthcare expenses. The pattern of medication resistance in our SSI-related isolates was our aim in this analysis. Wound swabs were treated using standard aerobic and anaerobic culture for 191 clinically confirmed SSIs (postbiliary tract and postgastrointestinal surgery) during a 2-year period. The Epsilometer was used to determine the minimum inhibitory concentration (MIC) of the antibiotic. According to the criteria, phenotypes of multidrug resistance were identified. There were 5.3% SSIs, mostly caused by *Klebsiella*, *Staphylococcus*, and *Pseudomonas*, with no anaerobes found. Nineteen percent of the *Staphylococcus aureus* bacteria were resistant to methicillin, and a third of those bacteria showed an elevated macrolide minimum inhibitory concentration (MIC). Out of all the *Enterobacteriaceae* isolates, about 58.2% were found to generate extended-spectrum beta-lactamases. We found isolates that had a higher meropenem MIC. The dangerously increasing proportion of antibiotic resistance in SSI patients is accompanied with MICs that are rapidly nearing resistance in susceptible isolates. Immediate remedial measures are required by law.

Search Terms:

Minimum inhibitory concentration, health care-associated infection, surgical-site infection, extended-spectrum beta-lactamase, and methicillin-resistant *Staphylococcus aureus* Despite being avoidable in over half of instances, surgical-site infections (SSIs) are linked to higher rates of patient morbidity, death, and healthcare-associated costs. Up to 30% of patients in poor and medium income countries who have surgery are affected by surgical site infections (SSIs), making them the most prevalent kind of healthcare-associated illness (HAI).[2] SSI is the second most common kind of healthcare-associated infection (HAI), accounting for up to 20% of all HAIs in developed nations.[5]

Introduction

The average SSI rate here was 4.2%, according to a comprehensive multicentric research that included data from six Indian cities. Bacterial isolates associated with SSIs are typically found in healthcare settings, where medication resistance is prevalent. Drug resistance may be associated with surgery-related variables such emergency operations and extended surgical prophylaxis. For




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICOP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A tertiary care hospital's drug resistance profile in instances of gastrointestinal and postbiliary surgical-site infections

Ms.A R Sridevi ,Mrs.S Usharani ,Mr.SSivakotewara Rao ,Mr.B Nagendra Prasad,
Mr.M Kalyan Babu

Department of pharmacology

Email ID: sridevipharma93@gmail.com, Mobile no: 9182727657

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

Surgical-site infection (SSI)-associated bacteria in underdeveloped regions are showing signs of increasing medication resistance, which is leading to more severe complications and increased healthcare expenses. The pattern of medication resistance in our SSI-related isolates was our aim in this analysis. Wound swabs were treated using standard aerobic and anaerobic culture for 191 clinically confirmed SSIs (postbiliary tract and postgastrointestinal surgery) during a 2-year period. The Epsilometer was used to determine the minimum inhibitory concentration (MIC) of the antibiotic. According to the criteria, phenotypes of multidrug resistance were identified. There were 5.3% SSIs, mostly caused by *Klebsiella*, *Staphylococcus*, and *Pseudomonas*, with no anaerobes found. Nineteen percent of the *Staphylococcus aureus* bacteria were resistant to methicillin, and a third of those bacteria showed an elevated macrolide minimum inhibitory concentration (MIC). Out of all the Enterobacteriaceae isolates, about 58.2% were found to generate extended-spectrum beta-lactamases. We found isolates that had a higher meropenem MIC. The dangerously increasing proportion of antibiotic resistance in SSI patients is accompanied with MICs that are rapidly nearing resistance in susceptible isolates. Immediate remedial measures are required by law.

Search Terms:

Minimum inhibitory concentration, health care-associated infection, surgical-site infection, extended-spectrum beta-lactamase, and methicillin-resistant *Staphylococcus aureus* Despite being avoidable in over half of instances, surgical-site infections (SSIs) are linked to higher rates of patient morbidity, death, and healthcare-associated costs. Up to 30% of patients in poor and medium income countries who have surgery are affected by surgical site infections (SSIs), making them the most prevalent kind of healthcare-associated illness (HAI).[2] SSI is the second most common kind of healthcare-associated infection (HAI), accounting for up to 20% of all HAIs in developed nations.[5]

Introduction

The average SSI rate here was 4.2%, according to a comprehensive multicentric research that included data from six Indian cities. Bacterial isolates associated with SSIs are typically found in healthcare settings, where medication resistance is prevalent. Drug resistance may be associated with surgery-related variables such emergency operations and extended surgical prophylaxis. For




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

A tertiary care hospital's drug resistance profile in instances of gastrointestinal and postbiliary surgical-site infections

Ms.A R Sridevi ,Mrs.S Usharani ,Mr.SSivakotewara Rao ,Mr.B Nagendra Prasad,
Mr.M Kalyan Babu

Department of pharmacology

Email ID: sridevipharma93@gmail.com, Mobile no: 9182727657

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

Surgical-site infection (SSI)-associated bacteria in underdeveloped regions are showing signs of increasing medication resistance, which is leading to more severe complications and increased healthcare expenses. The pattern of medication resistance in our SSI-related isolates was our aim in this analysis. Wound swabs were treated using standard aerobic and anaerobic culture for 191 clinically confirmed SSIs (postbiliary tract and postgastrointestinal surgery) during a 2-year period. The Epsilometer was used to determine the minimum inhibitory concentration (MIC) of the antibiotic. According to the criteria, phenotypes of multidrug resistance were identified. There were 5.3% SSIs, mostly caused by *Klebsiella*, *Staphylococcus*, and *Pseudomonas*, with no anaerobes found. Nineteen percent of the *Staphylococcus aureus* bacteria were resistant to methicillin, and a third of those bacteria showed an elevated macrolide minimum inhibitory concentration (MIC). Out of all the Enterobacteriaceae isolates, about 58.2% were found to generate extended-spectrum beta-lactamases. We found isolates that had a higher meropenem MIC. The dangerously increasing proportion of antibiotic resistance in SSI patients is accompanied with MICs that are rapidly nearing resistance in susceptible isolates. Immediate remedial measures are required by law.

Search Terms:

Minimum inhibitory concentration, health care-associated infection, surgical-site infection, extended-spectrum beta-lactamase, and methicillin-resistant *Staphylococcus aureus* Despite being avoidable in over half of instances, surgical-site infections (SSIs) are linked to higher rates of patient morbidity, death, and healthcare-associated costs. Up to 30% of patients in poor and medium income countries who have surgery are affected by surgical site infections (SSIs), making them the most prevalent kind of healthcare-associated illness (HAI). [2] SSI is the second most common kind of healthcare-associated infection (HAI), accounting for up to 20% of all HAIs in developed nations. [5]

Introduction

The average SSI rate here was 4.2%, according to a comprehensive multicentric research that included data from six Indian cities. Bacterial isolates associated with SSIs are typically found in healthcare settings, where medication resistance is prevalent. Drug resistance may be associated with surgery-related variables such emergency operations and extended surgical prophylaxis. For




Dr. BALAGANIPAVAN KUMAR
M. Pharm, Ph.D, F.C. FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347 - 2243

*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



The Impact of Shear Stress on Compression-induced Polymorphic Transformation in Tablets and the Creation of Strategies to Minimize It

Mrs.P K Devi Bala , Dr.MSujanya ,Ms.A Manogna ,Mr B Kondal rao , Mrs.Y R Anitha

ABSTRACT

Our objective was to ascertain the effects of (i) hydrostatic pressure alone and (ii) hydrostatic pressure combined with shear stress during compaction on the polymorphic transformation (form C / A) of chlorpropamide, a generic drug. The powder was subjected to pressures ranging from 25 to 150 MPa using a combination of hydrostatic pressure in a pressure vessel and tablet pressing. The overall quantity of phase change was determined using powder X-ray diffractometry, and the distribution of phase composition in tablets was quantified using 2D-XRD. Due to the presence of shear stress during compaction, which was independent of pressure, the quantity of transformation that took place after compaction exceeded expectations based on hydrostatic pressure alone. When compressed to 25 MPa, the radical tablet surface and the core showed vastly different degrees of phase shift. This gradient became smaller with increasing compression pressure. To mitigate the effects of compression-induced phase change, four different approaches were considered: a cavity tablet, a ceramic-lined die, a site-specific lubricant, and a viscoelastic excipient. The ceramic-lined die and site-specific lubrication effectively decreased the amount of compression-induced phase shift.

Introduction

Product efficacy may be affected by the physical characteristics of an API in solid dosage form, including its polymorphic shape, solvation state, and degree of crystallinity. The most stable physical form of an API is chosen when bioavailability is not a concern since it is expected to experience minimal changes when scaling up, processing, and storage.² The production process of a pharmaceutical drug may impact the formation of kinetically stable but thermodynamically metastable forms, as Ostwald's rule makes evident.³ A number of processing steps may be performed on the API in order to create a solid dosage form, such a tablet. Milling, drying,

wet/dry granulation, compression, and coating are all part of these processes. In the course of these production processes, the API may come into contact with a wide range of solvents, including granulating fluid, coating solutions, and even water vapour pressure and very high temperatures. Metastable to stable polymorph states, phase transitions (from amorphous to crystalline, anhydrous to hydrate, and back again), and environmental variables all have a role in the potential occurrence of these changes. Processing may create phase shifts, which can sometimes have a major effect on how well the end product works.⁴

Department of pharmaceuticals,
Email ID: devinov15@gmail.com, Mobile no:9177579805

GOKULA KRISHNA COLLEGE OF PHARMACY





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347 - 2243

Indo - American Journal of Life Sciences and Biotechnology



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Narayana
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



The Impact of Shear Stress on Compression-induced Polymorphic Transformation in Tablets and the Creation of Strategies to Minimize It

Mrs.P K Devi Bala , Dr.MSujanya ,Ms.A Manogna ,Mr B Kondal rao , Mrs.Y R Anitha

ABSTRACT

Our objective was to ascertain the effects of (i) hydrostatic pressure alone and (ii) hydrostatic pressure combined with shear stress during compaction on the polymorphic transformation (form C / A) of chlorpropamide, a generic drug. The powder was subjected to pressures ranging from 25 to 150 MPa using a combination of hydrostatic pressure in a pressure vessel and tablet pressing. The overall quantity of phase change was determined using powder X-ray diffractometry, and the distribution of phase composition in tablets was quantified using 2D-XRD. Due to the presence of shear stress during compaction, which was independent of pressure, the quantity of transformation that took place after compaction exceeded expectations based on hydrostatic pressure alone. When compressed to 25 MPa, the radical tablet surface and the core showed vastly different degrees of phase shift. This gradient became smaller with increasing compression pressure. To mitigate the effects of compression-induced phase change, four different approaches were considered: a cavity tablet, a ceramic-lined die, a site-specific lubricant, and a viscoelastic excipient. The ceramic-lined die and site-specific lubrication effectively decreased the amount of compression-induced phase shift.

Introduction


Product efficacy may be affected by the physical characteristics of an API in solid dosage form, including its polymorphic shape, solvation state, and degree of crystallinity. The most stable physical form of an API is chosen when bioavailability is not a concern since it is expected to experience minimal changes when scaling up, processing, and storage.² The production process of a pharmaceutical drug may impact the formation of kinetically stable but thermodynamically metastable forms, as Ostwald's rule makes evident. A number of processing steps may be performed on the API in order to create a solid dosage form, such a tablet. Milling, drying,

wet/dry granulation, compression, and coating are all part of these processes. In the course of these production processes, the API may come into contact with a wide range of solvents, including granulating fluid, coating solutions, and even water vapour pressure and very high temperatures. Metastable to stable polymorph states, phase transitions (from amorphous to crystalline, anhydrous to hydrate, and back again), and environmental variables all have a role in the potential occurrence of these changes. Processing may create phase shifts, which can sometimes have a major effect on how well the end product works.⁴

Department of pharmaceutics,
Email ID: devinov15@gmail.com, Mobile no:9177579805

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph. D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347 - 2243

*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



The Impact of Shear Stress on Compression-induced Polymorphic Transformation in Tablets and the Creation of Strategies to Minimize It

Mrs.P K Devi Bala , Dr.MSujanya ,Ms.A Manogna ,Mr B Kondal rao , Mrs.Y R Anitha

ABSTRACT

Our objective was to ascertain the effects of (i) hydrostatic pressure alone and (ii) hydrostatic pressure combined with shear stress during compaction on the polymorphic transformation (form C / A) of chlorpropamide, a generic drug. The powder was subjected to pressures ranging from 25 to 150 MPa using a combination of hydrostatic pressure in a pressure vessel and tablet pressing. The overall quantity of phase change was determined using powder X-ray diffractometry, and the distribution of phase composition in tablets was quantified using 2D-XRD. Due to the presence of shear stress during compaction, which was independent of pressure, the quantity of transformation that took place after compaction exceeded expectations based on hydrostatic pressure alone. When compressed to 25 MPa, the radical tablet surface and the core showed vastly different degrees of phase shift. This gradient became smaller with increasing compression pressure. To mitigate the effects of compression-induced phase change, four different approaches were considered: a cavity tablet, a ceramic-lined die, a site-specific lubricant, and a viscoelastic excipient. The ceramic-lined die and site-specific lubrication effectively decreased the amount of compression-induced phase shift.

Introduction

Product efficacy may be affected by the physical characteristics of an API in solid dosage form, including its polymorphic shape, solvation state, and degree of crystallinity. The most stable physical form of an API is chosen when bioavailability is not a concern since it is expected to experience minimal changes when scaling up, processing, and storage.² The production process of a pharmaceutical drug may impact the formation of kinetically stable but thermodynamically metastable forms, as Ostwald's rule makes evident. A number of processing steps may be performed on the API in order to create a solid dosage form, such a tablet. Milling, drying,

wet/dry granulation, compression, and coating are all part of these processes. In the course of these production processes, the API may come into contact with a wide range of solvents, including granulating fluid, coating solutions, and even water vapour pressure and very high temperatures. Metastable to stable polymorph states, phase transitions (from amorphous to crystalline, anhydrous to hydrate, and back again), and environmental variables all have a role in the potential occurrence of these changes. Processing may create phase shifts, which can sometimes have a major effect on how well the end product works.⁴

Department of pharmaceuticals,
Email ID: devinov15@gmail.com, Mobile no:9177579805

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347 - 2243

Indo - American Journal of Life Sciences and Biotechnology



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANTPAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



The Impact of Shear Stress on Compression-induced Polymorphic Transformation in Tablets and the Creation of Strategies to Minimize It

Mrs.P K Devi Bala , Dr.MSujanya ,Ms.A Manogna ,Mr B Kondal rao , Mrs.Y R Anitha

ABSTRACT

Our objective was to ascertain the effects of (i) hydrostatic pressure alone and (ii) hydrostatic pressure combined with shear stress during compaction on the polymorphic transformation (form C / A) of chlorpropamide, a generic drug. The powder was subjected to pressures ranging from 25 to 150 MPa using a combination of hydrostatic pressure in a pressure vessel and tablet pressing. The overall quantity of phase change was determined using powder X-ray diffractometry, and the distribution of phase composition in tablets was quantified using 2D-XRD. Due to the presence of shear stress during compaction, which was independent of pressure, the quantity of transformation that took place after compaction exceeded expectations based on hydrostatic pressure alone. When compressed to 25 MPa, the radical tablet surface and the core showed vastly different degrees of phase shift. This gradient became smaller with increasing compression pressure. To mitigate the effects of compression-induced phase change, four different approaches were considered: a cavity tablet, a ceramic-lined die, a site-specific lubricant, and a viscoelastic excipient. The ceramic-lined die and site-specific lubrication effectively decreased the amount of compression-induced phase shift.

Introduction


Product efficacy may be affected by the physical characteristics of an API in solid dosage form, including its polymorphic shape, solvation state, and degree of crystallinity. The most stable physical form of an API is chosen when bioavailability is not a concern since it is expected to experience minimal changes when scaling up, processing, and storage.² The production process of a pharmaceutical drug may impact the formation of kinetically stable but thermodynamically metastable forms, as Ostwald's rule makes evident. A number of processing steps may be performed on the API in order to create a solid dosage form, such a tablet. Milling, drying,

wet/dry granulation, compression, and coating are all part of these processes. In the course of these production processes, the API may come into contact with a wide range of solvents, including granulating fluid, coating solutions, and even water vapour pressure and very high temperatures. Metastable to stable polymorph states, phase transitions (from amorphous to crystalline, anhydrous to hydrate, and back again), and environmental variables all have a role in the potential occurrence of these changes. Processing may create phase shifts, which can sometimes have a major effect on how well the end product works.⁴

Department of pharmaceutics,
Email ID: devinov15@gmail.com, Mobile no:9177579805

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347 - 2243

Indo - American Journal of Life Sciences and Biotechnology



www.iajlb.com

Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



The Impact of Shear Stress on Compression-induced Polymorphic Transformation in Tablets and the Creation of Strategies to Minimize It

Mrs.P K Devi Bala , Dr.MSujanya ,Ms.A Manogna ,Mr B Kondal rao , Mrs.Y R Anitha

ABSTRACT

Our objective was to ascertain the effects of (i) hydrostatic pressure alone and (ii) hydrostatic pressure combined with shear stress during compaction on the polymorphic transformation (form C / A) of chlorpropamide, a generic drug. The powder was subjected to pressures ranging from 25 to 150 MPa using a combination of hydrostatic pressure in a pressure vessel and tablet pressing. The overall quantity of phase change was determined using powder X-ray diffractometry, and the distribution of phase composition in tablets was quantified using 2D-XRD. Due to the presence of shear stress during compaction, which was independent of pressure, the quantity of transformation that took place after compaction exceeded expectations based on hydrostatic pressure alone. When compressed to 25 MPa, the radical tablet surface and the core showed vastly different degrees of phase shift. This gradient became smaller with increasing compression pressure. To mitigate the effects of compression-induced phase change, four different approaches were considered: a cavity tablet, a ceramic-lined die, a site-specific lubricant, and a viscoelastic excipient. The ceramic-lined die and site-specific lubrication effectively decreased the amount of compression-induced phase shift.

Introduction

Product efficacy may be affected by the physical characteristics of an API in solid dosage form, including its polymorphic shape, solvation state, and degree of crystallinity. The most stable physical form of an API is chosen when bioavailability is not a concern since it is expected to experience minimal changes when scaling up, processing, and storage.² The production process of a pharmaceutical drug may impact the formation of kinetically stable but thermodynamically metastable forms, as Ostwald's rule makes evident. A number of processing steps may be performed on the API in order to create a solid dosage form, such a tablet. Milling, drying,

wet/dry granulation, compression, and coating are all part of these processes. In the course of these production processes, the API may come into contact with a wide range of solvents, including granulating fluid, coating solutions, and even water vapour pressure and very high temperatures. Metastable to stable polymorph states, phase transitions (from amorphous to crystalline, anhydrous to hydrate, and back again), and environmental variables all have a role in the potential occurrence of these changes. Processing may create phase shifts, which can sometimes have a major effect on how well the end product works.⁴

Department of pharmaceuticals,
Email ID: devinov15@gmail.com, Mobile no:9177579805
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DI. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

NO. OF RESEARCH PAPERS PUBLISHED PER TEACHER IN THE JOURNALS NOTIFIED ON UGC CARE LIST DURING THE LAST FIVE YEARS

CALENDER YEAR - 2019

S.No	Title of the Paper	Name of the Author/s	Name of the Journal and ISSN No	Year, Volume, Issue, & Page No.
1	3-Thiocyanato- 1H- indoles as potential anticancer agents: Two dimensional quantitative structure activity relationship study	Mr.Sivakumar Peta	International Journal of Pharmaceutical Sciences Letters	2277-2685
2	3-Thiocyanato- 1H- indoles as potential anticancer agents: Two dimensional quantitative structure activity relationship study	Dr.M.Soujanya	International Journal of Pharmaceutical Sciences Letters	2277-2685
3	3-Thiocyanato- 1H- indoles as potential anticancer agents: Two dimensional quantitative structure activity relationship study	Mrs.S.Usharani	International Journal of Pharmaceutical Sciences Letters	2277-2685
4	3-Thiocyanato- 1H- indoles as potential anticancer agents: Two dimensional quantitative structure activity relationship study	Mr.B.Kondalrao	International Journal of Pharmaceutical Sciences Letters	2277-2685
5	Analysis on fat-soluble components of sinapisemina from different habitats by GC-MS	Mrs.Y.R.Anitha	International Journal of Gender, Science and Technology	2040-0748
6	Analysis on fat-soluble components of sinapisemina from different habitats by GC-MS	Ms A R Sridevi	International Journal of Gender, Science and Technology	2040-0748



Navay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FRS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL, A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

7	Analysis on fat-soluble components of sinapisemina from different habitats by GC-MS	Mr. M Kalyan babu	International Journal of Gender, Science and Technology	2040-0748
8	Analysis on fat-soluble components of sinapisemina from different habitats by GC-MS	Mr, Y Naveen Kumar	International Journal of Gender, Science and Technology	2040-0748
9	Analysis on fat-soluble components of sinapisemina from different habitats by GC-MS	Mr.S.Buggareddy	International Journal of Gender, Science and Technology	2040-0748
10	Comparative pharmacokinetics of chlorogenic acid after oral administration in rats	Ms S Naga manasa	International Journal of Gender, Science and Technology	2040-0748
11	Comparative pharmacokinetics of chlorogenic acid after oral administration in rats	Mr.Sivakumar Peta	International Journal of Gender, Science and Technology	2040-0748
12	Comparative pharmacokinetics of chlorogenic acid after oral administration in rats	Mr AVLS Ramakrishna	International Journal of Gender, Science and Technology	2040-0748
13	Comparative pharmacokinetics of chlorogenic acid after oral administration in rats	Mr.B.NagendraPrasad	International Journal of Gender, Science and Technology,	2040-0748
14	Comparative pharmacokinetics of chlorogenic acid after oral administration in rats	Ms Y Radhika	International Journal of Gender, Science and Technology	2040-0748
15	A Study on the Characterization and Stability Implications of Investigating Local Mobility in Amorphous Pharmaceuticals	Mrs. P K Devibala	Indo-American Journal of Life sciences and Biotechnology	2347-2243



Naveen
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC 1995, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DI. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

16	A Study on the Characterization and Stability Implications of Investigating Local Mobility in Amorphous Pharmaceuticals	Dr.B. Pavan kumar	Indo-American Journal of Life sciences and Biotechnology	2347-2243
17	A Study on the Characterization and Stability Implications of Investigating Local Mobility in Amorphous Pharmaceuticals	Ms KVanithadevi	Indo-American Journal of Life sciences and Biotechnology	2347-2243
18	A Study on the Characterization and Stability Implications of Investigating Local Mobility in Amorphous Pharmaceuticals	MR B Kondalrao	Indo-American Journal of Life sciences and Biotechnology	2347-2243
19	A Study on the Characterization and Stability Implications of Investigating Local Mobility in Amorphous Pharmaceuticals	Mrs Y Swaroopa	Indo-American Journal of Life sciences and Biotechnology	2347-2243
20	Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine	Dr.Balagani Pavan Kumar	Indo-American Journal of Pharma and Biosciences	2347-2251
21	Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine	Ms.P Kavitha	Indo-American Journal of Pharma and Biosciences	2347-2251
22	Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine	Mrs.P Sukanya	Indo-American Journal of Pharma and Biosciences	2347-2251
23	Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine	Mr KRSC Bharath kumar	Indo-American Journal of Pharma and Biosciences	2347-2251



Navay

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P. - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

24	Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine	Ms.A.Manogna	Indo-American Journal of Pharma and Biosciences	2347-2251
25	Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine	Ms P Madhavi	Indo-American Journal of Pharma and Biosciences	2347-2251



Balagan
PRINCIPAL

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

3-Thiocyanato- 1H- indoles as potential anticancer agents: Two dimensional quantitative structure activity relationship study

Mr.Sivakumar Peta ,Dr.M.Soujanya , Mrs.S.Usharani , Mr.B.Kondalrao

Department of Pharmaceutical Chemistry,

Email ID: sivapeta369@gmail.com , Mobile no: 9494144800

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

We conducted two-dimensional quantitative structure activity relationship (2D QSAR) research on a new series of 3-thiocyanato-1H-indoles in an effort to identify powerful anti-cancer drugs. variety of 3-thiocyanato-1H-indoles were subjected to 2D-QSAR using Vlife MDS 4.3. The k-nearest neighbors (kNN) approach, used to Vlife molecular design suites (MDS), yielded a statistically verified two-dimensional quantitative structure activity relationship model. Cytotoxicity activity against the HL60 human cancer cell line was associated with Model 3 statistical data ($q^2 = 0.8001$, $pred\ r^2 = 0.4082$). The LOO approach was used for validation. Final Thoughts: The model now includes three attributes that positively correlate with the cytotoxicity activity. There is hope that novel, more effective anticancer drugs could be developed using this proven 2D QSAR model.

Keywords: 2-dimensional quantum search for anticancer drugs using regression analysis, 3-thiocyanato-1H-indoles; HL60 cell line.

Introduction

The unique capacity of the compounds produced by heterocyclic chemistry to bind reversibly to proteins and imitate the structure of peptides makes it a very useful source of new molecules with various biological functions. (1) to four (3) Indole, also known as benzopyrrole, is a heterocyclic compound with one nitrogen atom (N) substituted for one carbon atom in the ring. As a privileged structure that binds to several receptors with high affinity, the indole moiety is widespread and ranks among the most prevalent heterocycles among physiologically active natural compounds, medicines, and agrochemicals (5). The therapeutic implications of Indole have been highlighted in published publications as follows: anti-viral, anti-depressant, anti-hyperlipidemic, anti-inflammatory, anti-psychotic, anti-microbial, anti-oxidants, anti-HIV, immunomodulator, anti-leukemia, (19).(21-22) Natural substances with strong pharmacodynamic Indole nucleus activity include reserpine, bufotenine, tryptophan, serotonin, vinblastine, vincristine, tryptamine derivatives, and others.

As the second-biggest killer of humans, cancer poses a serious danger to human health. (29-32) The World Health Organization (WHO) projects that 12 million people will lose their lives to cancer by the year 2030. (33) radiation and chemotherapy are two of the current cancer therapies, however the most remarkable pharmaceutical approach to cancer would still be a combination of radiation and significant surgery. The limitations of the current anticancer drugs, including as their toxicity to normal cells and acquired tumor resistance, persist despite ongoing research. Thus, enhancing the pharmacological profile and conducting cutting-edge cancer research depend on the discovery of effective, safe, and selective anticancer agents. (34) For the purpose of predicting biological activities, especially in medication design, the quantitative structure-activity relationship (QSAR) method became very helpful and extensively used. The premise upon which this method rests is that alterations to their biological activity may be associated with changes to their chemical structures. (35 and 36) Margiani et al. prepared a battery of 3-thiocyanato-1H-indoles and tested their cytotoxic effects on several cancer cell lines. Anticancer activities with improved treatment safety and effectiveness were the goals of this work, which intended to clarify the structural properties of 3-thiocyanato-1H-indole derivatives. (37)




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

3-Thiocyanato- 1H- indoles as potential anticancer agents: Two dimensional quantitative structure activity relationship study

Mr.Sivakumar Peta ,Dr.M.Soujanya , Mrs.S.Usharani , Mr.B.Kondalrao

Department of Pharmaceutical Chemistry,

Email ID: sivapeta369@gmail.com , Mobile no: 9494144800

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

We conducted two-dimensional quantitative structure activity relationship (2D QSAR) research on a new series of 3-thiocyanato-1H-indoles in an effort to identify powerful anti-cancer drugs. variety of 3-thiocyanato-1H-indoles were subjected to 2D-QSAR using Vlife MDS 4.3. The k-nearest neighbors (kNN) approach, used to Vlife molecular design suites (MDS), yielded a statistically verified two-dimensional quantitative structure activity relationship model. Cytotoxicity activity against the HL60 human cancer cell line was associated with Model 3 statistical data ($q^2 = 0.8001$, pred $r^2 = 0.4082$). The LOO approach was used for validation. Final Thoughts: The model now includes three attributes that positively correlate with the cytotoxicity activity. There is hope that novel, more effective anticancer drugs could be developed using this proven 2D-QSAR model.


Keywords: 2-dimensional quantum search for anticancer drugs using regression analysis; 3-thiocyanato-1H-indoles; HL60 cell line.

Introduction

The unique capacity of the compounds produced by heterocyclic chemistry to bind reversibly to proteins and imitate the structure of peptides makes it a very useful source of new molecules with various biological functions. (1) to four (3) Indole, also known as benzopyrrole, is a heterocyclic compound with one nitrogen atom (N) substituted for one carbon atom in the ring. As a privileged structure that binds to several receptors with high affinity, the indole moiety is widespread and ranks among the most prevalent heterocycles among physiologically active natural compounds, medicines, and agrochemicals (5). The therapeutic implications of Indole have been highlighted in published publications as follows: anti-viral, anti-depressant, anti-hyperlipidemic, anti-inflammatory, anti-psychotic, anti-microbial, anti-oxidants, anti-HIV, immunomodulator, anti-leukemia, (19).(21-22) Natural substances with strong pharmacodynamic Indole nucleus activity include reserpine, bufotenine, tryptophan, serotonin, vinblastine, vincristine, tryptamine derivatives, and others.

As the second-biggest killer of humans, cancer poses a serious danger to human health. chapters 29-32) The World Health Organization (WHO) projects that 12 million people will lose their lives to cancer by the year 2030. (33) radiation and chemotherapy are two of the current cancer therapies, however the most remarkable pharmaceutical approach to cancer would still be a combination of radiation and significant surgery. The limitations of the current anticancer drugs, including as their toxicity to normal cells and acquired tumor resistance, persist despite ongoing research. Thus, enhancing the pharmacological profile and conducting cutting-edge cancer research depend on the discovery of effective, safe, and selective anticancer agents. (34) For the purpose of predicting biological activities, especially in medication design, the quantitative structure-activity relationship (QSAR) method became very helpful and extensively used. The premise upon which this method rests is that alterations to their biological activity may be associated with changes to their chemical structures. places 35 and 36 Margiani et al. prepared a battery of 3-thiocyanato-1H-indoles and tested their cytotoxic effects on several cancer cell lines. Anticancer activities with improved treatment safety and effectiveness were the goals of this work, which intended to clarify the structural properties of 3-thiocyanato-1H-indole derivatives. (37)




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

3-Thiocyanato- 1H- indoles as potential anticancer agents: Two dimensional quantitative structure activity relationship study

Mr.Sivakumar Peta ,Dr.M.Soujanya , Mrs.S.Usharani , Mr.B.Kondalrao

Department of Pharmaceutical Chemistry,

Email ID: sivapeta369@gmail.com , Mobile no: 9494144800

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

We conducted two-dimensional quantitative structure activity relationship (2D QSAR) research on a new series of 3-thiocyanato-1H-indoles in an effort to identify powerful anti-cancer drugs. variety of 3-thiocyanato-1H-indoles were subjected to 2D-QSAR using Vlife MDS 4.3. The k-nearest neighbors (kNN) approach, used to Vlife molecular design suites (MDS), yielded a statistically verified two-dimensional quantitative structure activity relationship model. Cytotoxicity activity against the HL60 human cancer cell line was associated with Model 3 statistical data ($q^2 = 0.8001$, $\text{pred } r^2 = 0.4082$). The LOO approach was used for validation. Final Thoughts: The model now includes three attributes that positively correlate with the cytotoxicity activity. There is hope that novel, more effective anticancer drugs could be developed using this proven 2D-QSAR model.

Keywords: 2-dimensional quantum search for anticancer drugs using regression analysis; 3-thiocyanato-1H-indoles; HL60 cell line.

Introduction

The unique capacity of the compounds produced by heterocyclic chemistry to bind reversibly to proteins and imitate the structure of peptides makes it a very useful source of new molecules with various biological functions. (1) to four (3) Indole, also known as benzopyrrole, is a heterocyclic compound with one nitrogen atom (N) substituted for one carbon atom in the ring. As a privileged structure that binds to several receptors with high affinity, the indole moiety is widespread and ranks among the most prevalent heterocycles among physiologically active natural compounds, medicines, and agrochemicals (5). The therapeutic implications of Indole have been highlighted in published publications as follows: anti-viral, anti-depressant, anti-hyperlipidemic, anti-inflammatory, anti-psychotic, anti-microbial, anti-oxidants, anti-HIV, immunomodulator, anti-leukemia, (19).(21-22) Natural substances with strong pharmacodynamic Indole nucleus activity include reserpine, bufotenine, tryptophan, serotonin, vinblastine, vincristine, tryptamine derivatives, and others.

As the second-biggest killer of humans, cancer poses a serious danger to human health. (29-32) The World Health Organization (WHO) projects that 12 million people will lose their lives to cancer by the year 2030. (33) radiation and chemotherapy are two of the current cancer therapies, however the most remarkable pharmaceutical approach to cancer would still be a combination of radiation and significant surgery. The limitations of the current anticancer drugs, including as their toxicity to normal cells and acquired tumor resistance, persist despite ongoing research. Thus, enhancing the pharmacological profile and conducting cutting-edge cancer research depend on the discovery of effective, safe, and selective anticancer agents. (34) For the purpose of predicting biological activities, especially in medication design, the quantitative structure-activity relationship (QSAR) method became very helpful and extensively used. The premise upon which this method rests is that alterations to their biological activity may be associated with changes to their chemical structures. (35 and 36) Margiani et al. prepared a battery of 3-thiocyanato-1H-indoles and tested their cytotoxic effects on several cancer cell lines. Anticancer activities with improved treatment safety and effectiveness were the goals of this work, which intended to clarify the structural properties of 3-thiocyanato-1H-indole derivatives. (37)




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

3-Thiocyanato- 1H- indoles as potential anticancer agents: Two dimensional quantitative structure activity relationship study

Mr.Sivakumar Peta ,Dr.M.Soujanya , Mrs.S.Usharani , Mr.B.Kondalrao

Department of Pharmaceutical Chemistry,

Email ID: sivapeta369@gmail.com , Mobile no: 9494144800

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

We conducted two-dimensional quantitative structure activity relationship (2D QSAR) research on a new series of 3-thiocyanato-1H-indoles in an effort to identify powerful anti-cancer drugs. variety of 3-thiocyanato-1H-indoles were subjected to 2D-QSAR using Vlife MDS 4.3. The k-nearest neighbors (kNN) approach, used to Vlife molecular design suites (MDS), yielded a statistically verified two-dimensional quantitative structure activity relationship model. Cytotoxicity activity against the HL60 human cancer cell line was associated with Model 3 statistical data ($q_2 = 0.8001$, $pred-r^2 = 0.4082$). The LOO approach was used for validation. Final Thoughts: The model now includes three attributes that positively correlate with the cytotoxicity activity. There is hope that novel, more effective anticancer drugs could be developed using this proven 2D-QSAR model.

Keywords: 2-dimensional quantum search for anticancer drugs using regression analysis; 3-thiocyanato-1H-indoles; HL60 cell line.

Introduction

The unique capacity of the compounds produced by heterocyclic chemistry to bind reversibly to proteins and imitate the structure of peptides makes it a very useful source of new molecules with various biological functions. (1) to four (3) Indole, also known as benzopyrrole, is a heterocyclic compound with one nitrogen atom (N) substituted for one carbon atom in the ring. As a privileged structure that binds to several receptors with high affinity, the indole moiety is widespread and ranks among the most prevalent heterocycles among physiologically active natural compounds, medicines, and agrochemicals (5). The therapeutic implications of indole have been highlighted in published publications as follows: anti-viral, anti-depressant, anti-hyperlipidemic, anti-inflammatory, anti-psychotic, anti-microbial, anti-oxidants, anti-HIV, immunomodulator, anti-leukemia, (19).(21-22) Natural substances with strong pharmacodynamic Indole nucleus activity include reserpine, bufotenine, tryptophan, serotonin, vinblastine, vincristine, tryptamine derivatives, and others.

As the second-biggest killer of humans, cancer poses a serious danger to human health. (29-32) The World Health Organization (WHO) projects that 12 million people will lose their lives to cancer by the year 2030. (33) radiation and chemotherapy are two of the current cancer therapies, however the most remarkable pharmaceutical approach to cancer would still be a combination of radiation and significant surgery. The limitations of the current anticancer drugs, including as their toxicity to normal cells and acquired tumor resistance, persist despite ongoing research. Thus, enhancing the pharmacological profile and conducting cutting-edge cancer research depend on the discovery of effective, safe, and selective anticancer agents. (34) For the purpose of predicting biological activities, especially in medication design, the quantitative structure-activity relationship (QSAR) method became very helpful and extensively used. The premise upon which this method rests is that alterations to their biological activity may be associated with changes to their chemical structures. (35 and 36) Margiani et al prepared a battery of 3-thiocyanato-1H-indoles and tested their cytotoxic effects on several cancer cell lines. Anticancer activities with improved treatment safety and effectiveness were the goals of this work, which intended to clarify the structural properties of 3-thiocyanato-1H-indole derivatives. (37)




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DI. A.P - 524121

Analysis on fat-soluble components of sinapis semina from different habitats by GC-MS

Mrs. Y.R. Anitha, Ms A R Sridevi, Mr. M Kalyan babu ,Mr, Y Naveen Kumar, Mr.S. Buggareddy

Department of Pharmaceutical Analysis

Email ID: anitharobert17@gmail.com , Mobile no:7207165156

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

The fat-soluble components of sinapis semina were identified using a fast and easy gas chromatography/mass spectrometry (GC/MS) analytical technique. In order to test the efficacy of the procedure, four chemicals were selected as marker compounds. Following an analysis of many extraction methods, sonication extraction with diethyl ether proved to be the most effective. After checking the resolutions, tailing factors, and theoretical plate number of the marker chemicals, we were able to determine that the apparatus was suitable for the approach. We also checked that the accuracy and repeatability, measured as relative standard deviation (RSD), were within the allowed limits. Eight sinapis semina samples were tracked using the approach after being acquired from Xi'an markets. Hierarchical cluster analysis (HCA) similarity analysis was used to examine the fingerprints of those samples. A combination of fingerprint and HCA allowed for the analysis of sinapis semina from various habitats, according to the results.

KEYWORDS : Sinapis semina, GC/MS, fingerprinting, and hydrophilic extraction

1. Introduction

Dried Sinapis semina are the seeds of the Sinapis alba lineage. Among the pharmacological effects of this traditional Chinese medicine include anti-cancer, analgesic, and antiviral properties [1]. Sapidus semina relies on its fat-soluble components. Isolating and identifying the fat-soluble chemicals is crucial for sinapis semina study. Gas chromatography/mass spectrometry (GC-MS) and gas chromatography have seen extensive application for the investigation of herbal medicines' fat-soluble components [2,3]. As an especially applicable and trustworthy technique,

GC/MS has been used for the determination of

plant medicinal components that are fat-soluble, because of their superior capacity for isolation and identification.

To ensure the efficacy of herbal medicines, quality control is essential, and one aspect of this procedure is regularly monitoring the amounts of chemical ingredients [4,5]. Herbal remedies have a complicated chemical makeup, and the quantification of substances depends on factors such as harvest time, storage conditions, processing technique, and environmental factors. A lot of places have started growing Sinapis semina.

country. Sinapis semina's impact is associated with its fat-soluble components, which come from several places.

Quantitative extraction of fat-soluble components from herbal medicines has been accomplished using a variety of procedures, such as steam distillation, solvent immersion, and solid-phase extraction [6, 7, 8]. Having said that, these approaches are tedious and time consuming. The fast extraction of herbal medicine's fat-soluble components has been achieved by the use of sonication extraction. Its low organic solvent consumption and ease of operation make it a practical choice [9-12].

It is not sufficient to only quantify one or even many substances in herbal medicine in order to assess the quality of sinapis semina. One form of thorough, quantifiable chromatographic identification approach is the Chinese medicine chromatographic fingerprint technique. A comprehensive analysis of the chemical composition of Chinese herbal medicine forms the basis of the technique. There has been a recent uptick in interest in chromatographic fingerprint analysis of herbal medicines [13-16]. This is because the technology incorporates the holistic and systemic aspects of Chinese traditional medicine. In addition, by comparing how similar two samples are,



DR. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

Analysis on fat-soluble components of sinapis semina from different habitats by GC-MS

Mrs.Y.R.Anitha, Ms A R Sridevi, Mr. M Kalyan babu ,Mr,Y Naveen Kumar,Mr.S.Buggareddy

Department of Pharmaceutical Analysis

Email ID: anitharobert17@gmail.com , Mobile no:7207165156

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

The fat-soluble components of sinapis semina were identified using a fast and easy gas chromatography/mass spectrometry (GC/MS) analytical technique. In order to test the efficacy of the procedure, four chemicals were selected as marker compounds. Following an analysis of many extraction methods, sonication extraction with diethyl ether proved to be the most effective. After checking the resolutions, tailing factors, and theoretical plate number of the marker chemicals, we were able to determine that the apparatus was suitable for the approach. We also checked that the accuracy and repeatability, measured as relative standard deviation (RSD), were within the allowed limits. Eight sinapis semina samples were tracked using the approach after being acquired from Xi'an markets. Hierarchical cluster analysis (HCA) similarity analysis was used to examine the fingerprints of those samples. A combination of fingerprint and HCA allowed for the analysis of sinapis semina from various habitats, according to the results.

KEYWORDS : Sinapis semina, GC/MS, fingerprinting, and hydrophilic extraction

1. Introduction

Dried Sinapis semina are the seeds of the Sinapis alba lineage. Among the pharmacological effects of this traditional Chinese medicine include anti-cancer, analgesic, and antiviral properties [1]. Sapidus semina relies on its fat-soluble components. Isolating and identifying the fat-soluble chemicals is crucial for sinapis semina study. Gas chromatography/mass spectrometry (GC-MS) and gas chromatography have seen extensive application for the investigation of herbal medicines' fat-soluble components [2,3]. As an especially applicable and trustworthy technique,

GC/MS has been used for the determination of

plant medicinal components that are fat-soluble, because of their superior capacity for isolation and identification.

To ensure the efficacy of herbal medicines, quality control is essential, and one aspect of this procedure is regularly monitoring the amounts of chemical ingredients [4,5]. Herbal remedies have a complicated chemical makeup, and the quantification of substances depends on factors such as harvest time, storage conditions, processing technique, and environmental factors. A lot of places have started growing Sinapis semina.

country. Sinapis semina's impact is associated with its fat-soluble components, which come from several places.

Quantitative extraction of fat-soluble components from herbal medicines has been accomplished using a variety of procedures, such as steam distillation, solvent immersion, and solid-phase extraction [6, 7, 8]. Having said that, these approaches are tedious and time consuming. The fast extraction of herbal medicine's fat-soluble components has been achieved by the use of sonication extraction. Its low organic solvent consumption and ease of operation make it a practical choice [9-12].

It is not sufficient to only quantify one or even many substances in herbal medicine in order to assess the quality of sinapis semina. One form of thorough, quantifiable chromatographic identification approach is the Chinese medicine chromatographic fingerprint technique. A comprehensive analysis of the chemical composition of Chinese herbal medicine forms the basis of the technique. There has been a recent uptick in interest in chromatographic fingerprint analysis of herbal medicines [13-16]. This is because the technology incorporates the holistic and systemic aspects of Chinese traditional medicine. In addition, by comparing how similar two samples are,

Dr. BALAGANI PAVAN KUMAR

M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE

PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY

SULLURPET, TIRUPATI Dt. A.P - 524121



Analysis on fat-soluble components of sinapis semina from different habitats by GC-MS

Mrs. Y.R. Anitha, Ms A R Sridevi, Mr. M Kalyan babu, Mr. Y Naveen Kumar, Mr. S. Buggareddy

Department of Pharmaceutical Analysis

Email ID: anitharobert17@gmail.com, Mobile no: 7207165156

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

The fat-soluble components of sinapis semina were identified using a fast and easy gas chromatography/mass spectrometry (GC/MS) analytical technique. In order to test the efficacy of the procedure, four chemicals were selected as marker compounds. Following an analysis of many extraction methods, sonication extraction with diethyl ether proved to be the most effective. After checking the resolutions, tailing factors, and theoretical plate number of the marker chemicals, we were able to determine that the apparatus was suitable for the approach. We also checked that the accuracy and repeatability, measured as relative standard deviation (RSD), were within the allowed limits. Eight sinapis semina samples were tracked using the approach after being acquired from Xi'an markets. Hierarchical cluster analysis (HCA) similarity analysis was used to examine the fingerprints of those samples. A combination of fingerprint and HCA allowed for the analysis of sinapis semina from various habitats, according to the results.

KEYWORDS : Sinapis semina, GC/MS, fingerprinting, and hydrophilic extraction

1. Introduction

Dried Sinapis semina are the seeds of the Sinapis alba lineage. Among the pharmacological effects of this traditional Chinese medicine include anti-cancer, analgesic, and antiviral properties [1]. Sapidus semina relies on its fat-soluble components. Isolating and identifying the fat-soluble chemicals is crucial for sinapis semina study. Gas chromatography/mass spectrometry (GC-MS) and gas chromatography have seen extensive application for the investigation of herbal medicines' fat-soluble components [2,3]. As an especially applicable and trustworthy technique,

GC/MS has been used for the determination of

plant medicinal components that are fat-soluble, because of their superior capacity for isolation and identification.

To ensure the efficacy of herbal medicines, quality control is essential, and one aspect of this procedure is regularly monitoring the amounts of chemical ingredients [4,5]. Herbal remedies have a complicated chemical makeup, and the quantification of substances depends on factors such as harvest time, storage conditions, processing technique, and environmental factors. A lot of places have started growing Sinapis semina.

country. Sinapis semina's impact is associated with its fat-soluble components, which come from several places.

Quantitative extraction of fat-soluble components from herbal medicines has been accomplished using a variety of procedures, such as steam distillation, solvent immersion, and solid-phase extraction [6, 7, 8]. Having said that, these approaches are tedious and time consuming. The fast extraction of herbal medicine's fat-soluble components has been achieved by the use of sonication extraction. Its low organic solvent consumption and ease of operation make it a practical choice [9-12].

It is not sufficient to only quantify one or even many substances in herbal medicine in order to assess the quality of sinapis semina. One form of thorough, quantifiable chromatographic identification approach is the Chinese medicine chromatographic fingerprint technique. A comprehensive analysis of the chemical composition of Chinese herbal medicine forms the basis of the technique. There has been a recent uptick in interest in chromatographic fingerprint analysis of herbal medicines [13-16]. This is because the technology incorporates the holistic and systemic aspects of Chinese traditional medicine. In addition, by comparing how similar two samples are,



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

Analysis on fat-soluble components of sinapis semina from different habitats by GC-MS

Mrs.Y.R.Anitha, Ms A R Sridevi, Mr. M Kalyan babu, Mr. Y Naveen Kumar, Mr.S.Buggareddy

Department of Pharmaceutical Analysis

Email ID: anitharobert17@gmail.com , Mobile no:7207165156

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

The fat-soluble components of sinapis semina were identified using a fast and easy gas chromatography/mass spectrometry (GC/MS) analytical technique. In order to test the efficacy of the procedure, four chemicals were selected as marker compounds. Following an analysis of many extraction methods, sonication extraction with diethyl ether proved to be the most effective. After checking the resolutions, tailing factors, and theoretical plate number of the marker chemicals, we were able to determine that the apparatus was suitable for the approach. We also checked that the accuracy and repeatability, measured as relative standard deviation (RSD), were within the allowed limits. Eight sinapis semina samples were tracked using the approach after being acquired from Xi'an markets. Hierarchical cluster analysis (HCA) similarity analysis was used to examine the fingerprints of those samples. A combination of fingerprint and HCA allowed for the analysis of sinapis semina from various habitats, according to the results.

KEYWORDS : Sinapis semina, GC/MS, fingerprinting, and hydrophilic extraction

1. Introduction

Dried Sinapis semina are the seeds of the Sinapis alba lineage. Among the pharmacological effects of this traditional Chinese medicine include anti-cancer, analgesic, and antiviral properties [1]. Sapidus semina relies on its fat-soluble components. Isolating and identifying the fat-soluble chemicals is crucial for sinapis semina study. Gas chromatography/mass spectrometry (GC-MS) and gas chromatography have seen extensive application for the investigation of herbal medicines' fat-soluble components [2,3]. As an especially applicable and trustworthy technique

GC/MS has been used for the determination of

plant medicinal components that are fat-soluble, because of their superior capacity for isolation and identification.

To ensure the efficacy of herbal medicines, quality control is essential, and one aspect of this procedure is regularly monitoring the amounts of chemical ingredients [4,5]. Herbal remedies have a complicated chemical makeup, and the quantification of substances depends on factors such as harvest time, storage conditions, processing technique, and environmental factors. A lot of places have started growing Sinapis semina.

country. Sinapis semina's impact is associated with its fat-soluble components, which come from several places.

Quantitative extraction of fat-soluble components from herbal medicines has been accomplished using a variety of procedures, such as steam distillation, solvent immersion, and solid-phase extraction [6, 7, 8]. Having said that, these approaches are tedious and time consuming. The fast extraction of herbal medicine's fat-soluble components has been achieved by the use of sonication extraction. Its low organic solvent consumption and ease of operation make it a practical choice [9-12].

It is not sufficient to only quantify one or even many substances in herbal medicine in order to assess the quality of sinapis semina. One form of thorough, quantifiable chromatographic identification approach is the Chinese medicine chromatographic fingerprint technique. A comprehensive analysis of the chemical composition of Chinese herbal medicine forms the basis of the technique. There has been a recent uptick in interest in chromatographic fingerprint analysis of herbal medicines [13-16]. This is because the technology incorporates the holistic and systemic aspects of Chinese traditional medicine. In addition, by comparing how similar two samples are,



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FESS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DI. A.P - 524121

Analysis on fat-soluble components of sinapis semina from different habitats by GC-MS

Mrs.Y.R.Anitha, Ms A R Sridevi, Mr. M Kalyan babu ,Mr,Y Naveen Kumar, Mr.S.Buggareddy

Department of Pharmaceutical Analysis

Email ID: anitharobert17@gmail.com , Mobile no:7207165156

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

The fat-soluble components of sinapis semina were identified using a fast and easy gas chromatography/mass spectrometry (GC/MS) analytical technique. In order to test the efficacy of the procedure, four chemicals were selected as marker compounds. Following an analysis of many extraction methods, sonication extraction with diethyl ether proved to be the most effective. After checking the resolutions, tailing factors, and theoretical plate number of the marker chemicals, we were able to determine that the apparatus was suitable for the approach. We also checked that the accuracy and repeatability, measured as relative standard deviation (RSD), were within the allowed limits. Eight sinapis semina samples were tracked using the approach after being acquired from Xi'an markets. Hierarchical cluster analysis (HCA) similarity analysis was used to examine the fingerprints of those samples. A combination of fingerprint and HCA allowed for the analysis of sinapis semina from various habitats, according to the results.

KEYWORDS : Sinapis semina, GC/MS, fingerprinting, and hydrophilic extraction

1. Introduction

Dried Sinapis semina are the seeds of the Sinapis alba lineage. Among the pharmacological effects of this traditional Chinese medicine include anti-cancer, analgesic, and antiviral properties [1]. Sapidus semina relies on its fat-soluble components. Isolating and identifying the fat-soluble chemicals is crucial for sinapis semina study. Gas chromatography/mass spectrometry (GC-MS) and gas chromatography have seen extensive application for the investigation of herbal medicines' fat-soluble components [2,3]. As an especially applicable and trustworthy technique,

GC/MS has been used for the determination of


plant medicinal components that are fat-soluble, because of their superior capacity for isolation and identification.

To ensure the efficacy of herbal medicines, quality control is essential, and one aspect of this procedure is regularly monitoring the amounts of chemical ingredients [4,5]. Herbal remedies have a complicated chemical makeup, and the quantification of substances depends on factors such as harvest time, storage conditions, processing technique, and environmental factors. A lot of places have started growing Sinapis semina.

country. Sinapis semina's impact is associated with its fat-soluble components, which come from several places.

Quantitative extraction of fat-soluble components from herbal medicines has been accomplished using a variety of procedures, such as steam distillation, solvent immersion, and solid-phase extraction [6, 7, 8]. Having said that, these approaches are tedious and time consuming. The fast extraction of herbal medicine's fat-soluble components has been achieved by the use of sonication extraction. Its low organic solvent consumption and ease of operation make it a practical choice [9-12].

It is not sufficient to only quantify one or even many substances in herbal medicine in order to assess the quality of sinapis semina. One form of thorough, quantifiable chromatographic identification approach is the Chinese medicine chromatographic fingerprint technique. A comprehensive analysis of the chemical composition of Chinese herbal medicine forms the basis of the technique. There has been a recent uptick in interest in chromatographic fingerprint analysis of herbal medicines [13-16]. This is because the technology incorporates the holistic and systemic aspects of Chinese traditional medicine. In addition, comparing how similar two samples are,



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P. - 524121

Comparative pharmacokinetics of chlorogenic acid after oral administration in rats

Ms S Naga manasa, Mr.Sivakumar Peta, Mr AVLS Ramakrishna, Mr.B.NagendraPrasad
Ms Y Radhika

Department of Pharmaceutical Analysis

Email ID: nagamanasa36@gmail.com, Mobile no:7288837695

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

The present study was aimed at the comparison of the pharmacokinetics of pure chlorogenic acid and extract of *Solanum lyratum* Thunb. The animals were allocated to two groups, and were administered chlorogenic acid or extract of *S. lyratum* Thunb. at a dose of 50.0 mg/kg orally. Blood samples were collected up to 8 h post-dosing. Plasma chlorogenic acid analyses were performed using an HPLC method with UV detector. The pharmacokinetic parameters were evaluated using non-compartmental assessment. Significant differences existed in the two groups for AUC_{0-8} , AUC_{0-N} and CL_z/F . The reliable HPLC method was successfully applied to the determination of chlorogenic acid in rat plasma at dosage of 50.0 mg/kg.

1. Introduction

Solanum lyratum Thunb (Solanaceae) is one of the most valued Chinese traditional medicines. It is well known as "*Hedra Solani Lyrati*" in mainland of China, which has been

used for regulating body immune function and ability [1-4]. It was also reported to have anticancer activity [5]. The plant is known to contain steroidal glucuronides, steroidal alkaloid glucosides, coumarin and phenolic acid, etc. [6-10].

Chlorogenic acid (3-O-caffeoylquinic acid) is composed of quinic acid and caffeic acid. It is the major active component of *S. lyratum*, and its amount could reach up to 3.0 mg/g [11]. The compound has a variety of biological activities such as anti-microbes, anti-virus, oxidation prevention, anti-tumor and anti-hypertension [12].

Several HPLC methods were developed for the pharmacokinetic studies of chlorogenic acid [13-18]. Ren et al. [19] reported that the pharmacokinetic behavior of chlorogenic acid after oral administration has obvious difference among different dosages (200, 400 and 600 mg/kg). It is well known that the contents of active

ingredients in traditional Chinese medicine are usually low, so the studies of their pharmacokinetic behavior at small dose (50.0 mg/kg) are important and necessary. In addition, other components in *S. lyratum* may change the pharmacokinetics of chlorogenic acid, and there was no report related to this issue.

In this study, a reliable HPLC method was established to determine the concentration of chlorogenic acid in rat plasma. The pharmacokinetic behaviors between chlorogenic acid and extract of *S. lyratum* after oral administration were compared. It is important for understanding of the synergism of components among *S. lyratum* and designing rational dosage regimens.

2. Materials and methods


2.1. Chemicals and reagents

Chlorogenic acid (Fig. 1A) and the internal standard (IS), puerarin (Fig. 1B), were provided by the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). *S. lyratum* was purchased from Xuhui Pharmaceutical Co. Ltd. (Shanghai, China) and was genuinely identified by Prof. Qi-Shi Sun (Shenyang Pharmaceutical University, China). Methanol (HPLC grade) and other analytical grade reagents were obtained from Yuwang Reagent Company (Shenyang, China).

2.2. Instruments and chromatographic conditions

The HPLC system consisted of a Shimadzu LC-10A pump, an SPD-10AV detector and a column oven. Data were processed using Anashtar software (Autoscience Instrument Co. Ltd., China). The separation was performed on a Diamonsil-C₁₈ column (250 mm 4.6 mm, 5 mm). The mobile phase was methanol-0.05% phosphoric acid (23:77, v/v) at a flow rate of 1 mL/min.

A



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Comparative pharmacokinetics of chlorogenic acid after oral administration in rats

Ms S Naga manasa , Mr.Sivakumar Peta , Mr AVLS Ramakrishna , Mr.B.NagendraPrasad
Ms Y Radhika

Department of Pharmaceutical Analysis

Email ID: nagamanasa36@gmail.com , Mobile no:7288837695

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

The present study was aimed at the comparison of the pharmacokinetics of pure chlorogenic acid and extract of *Solanum lyratum* Thunb. The animals were allocated to two groups, and were administered chlorogenic acid or extract of *S. lyratum* Thunb. at a dose of 50.0 mg/kg orally. Blood samples were collected up to 8 h post-dosing. Plasma chlorogenic acid analyses were performed using an HPLC method with UV detector. The pharmacokinetic parameters were evaluated using non-compartmental assessment. Significant differences existed in the two groups for AUC_{0-8} , AUC_{0-N} and CL_z/F . The reliable HPLC method was successfully applied to the determination of chlorogenic acid in rat plasma at dosage of 50.0 mg/kg.

1. Introduction

Solanum lyratum Thunb (Solanaceae) is one of the most valued Chinese traditional medicines. It is well known as "*Heirba Solani Lyrati*" in mainland of China, which has been

used for regulating body immune function and ability [1-4]. It was also reported to have anticancer activity [5]. The plant is known to contain steroidal glucuronides, steroidal alkaloid glucosides, coumarin and phenolic acid, etc. [6-10].

Chlorogenic acid (3-*O*-caffeoylquinic acid) is composed of quinic acid and caffeic acid. It is the major active component of *S. lyratum*, and its amount could reach up to 3.0 mg/g [11]. The compound has a variety of biological activities such as anti-microbes, anti-virus, oxidation prevention, anti-tumor and anti-hypertension [12].

Several HPLC methods were developed for the pharmacokinetic studies of chlorogenic acid [13-18]. Ren et al. [19] reported that the pharmacokinetic behavior of chlorogenic acid after oral administration has obvious difference among different dosages (200, 400 and 600 mg/kg). It is well known that the contents of active

ingredients in traditional Chinese medicine are usually low, so the studies of their pharmacokinetic behavior at small dose (50.0 mg/kg) are important and necessary. In addition, other components in *S. lyratum* may change the pharmacokinetics of chlorogenic acid, and there was no report related to this issue.

In this study, a reliable HPLC method was established to determine the concentration of chlorogenic acid in rat plasma. The pharmacokinetic behaviors between chlorogenic acid and extract of *S. lyratum* after oral administration were compared. It is important for understanding of the synergism of components among *S. lyratum* and designing rational dosage regimens.

2. Materials and methods


2.1. Chemicals and reagents


Chlorogenic acid (Fig. 1A) and the internal standard (IS), puerarin (Fig. 1B), were provided by the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). *S. lyratum* was purchased from Xuhui Pharmaceutical Co. Ltd. (Shanghai, China) and was genuinely identified by Prof. Qi-Shi Sun (Shenyang Pharmaceutical University, China). Methanol (HPLC grade) and other analytical grade reagents were obtained from Yuwang Reagent Company (Shenyang, China).

2.2. Instruments and chromatographic conditions

The HPLC system consisted of a Shimadzu LC-10A pump, an SPD-10AV detector and a column oven. Data were processed using Amstar software (Autoscience Instrument Co. Ltd., China). The separation was performed on a Diamonsil- C_{18} column (250 mm 4.6 mm, 5 μ m). The mobile phase was methanol-0.05% phosphoric acid (23:77, v/v) at a flow rate of 1 mL/min.

A




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Comparative pharmacokinetics of chlorogenic acid after oral administration in rats

Ms S Naga manasa , Mr.Sivakumar Peta , Mr AVLS Ramakrishna , Mr.B.NagendraPrasad
Ms Y Radhika

Department of Pharmaceutical Analysis

Email ID: nagamanasa36@gmail.com , Mobile no:7288837695

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

The present study was aimed at the comparison of the pharmacokinetics of pure chlorogenic acid and extract of *Solanum lyratum* Thunb. The animals were allocated to two groups, and were administered chlorogenic acid or extract of *S. lyratum* Thunb. at a dose of 50.0 mg/kg orally. Blood samples were collected up to 8 h post-dosing. Plasma chlorogenic acid analyses were performed using an HPLC method with UV detector. The pharmacokinetic parameters were evaluated using non-compartmental assessment. Significant differences existed in the two groups for AUC_{0-8} , AUC_{0-N} and CLZ/F . The reliable HPLC method was successfully applied to the determination of chlorogenic acid in rat plasma at dosage of 50.0 mg/kg.

1. Introduction

Solanum lyratum Thunb (Solanaceae) is one of the most valued Chinese traditional medicines. It is well known as "*Hedra Solani Lyrati*" in mainland of China, which has been

used for regulating body immune function and ability [1-4]. It was also reported to have anticancer activity [5]. The plant is known to contain steroidal glucuronides, steroidal alkaloid glucosides, coumarin and phenolic acid, etc. [6-10].

Chlorogenic acid (3-*O*-caffeoylquinic acid) is composed of quinic acid and caffeic acid. It is the major active component of *S. lyratum*, and its amount could reach up to 3.0 mg/g [11]. The compound has a variety of biological activities such as anti-microbes, anti-virus, oxidation prevention, anti-tumor and anti-hypertension [12].

Several HPLC methods were developed for the pharmacokinetic studies of chlorogenic acid [13-18]. Ren et al. [19] reported that the pharmacokinetic behavior of chlorogenic acid after oral administration has obvious difference among different dosages (200, 400 and 600 mg/kg). It is well known that the contents of active

ingredients in traditional Chinese medicine are usually low, so the studies of their pharmacokinetic behavior at small dose (50.0 mg/kg) are important and necessary. In addition, other components in *S. lyratum* may change the pharmacokinetics of chlorogenic acid, and there was no report related to this issue.

In this study, a reliable HPLC method was established to determine the concentration of chlorogenic acid in rat plasma. The pharmacokinetic behaviors between chlorogenic acid and extract of *S. lyratum* after oral administration were compared. It is important for understanding of the synergism of components among *S. lyratum* and designing rational dosage regimens.

2. Materials and methods



2.1. Chemicals and reagents

Chlorogenic acid (Fig. 1A) and the internal standard (IS), puerarin (Fig. 1B), were provided by the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). *S. lyratum* was purchased from Xuhui Pharmaceutical Co. Ltd. (Shanghai, China) and was genuinely identified by Prof. Qi-Shi Sun (Shenyang Pharmaceutical University, China). Methanol (HPLC grade) and other analytical grade reagents were obtained from Yuwang Reagent Company (Shenyang, China).

2.2. Instruments and chromatographic conditions

The HPLC system consisted of a Shimadzu LC-10A pump, an SPD-10AV detector and a column oven. Data were processed using Anastar software (Autoscience Instrument Co. Ltd., China). The separation was performed on a Diamonsil- C_{18} column (250 mm 4.6 mm, 5 μ m). The mobile phase was methanol-0.05% phosphoric acid (23:77, v/v) at a flow rate of 1 mL/min.

A



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Comparative pharmacokinetics of chlorogenic acid after oral administration in rats

Ms S Naga manasa , Mr.Sivakumar Peta , Mr AVLS Ramakrishna , Mr.B.NagendraPrasad
Ms Y Radhika

Department of Pharmaceutical Analysis
Email ID: nagamanasa36@gmail.com , Mobile no:7288837695
GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

The present study was aimed at the comparison of the pharmacokinetics of pure chlorogenic acid and extract of *Solanum lyratum* Thunb. The animals were allocated to two groups, and were administered chlorogenic acid or extract of *S. lyratum* Thunb. at a dose of 50.0 mg/kg orally. Blood samples were collected up to 8 h post-dosing. Plasma chlorogenic acid analyses were performed using an HPLC method with UV detector. The pharmacokinetic parameters were evaluated using non-compartmental assessment. Significant differences existed in the two groups for AUC_{0-4} , AUC_{0-N} and CL_z/F . The reliable HPLC method was successfully applied to the determination of chlorogenic acid in rat plasma at dosage of 50.0 mg/kg.

1. Introduction

Solanum lyratum Thunb (Solanaceae) is one of the most valued Chinese traditional medicines. It is well known as "Herba Solani Lyrati" in mainland of China, which has been

used for regulating body immune function and ability [1-4]. It was also reported to have anticancer activity [5]. The plant is known to contain steroidal glucuronides, steroidal alkaloid glucosides, coumarin and phenolic acid, etc. [6-10].

Chlorogenic acid (3-O-caffeoylquinic acid) is composed of quinic acid and caffeic acid. It is the major active component of *S. lyratum*, and its amount could reach up to 3.0 mg/g [11]. The compound has a variety of biological activities such as anti-microbes, anti-virus, oxidation prevention, anti-tumor and anti-hypertension [12].

Several HPLC methods were developed for the pharmacokinetic studies of chlorogenic acid [13-18]. Ren et al. [19] reported that the pharmacokinetic behavior of chlorogenic acid after oral administration has obvious difference among different dosages (200, 400 and 600 mg/kg). It is well known that the contents of active

ingredients in traditional Chinese medicine are usually low, so the studies of their pharmacokinetic behavior at small dose (50.0 mg/kg) are important and necessary. In addition, other components in *S. lyratum* may change the pharmacokinetics of chlorogenic acid, and there was no report related to this issue.

In this study, a reliable HPLC method was established to determine the concentration of chlorogenic acid in rat plasma. The pharmacokinetic behaviors between chlorogenic acid and extract of *S. lyratum* after oral administration were compared. It is important for understanding of the synergism of components among *S. lyratum* and designing rational dosage regimens.

2. Materials and methods


2.1. Chemicals and reagents

Chlorogenic acid (Fig. 1A) and the internal standard (IS), puerarin (Fig. 1B), were provided by the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). *S. lyratum* was purchased from Xuhui Pharmaceutical Co. Ltd. (Shanghai, China) and was genuinely identified by Prof. Qi-Shi Sun (Shenyang Pharmaceutical University, China). Methanol (HPLC grade) and other analytical grade reagents were obtained from Yuwang Reagent Company (Shenyang, China).

2.2. Instruments and chromatographic conditions

The HPLC system consisted of a Shimadzu LC-10A pump, an SPD-10AV detector and a column oven. Data were processed using Anastar software (Autoscience Instrument Co. Ltd., China). The separation was performed on a Diamonsil-C₁₈ column (250 mm 4.6 mm, 5 mm). The mobile phase was methanol-0.05% phosphoric acid (23:77, v/v) at a flow rate of 1 mL/min.

A



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

Comparative pharmacokinetics of chlorogenic acid after oral administration in rats

Ms S Naga manasa , Mr.Sivakumar Peta , Mr AVLS Ramakrishna , Mr.B.NagendraPrasad
Ms Y Radhika

Department of Pharmaceutical Analysis
Email ID: nagamanasa36@gmail.com , Mobile no:7288837695
GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract

The present study was aimed at the comparison of the pharmacokinetics of pure chlorogenic acid and extract of *Solanum lyratum* Thunb. The animals were allocated to two groups, and were administered chlorogenic acid or extract of *S. lyratum* Thunb. at a dose of 50.0 mg/kg orally. Blood samples were collected up to 8 h post-dosing. Plasma chlorogenic acid analyses were performed using an HPLC method with UV detector. The pharmacokinetic parameters were evaluated using non-compartmental assessment. Significant differences existed in the two groups for AUC_{0-8} , AUC_{0-N} and CL_z/F . The reliable HPLC method was successfully applied to the determination of chlorogenic acid in rat plasma at dosage of 50.0 mg/kg.

1. Introduction

Solanum lyratum Thunb (Solanaceae) is one of the most valued Chinese traditional medicines. It is well known as "*Hedra Solani Lyrati*" in mainland of China, which has been

used for regulating body immune function and ability [1-4]. It was also reported to have anticancer activity [5]. The plant is known to contain steroidal glucuronides, steroidal alkaloid glucosides, coumarin and phenolic acid, etc. [6-10].

Chlorogenic acid (3-O-caffeoylquinic acid) is composed of quinic acid and caffeic acid. It is the major active component of *S. lyratum*, and its amount could reach up to 3.0 mg/g [11]. The compound has a variety of biological activities such as anti-microbes, anti-virus, oxidation prevention, anti-tumor and anti-hypertension [12].

Several HPLC methods were developed for the pharmacokinetic studies of chlorogenic acid [13-18]. Ren et al. [19] reported that the pharmacokinetic behavior of chlorogenic acid after oral administration has obvious difference among different dosages (200, 400 and 600 mg/kg). It is well known that the contents of active

ingredients in traditional Chinese medicine are usually low, so the studies of their pharmacokinetic behavior at small dose (50.0 mg/kg) are important and necessary. In addition, other components in *S. lyratum* may change the pharmacokinetics of chlorogenic acid, and there was no report related to this issue.

In this study, a reliable HPLC method was established to determine the concentration of chlorogenic acid in rat plasma. The pharmacokinetic behaviors between chlorogenic acid and extract of *S. lyratum* after oral administration were compared. It is important for understanding of the synergism of components among *S. lyratum* and designing rational dosage regimens.

2. Materials and methods


2.1. Chemicals and reagents

Chlorogenic acid (Fig. 1A) and the internal standard (IS), puerarin (Fig. 1B), were provided by the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). *S. lyratum* was purchased from Xuhui Pharmaceutical Co. Ltd. (Shanghai, China) and was genuinely identified by Prof. Qi-Shi Sun (Shenyang Pharmaceutical University, China). Methanol (HPLC grade) and other analytical grade reagents were obtained from Yuwang Reagent Company (Shenyang, China).

2.2. Instruments and chromatographic conditions

The HPLC system consisted of a Shimadzu LC-10A pump, an SPD-10AV detector and a column oven. Data were processed using Anasart software (Autoscience Instrument Co. Ltd., China). The separation was performed on a Diamonsil-C₁₈ column (250 mm 4.6 mm, 5 μm). The mobile phase was methanol-0.05% phosphoric acid (23:77, v/v) at a flow rate of 1 mL/min.

A



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

ISSN : 2347 - 2243



*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



A Study on the Characterization and Stability Implications of Investigating Local Mobility in Amorphous Pharmaceuticals

Mrs. P K Devibala, Dr. B. Pavan Kumar, Ms K Vanithadevi, MR B Kondalrao, Mrs Y Swaroopa

ABSTRACT: There has been a deluge of research on the relationship between molecular mobility and the physical and chemical stability of amorphous drugs in recent years. Glass transition and global mobility-related molecular movements have been the primary targets of these investigations. There were, however, a handful of cases where the volatility could not be explained by international migration. The idea that β -relaxations, which occur at local scales well below the glass transition temperature, may be impacting stability is gaining traction. One common method for determining an amorphous pharmaceutical's mobility below the glass transition temperature (T_g) is to extrapolate data collected above T_g . While not well-suited to pinpointing precise local mobility, this kind of investigation may provide data about mobility in general. Our main goal from a pharmacological standpoint is to prove that local movements are important in amorphous drugs, especially in the Johari-Goldstein relaxations. In order to highlight the possible influence of local mobility on the stability of amorphous phases, an assessment of the coupling model was carried out that linked local movements with global mobility. We took into account the effects of water and other additives when studying the local movements in an amorphous matrix present in molecular dispersions. In conclusion, we have offered a concise review, highlighting the advantages and disadvantages, of the most widely used instrumental methods for characterizing local movements. To this day, Wiley-Liss, Inc., the publisher, has all rights.

Keywords: Amorphous, solid dispersion, lyophilization, mobility, and crystallization

INTRODUCTION

Pharmaceutical companies often produce amorphous forms of certain APIs used in drug formulation. An increasingly well-known problem that this method solves is the sluggish pace of dissolution caused by compounds' poor water solubility. As a result of their higher free energies, amorphous states may be less physically stable; crystallization tendencies are one indicator

of this. Reduced chemical stability may also cause an intolerably short storage life. Thus, there is a lot of focus in the field right now on predicting stability and making amorphous pharmaceuticals. Investigators in the pharmaceutical industry have good cause to wonder if there is a link between molecular dynamics and the stability of amorphous phases.

Department of Pharmaceutics

Email ID: devinov15@gmail.com, Mobile no: 9177579805

GOKULA KRISHNA COLLEGE OF PHARMACY



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347 - 2243

*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



N. K.
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBS, FAGE, FICPP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



A Study on the Characterization and Stability Implications of Investigating Local Mobility in Amorphous Pharmaceuticals

Mrs. P K Devibala, Dr. B. Pavan kumar, Ms K Vanithadevi, MR B Kondalrao, Mrs Y Swaroopa

ABSTRACT: There has been a deluge of research on the relationship between molecular mobility and the physical and chemical stability of amorphous drugs in recent years. Glass transition and global mobility-related molecular movements have been the primary targets of these investigations. There were, however, a handful of cases where the volatility could not be explained by international migration. The idea that β -relaxations, which occur at local scales well below the glass transition temperature, may be impacting stability is gaining traction. One common method for determining an amorphous pharmaceutical's mobility below the glass transition temperature (T_g) is to extrapolate data collected above T_g . While not well-suited to pinpointing precise local mobility, this kind of investigation may provide data about mobility in general. Our main goal from a pharmacological standpoint is to prove that local movements are important in amorphous drugs, especially in the Johari-Goldstein relaxations. In order to highlight the possible influence of local mobility on the stability of amorphous phases, an assessment of the coupling model was carried out that linked local movements with global mobility. We took into account the effects of water and other additives when studying the local movements in an amorphous matrix present in molecular dispersions. In conclusion, we have offered a concise review, highlighting the advantages and disadvantages, of the most widely used instrumental methods for characterizing local movements. To this day, Wiley-Liss, Inc., the publisher, has all rights.

Keywords: Amorphous, solid dispersion, lyophilization, mobility, and crystallization

INTRODUCTION

Pharmaceutical companies often produce amorphous forms of certain APIs used in drug formulation.¹ An increasingly well-known problem that this method solves is the sluggish pace of dissolution caused by compounds' poor water solubility.¹ As a result of their higher free energies, amorphous states may be less physically stable; crystallization tendencies are one indicator

of this. Reduced chemical stability may also cause an intolerably short storage life. Thus, there is a lot of focus in the field right now on predicting stability and making amorphous pharmaceuticals. Investigators in the pharmaceutical industry have good cause to wonder if there is a link between molecular dynamics and the stability of amorphous phases.

Department of Pharmaceutics

Email ID: devinov15@gmail.com, Mobile no: 9177579805

GOKULA KRISHNA COLLEGE OF PHARMACY



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



ISSN : 2347 - 2243

Indo - American Journal of Life Sciences and Biotechnology



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Narayana
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



A Study on the Characterization and Stability Implications of Investigating Local Mobility in Amorphous Pharmaceuticals

Mrs. P K Devibala, Dr. B. Pavan kumar, Ms K Vanithadevi, MR B Kondalrao, Mrs Y Swaroopa

ABSTRACT: There has been a deluge of research on the relationship between molecular mobility and the physical and chemical stability of amorphous drugs in recent years. Glass transition and global mobility-related molecular movements have been the primary targets of these investigations. There were, however, a handful of cases where the volatility could not be explained by international migration. The idea that β -relaxations, which occur at local scales well below the glass transition temperature, may be impacting stability is gaining traction. One common method for determining an amorphous pharmaceutical's mobility below the glass transition temperature (T_g) is to extrapolate data collected above T_g . While not well-suited to pinpointing precise local mobility, this kind of investigation may provide data about mobility in general. Our main goal from a pharmacological standpoint is to prove that local movements are important in amorphous drugs, especially in the Johari-Goldstein relaxations. In order to highlight the possible influence of local mobility on the stability of amorphous phases, an assessment of the coupling model was carried out that linked local movements with global mobility. We took into account the effects of water and other additives when studying the local movements in an amorphous matrix present in molecular dispersions. In conclusion, we have offered a concise review, highlighting the advantages and disadvantages, of the most widely used instrumental methods for characterizing local movements. To this day, Wiley-Liss, Inc., the publisher, has all rights.

Keywords: Amorphous, solid dispersion, lyophilization, mobility, and crystallization

INTRODUCTION

Pharmaceutical companies often produce amorphous forms of certain APIs used in drug formulation. An increasingly well-known problem that this method solves is the sluggish pace of dissolution caused by compounds' poor water solubility. As a result of their higher free energies, amorphous states may be less physically stable; crystallization tendencies are one indicator

of this. Reduced chemical stability may also cause an intolerably short storage life. Thus, there is a lot of focus in the field right now on predicting stability and making amorphous pharmaceuticals. Investigators in the pharmaceutical industry have good cause to wonder if there is a link between molecular dynamics and the stability of amorphous phases.

Department of Pharmaceutics

Email ID: devinov15@gmail.com, Mobile no: 9177579805

GOKULA KRISHNA COLLEGE OF PHARMACY





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FDES, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347 - 2243

*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICOP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



A Study on the Characterization and Stability Implications of Investigating Local Mobility in Amorphous Pharmaceuticals

Mrs. P K Devibala, Dr. B. Pavan kumar, Ms K Vanithadevi, MR B Kondalrao,
Mrs Y Swaroopa

ABSTRACT: There has been a deluge of research on the relationship between molecular mobility and the physical and chemical stability of amorphous drugs in recent years. Glass transition and global mobility-related molecular movements have been the primary targets of these investigations. There were, however, a handful of cases where the volatility could not be explained by international migration. The idea that β -relaxations, which occur at local scales well below the glass transition temperature, may be impacting stability is gaining traction. One common method for determining an amorphous pharmaceutical's mobility below the glass transition temperature (T_g) is to extrapolate data collected above T_g . While not well-suited to pinpointing precise local mobility, this kind of investigation may provide data about mobility in general. Our main goal from a pharmacological standpoint is to prove that local movements are important in amorphous drugs, especially in the Johari-Goldstein relaxations. In order to highlight the possible influence of local mobility on the stability of amorphous phases, an assessment of the coupling model was carried out that linked local movements with global mobility. We took into account the effects of water and other additives when studying the local movements in an amorphous matrix present in molecular dispersions. In conclusion, we have offered a concise review, highlighting the advantages and disadvantages, of the most widely used instrumental methods for characterizing local movements. To this day, Wiley-Liss, Inc., the publisher, has all rights.

Keywords: Amorphous, solid dispersion, lyophilization, mobility, and crystallization

INTRODUCTION

Pharmaceutical companies often produce amorphous forms of certain APIs used in drug formulation.¹ An increasingly well-known problem that this method solves is the sluggish pace of dissolution caused by compounds' poor water solubility.¹ As a result of their higher free energies, amorphous states may be less physically stable; crystallization tendencies are one indicator

of this. Reduced chemical stability may also cause an intolerably short storage life. Thus, there is a lot of focus in the field right now on predicting stability and making amorphous pharmaceuticals. Investigators in the pharmaceutical industry have good cause to wonder if there is a link between molecular dynamics and the stability of amorphous phases.

Department of Pharmaceutics

Email ID: devinov15@gmail.com, Mobile no: 9177579805
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347 - 2243

Indo - American Journal of Life Sciences and Biotechnology



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICOP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



A Study on the Characterization and Stability Implications of Investigating Local Mobility in Amorphous Pharmaceuticals

Mrs. P K Devibala, Dr. B. Pavan kumar, Ms K Vanithadevi, MR B Kondalrao,
Mrs Y Swaroopa

ABSTRACT: There has been a deluge of research on the relationship between molecular mobility and the physical and chemical stability of amorphous drugs in recent years. Glass transition and global mobility-related molecular movements have been the primary targets of these investigations. There were, however, a handful of cases where the volatility could not be explained by international migration. The idea that β -relaxations, which occur at local scales well below the glass transition temperature, may be impacting stability is gaining traction. One common method for determining an amorphous pharmaceutical's mobility below the glass transition temperature (T_g) is to extrapolate data collected above T_g . While not well-suited to pinpointing precise local mobility, this kind of investigation may provide data about mobility in general. Our main goal from a pharmacological standpoint is to prove that local movements are important in amorphous drugs, especially in the Johari-Goldstein relaxations. In order to highlight the possible influence of local mobility on the stability of amorphous phases, an assessment of the coupling model was carried out that linked local movements with global mobility. We took into account the effects of water and other additives when studying the local movements in an amorphous matrix present in molecular dispersions. In conclusion, we have offered a concise review, highlighting the advantages and disadvantages, of the most widely used instrumental methods for characterizing local movements. To this day, Wiley-Liss, Inc., the publisher, has all rights.

Keywords: Amorphous, solid dispersion, lyophilization, mobility, and crystallization

INTRODUCTION

Pharmaceutical companies often produce amorphous forms of certain APIs used in drug formulation. An increasingly well-known problem that this method solves is the sluggish pace of dissolution caused by compounds' poor water solubility. As a result of their higher free energies, amorphous states may be less physically stable; crystallization tendencies are one indicator

of this. Reduced chemical stability may also cause an intolerably short storage life. Thus, there is a lot of focus in the field right now on predicting stability and making amorphous pharmaceuticals. Investigators in the pharmaceutical industry have good cause to wonder if there is a link between molecular dynamics and the stability of amorphous phases.

Department of Pharmaceutics

Email ID: devinov15@gmail.com, Mobile no: 9177579805


GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347-2251
Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com
editor@iajpb.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine

Dr. Balagani Pavan Kumar, Ms. P Kavitha, Mrs. P Sukanya, Mr KRSC Bharath kumar, Ms. A. Manogna
Ms P Madhavi

ABSTRACT

The oral cavity is of great importance to the performance of orally retained formulations, including: orally disintegrating tablets, taste-masked formulations, and buccal/sublingual delivery systems. With regards to *in vitro* dissolution assessment of these dosage forms, human saliva should be represented by the dissolution media. Currently there is no general consensus regarding oral cavity dissolution. In this study pooled human saliva was characterised and utilised as dissolution media for biorelevant oral cavity dissolution studies and to assess drug release. Lipophilic drug felodipine with challenging biopharmaceutical properties was selected for assessment in oral cavity dissolution studies. These saliva dissolution studies investigated for the first time how biorelevant dissolution can be implemented as a screening tool to guide the formulation development process and to predict dosage form performance within the mouth. In this study a combination of three dissolution enhancement strategies (cryomilling, solid dispersion, and inclusion complexation) were employed to eventually increase the concentration of felodipine in saliva 150-fold. Using this successful formulation strategy orally disintegrating tablets of felodipine were produced. Interestingly, the percentage release of felodipine in compendial dissolution apparatus was shown to be over 80% after 10 min. On the other hand, saliva-based dissolution showed that percentage release of felodipine was only 0.2% after 10 min using the same formulation. This discrepancy in drug release between dissolution media highlights the need for biorelevant dissolution apparatus for the oral cavity to reliably assess performance of relevant dosage forms *in vitro*.

1. Introduction

The oral cavity is a site for drug dissolution that is generally overlooked in pharmaceutical development. Following the oral administration of drugs there are several processes which take place over a relatively short period of time. These processes include: disintegration, dissolution, taste perception, drug absorption, and drug removal via swallowing. Compared to conventional solid oral dosage forms,

such as tablets and capsules, orally retained formulations can be greatly impacted by the time spent within the oral cavity. The performance of orally retained formulations such as sublingual and buccal tablets, orally disintegrating tablets (ODTs), and oral films in the oral cavity rely on disintegration and dissolution in saliva (Bartlett and van der Voort Maarschalk, 2012).

Department of pharmaceuticals,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380.
GOKULA KRISHNA COLLEGE OF PHARMACY





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com

editor@iajpb.com



Pavani
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine

Dr. Balagani Pavan Kumar, Ms. P Kavitha, Mrs. P Sukanya, Mr KRSC Bharath kumar, Ms. A. Manogna
Ms P Madhavi

ABSTRACT

The oral cavity is of great importance to the performance of orally retained formulations, including: orally disintegrating tablets, taste-masked formulations, and buccal/sublingual delivery systems. With regards to *in vitro* dissolution assessment of these dosage forms, human saliva should be represented by the dissolution media. Currently there is no general consensus regarding oral cavity dissolution. In this study pooled human saliva was characterised and utilised as dissolution media for biorelevant oral cavity dissolution studies and to assess drug release. Lipophilic drug felodipine with challenging biopharmaceutical properties was selected for assessment in oral cavity dissolution studies. These saliva dissolution studies investigated for the first time how biorelevant dissolution can be implemented as a screening tool to guide the formulation development process and to predict dosage form performance within the mouth. In this study a combination of three dissolution enhancement strategies (cryomilling, solid dispersion, and inclusion complexation) were employed to eventually increase the concentration of felodipine in saliva 150-fold. Using this successful formulation strategy orally disintegrating tablets of felodipine were produced. Interestingly, the percentage release of felodipine in compendial dissolution apparatus was shown to be over 80% after 10 min. On the other hand, saliva-based dissolution showed that percentage release of felodipine was only 0.2% after 10 min using the same formulation. This discrepancy in drug release between dissolution media highlights the need for biorelevant dissolution apparatus for the oral cavity to reliably assess performance of relevant dosage forms *in vitro*.


1. Introduction

The oral cavity is a site for drug dissolution that is generally overlooked in pharmaceutical development. Following the oral administration of drugs there are several processes which take place over a relatively short period of time. These processes include: disintegration, dissolution, taste perception, drug absorption, and drug removal via swallowing. Compared to conventional solid oral dosage forms,

such as tablets and capsules, orally retained formulations can be greatly impacted by the time spent within the oral cavity. The performance of orally retained formulations such as sublingual and buccal tablets, orally disintegrating tablets (ODTs), and oral films in the oral cavity rely on disintegration and dissolution in saliva (Bartlett and van der Voort Maarschalk, 2012).

Department of pharmaceuticals,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380.
GOKULA KRISHNA COLLEGE OF PHARMACY





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com

editor@iajpb.com



Pavan

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, PAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine

Dr. Balagani Pavan Kumar, Ms. P Kavitha, Mrs. P Sukanya, Mr KRSC Bharath kumar, Ms. A. Manogna
Ms P Madhavi

ABSTRACT

The oral cavity is of great importance to the performance of orally retained formulations, including: orally disintegrating tablets, taste-masked formulations, and buccal/sublingual delivery systems. With regards to *in vitro* dissolution assessment of these dosage forms, human saliva should be represented by the dissolution media. Currently there is no general consensus regarding oral cavity dissolution. In this study pooled human saliva was characterised and utilised as dissolution media for biorelevant oral cavity dissolution studies and to assess drug release. Lipophilic drug felodipine with challenging biopharmaceutical properties was selected for assessment in oral cavity dissolution studies. These saliva dissolution studies investigated for the first time how biorelevant dissolution can be implemented as a screening tool to guide the formulation development process and to predict dosage form performance within the mouth. In this study a combination of three dissolution enhancement strategies (cryomilling, solid dispersion, and inclusion complexation) were employed to eventually increase the concentration of felodipine in saliva 150-fold. Using this successful formulation strategy orally disintegrating tablets of felodipine were produced. Interestingly, the percentage release of felodipine in compendial dissolution apparatus was shown to be over 80% after 10 min. On the other hand, saliva-based dissolution showed that percentage release of felodipine was only 0.2% after 10 min using the same formulation. This discrepancy in drug release between dissolution media highlights the need for biorelevant dissolution apparatus for the oral cavity to reliably assess performance of relevant dosage forms *in vitro*.

1. Introduction

The oral cavity is a site for drug dissolution that is generally overlooked in pharmaceutical development. Following the oral administration of drugs there are several processes which take place over a relatively short period of time. These processes include: disintegration, dissolution, taste perception, drug absorption, and drug removal via swallowing. Compared to conventional solid oral dosage forms,

such as tablets and capsules, orally retained formulations can be greatly impacted by the time spent within the oral cavity. The performance of orally retained formulations such as sublingual and buccal tablets, orally disintegrating tablets (ODTs), and oral films in the oral cavity rely on disintegration and dissolution in saliva (Bartlett and van der Voort Maarschalk, 2012).

Department of pharmaceuticals,

Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380.

GOKULA KRISHNA COLLEGE OF PHARMACY





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com

editor@iajpb.com



Balagan

Dr. BALAGANI PAVAN KUMAR

M. Pharm, Ph.D, FIC, F855, FAGE, FICCP, MISTE

PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY

SULLURPET, TIRUPATI DL. A.P - 524121



Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine

Dr. Balagani Pavan Kumar, Ms. P Kavitha, Mrs. P Sukanya, Mr. KRSC Bharath Kumar, Ms. A. Manogna
Ms P Madhavi

ABSTRACT

The oral cavity is of great importance to the performance of orally retained formulations, including: orally disintegrating tablets, taste-masked formulations, and buccal/sublingual delivery systems. With regards to *in vitro* dissolution assessment of these dosage forms, human saliva should be represented by the dissolution media. Currently there is no general consensus regarding oral cavity dissolution. In this study pooled human saliva was characterised and utilised as dissolution media for biorelevant oral cavity dissolution studies and to assess drug release. Lipophilic drug felodipine with challenging biopharmaceutical properties was selected for assessment in oral cavity dissolution studies. These saliva dissolution studies investigated for the first time how biorelevant dissolution can be implemented as a screening tool to guide the formulation development process and to predict dosage form performance within the mouth. In this study a combination of three dissolution enhancement strategies (cryomilling, solid dispersion, and inclusion complexation) were employed to eventually increase the concentration of felodipine in saliva 150-fold. Using this successful formulation strategy orally disintegrating tablets of felodipine were produced. Interestingly, the percentage release of felodipine in compendial dissolution apparatus was shown to be over 80% after 10 min. On the other hand, saliva-based dissolution showed that percentage release of felodipine was only 0.2% after 10 min using the same formulation. This discrepancy in drug release between dissolution media highlights the need for biorelevant dissolution apparatus for the oral cavity to reliably assess performance of relevant dosage forms *in vitro*.

1. Introduction

The oral cavity is a site for drug dissolution that is generally overlooked in pharmaceutical development. Following the oral administration of drugs there are several processes which take place over a relatively short period of time. These processes include: disintegration, dissolution, taste perception, drug absorption, and drug removal via swallowing. Compared to conventional solid oral dosage forms,

such as tablets and capsules, orally retained formulations can be greatly impacted by the time spent within the oral cavity. The performance of orally retained formulations such as sublingual and buccal tablets, orally disintegrating tablets (ODTs), and oral films in the oral cavity rely on disintegration and dissolution in saliva (Bartlett and van der Voor Maarschalk, 2012).

Department of pharmaceuticals,

Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380.

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347-2251

Indo-American Journal of
Pharma and Bio Sciences



www.iajpb.com

iajpb.editor@gmail.com

editor@iajpb.com



Pavan

Dr. BALAGANI PAVAN KUMAR

M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE

PROFESSOR & PRINCIPAL

GOKULA KRISHNA COLLEGE OF PHARMACY

SULLURPET, TIRUPATI DL. A.P - 524121



Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine

Dr. Balagani Pavan Kumar, Ms. P Kavitha, Mrs. P Sukanya, Mr. KRSC Bharath Kumar, Ms. A. Manogna, Ms. P Madhavi

ABSTRACT

The oral cavity is of great importance to the performance of orally retained formulations, including: orally disintegrating tablets, taste-masked formulations, and buccal/sublingual delivery systems. With regards to *in vitro* dissolution assessment of these dosage forms, human saliva should be represented by the dissolution media. Currently there is no general consensus regarding oral cavity dissolution. In this study pooled human saliva was characterised and utilised as dissolution media for biorelevant oral cavity dissolution studies and to assess drug release. Lipophilic drug felodipine with challenging biopharmaceutical properties was selected for assessment in oral cavity dissolution studies. These saliva dissolution studies investigated for the first time how biorelevant dissolution can be implemented as a screening tool to guide the formulation development process and to predict dosage form performance within the mouth. In this study a combination of three dissolution enhancement strategies (cryomilling, solid dispersion, and inclusion complexation) were employed to eventually increase the concentration of felodipine in saliva 150-fold. Using this successful formulation strategy orally disintegrating tablets of felodipine were produced. Interestingly, the percentage release of felodipine in compendial dissolution apparatus was shown to be over 80% after 10 min. On the other hand, saliva-based dissolution showed that percentage release of felodipine was only 0.2% after 10 min using the same formulation. This discrepancy in drug release between dissolution media highlights the need for biorelevant dissolution apparatus for the oral cavity to reliably assess performance of relevant dosage forms *in vitro*.

1. Introduction

The oral cavity is a site for drug dissolution that is generally overlooked in pharmaceutical development. Following the oral administration of drugs there are several processes which take place over a relatively short period of time. These processes include: disintegration, dissolution, taste perception, drug absorption, and drug removal via swallowing. Compared to conventional solid oral dosage forms,

such as tablets and capsules, orally retained formulations can be greatly impacted by the time spent within the oral cavity. The performance of orally retained formulations such as sublingual and buccal tablets, orally disintegrating tablets (ODTs), and oral films in the oral cavity rely on disintegration and dissolution in saliva (Bartlett and van der Voort Maarschalk, 2012).

Department of pharmaceuticals,

Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380.

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FGSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine

Dr. Balagani Pavan Kumar, Ms. P Kavitha, Mrs. P Sukanya, Mr. KRSC Bharath Kumar, Ms. A. Manogna
Ms P Madhavi

ABSTRACT

The oral cavity is of great importance to the performance of orally retained formulations, including: orally disintegrating tablets, taste-masked formulations, and buccal/sublingual delivery systems. With regards to *in vitro* dissolution assessment of these dosage forms, human saliva should be represented by the dissolution media. Currently there is no general consensus regarding oral cavity dissolution. In this study pooled human saliva was characterised and utilised as dissolution media for biorelevant oral cavity dissolution studies and to assess drug release. Lipophilic drug felodipine with challenging biopharmaceutical properties was selected for assessment in oral cavity dissolution studies. These saliva dissolution studies investigated for the first time how biorelevant dissolution can be implemented as a screening tool to guide the formulation development process and to predict dosage form performance within the mouth. In this study a combination of three dissolution enhancement strategies (cryomilled solid dispersion, and inclusion complexation) were employed to eventually increase the concentration of felodipine in saliva 150-fold. Using this successful formulation strategy orally disintegrating tablets of felodipine were produced. Interestingly, the percentage release of felodipine in compendial dissolution apparatus was shown to be over 80% after 10 min. On the other hand, saliva-based dissolution showed that percentage release of felodipine was only 0.2% after 10 min using the same formulation. This discrepancy in drug release between dissolution media highlights the need for biorelevant dissolution apparatus for the oral cavity to reliably assess performance of biorelevant dosage forms *in vitro*.

1. Introduction

The oral cavity is a site for drug dissolution that is generally overlooked in pharmaceutical development. Following the oral administration of drugs there are several processes which take place over a relatively short period of time. These processes include: disintegration, dissolution, taste perception, drug absorption, and drug removal via swallowing. Compared to conventional solid oral dosage forms,

such as tablets and capsules, orally retained formulations can be greatly impacted by the time spent within the oral cavity. The performance of orally retained formulations such as sublingual and buccal tablets, orally disintegrating tablets (ODTs), and oral films in the oral cavity rely on disintegration and dissolution in saliva (Bartlett and van der Voort Maarschalk, 2012).

Department of pharmaceuticals,

Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380.

GOKULA KRISHNA COLLEGE OF PHARMACY



Pavan

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

NO. OF RESEARCH PAPERS PUBLISHED PER TEACHER IN THE JOURNALS NOTIFIED ON UGC CARE LIST DURING THE LAST FIVE YEARS

CALENDER YEAR - 2018

S.No	Title of the Paper	Name of the Author/s	Name of the Journal	ISSN NO
1	A thorough analysis of Thymus serpyllum's traditional uses, phytochemistry, pharmacology, and toxicity	Ms A R Sridevi	International Journal of Pharmaceutical Sciences Letters	2277-2685
2	A thorough analysis of Thymus serpyllum's traditional uses, phytochemistry, pharmacology, and toxicity	Ms.B.Geethanjali Bai.	International Journal of Pharmaceutical Sciences Letters	2277-2685
3	A thorough analysis of Thymus serpyllum's traditional uses, phytochemistry, pharmacology, and toxicity	Mr C G Bhaskar	International Journal of Pharmaceutical Sciences Letters	2277-2685
4	A thorough analysis of Thymus serpyllum's traditional uses, phytochemistry, pharmacology, and toxicity	Ms.A.AksaAnvija	International Journal of Pharmaceutical Sciences Letters	2277-2685
5	A thorough analysis of Thymus serpyllum's traditional uses, phytochemistry, pharmacology, and toxicity	Ms B silpa	International Journal of Pharmaceutical Sciences Letters	2277-2685
6	A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro	Ms.P Kavitha	Indo-American Journal of Life sciences and Biotechnology	2347-2243
7	A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro	Mr.K.R.S.C Bharath kumar	Indo-American Journal of Life sciences and Biotechnology	2347-2243



Pavan

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph D, FIC, FBNSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



GOKULA KRISHNA COLLEGE OF PHARMACY

Approved by PCI-New Delhi, Government of AP & Affiliated to JNTUA

An ISO 9001:2015 Certified Institution

Behind RTC Depot, Sullurupeta, Tirupati Dist, A.P, INDIA - 524121

Mobile : 9948990116

E-Mail : gkcp@rediffmail.com

website: www.gkcp.edu.in

8	A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro	Mrs.M.Sindhuri	Indo-American Journal of Life sciences and Biotechnology	2347-2243
9	A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro	Ms P Madhavi	Indo-American Journal of Life sciences and Biotechnology	2347-2243
10	A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro	Mr. Y.Naveenkumar	Indo-American Journal of Life sciences and Biotechnology	2347-2243
11	Shifting Focus from Fundamentals to Systems Pharmacodynamic Models	Dr.Balagani Pavan Kumar	Indo-American Journal of Life sciences and Biotechnology	2347-2243
12	Shifting Focus from Fundamentals to Systems Pharmacodynamic Models	Mrs. P K Devibala	Indo-American Journal of Life sciences and Biotechnology	2347-2243
13	Shifting Focus from Fundamentals to Systems Pharmacodynamic Models	MsC.B.Hanisha	Indo-American Journal of Life sciences and Biotechnology	2347-2243
14	Shifting Focus from Fundamentals to Systems Pharmacodynamic Models	Mrs. Swaroopa	Indo-American Journal of Life sciences and Biotechnology	2347-2243
15	Shifting Focus from Fundamentals to Systems Pharmacodynamic Models	Ms.A.Manogna	Indo-American Journal of Life sciences and Biotechnology	2347-2243

PRINCIPAL



Dr. BALAGANI PAVAN KUMAR
Pharm, Ph.D, FIC, FSSS, FAGE, FICC, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL, A.P - 524121

A thorough analysis of *Thymus serpyllum*'s traditional uses, phytochemistry, pharmacology, and toxicity

Ms A R Sridevi, Ms.B.Geethanjali Bai., Mr C G Bhaskar, Ms.A.AksaAnvija, Ms B silpa

Department of pharmacology

Email ID: sridevipharma93@gmail.com , Mobile no: 9182727657

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

The Lamiaceae family's understudied perennial plant Thymus serpyllum L. has a long history of use in the treatment of gastrointestinal and respiratory disorders in the higher foothills of India. Our present understanding of T. serpyllum's traditional applications, phytochemistry, and pharmacology is not well-rounded, and that is the goal of this review. Gathering up-to-date knowledge on this plant is our top priority, as is promoting more in vivo and in vitro studies to back up local claims. Due to its varied pharmacological qualities, such as antioxidative, antibacterial, anti-inflammatory, and anticancer activity, the essential oil extracted from T. serpyllum has garnered substantial interest as a plant-derived product. When it comes to creating novel medications to tackle a wide range of health sector issues, ethnomedicinal research has shown that T. serpyllum has a lot of potential. Pharmacological investigations alone are insufficient to support the widespread usage of T. serpyllum. In most cases, researchers use either in vitro or in vivo methods. To evaluate these medical assertions, more research is needed in the form of carefully orchestrated pharmacological trials. The findings of this evaluation will serve as a springboard for more studies. Despite T. serpyllum's extensive traditional usage, there has been a dearth of pharmacological research, with the majority of investigations conducted in either in vitro or in vivo settings. Important topics to explore include further chemical isolation, thorough pharmacological study, and potential culinary uses.

Keywords:

Pharmacological properties, phytochemistry, *Thymus serpyllum*, toxicity, traditional applications

Introduction :

The contemporary world is responsible for improving immune responses and achieving excellent health via the use of medicinal herbs. For generations, from 4000 to 5000 B.C., people have turned to traditional remedies as a cost-effective and easily accessible means of illness treatment. The first known medicinal formulation derived from herbs was acquired by the Chinese. The first text on the use of plants as medicines in India was found in the Rig-Veda, which dates back to 1600-3500 B.C. Traditional Indian medicine has long made use of herbs for their therapeutic properties.[1] New medicinal treatments may be derived from plants.




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D. FIC, FBSS, FAGE, FICOP, MSTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A thorough analysis of *Thymus serpyllum*'s traditional uses, phytochemistry, pharmacology, and toxicity

Ms A R Sridevi, Ms. B. Geethanjali Bai., Mr C G Bhaskar, Ms. A. Aksa Anvija, Ms B silpa

Department of pharmacology

Email ID: sridevipharma93@gmail.com, Mobile no: 9182727657

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

The Lamiaceae family's understudied perennial plant Thymus serpyllum L. has a long history of use in the treatment of gastrointestinal and respiratory disorders in the higher foothills of India. Our present understanding of T. serpyllum's traditional applications, phytochemistry, and pharmacology is not well-rounded, and that is the goal of this review. Gathering up-to-date knowledge on this plant is our top priority, as is promoting more in vivo and in vitro studies to back up local claims. Due to its varied pharmacological qualities, such as antioxidative, antibacterial, anti-inflammatory, and anticancer activity, the essential oil extracted from T. serpyllum has garnered substantial interest as a plant-derived product. When it comes to creating novel medications to tackle a wide range of health sector issues, ethnomedicinal research has shown that T. serpyllum has a lot of potential. Pharmacological investigations alone are insufficient to support the widespread usage of T. serpyllum. In most cases, researchers use either in vitro or in vivo methods. To evaluate these medical assertions, more research is needed in the form of carefully orchestrated pharmacological trials. The findings of this evaluation will serve as a springboard for more studies. Despite T. serpyllum's extensive traditional usage, there has been a dearth of pharmacological research, with the majority of investigations conducted in either in vitro or in vivo settings. Important topics to explore include further chemical isolation, thorough pharmacological study, and potential culinary uses.


Keywords:

Pharmacological properties, phytochemistry, *Thymus serpyllum*, toxicity, traditional applications

Introduction :

The contemporary world is responsible for improving immune responses and achieving excellent health via the use of medicinal herbs. For generations, from 4000 to 5000 B.C., people have turned to traditional remedies as a cost-effective and easily accessible means of illness treatment. The first known medicinal formulation derived from herbs was acquired by the Chinese. The first text on the use of plants as medicines in India was found in the Rig-Veda, which dates back to 1600-3500 B.C. Traditional Indian medicine has long made use of herbs for their therapeutic properties.[1] New medicinal treatments may be derived from plants.




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A thorough analysis of *Thymus serpyllum*'s traditional uses, phytochemistry, pharmacology, and toxicity

Ms A R Sridevi, Ms.B.Geethanjali Bai., Mr C G Bhaskar, Ms.A.AksaAnviya, Ms B silpa

Department of pharmacology

Email ID: sridevipharma93@gmail.com , Mobile no: 9182727657

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

The Lamiaceae family's understudied perennial plant Thymus serpyllum L. has a long history of use in the treatment of gastrointestinal and respiratory disorders in the higher foothills of India. Our present understanding of T. serpyllum's traditional applications, phytochemistry, and pharmacology is not well-rounded, and that is the goal of this review. Gathering up-to-date knowledge on this plant is our top priority, as is promoting more in vivo and in vitro studies to back up local claims. Due to its varied pharmacological qualities, such as antioxidative, antibacterial, anti-inflammatory, and anticancer activity, the essential oil extracted from T. serpyllum has garnered substantial interest as a plant-derived product. When it comes to creating novel medications to tackle a wide range of health sector issues, ethnomedicinal research has shown that T. serpyllum has a lot of potential. Pharmacological investigations alone are insufficient to support the widespread usage of T. serpyllum. In most cases, researchers use either in vitro or in vivo methods. To evaluate these medical assertions, more research is needed in the form of carefully orchestrated pharmacological trials. The findings of this evaluation will serve as a springboard for more studies. Despite T. serpyllum's extensive traditional usage, there has been a dearth of pharmacological research, with the majority of investigations conducted in either in vitro or in vivo settings. Important topics to explore include further chemical isolation, thorough pharmacological study, and potential culinary uses.

Keywords:

Pharmacological properties, phytochemistry, *Thymus serpyllum*, toxicity, traditional applications

Introduction :

The contemporary world is responsible for improving immune responses and achieving excellent health via the use of medicinal herbs. For generations, from 4000 to 5000 B.C., people have turned to traditional remedies as a cost-effective and easily accessible means of illness treatment. The first known medicinal formulation derived from herbs was acquired by the Chinese. The first text on the use of plants as medicines in India was found in the Rig-Veda, which dates back to 1600-3500 B.C. Traditional Indian medicine has long made use of herbs for their therapeutic properties.[1] New medicinal treatments may be derived from plants.




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICPR, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

A thorough analysis of *Thymus serpyllum*'s traditional uses, phytochemistry, pharmacology, and toxicity

Ms A R Sridevi, Ms.B.Geethanjali Bai., Mr C G Bhaskar, Ms.A.Aksha Anviya, Ms B silpa

Department of pharmacology

Email ID: sridevipharma93@gmail.com , Mobile no: 9182727657

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

The Lamiaceae family's understudied perennial plant Thymus serpyllum L. has a long history of use in the treatment of gastrointestinal and respiratory disorders in the higher foothills of India. Our present understanding of T. serpyllum's traditional applications, phytochemistry, and pharmacology is not well-rounded, and that is the goal of this review. Gathering up-to-date knowledge on this plant is our top priority, as is promoting more in vivo and in vitro studies to back up local claims. Due to its varied pharmacological qualities, such as antioxidative, antibacterial, anti-inflammatory, and anticancer activity, the essential oil extracted from T. serpyllum has garnered substantial interest as a plant-derived product. When it comes to creating novel medications to tackle a wide range of health sector issues, ethnomedicinal research has shown that T. serpyllum has a lot of potential. Pharmacological investigations alone are insufficient to support the widespread usage of T. serpyllum. In most cases, researchers use either in vitro or in vivo methods. To evaluate these medical assertions, more research is needed in the form of carefully orchestrated pharmacological trials. The findings of this evaluation will serve as a springboard for more studies. Despite T. serpyllum's extensive traditional usage, there has been a dearth of pharmacological research, with the majority of investigations conducted in either in vitro or in vivo settings. Important topics to explore include further chemical isolation, thorough pharmacological study, and potential culinary uses.

Keywords:

Pharmacological properties, phytochemistry, *Thymus serpyllum*, toxicity, traditional applications

Introduction :

The contemporary world is responsible for improving immune responses and achieving excellent health via the use of medicinal herbs. For generations, from 4000 to 5000 B.C., people have turned to traditional remedies as a cost-effective and easily accessible means of illness treatment. The first known medicinal formulation derived from herbs was acquired by the Chinese. The first text on the use of plants as medicines in India was found in the Rig-Veda, which dates back to 1600-3500 B.C. Traditional Indian medicine has long made use of herbs for their therapeutic properties.[1] New medicinal treatments may be derived from plants.




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

A thorough analysis of *Thymus serpyllum*'s traditional uses, phytochemistry, pharmacology, and toxicity

Ms A R Sridevi, Ms. B. Geethanjali Bai., Mr C G Bhaskar, Ms. A. Aksa Anvija, Ms B silpa

Department of pharmacology

Email ID: sridevipharma93@gmail.com, Mobile no: 9182727657

GOKULA KRISHNA COLLEGE OF PHARMACY

Abstract:

The Lamiaceae family's understudied perennial plant Thymus serpyllum L. has a long history of use in the treatment of gastrointestinal and respiratory disorders in the higher foothills of India. Our present understanding of T. serpyllum's traditional applications, phytochemistry, and pharmacology is not well-rounded, and that is the goal of this review. Gathering up-to-date knowledge on this plant is our top priority, as is promoting more in vivo and in vitro studies to back up local claims. Due to its varied pharmacological qualities, such as antioxidative, antibacterial, anti-inflammatory, and anticancer activity, the essential oil extracted from T. serpyllum has garnered substantial interest as a plant-derived product. When it comes to creating novel medications to tackle a wide range of health sector issues, ethnomedicinal research has shown that T. serpyllum has a lot of potential. Pharmacological investigations alone are insufficient to support the widespread usage of T. serpyllum. In most cases, researchers use either in vitro or in vivo methods. To evaluate these medical assertions, more research is needed in the form of carefully orchestrated pharmacological trials. The findings of this evaluation will serve as a springboard for more studies. Despite T. serpyllum's extensive traditional usage, there has been a dearth of pharmacological research, with the majority of investigations conducted in either in vitro or in vivo settings. Important topics to explore include further chemical isolation, thorough pharmacological study, and potential culinary uses.

Keywords:

Pharmacological properties, phytochemistry, *Thymus serpyllum*, toxicity, traditional applications

Introduction :

The contemporary world is responsible for improving immune responses and achieving excellent health via the use of medicinal herbs. For generations, from 4000 to 5000 B.C., people have turned to traditional remedies as a cost-effective and easily accessible means of illness treatment. The first known medicinal formulation derived from herbs was acquired by the Chinese. The first text on the use of plants as medicines in India was found in the Rig-Veda, which dates back to 1600-3500 B.C. Traditional Indian medicine has long made use of herbs for their therapeutic properties.[1] New medicinal treatments may be derived from plants.





Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347 - 2241

Indo - American Journal of Life Sciences and Biotechnology



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Pavan
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, F&SS, F&GE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro

Ms.P Kavitha, Mr.K.R.S.C Bharath kumar, Mrs.M.Sindhuri, Ms P Madhavi, Mr. Y.Naveenkumar

ABSTRACT - The purpose of this contribution is to evaluate the cytotoxicity and apoptosis inducing ability of structurally diverse anthraquinones to establish a relationship between structure and toxicity. Besides the wide spread use of anthraquinones in pharmacological drugs for constipation and non-prescription dietary supplements for weight loss, extracts are still commercialized as crude extracts and long-term side effects are still relevant. In this work we developed a method to quantify the cascariosides isolated from *Rhamnus purshiana* (Cascara Sagrada) using LC-MS/MS and evaluated the effects of this extract and isolated compounds on cellular viability using NOK-SI, HeLa, and T98G cell lineages. Apoptosis inducing ability was also analyzed via evaluating key-proteins involved in apoptosis pathways. Using cascariosides isolated from bark extracts, we found that the presence of glucose moieties in the chemical structure reduced the toxicity. This communication reviewed the mechanisms of action, toxicity of anthraquinones and correlated the toxicity with chemical structures of cascariosides. Results indicate that cascariosides-enriched cascara extract, as well as glycosylated anthraquinones, may have some beneficial effects for laxative action of herbal medicines. Considering our results, a cascariosides-enrichment in cascara extract is recommended.

INTRODUCTION

Anthraquinones are extensively present in nature, found in plants, bacteria, fungi, and insects. They are widely used as pharmacological drugs for constipation and as non-prescription dietary supplements for weight loss. Currently, these compounds are used to treat a variety of conditions because of their wide ranging biological activities, including anti-inflammatory, antifungal, antibacterial, antiviral, and antiarthritic actions (1).

Due to the cytotoxic action of some anthraquinone components, as doxorubicin (natural), daunorubicin (natural) and valrubicin (semisynthetic), several medicines have been developed to treat cancer (1-3). One important mechanism of action for cytotoxic agents used in cancer treatment is apoptosis induction. However, apoptosis is also responsible for the long-term sideeffects – as mucosa darkening – of anthraquinone- rich plants.

The mucosa darkening, also known as pseudo- melanosis coli, is a lipofuscin-like pigment found in macrophages from colonic lamina propria. The melanosis coli has been linked to the chronic use of laxative/purgative

anthranoid-rich plants (4, 5). Despite effective laxative action of anthraquinone- rich plants, clinical studies demonstrated that 73.4% of patients who chronically used anthranoids laxatives had melanosis coli, showing a clear association between anthraquinones and colon darkening (6). Histological studies have shown that a large number of apoptotic bodies are not caused by natural renewal, but by laxative action, suggesting that melanic substances are formed by the action of anthraquinones (7). Chen *et al.* (8) proposed a melanosis-forming mechanism that correlated the accumulation of pigments to the long-term use of these natural compounds. When such compounds enter the colon, they produce a laxative effect and damage the epithelial cells. These cells release TNF- α for the cell renewal induction mechanism via triggering apoptosis. Furthermore, damaged epithelial cells are phagocytized by macrophages, which migrate to lamina propria of the epithelium. In the lamina propria, the apoptotic bodies become lipofuscin, giving rise to black patches that darken the colon.

Department of pharmaceutics,

Email ID: kavithapharma147@gmail.com, Mobile no: 9393835500

GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MSTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

ISSN : 2347 - 224



*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. Balaganth Pavan Kumar
Dr. BALAGANTPAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro

Ms.P Kavitha, Mr.K.R.S.C Bharath kumar, Mrs.M.Sindhuri, Ms P Madhavi, Mr.Y.Naveenkumar

ABSTRACT - The purpose of this contribution is to evaluate the cytotoxicity and apoptosis inducing ability of structurally diverse anthraquinones to establish a relationship between structure and toxicity. Besides the wide spread use of anthraquinones in pharmacological drugs for constipation and non-prescription dietary supplements for weight loss, extracts are still commercialized as crude extracts and long-term side effects are still relevant. In this work we developed a method to quantify the cascariosides isolated from *Rhamnus purshiana* (Cascara Sagrada) using LC-MS/MS and evaluated the effects of this extract and isolated compounds on cellular viability using NOK-SI, HeLa, and T98G cell lineages. Apoptosis inducing ability was also analyzed via evaluating key-proteins involved in apoptosis pathways. Using cascariosides isolated from bark extracts, we found that the presence of glucose moieties in the chemical structure reduced the toxicity. This communication reviewed the mechanisms of action, toxicity of anthraquinones and correlated the toxicity with chemical structures of cascariosides. Results indicate that cascariosides-enriched cascara extract, as well as glycosylated anthraquinones, may have some beneficial effects for laxative action of herbal medicines. Considering our results, a cascariosides-enrichment in cascara extract is recommended.

INTRODUCTION

Anthraquinones are extensively present in nature, found in plants, bacteria, fungi, and insects. They are widely used as pharmacological drugs for constipation and as non-prescription dietary supplements for weight loss. Currently, these compounds are used to treat a variety of conditions because of their wide ranging biological activities, including anti-inflammatory, antifungal, antibacterial, antiviral, and antiarthritic actions (1).

Due to the cytotoxic action of some anthraquinone components, as doxorubicin (natural), daunorubicin (natural) and valrubicin (semisynthetic), several medicines have been developed to treat cancer (1-3). One important mechanism of action for cytotoxic agents used in cancer treatment is apoptosis induction. However, apoptosis is also responsible for the long-term sideeffects – as mucosa darkening – of anthraquinone- rich plants.

The mucosa darkening, also known as pseudo- melanosis coli, is a lipofuscin-like pigment found in macrophages from colonic lamina propria. The melanosis coli has been linked to the chronic use of laxative/purgative

anthranoid-rich plants (4, 5). Despite effective laxative action of anthraquinone- rich plants, clinical studies demonstrated that 73.4% of patients who chronically used anthranoids laxatives had melanosis coli, showing a clear association between anthraquinones and colon darkening (6). Histological studies have shown that a large number of apoptotic bodies are not caused by natural renewal, but by laxative action, suggesting that melanic substances are formed by the action of anthraquinones (7). Chen *et al.* (8) proposed a melanosis-forming mechanism that correlated the accumulation of pigments to the long-term use of these natural compounds. When such compounds enter the colon, they produce a laxative effect and damage the epithelial cells. These cells release TNF- α for the cell renewal induction mechanism via triggering apoptosis. Furthermore, damaged epithelial cells are phagocytized by macrophages, which migrate to lamina propria of the epithelium. In the lamina propria, the apoptotic bodies become lipofuscin, giving rise to black patches that darken the colon.

Department of pharmaceutics,

Email ID: kavithapharma147@gmail.com, Mobile no: 9393835500

GOKULA KRISHNA COLLEGE OF PHARMACY



Pavan

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FRSS, FAGE, FICCP, MSTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

ISSN : 2347 - 2243



*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FRSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DI. A.P - 524121



A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro

Ms.P Kavitha ,Mr.K.R.S.C Bharath kumar, Mrs.M.Sindhuri, Ms P Madhavi , Mr.Y.Naveenkumar

ABSTRACT - The purpose of this contribution is to evaluate the cytotoxicity and apoptosis inducing ability of structurally diverse anthraquinones to establish a relationship between structure and toxicity. Besides the wide spread use of anthraquinones in pharmacological drugs for constipation and non-prescription dietary supplements for weight loss, extracts are still commercialized as crude extracts and long-term side effects are still relevant. In this work we developed a method to quantify the cascariosides isolated from *Rhamnus purshiana* (Cascara Sagrada) using LC-MS/MS and evaluated the effects of this extract and isolated compounds on cellular viability using NOK-SI, HeLa, and T98G cell lineages. Apoptosis inducing ability was also analyzed via evaluating key-proteins involved in apoptosis pathways. Using cascariosides isolated from bark extracts, we found that the presence of glucose moieties in the chemical structure reduced the toxicity. This communication reviewed the mechanisms of action, toxicity of anthraquinones and correlated the toxicity with chemical structures of cascariosides. Results indicate that cascariosides-enriched cascara extract, as well as glycosylated anthraquinones, may have some beneficial effects for laxative action of herbal medicines. Considering our results, a cascariosides-enrichment in cascara extract is recommended.

INTRODUCTION

Anthraquinones are extensively present in nature, found in plants, bacteria, fungi, and insects. They are widely used as pharmacological drugs for constipation and as non-prescription dietary supplements for weight loss. Currently, these compounds are used to treat a variety of conditions because of their wide ranging biological activities, including anti-inflammatory, antifungal, antibacterial, antiviral, and antiarthritic actions (1).

Due to the cytotoxic action of some anthraquinone components, as doxorubicin (natural), daunorubicin (natural) and valrubicin (semisynthetic), several medicines have been developed to treat cancer (1-3). One important mechanism of action for cytotoxic agents used in cancer treatment is apoptosis induction. However, apoptosis is also responsible for the long-term sideeffects – as mucosa darkening – of anthraquinone- rich plants.

The mucosa darkening, also known as pseudo- melanosis coli, is a lipofuscin-like pigment found in macrophages from colonic lamina propria. The melanosis coli has been linked to the chronic use of laxative/purgative

anthranoid-rich plants (4, 5). Despite effective laxative action of anthraquinone- rich plants, clinical studies demonstrated that 73.4% of patients who chronically used anthranoids laxatives had melanosis coli, showing a clear association between anthraquinones and colon darkening (6). Histological studies have shown that a large number of apoptotic bodies are not caused by natural renewal, but by laxative action, suggesting that melanic substances are formed by the action of anthraquinones (7). Chen *et al.* (8) proposed a melanosis-forming mechanism that correlated the accumulation of pigments to the long-term use of these natural compounds. When such compounds enter the colon, they produce a laxative effect and damage the epithelial cells. These cells release TNF- α for the cell renewal induction mechanism via triggering apoptosis. Furthermore, damaged epithelial cells are phagocytized by macrophages, which migrate to lamina propria of the epithelium. In the lamina propria, the apoptotic bodies become lipofuscin, giving rise to black patches that darken the colon.

Department of pharmaceutics,
Email ID: kavithapharma147@gmail.com , Mobile no: 9393835500
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICOR, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

ISSN : 2347 - 224



*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Narayana
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro

Ms.P Kavitha ,Mr.K.R.S.C Bharath kumar,Mrs.M.Sindhuri ,Ms P Madhavi , Mr. Y.Naveenkumar

ABSTRACT - The purpose of this contribution is to evaluate the cytotoxicity and apoptosis inducing ability of structurally diverse anthraquinones to establish a relationship between structure and toxicity. Besides the wide spread use of anthraquinones in pharmacological drugs for constipation and non-prescription dietary supplements for weight loss, extracts are still commercialized as crude extracts and long-term side effects are still relevant. In this work we developed a method to quantify the cascariosides isolated from *Rhamnus purshiana* (Cascara Sagrada) using LC-MS/MS and evaluated the effects of this extract and isolated compounds on cellular viability using NOK-SI, HeLa, and T98G cell lineages. Apoptosis inducing ability was also analyzed via evaluating key-proteins involved in apoptosis pathways. Using cascariosides isolated from bark extracts, we found that the presence of glucose moieties in the chemical structure reduced the toxicity. This communication reviewed the mechanisms of action, toxicity of anthraquinones and correlated the toxicity with chemical structures of cascariosides. Results indicate that cascariosides-enriched cascara extract, as well as glycosylated anthraquinones, may have some beneficial effects for laxative action of herbal medicines. Considering our results, a cascariosides-enrichment in cascara extract is recommended.

INTRODUCTION

Anthraquinones are extensively present in nature, found in plants, bacteria, fungi, and insects. They are widely used as pharmacological drugs for constipation and as non-prescription dietary supplements for weight loss. Currently, these compounds are used to treat a variety of conditions because of their wide ranging biological activities, including anti-inflammatory, antifungal, antibacterial, antiviral, and antiarthritic actions (1).

Due to the cytotoxic action of some anthraquinone components, as doxorubicin (natural), daunorubicin (natural) and valrubicin (semisynthetic), several medicines have been developed to treat cancer (1-3). One important mechanism of action for cytotoxic agents used in cancer treatment is apoptosis induction. However, apoptosis is also responsible for the long-term sideeffects – as mucosa darkening – of anthraquinone- rich plants.

The mucosa darkening, also known as pseudo-melanosis coli, is a lipofuscin-like pigment found in macrophages from colonic lamina propria. The melanosis coli has been linked to the chronic use of laxative/purgative

anthranoid-rich plants (4, 5). Despite effective laxative action of anthraquinone- rich plants, clinical studies demonstrated that 73.4% of patients who chronically used anthranoids laxatives had melanosis coli, showing a clear association between anthraquinones and colon darkening (6). Histological studies have shown that a large number of apoptotic bodies are not caused by natural renewal, but by laxative action, suggesting that melanic substances are formed by the action of anthraquinones (7). Chen *et al.* (8) proposed a melanosis-forming mechanism that correlated the accumulation of pigments to the long-term use of these natural compounds. When such compounds enter the colon, they produce a laxative effect and damage the epithelial cells. These cells release TNF- α for the cell renewal induction mechanism via triggering apoptosis. Furthermore, damaged epithelial cells are phagocytized by macrophages, which migrate to lamina propria of the epithelium. In the lamina propria, the apoptotic bodies become lipofuscin, giving rise to black patches that darken the colon.

Department of pharmaceutics,

Email ID: kavithapharma147@gmail.com , Mobile no: 9393835500

GOKULA KRISHNA COLLEGE OF PHARMACY



Pavan
Dr. BALAGANI PAVAN KUMAR
 M. Pharm, Ph.D, FIC, FESS, FAGE, FICOP, MISTE
 PROFESSOR & PRINCIPAL
 GOKULA KRISHNA COLLEGE OF PHARMACY
 SULLURPET, TIRUPATI Dt. A.P - 524121

ISSN : 2347 - 2243



*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com

Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P. - 524121



A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro

Ms.P Kavitha ,Mr.K.R.S.C Bharath kumar, Mrs.M.Sindhuri ,Ms P Madhavi , Mr.Y.Naveenkumar

ABSTRACT - The purpose of this contribution is to evaluate the cytotoxicity and apoptosis inducing ability of structurally diverse anthraquinones to establish a relationship between structure and toxicity. Besides the wide spread use of anthraquinones in pharmacological drugs for constipation and non-prescription dietary supplements for weight loss, extracts are still commercialized as crude extracts and long-term side effects are still relevant. In this work we developed a method to quantify the cascarosides isolated from *Rhamnus purshiana* (Cascara Sagrada) using LC-MS/MS and evaluated the effects of this extract and isolated compounds on cellular viability using NOK-SI, HeLa, and T98G cell lineages. Apoptosis inducing ability was also analyzed via evaluating key-proteins involved in apoptosis pathways. Using cascarosides isolated from bark extracts, we found that the presence of glucose moieties in the chemical structure reduced the toxicity. This communication reviewed the mechanisms of action, toxicity of anthraquinones and correlated the toxicity with chemical structures of cascarosides. Results indicate that cascarosides-enriched cascara extract, as well as glycosylated anthraquinones, may have some beneficial effects for laxative action of herbal medicines. Considering our results, a cascarosides-enrichment in cascara extract is recommended.

INTRODUCTION

Anthraquinones are extensively present in nature, found in plants, bacteria, fungi, and insects. They are widely used as pharmacological drugs for constipation and as non-prescription dietary supplements for weight loss. Currently, these compounds are used to treat a variety of conditions because of their wide ranging biological activities, including anti-inflammatory, antifungal, antibacterial, antiviral, and antiarthritic actions (1).

Due to the cytotoxic action of some anthraquinone components, as doxorubicin (natural), daunorubicin (natural) and valrubicin (semisynthetic), several medicines have been developed to treat cancer (1-3). One important mechanism of action for cytotoxic agents used in cancer treatment is apoptosis induction. However, apoptosis is also responsible for the long-term sideeffects – as mucosa darkening – of anthraquinone- rich plants.

The mucosa darkening, also known as pseudo-melanosis coli, is a lipofuscin-like pigment found in macrophages from colonic lamina propria. The melanosis coli has been linked to the chronic use of laxative/purgative

anthranoid-rich plants (4, 5). Despite effective laxative action of anthraquinone- rich plants, clinical studies demonstrated that 73.4% of patients who chronically used anthranoids laxatives had melanosis coli, showing a clear association between anthraquinones and colon darkening (6). Histological studies have shown that a large number of apoptotic bodies are not caused by natural renewal, but by laxative action, suggesting that melanic substances are formed by the action of anthraquinones (7). Chen *et al.* (8) proposed a melanosis-forming mechanism that correlated the accumulation of pigments to the long-term use of these natural compounds. When such compounds enter the colon, they produce a laxative effect and damage the epithelial cells. These cells release TNF- α for the cell renewal induction mechanism via triggering apoptosis. Furthermore, damaged epithelial cells are phagocytized by macrophages, which migrate to lamina propria of the epithelium. In the lamina propria, the apoptotic bodies become lipofuscin, giving rise to black patches that darken the colon.

Department of pharmaceutics,

Email ID: kavithapharma147@gmail.com , Mobile no: 9393835500

GOKULA KRISHNA COLLEGE OF PHARMACY



Pavan

Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FDS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



ISSN : 2347 - 2243

*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



Shifting Focus from Fundamentals to Systems Pharmacodynamic Models

Dr. Balagani Pavan Kumar, Mrs. P K Devibala, MsC.B.Hanisha, Mrs. Swaroopa
Ms.A.Manogna

ABSTRACT: A number of PK/PD models have been established, building on various classical pharmacology foundations; these models are based on the principles of pharmacological action and the primary physiological processes that limit or turnover the drug's effectiveness. You can design better PK/PD or small system models by adding complexity to many fundamental models; tolerance is only one of many such additions. We demonstrate all of these concepts in our corticosteroid models, along with features of the horizontal and vertical integration of molecular to whole-body processes. The potential advantages and disadvantages of moving PK/PD towards systems models are outlined here. The paper "J Pharm Sci 102:2930-2940" was published in 2013 and was written by Wiley Periodicals, Inc. and the American Pharmacists Association. Words like "pharmacodynamics," "systems pharmacology," "mathematical models," "dosage response," and "indirect response models" are utilized.

INTRODUCTION

The areas of pharmacokinetics and pharmacodynamics (PK/PD) emerged from a long history of understanding basic pharmacological principles, mostly in relation to static or in vitro methods. A wide variety of small-to-large systems models have evolved to capture drug actions at various levels of biological structure, and several basic PK/PD models for in vivo drug effects have evolved into

more complicated ones. This review will go over the various areas that have embraced pharmacometrics and PK/PD, highlight key aspects of popular PK/PD models, demonstrate how to construct models that enhance PK/PD and small systems models, and highlight the difficulties in creating more accurate quantitative approaches for larger systems models.

Department of Pharmaceutics,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

ISSN : 2347 - 2243



Indo - American Journal of Life Sciences and Biotechnology



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MSTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DI. A.P - 524121



Shifting Focus from Fundamentals to Systems Pharmacodynamic Models

Dr. Balagani Pavan Kumar, Mrs. P K Devibala, MsC.B.Hanisha, Mrs. Swaroopa
Ms.A.Manogna

ABSTRACT: A number of PK/PD models have been established, building on various classical pharmacology foundations; these models are based on the principles of pharmacological action and the primary physiological processes that limit or turnover the drug's effectiveness. You can design better PK/PD or small system models by adding complexity to many fundamental models; tolerance is only one of many such additions. We demonstrate all of these concepts in our corticosteroid models, along with features of the horizontal and vertical integration of molecular to whole-body processes. The potential advantages and disadvantages of moving PK/PD towards systems models are outlined here. The paper "J Pharm Sci 102:2930-2940" was published in 2013 and was written by Wiley Periodicals, Inc. and the American Pharmacists Association. Words like "pharmacodynamics," "systems pharmacology," "mathematical models," "dosage response," and "indirect response models" are utilized.

INTRODUCTION

The areas of pharmacokinetics and pharmacodynamics (PK/PD) emerged from a long history of understanding basic pharmacological principles, mostly in relation to static or in vitro methods. A wide variety of small-to-large systems models have evolved to capture drug actions at various levels of biological structure, and several basic PK/PD models for in vivo drug effects have evolved into

more complicated ones. This review will go over the various areas that have embraced pharmacometrics and PK/PD, highlight key aspects of popular PK/PD models, demonstrate how to construct models that enhance PK/PD and small systems models, and highlight the difficulties in creating more accurate quantitative approaches for larger systems models.

Department of Pharmaceutics,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DI. A.P - 524121

ISSN : 2347 - 224



*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



K. Balagani
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FDS, FAGE, FICPR, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL A.P - 524121



Shifting Focus from Fundamentals to Systems Pharmacodynamic Models

Dr. Balagani Pavan Kumar, Mrs. P K Devibala, MsC.B.Hanisha, Mrs. Swaroopa
Ms.A.Manogna

ABSTRACT: A number of PK/PD models have been established, building on various classical pharmacology foundations; these models are based on the principles of pharmacological action and the primary physiological processes that limit or turnover the drug's effectiveness. You can design better PK/PD or small system models by adding complexity to many fundamental models; tolerance is only one of many such additions. We demonstrate all of these concepts in our corticosteroid models, along with features of the horizontal and vertical integration of molecular to whole-body processes. The potential advantages and disadvantages of moving PK/PD towards systems models are outlined here. The paper "J Pharm Sci 102:2930-2940" was published in 2013 and was written by Wiley Periodicals, Inc. and the American Pharmacists Association. Words like "pharmacodynamics," "systems pharmacology," "mathematical models," "dosage response," and "indirect response models" are utilized.

INTRODUCTION

The areas of pharmacokinetics and pharmacodynamics (PK/PD) emerged from a long history of understanding basic pharmacological principles, mostly in relation to static or in vitro methods. A wide variety of small-to-large systems models have evolved to capture drug actions at various levels of biological structure, and several basic PK/PD models for in vivo drug effects have evolved into

more complicated ones. This review will go over the various areas that have embraced pharmacometrics and PK/PD, highlight key aspects of popular PK/PD models, demonstrate how to construct models that enhance PK/PD and small systems models, and highlight the difficulties in creating more accurate quantitative approaches for larger systems models.

Department of Pharmaceutics,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FDES, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121

ISSN : 2347 - 2243



*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121



Shifting Focus from Fundamentals to Systems Pharmacodynamic Models

Dr. Balagani Pavan Kumar, Mrs. P K Devibala, MsC.B.Hanisha, Mrs. Swaroopa
Ms.A.Manogna

ABSTRACT: A number of PK/PD models have been established, building on various classical pharmacology foundations; these models are based on the principles of pharmacological action and the primary physiological processes that limit or turnover the drug's effectiveness. You can design better PK/PD or small system models by adding complexity to many fundamental models; tolerance is only one of many such additions. We demonstrate all of these concepts in our corticosteroid models, along with features of the horizontal and vertical integration of molecular to whole-body processes. The potential advantages and disadvantages of moving PK/PD towards systems models are outlined here. The paper "J Pharm Sci 102:2930-2940" was published in 2013 and was written by Wiley Periodicals, Inc. and the American Pharmacists Association. Words like "pharmacodynamics," "systems pharmacology," "mathematical models," "dosage response," and "indirect response models" are utilized.

INTRODUCTION

The areas of pharmacokinetics and pharmacodynamics (PK/PD) emerged from a long history of understanding basic pharmacological principles, mostly in relation to static or in vitro methods. A wide variety of small-to-large systems models have evolved to capture drug actions at various levels of biological structure, and several basic PK/PD models for in vivo drug effects have evolved into

more complicated ones. This review will go over the various areas that have embraced pharmacometrics and PK/PD, highlight key aspects of popular PK/PD models, demonstrate how to construct models that enhance PK/PD and small systems models, and highlight the difficulties in creating more accurate quantitative approaches for larger systems models.

Department of Pharmaceutics,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI Dt. A.P - 524121

ISSN : 2347 - 224



*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



Balagan
Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121



Shifting Focus from Fundamentals to Systems Pharmacodynamic Models

Dr. Balagani Pavan Kumar, Mrs. P K Devibala, MsC.B.Hanisha, Mrs. Swaroopa
Ms.A.Manogna

ABSTRACT: A number of PK/PD models have been established, building on various classical pharmacology foundations; these models are based on the principles of pharmacological action and the primary physiological processes that limit or turnover the drug's effectiveness. You can design better PK/PD or small system models by adding complexity to many fundamental models; tolerance is only one of many such additions. We demonstrate all of these concepts in our corticosteroid models, along with features of the horizontal and vertical integration of molecular to whole-body processes. The potential advantages and disadvantages of moving PK/PD towards systems models are outlined here. The paper "J Pharm Sci 102:2930-2940" was published in 2013 and was written by Wiley Periodicals, Inc. and the American Pharmacists Association. Words like "pharmacodynamics," "systems pharmacology," "mathematical models," "dosage response," and "indirect response models" are utilized.


INTRODUCTION

The areas of pharmacokinetics and pharmacodynamics (PK/PD) emerged from a long history of understanding basic pharmacological principles, mostly in relation to static or in vitro methods. A wide variety of small-to-large systems models have evolved to capture drug actions at various levels of biological structure, and several basic PK/PD models for in vivo drug effects have evolved into

more complicated ones. This review will go over the various areas that have embraced pharmacometrics and PK/PD, highlight key aspects of popular PK/PD models, demonstrate how to construct models that enhance PK/PD and small systems models, and highlight the difficulties in creating more accurate quantitative approaches for larger systems models.

Department of Pharmaceutics,
Email ID: pavan.gkcp@gmail.com, Mobile no: 9849280380
GOKULA KRISHNA COLLEGE OF PHARMACY




Dr. BALAGANI PAVAN KUMAR
M. Pharm, Ph.D, FIC, FBSS, FAGE, FICCP, MISTE
PROFESSOR & PRINCIPAL
GOKULA KRISHNA COLLEGE OF PHARMACY
SULLURPET, TIRUPATI DL. A.P - 524121